-DOCSTART- -X- -X- O

8589722 NN NN O
BRCA1 NN NN O
is NN NN O
secreted NN NN O
and NN NN O
exhibits NN NN O
properties NN NN O
of NN NN O
a NN NN O
granin NN NN O
. NN NN O

Germline NN NN O
mutations NN NN O
in NN NN O
BRCA1 NN NN O
are NN NN O
responsible NN NN O
for NN NN O
most NN NN O
cases NN NN O
of NN NN O
inherited NN NN B-CompositeMention
breast NN NN I-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

However NN NN O
, NN NN O
the NN NN O
function NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
protein NN NN O
has NN NN O
remained NN NN O
elusive NN NN O
. NN NN O

We NN NN O
now NN NN O
show NN NN O
that NN NN O
BRCA1 NN NN O
encodes NN NN O
a NN NN O
190-kD NN NN O
protein NN NN O
with NN NN O
sequence NN NN O
homology NN NN O
and NN NN O
biochemical NN NN O
analogy NN NN O
to NN NN O
the NN NN O
granin NN NN O
protein NN NN O
family NN NN O
. NN NN O

Interestingly NN NN O
, NN NN O
BRCA2 NN NN O
also NN NN O
includes NN NN O
a NN NN O
motif NN NN O
similar NN NN O
to NN NN O
the NN NN O
granin NN NN O
consensus NN NN O
at NN NN O
the NN NN O
C NN NN O
terminus NN NN O
of NN NN O
the NN NN O
protein NN NN O
. NN NN O

Both NN NN O
BRCA1 NN NN O
and NN NN O
the NN NN O
granins NN NN O
localize NN NN O
to NN NN O
secretory NN NN O
vesicles NN NN O
, NN NN O
are NN NN O
secreted NN NN O
by NN NN O
a NN NN O
regulated NN NN O
pathway NN NN O
, NN NN O
are NN NN O
post-translationally NN NN O
glycosylated NN NN O
and NN NN O
are NN NN O
responsive NN NN O
to NN NN O
hormones NN NN O
. NN NN O

As NN NN O
a NN NN O
regulated NN NN O
secretory NN NN O
protein NN NN O
, NN NN O
BRCA1 NN NN O
appears NN NN O
to NN NN O
function NN NN O
by NN NN O
a NN NN O
mechanism NN NN O
not NN NN O
previously NN NN O
described NN NN O
for NN NN O
tumour NN NN B-Modifier
suppressor NN NN O
gene NN NN O
products NN NN O
. NN NN O

. NN NN O

8589723 NN NN O
Ovarian NN NN B-Modifier
cancer NN NN I-Modifier
risk NN NN O
in NN NN O
BRCA1 NN NN O
carriers NN NN O
is NN NN O
modified NN NN O
by NN NN O
the NN NN O
HRAS1 NN NN O
variable NN NN O
number NN NN O
of NN NN O
tandem NN NN O
repeat NN NN O
( NN NN O
VNTR NN NN O
) NN NN O
locus NN NN O
. NN NN O

Women NN NN O
who NN NN O
carry NN NN O
a NN NN O
mutation NN NN O
in NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
( NN NN O
on NN NN O
chromosome NN NN O
17q21 NN NN O
) NN NN O
, NN NN O
have NN NN O
an NN NN O
80 NN NN O
% NN NN O
risk NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
and NN NN O
a NN NN O
40 NN NN O
% NN NN O
risk NN NN O
of NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
by NN NN O
the NN NN O
age NN NN O
of NN NN O
70 NN NN O
( NN NN O
ref NN NN O
. NN NN O

1 NN NN O
) NN NN O
. NN NN O

The NN NN O
variable NN NN O
penetrance NN NN O
of NN NN O
BRCA1 NN NN O
suggests NN NN O
that NN NN O
other NN NN O
genetic NN NN O
and NN NN O
non-genetic NN NN O
factors NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
tumourigenesis NN NN O
in NN NN O
these NN NN O
individuals NN NN O
. NN NN O

The NN NN O
HRAS1 NN NN O
variable NN NN O
number NN NN O
of NN NN O
tandem NN NN O
repeats NN NN O
( NN NN O
VNTR NN NN O
) NN NN O
polymorphism NN NN O
, NN NN O
located NN NN O
1 NN NN O
kilobase NN NN O
( NN NN O
kb NN NN O
) NN NN O
downstream NN NN O
of NN NN O
the NN NN O
HRAS1 NN NN O
proto-oncogene NN NN O
( NN NN O
chromosome NN NN O
11p15 NN NN O
. NN NN O

5 NN NN O
) NN NN O
is NN NN O
one NN NN O
possible NN NN O
genetic NN NN O
modifier NN NN O
of NN NN O
cancer NN NN B-Modifier
penetrance NN NN O
. NN NN O

Individuals NN NN O
who NN NN O
have NN NN O
rare NN NN O
alleles NN NN O
of NN NN O
the NN NN O
VNTR NN NN O
have NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
certain NN NN O
types NN NN O
of NN NN O
cancers NN NN B-DiseaseClass
, NN NN O
including NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
( NN NN O
2-4 NN NN O
) NN NN O
. NN NN O

To NN NN O
investigate NN NN O
whether NN NN O
the NN NN O
presence NN NN O
of NN NN O
rare NN NN O
HRAS1 NN NN O
alleles NN NN O
increases NN NN O
susceptibility NN NN O
to NN NN O
hereditary NN NN B-CompositeMention
breast NN NN I-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
, NN NN O
we NN NN O
have NN NN O
typed NN NN O
a NN NN O
panel NN NN O
of NN NN O
307 NN NN O
female NN NN O
BRCA1 NN NN O
carriers NN NN O
at NN NN O
this NN NN O
locus NN NN O
using NN NN O
a NN NN O
PCR-based NN NN O
technique NN NN O
. NN NN O

The NN NN O
risk NN NN O
for NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
was NN NN O
2 NN NN O
. NN NN O

11 NN NN O
times NN NN O
greater NN NN O
for NN NN O
BRCA1 NN NN O
carriers NN NN O
harbouring NN NN O
one NN NN O
or NN NN O
two NN NN O
rare NN NN O
HRAS1 NN NN O
alleles NN NN O
, NN NN O
compared NN NN O
to NN NN O
carriers NN NN O
with NN NN O
only NN NN O
common NN NN O
alleles NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O

015 NN NN O
) NN NN O
. NN NN O

The NN NN O
magnitude NN NN O
of NN NN O
the NN NN O
relative NN NN O
risk NN NN O
associated NN NN O
with NN NN O
a NN NN O
rare NN NN O
HRAS1 NN NN O
allele NN NN O
was NN NN O
not NN NN O
altered NN NN O
by NN NN O
adjusting NN NN O
for NN NN O
the NN NN O
other NN NN O
known NN NN O
risk NN NN O
factors NN NN O
for NN NN O
hereditary NN NN B-SpecificDisease
ovarian NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
( NN NN O
5 NN NN O
) NN NN O
. NN NN O

Susceptibility NN NN O
to NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
did NN NN O
not NN NN O
appear NN NN O
to NN NN O
be NN NN O
affected NN NN O
by NN NN O
the NN NN O
presence NN NN O
of NN NN O
rare NN NN O
HRAS1 NN NN O
alleles NN NN O
. NN NN O

This NN NN O
study NN NN O
is NN NN O
the NN NN O
first NN NN O
to NN NN O
show NN NN O
the NN NN O
effect NN NN O
of NN NN O
a NN NN O
modifying NN NN O
gene NN NN O
on NN NN O
the NN NN O
penetrance NN NN O
of NN NN O
an NN NN O
inherited NN NN B-DiseaseClass
cancer NN NN I-DiseaseClass
syndrome NN NN I-DiseaseClass

8595416 NN NN O
A NN NN O
novel NN NN O
homeodomain-encoding NN NN O
gene NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
large NN NN O
CpG NN NN O
island NN NN O
interrupted NN NN O
by NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
unstable NN NN O
( NN NN O
CTG NN NN O
) NN NN O
n NN NN O
repeat NN NN O
. NN NN O

Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
( NN NN O
CTG NN NN O
) NN NN O
n NN NN O
trinucleotide NN NN O
repeat NN NN O
expansion NN NN O
in NN NN O
the NN NN O
3-untranslated NN NN O
region NN NN O
of NN NN O
a NN NN O
protein NN NN O
kinase-encoding NN NN O
gene NN NN O
, NN NN O
DMPK NN NN O
, NN NN O
which NN NN O
maps NN NN O
to NN NN O
chromosome NN NN O
19q13 NN NN O
. NN NN O

3 NN NN O
. NN NN O

Characterisation NN NN O
of NN NN O
the NN NN O
expression NN NN O
of NN NN O
this NN NN O
gene NN NN O
in NN NN O
patient NN NN O
tissues NN NN O
has NN NN O
thus NN NN O
far NN NN O
generated NN NN O
conflicting NN NN O
data NN NN O
on NN NN O
alterations NN NN O
in NN NN O
the NN NN O
steady NN NN O
state NN NN O
levels NN NN O
of NN NN O
DMPK NN NN O
mRNA NN NN O
, NN NN O
and NN NN O
on NN NN O
the NN NN O
final NN NN O
DMPK NN NN O
protein NN NN O
levels NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
expansion NN NN O
. NN NN O

The NN NN O
DM NN NN B-Modifier
region NN NN O
of NN NN O
chromosome NN NN O
19 NN NN O
is NN NN O
gene NN NN O
rich NN NN O
, NN NN O
and NN NN O
it NN NN O
is NN NN O
possible NN NN O
that NN NN O
the NN NN O
repeat NN NN O
expansion NN NN O
may NN NN O
lead NN NN O
to NN NN O
dysfunction NN NN O
of NN NN O
a NN NN O
number NN NN O
of NN NN O
transcription NN NN O
units NN NN O
in NN NN O
the NN NN O
vicinity NN NN O
, NN NN O
perhaps NN NN O
as NN NN O
a NN NN O
consequence NN NN O
of NN NN O
chromatin NN NN O
disruption NN NN O
. NN NN O

We NN NN O
have NN NN O
searched NN NN O
for NN NN O
genes NN NN O
associated NN NN O
with NN NN O
a NN NN O
CpG NN NN O
island NN NN O
at NN NN O
the NN NN O
3 NN NN O
end NN NN O
of NN NN O
DMPK NN NN O
. NN NN O

Sequencing NN NN O
of NN NN O
this NN NN O
region NN NN O
shows NN NN O
that NN NN O
the NN NN O
island NN NN O
extends NN NN O
over NN NN O
3 NN NN O
. NN NN O

5 NN NN O
kb NN NN O
and NN NN O
is NN NN O
interrupted NN NN O
by NN NN O
the NN NN O
( NN NN O
CTG NN NN O
) NN NN O
n NN NN O
repeat NN NN O
. NN NN O

Comparison NN NN O
of NN NN O
genomic NN NN O
sequences NN NN O
downstream NN NN O
( NN NN O
centromeric NN NN O
) NN NN O
of NN NN O
the NN NN O
repeat NN NN O
in NN NN O
human NN NN O
and NN NN O
mouse NN NN O
identified NN NN O
regions NN NN O
of NN NN O
significant NN NN O
homology NN NN O
. NN NN O

These NN NN O
correspond NN NN O
to NN NN O
exons NN NN O
of NN NN O
a NN NN O
gene NN NN O
predicted NN NN O
to NN NN O
encode NN NN O
a NN NN O
homeodomain NN NN O
protein NN NN O
. NN NN O

RT-PCR NN NN O
analysis NN NN O
shows NN NN O
that NN NN O
this NN NN O
gene NN NN O
, NN NN O
which NN NN O
we NN NN O
have NN NN O
called NN NN O
DM NN NN B-Modifier
locus-associated NN NN O
homeodomain NN NN O
protein NN NN O
( NN NN O
DMAHP NN NN O
) NN NN O
, NN NN O
is NN NN O
expressed NN NN O
in NN NN O
a NN NN O
number NN NN O
of NN NN O
human NN NN O
tissues NN NN O
, NN NN O
including NN NN O
skeletal NN NN O
muscle NN NN O
, NN NN O
heart NN NN O
and NN NN O
brain NN NN O
. NN NN O

8605116 NN NN O
Germline NN NN O
mutations NN NN O
in NN NN O
the NN NN O
RB1 NN NN O
gene NN NN O
in NN NN O
patients NN NN O
with NN NN O
hereditary NN NN B-SpecificDisease
retinoblastoma NN NN I-SpecificDisease
. NN NN O

We NN NN O
have NN NN O
analyzed NN NN O
the NN NN O
27 NN NN O
exons NN NN O
and NN NN O
the NN NN O
promoter NN NN O
region NN NN O
of NN NN O
the NN NN O
RB1 NN NN O
gene NN NN O
in NN NN O
familial NN NN B-CompositeMention
or NN NN I-CompositeMention
sporadic NN NN I-CompositeMention
bilateral NN NN I-CompositeMention
retinoblastoma NN NN I-CompositeMention
by NN NN O
using NN NN O
single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
analysis NN NN O
. NN NN O

For NN NN O
improvement NN NN O
over NN NN O
previous NN NN O
studies NN NN O
, NN NN O
a NN NN O
new NN NN O
set NN NN O
of NN NN O
primers NN NN O
has NN NN O
been NN NN O
designed NN NN O
, NN NN O
which NN NN O
allow NN NN O
for NN NN O
amplification NN NN O
of NN NN O
the NN NN O
coding NN NN O
and NN NN O
splicing NN NN O
sequences NN NN O
only NN NN O
. NN NN O

The NN NN O
positioning NN NN O
of NN NN O
the NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
PCR NN NN O
) NN NN O
primers NN NN O
was NN NN O
such NN NN O
that NN NN O
the NN NN O
resulting NN NN O
PCR NN NN O
products NN NN O
were NN NN O
of NN NN O
different NN NN O
sizes NN NN O
, NN NN O
which NN NN O
enabled NN NN O
us NN NN O
to NN NN O
analyze NN NN O
two NN NN O
different NN NN O
exons NN NN O
simultaneously NN NN O
and NN NN O
still NN NN O
distinguish NN NN O
between NN NN O
the NN NN O
banding NN NN O
profiles NN NN O
for NN NN O
both NN NN O
( NN NN O
biplex NN NN O
analysis NN NN O
) NN NN O
. NN NN O

By NN NN O
using NN NN O
this NN NN O
approach NN NN O
, NN NN O
we NN NN O
were NN NN O
able NN NN O
to NN NN O
identify NN NN O
mutation NN NN O
in NN NN O
22 NN NN O
new NN NN O
patients NN NN O
, NN NN O
but NN NN O
the NN NN O
overall NN NN O
efficiency NN NN O
of NN NN O
the NN NN O
procedure NN NN O
when NN NN O
we NN NN O
used NN NN O
a NN NN O
single-pass NN NN O
regimen NN NN O
was NN NN O
only NN NN O
48 NN NN O
% NN NN O
. NN NN O

The NN NN O
mutations NN NN O
were NN NN O
small NN NN O
insertions NN NN O
and NN NN O
deletions NN NN O
and NN NN O
point NN NN O
mutations NN NN O
in NN NN O
roughly NN NN O
equal NN NN O
proportions NN NN O
. NN NN O

. NN NN O

8621452 NN NN O
Type NN NN B-SpecificDisease
II NN NN I-SpecificDisease
human NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
C2 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Allele-specific NN NN O
amino NN NN O
acid NN NN O
substitutions NN NN O
( NN NN O
Ser189 NN NN O
-- NN NN O
Phe NN NN O
; NN NN O
Gly444 NN NN O
-- NN NN O
Arg NN NN O
) NN NN O
cause NN NN O
impaired NN NN O
C2 NN NN O
secretion NN NN O
. NN NN O

Type NN NN B-SpecificDisease
II NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
protein NN NN I-SpecificDisease
C2 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
characterized NN NN O
by NN NN O
a NN NN O
selective NN NN O
block NN NN O
in NN NN O
C2 NN NN O
secretion NN NN O
. NN NN O

The NN NN O
Type NN NN O
II NN NN O
C2 NN NN O
null NN NN O
allele NN NN O
( NN NN O
C2Q0 NN NN O
) NN NN O
is NN NN O
linked NN NN O
to NN NN O
two NN NN O
major NN NN O
histocompatibility NN NN O
haplotypes NN NN O
( NN NN O
MHC NN NN O
) NN NN O
that NN NN O
differ NN NN O
from NN NN O
the NN NN O
MHC NN NN O
of NN NN O
the NN NN O
more NN NN O
common NN NN O
Type NN NN B-SpecificDisease
I NN NN I-SpecificDisease
C2 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

To NN NN O
determine NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
Type NN NN B-SpecificDisease
II NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
the NN NN O
two NN NN O
Type NN NN O
II NN NN O
C2Q0 NN NN O
genes NN NN O
were NN NN O
isolated NN NN O
and NN NN O
transfected NN NN O
separately NN NN O
into NN NN O
L-cells NN NN O
. NN NN O

Subsequent NN NN O
molecular NN NN O
biology NN NN O
, NN NN O
biosynthetic NN NN O
, NN NN O
and NN NN O
immunofluorescence NN NN O
studies NN NN O
demonstrated NN NN O
that NN NN O
C2 NN NN O
secretion NN NN O
is NN NN O
impaired NN NN O
in NN NN O
Type NN NN B-SpecificDisease
II NN NN I-SpecificDisease
C2 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
because NN NN O
of NN NN O
different NN NN O
missense NN NN O
mutations NN NN O
at NN NN O
highly NN NN O
conserved NN NN O
residues NN NN O
in NN NN O
each NN NN O
of NN NN O
the NN NN O
C2Q0 NN NN O
alleles NN NN O
. NN NN O

One NN NN O
is NN NN O
in NN NN O
exon NN NN O
5 NN NN O
( NN NN O
nucleotide NN NN O
C566 NN NN O
-- NN NN O
T NN NN O
; NN NN O
Ser189 NN NN O
-- NN NN O
Phe NN NN O
) NN NN O
of NN NN O
the NN NN O
C2Q0 NN NN O
gene NN NN O
linked NN NN O
to NN NN O
the NN NN O
MHC NN NN O
haplotype NN NN O
A11 NN NN O
, NN NN O
B35 NN NN O
, NN NN O
DRw1 NN NN O
, NN NN O
BFS NN NN O
, NN NN O
C4A0B1 NN NN O
. NN NN O

The NN NN O
other NN NN O
is NN NN O
in NN NN O
exon NN NN O
11 NN NN O
( NN NN O
G1930 NN NN O
-- NN NN O
A NN NN O
; NN NN O
Gly444 NN NN O
-- NN NN O
Arg NN NN O
) NN NN O
of NN NN O
the NN NN O
C2Q0 NN NN O
gene NN NN O
linked NN NN O
to NN NN O
the NN NN O
MHC NN NN O
haplotype NN NN O
A2 NN NN O
, NN NN O
B5 NN NN O
, NN NN O
DRw4 NN NN O
, NN NN O
BFS NN NN O
, NN NN O
C4A3B1 NN NN O
. NN NN O

Each NN NN O
mutant NN NN O
C2 NN NN O
gene NN NN O
product NN NN O
is NN NN O
retained NN NN O
early NN NN O
in NN NN O
the NN NN O
secretory NN NN O
pathway NN NN O
. NN NN O

These NN NN O
mutants NN NN O
provide NN NN O
models NN NN O
for NN NN O
elucidating NN NN O
the NN NN O
C2 NN NN O
secretory NN NN O
pathway NN NN O
. NN NN O

. NN NN O

8622978 NN NN O
Defective NN NN O
dimerization NN NN O
of NN NN O
von NN NN B-Modifier
Willebrand NN NN I-Modifier
factor NN NN O
subunits NN NN O
due NN NN O
to NN NN O
a NN NN O
Cys- NN NN O
Arg NN NN O
mutation NN NN O
in NN NN O
type NN NN B-SpecificDisease
IID NN NN I-SpecificDisease
von NN NN I-SpecificDisease
Willebrand NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

The NN NN O
same NN NN O
heterozygous NN NN O
T NN NN O
- NN NN O
C NN NN O
transition NN NN O
at NN NN O
nt NN NN O
8567 NN NN O
of NN NN O
the NN NN O
von NN NN B-Modifier
Willebrand NN NN I-Modifier
factor NN NN O
( NN NN O
vWF NN NN O
) NN NN O
transcript NN NN O
was NN NN O
found NN NN O
in NN NN O
two NN NN O
unrelated NN NN O
patients NN NN O
with NN NN O
type NN NN B-SpecificDisease
IID NN NN I-SpecificDisease
von NN NN I-SpecificDisease
Willebrand NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN O
with NN NN O
no NN NN O
other NN NN O
apparent NN NN O
abnormality NN NN O
. NN NN O

In NN NN O
one NN NN O
family NN NN O
, NN NN O
both NN NN O
alleles NN NN O
were NN NN O
normal NN NN O
in NN NN O
the NN NN O
parents NN NN O
and NN NN O
one NN NN O
sister NN NN O
; NN NN O
thus NN NN O
, NN NN O
the NN NN O
mutation NN NN O
originated NN NN O
de NN NN O
novo NN NN O
in NN NN O
the NN NN O
proposita NN NN O
. NN NN O

The NN NN O
second NN NN O
patient NN NN O
also NN NN O
had NN NN O
asymptomatic NN NN O
parents NN NN O
who NN NN O
, NN NN O
however NN NN O
, NN NN O
were NN NN O
not NN NN O
available NN NN O
for NN NN O
study NN NN O
. NN NN O

The NN NN O
structural NN NN O
consequences NN NN O
of NN NN O
the NN NN O
identified NN NN O
mutation NN NN O
, NN NN O
resulting NN NN O
in NN NN O
the NN NN O
CyS2010 NN NN O
- NN NN O
Arg NN NN O
substitution NN NN O
, NN NN O
were NN NN O
evaluated NN NN O
by NN NN O
expression NN NN O
of NN NN O
the NN NN O
vWF NN NN O
carboxyl-terminal NN NN O
domain NN NN O
containing NN NN O
residues NN NN O
1366-2050 NN NN O
. NN NN O

Insect NN NN O
cells NN NN O
infected NN NN O
with NN NN O
recombinant NN NN O
baculovirus NN NN O
expressing NN NN O
normal NN NN O
vWF NN NN O
sequence NN NN O
secreted NN NN O
a NN NN O
disulfide NN NN O
linked NN NN O
dimeric NN NN O
molecule NN NN O
with NN NN O
an NN NN O
apparent NN NN O
molecular NN NN O
mass NN NN O
of NN NN O
150 NN NN O
kDa NN NN O
before NN NN O
reduction NN NN O
, NN NN O
yielding NN NN O
a NN NN O
single NN NN O
band NN NN O
of NN NN O
80 NN NN O
kDa NN NN O
after NN NN O
disulfide NN NN O
bond NN NN O
reduction NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
cells NN NN O
expressing NN NN O
the NN NN O
mutant NN NN O
fragment NN NN O
secreted NN NN O
a NN NN O
monomeric NN NN O
molecule NN NN O
of NN NN O
apparent NN NN O
molecular NN NN O
mass NN NN O
of NN NN O
80 NN NN O
kDa NN NN O
, NN NN O
which NN NN O
remained NN NN O
unchanged NN NN O
after NN NN O
reduction NN NN O
. NN NN O

We NN NN O
conclude NN NN O
that NN NN O
CyS2010 NN NN O
is NN NN O
essential NN NN O
for NN NN O
normal NN NN O
dimerization NN NN O
of NN NN O
vWF NN NN O
subunits NN NN O
through NN NN O
disulfide NN NN O
bonding NN NN O
of NN NN O
carboxyl-terminal NN NN O
domains NN NN O
and NN NN O
that NN NN O
a NN NN O
heterozygous NN NN O
mutation NN NN O
in NN NN O
the NN NN O
corresponding NN NN O
codon NN NN O
is NN NN O
responsible NN NN O
for NN NN O
defective NN NN O
multimer NN NN O
formation NN NN O
in NN NN O
type NN NN B-SpecificDisease
IID NN NN I-SpecificDisease
von NN NN I-SpecificDisease
Willebrand NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

. NN NN O

8625410 NN NN O
Wiskott-Aldrich NN NN B-Modifier
syndrome NN NN I-Modifier
protein NN NN O
, NN NN O
a NN NN O
novel NN NN O
effector NN NN O
for NN NN O
the NN NN O
GTPase NN NN O
CDC42Hs NN NN O
, NN NN O
is NN NN O
implicated NN NN O
in NN NN O
actin NN NN O
polymerization NN NN O
. NN NN O

The NN NN O
Rho NN NN O
family NN NN O
of NN NN O
GTPases NN NN O
control NN NN O
diverse NN NN O
biological NN NN O
processes NN NN O
, NN NN O
including NN NN O
cell NN NN O
morphology NN NN O
and NN NN O
mitogenesis NN NN O
. NN NN O

We NN NN O
have NN NN O
identified NN NN O
WASP NN NN O
, NN NN O
the NN NN O
protein NN NN O
that NN NN O
is NN NN O
defective NN NN O
in NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
WAS NN NN B-SpecificDisease
) NN NN O
, NN NN O
as NN NN O
a NN NN O
novel NN NN O
effector NN NN O
for NN NN O
CDC42Hs NN NN O
, NN NN O
but NN NN O
not NN NN O
for NN NN O
the NN NN O
other NN NN O
Rho NN NN O
family NN NN O
members NN NN O
, NN NN O
Rac NN NN O
and NN NN O
Rho NN NN O
. NN NN O

This NN NN O
interaction NN NN O
is NN NN O
dependent NN NN O
on NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
G NN NN O
protein-binding NN NN O
domain NN NN O
. NN NN O

Cellular NN NN O
expression NN NN O
of NN NN O
epitope-tagged NN NN O
WASP NN NN O
produces NN NN O
clusters NN NN O
of NN NN O
WASP NN NN O
that NN NN O
are NN NN O
highly NN NN O
enriched NN NN O
in NN NN O
polymerized NN NN O
actin NN NN O
. NN NN O

This NN NN O
clustering NN NN O
is NN NN O
not NN NN O
observed NN NN O
with NN NN O
a NN NN O
C-terminally NN NN O
deleted NN NN O
WASP NN NN O
and NN NN O
is NN NN O
inhibited NN NN O
by NN NN O
coexpression NN NN O
with NN NN O
dominant NN NN O
negative NN NN O
CDC42Hs-N17 NN NN O
, NN NN O
but NN NN O
not NN NN O
with NN NN O
dominant NN NN O
negative NN NN O
forms NN NN O
of NN NN O
Rac NN NN O
or NN NN O
Rho NN NN O
. NN NN O

Thus NN NN O
, NN NN O
WASP NN NN O
provides NN NN O
a NN NN O
novel NN NN O
link NN NN O
between NN NN O
CDC42Hs NN NN O
and NN NN O
the NN NN O
actin NN NN O
cytoskeleton NN NN O
, NN NN O
which NN NN O
suggests NN NN O
a NN NN O
molecular NN NN O
mechanism NN NN O
for NN NN O
many NN NN O
of NN NN O
the NN NN O
cellular NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
in NN NN O
WAS NN NN B-SpecificDisease
. NN NN O

The NN NN O
WASP NN NN O
sequence NN NN O
contains NN NN O
two NN NN O
novel NN NN O
domains NN NN O
that NN NN O
are NN NN O
homologous NN NN O
to NN NN O
other NN NN O
proteins NN NN O
involved NN NN O
in NN NN O
action NN NN O
organization NN NN O
. NN NN O

. NN NN O

8636252 NN NN O
X-linked NN NN B-SpecificDisease
adrenoleukodystrophy NN NN I-SpecificDisease
is NN NN O
a NN NN O
frequent NN NN O
cause NN NN O
of NN NN O
idiopathic NN NN O
Addison NN NN B-SpecificDisease
's NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
in NN NN O
young NN NN O
adult NN NN O
male NN NN O
patients NN NN O
. NN NN O

X-Linked NN NN B-SpecificDisease
adrenoleukodystrophy NN NN I-SpecificDisease
( NN NN O
ALD NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
genetic NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
associated NN NN O
with NN NN O
demyelination NN NN B-DiseaseClass
of NN NN I-DiseaseClass
the NN NN I-DiseaseClass
central NN NN I-DiseaseClass
nervous NN NN I-DiseaseClass
system NN NN I-DiseaseClass
, NN NN O
adrenal NN NN B-DiseaseClass
insufficiency NN NN I-DiseaseClass
, NN NN O
and NN NN O
accumulation NN NN O
of NN NN O
very NN NN O
long NN NN O
chain NN NN O
fatty NN NN O
acids NN NN O
in NN NN O
tissue NN NN O
and NN NN O
body NN NN O
fluids NN NN O
. NN NN O

ALD NN NN B-SpecificDisease
is NN NN O
due NN NN O
to NN NN O
mutation NN NN O
of NN NN O
a NN NN O
gene NN NN O
located NN NN O
in NN NN O
Xq28 NN NN O
that NN NN O
encodes NN NN O
a NN NN O
peroxisomal NN NN O
transporter NN NN O
protein NN NN O
of NN NN O
unknown NN NN O
function NN NN O
. NN NN O

The NN NN O
most NN NN O
common NN NN O
phenotype NN NN O
of NN NN O
ALD NN NN B-SpecificDisease
is NN NN O
the NN NN O
cerebral NN NN O
form NN NN O
( NN NN O
45 NN NN O
% NN NN O
) NN NN O
that NN NN O
develops NN NN O
in NN NN O
boys NN NN O
between NN NN O
5-12 NN NN O
yr NN NN O
. NN NN O

Adrenomyeloneuropathy NN NN B-SpecificDisease
( NN NN O
AMN NN NN B-SpecificDisease
) NN NN O
involves NN NN O
the NN NN O
spinal NN NN O
cord NN NN O
and NN NN O
peripheral NN NN O
nerves NN NN O
in NN NN O
young NN NN O
adults NN NN O
( NN NN O
35 NN NN O
% NN NN O
) NN NN O
. NN NN O

Adrenal NN NN B-DiseaseClass
insufficiency NN NN I-DiseaseClass
( NN NN O
Addisons NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
) NN NN O
is NN NN O
frequently NN NN O
associated NN NN O
with NN NN O
AMN NN NN B-SpecificDisease
or NN NN O
cerebral NN NN B-SpecificDisease
ALD NN NN I-SpecificDisease
and NN NN O
may NN NN O
remain NN NN O
the NN NN O
only NN NN O
clinical NN NN O
expression NN NN O
of NN NN O
ALD NN NN B-SpecificDisease
( NN NN O
8 NN NN O
% NN NN O
of NN NN O
cases NN NN O
) NN NN O
. NN NN O

The NN NN O
prevalence NN NN O
of NN NN O
ALD NN NN B-SpecificDisease
among NN NN O
adults NN NN O
with NN NN O
Addisons NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
remains NN NN O
unknown NN NN O
. NN NN O

To NN NN O
evaluate NN NN O
this NN NN O
prevalence NN NN O
, NN NN O
we NN NN O
performed NN NN O
biochemical NN NN O
analysis NN NN O
of NN NN O
very NN NN O
long NN NN O
chain NN NN O
fatty NN NN O
acids NN NN O
in NN NN O
14 NN NN O
male NN NN O
patients NN NN O
( NN NN O
age NN NN O
ranging NN NN O
from NN NN O
12-45 NN NN O
yr NN NN O
at NN NN O
diagnosis NN NN O
) NN NN O
previously NN NN O
diagnosed NN NN O
as NN NN O
having NN NN O
primary NN NN O
idiopathic NN NN O
adrenocortical NN NN B-DiseaseClass
insufficiency NN NN I-DiseaseClass
. NN NN O

In NN NN O
5 NN NN O
of NN NN O
14 NN NN O
patients NN NN O
( NN NN O
35 NN NN O
% NN NN O
) NN NN O
, NN NN O
elevated NN NN O
plasma NN NN O
concentrations NN NN O
of NN NN O
very NN NN O
long NN NN O
chain NN NN O
fatty NN NN O
acids NN NN O
were NN NN O
detected NN NN O
. NN NN O

None NN NN O
of NN NN O
these NN NN O
patients NN NN O
had NN NN O
adrenocortical NN NN O
antibodies NN NN O
. NN NN O

By NN NN O
electrophysiological NN NN O
tests NN NN O
and NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
it NN NN O
was NN NN O
determined NN NN O
that NN NN O
two NN NN O
patients NN NN O
had NN NN O
cerebral NN NN B-SpecificDisease
ALD NN NN I-SpecificDisease
, NN NN O
one NN NN O
had NN NN O
adrenomyeloneuropathy NN NN B-SpecificDisease
with NN NN O
cerebral NN NN O
involvement NN NN O
, NN NN O
and NN NN O
two NN NN O
had NN NN O
preclinical NN NN O
AMN NN NN B-SpecificDisease
. NN NN O

Our NN NN O
data NN NN O
support NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
ALD NN NN B-SpecificDisease
is NN NN O
a NN NN O
frequent NN NN O
cause NN NN O
of NN NN O
idiopathic NN NN O
Addisons NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
in NN NN O
children NN NN O
and NN NN O
adults NN NN O
. NN NN O

. NN NN O

8637912 NN NN O
Tumor NN NN B-Modifier
suppression NN NN O
and NN NN O
apoptosis NN NN O
of NN NN O
human NN NN O
prostate NN NN B-SpecificDisease
carcinoma NN NN I-SpecificDisease
mediated NN NN O
by NN NN O
a NN NN O
genetic NN NN O
locus NN NN O
within NN NN O
human NN NN O
chromosome NN NN O
10pter-q11 NN NN O
. NN NN O

Prostate NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
is NN NN O
the NN NN O
second NN NN O
leading NN NN O
cause NN NN O
of NN NN O
male NN NN O
cancer NN NN B-Modifier
deaths NN NN O
in NN NN O
the NN NN O
United NN NN O
States NN NN O
. NN NN O

Yet NN NN O
, NN NN O
despite NN NN O
a NN NN O
large NN NN O
international NN NN O
effort NN NN O
, NN NN O
little NN NN O
is NN NN O
known NN NN O
about NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
that NN NN O
underlie NN NN O
this NN NN O
devastating NN NN O
disease NN NN O
. NN NN O

Prostate NN NN O
secretory NN NN O
epithelial NN NN O
cells NN NN O
and NN NN O
androgen-dependent NN NN O
prostate NN NN B-SpecificDisease
carcinomas NN NN I-SpecificDisease
undergo NN NN O
apoptosis NN NN O
in NN NN O
response NN NN O
to NN NN O
androgen NN NN O
deprivation NN NN O
and NN NN O
, NN NN O
furthermore NN NN O
, NN NN O
most NN NN O
prostate NN NN B-SpecificDisease
carcinomas NN NN I-SpecificDisease
become NN NN O
androgen NN NN O
independent NN NN O
and NN NN O
refractory NN NN O
to NN NN O
further NN NN O
therapeutic NN NN O
manipulations NN NN O
during NN NN O
disease NN NN O
progression NN NN O
. NN NN O

Definition NN NN O
of NN NN O
the NN NN O
genetic NN NN O
events NN NN O
that NN NN O
trigger NN NN O
apoptosis NN NN O
in NN NN O
the NN NN O
prostate NN NN O
could NN NN O
provide NN NN O
important NN NN O
insights NN NN O
into NN NN O
critical NN NN O
pathways NN NN O
in NN NN O
normal NN NN O
development NN NN O
as NN NN O
well NN NN O
as NN NN O
elucidate NN NN O
the NN NN O
perturbations NN NN O
of NN NN O
those NN NN O
key NN NN O
pathways NN NN O
in NN NN O
neoplastic NN NN O
transformation NN NN O
. NN NN O

We NN NN O
report NN NN O
the NN NN O
functional NN NN O
definition NN NN O
of NN NN O
a NN NN O
novel NN NN O
genetic NN NN O
locus NN NN O
within NN NN O
human NN NN O
chromosome NN NN O
10pter-q11 NN NN O
that NN NN O
mediates NN NN O
both NN NN O
in NN NN O
vivo NN NN O
tumor NN NN O
suppression NN NN O
and NN NN O
in NN NN O
vitro NN NN O
apoptosis NN NN O
of NN NN O
prostatic NN NN B-Modifier
adenocarcinoma NN NN I-Modifier
cells NN NN O
. NN NN O

A NN NN O
defined NN NN O
fragment NN NN O
of NN NN O
human NN NN O
chromosome NN NN O
10 NN NN O
was NN NN O
transferred NN NN O
via NN NN O
microcell NN NN O
fusion NN NN O
into NN NN O
a NN NN O
prostate NN NN B-Modifier
adenocarcinoma NN NN I-Modifier
cell NN NN O
line NN NN O
. NN NN O

Microcell NN NN O
hybrids NN NN O
containing NN NN O
only NN NN O
the NN NN O
region NN NN O
10pter-q11 NN NN O
were NN NN O
suppressed NN NN O
for NN NN O
tumorigenicity NN NN O
following NN NN O
injection NN NN O
of NN NN O
microcell NN NN O
hybrids NN NN O
into NN NN O
nude NN NN O
mice NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
the NN NN O
complemented NN NN O
hybrids NN NN O
undergo NN NN O
programmed NN NN O
cell NN NN O
death NN NN O
in NN NN O
vitro NN NN O
via NN NN O
a NN NN O
mechanism NN NN O
that NN NN O
does NN NN O
not NN NN O
require NN NN O
nuclear NN NN O
localization NN NN O
of NN NN O
p53 NN NN O
. NN NN O

These NN NN O
data NN NN O
functionally NN NN O
define NN NN O
a NN NN O
novel NN NN O
genetic NN NN O
locus NN NN O
, NN NN O
designated NN NN O
PAC1 NN NN O
, NN NN O
for NN NN O
prostate NN NN O
adenocarcinoma NN NN O
1 NN NN O
, NN NN O
involved NN NN O
in NN NN O
tumor NN NN O
suppression NN NN O
of NN NN O
human NN NN O
prostate NN NN B-SpecificDisease
carcinoma NN NN I-SpecificDisease
and NN NN O
furthermore NN NN O
strongly NN NN O
suggest NN NN O
that NN NN O
the NN NN O
cell NN NN O
death NN NN O
pathway NN NN O
can NN NN O
be NN NN O
functionally NN NN O
restored NN NN O
in NN NN O
prostatic NN NN B-SpecificDisease
adenocarcinoma NN NN I-SpecificDisease
. NN NN O

. NN NN O

8640236 NN NN O
Low NN NN O
incidence NN NN O
of NN NN O
BRCA2 NN NN O
mutations NN NN O
in NN NN O
breast NN NN B-SpecificDisease
carcinoma NN NN I-SpecificDisease
and NN NN O
other NN NN O
cancers NN NN B-DiseaseClass
. NN NN O

Inherited NN NN O
mutant NN NN O
alleles NN NN O
of NN NN O
familial NN NN O
tumour NN NN B-Modifier
suppressor NN NN O
genes NN NN O
predispose NN NN O
individuals NN NN O
to NN NN O
particular NN NN O
types NN NN O
of NN NN O
cancer NN NN B-DiseaseClass
. NN NN O

In NN NN O
addition NN NN O
to NN NN O
an NN NN O
involvement NN NN O
in NN NN O
inherited NN NN O
susceptibility NN NN O
to NN NN O
cancer NN NN B-DiseaseClass
, NN NN O
these NN NN O
tumour NN NN B-Modifier
suppressor NN NN O
genes NN NN O
are NN NN O
targets NN NN O
for NN NN O
somatic NN NN O
mutations NN NN O
in NN NN O
sporadic NN NN B-DiseaseClass
cancers NN NN I-DiseaseClass
of NN NN O
the NN NN O
same NN NN O
type NN NN O
found NN NN O
in NN NN O
the NN NN O
familial NN NN O
forms NN NN O
. NN NN O

An NN NN O
exception NN NN O
is NN NN O
BRCA1 NN NN O
, NN NN O
which NN NN O
contributes NN NN O
to NN NN O
a NN NN O
significant NN NN O
fraction NN NN O
of NN NN O
familial NN NN B-CompositeMention
breast NN NN I-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
, NN NN O
but NN NN O
undergoes NN NN O
mutation NN NN O
at NN NN O
very NN NN O
low NN NN O
rates NN NN O
in NN NN O
sporadic NN NN B-CompositeMention
breast NN NN I-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancers NN NN I-CompositeMention
. NN NN O

This NN NN O
finding NN NN O
suggests NN NN O
that NN NN O
other NN NN O
genes NN NN O
may NN NN O
be NN NN O
the NN NN O
principal NN NN O
targets NN NN O
for NN NN O
somatic NN NN O
mutation NN NN O
in NN NN O
breast NN NN B-SpecificDisease
carcinoma NN NN I-SpecificDisease
. NN NN O

A NN NN O
second NN NN O
, NN NN O
recently NN NN O
identified NN NN O
familial NN NN B-Modifier
breast NN NN I-Modifier
cancer NN NN I-Modifier
gene NN NN O
, NN NN O
BRCA2 NN NN O
( NN NN O
refs NN NN O
5-8 NN NN O
) NN NN O
, NN NN O
accounts NN NN O
for NN NN O
a NN NN O
proportion NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
roughly NN NN O
equal NN NN O
to NN NN O
BRCA1 NN NN O
. NN NN O

Like NN NN O
BRCA1 NN NN O
, NN NN O
BRCA2 NN NN O
behaves NN NN O
as NN NN O
a NN NN O
dominantly NN NN O
inherited NN NN O
tumour NN NN B-Modifier
suppressor NN NN O
gene NN NN O
. NN NN O

Individuals NN NN O
who NN NN O
inherit NN NN O
one NN NN O
mutant NN NN O
allele NN NN O
are NN NN O
at NN NN O
increased NN NN O
risk NN NN O
for NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
and NN NN O
the NN NN O
tumours NN NN B-DiseaseClass
they NN NN O
develop NN NN O
lose NN NN O
the NN NN O
wild-type NN NN O
allele NN NN O
by NN NN O
heterozygous NN NN O
deletion NN NN O
. NN NN O

The NN NN O
BRCA2 NN NN O
coding NN NN O
sequence NN NN O
is NN NN O
huge NN NN O
, NN NN O
composed NN NN O
of NN NN O
26 NN NN O
exons NN NN O
that NN NN O
span NN NN O
10 NN NN O
, NN NN O
443 NN NN O
bp NN NN O
. NN NN O

Here NN NN O
we NN NN O
investigate NN NN O
the NN NN O
rate NN NN O
of NN NN O
BRCA2 NN NN O
mutation NN NN O
in NN NN O
sporadic NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancers NN NN I-SpecificDisease
and NN NN O
in NN NN O
a NN NN O
set NN NN O
of NN NN O
cell NN NN O
lines NN NN O
that NN NN O
represent NN NN O
twelve NN NN O
other NN NN O
tumour NN NN B-Modifier
types NN NN O
. NN NN O

Surprisingly NN NN O
, NN NN O
mutations NN NN O
in NN NN O
BRCA2 NN NN O
are NN NN O
infrequent NN NN O
in NN NN O
cancers NN NN B-DiseaseClass
including NN NN O
breast NN NN B-SpecificDisease
carcinoma NN NN I-SpecificDisease
. NN NN O

However NN NN O
, NN NN O
a NN NN O
probable NN NN O
germline NN NN O
mutation NN NN O
in NN NN O
a NN NN O
pancreatic NN NN B-Modifier
tumour NN NN I-Modifier
cell NN NN O
line NN NN O
suggests NN NN O
a NN NN O
role NN NN O
for NN NN O
BRCA2 NN NN O
in NN NN O
susceptibility NN NN O
to NN NN O
pancreatic NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

. NN NN O

8644702 NN NN O
Founding NN NN O
BRCA1 NN NN O
mutations NN NN O
in NN NN O
hereditary NN NN B-CompositeMention
breast NN NN I-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
in NN NN O
southern NN NN O
Sweden NN NN O
. NN NN O

Nine NN NN O
different NN NN O
germ-line NN NN O
mutations NN NN O
in NN NN O
the NN NN O
BRCA1 NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
susceptibility NN NN O
gene NN NN O
were NN NN O
identified NN NN O
in NN NN O
15 NN NN O
of NN NN O
47 NN NN O
kindreds NN NN O
from NN NN O
southern NN NN O
Sweden NN NN O
, NN NN O
by NN NN O
use NN NN O
of NN NN O
SSCP NN NN O
and NN NN O
heteroduplex NN NN O
analysis NN NN O
of NN NN O
all NN NN O
exons NN NN O
and NN NN O
flanking NN NN O
intron NN NN O
region NN NN O
and NN NN O
by NN NN O
a NN NN O
protein-truncation NN NN O
test NN NN O
for NN NN O
exon NN NN O
11 NN NN O
, NN NN O
followed NN NN O
by NN NN O
direct NN NN O
sequencing NN NN O
. NN NN O

All NN NN O
but NN NN O
one NN NN O
of NN NN O
the NN NN O
mutations NN NN O
are NN NN O
predicted NN NN O
to NN NN O
give NN NN O
rise NN NN O
to NN NN O
premature NN NN O
translation NN NN O
termination NN NN O
and NN NN O
include NN NN O
seven NN NN O
frameshift NN NN O
insertions NN NN O
or NN NN O
deletions NN NN O
, NN NN O
a NN NN O
nonsense NN NN O
mutation NN NN O
, NN NN O
and NN NN O
a NN NN O
splice NN NN O
acceptor NN NN O
site NN NN O
mutation NN NN O
. NN NN O

The NN NN O
remaining NN NN O
mutation NN NN O
is NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
( NN NN O
Cys61Gly NN NN O
) NN NN O
in NN NN O
the NN NN O
zinc-binding NN NN O
motif NN NN O
. NN NN O

Four NN NN O
novel NN NN O
Swedish NN NN O
founding NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
the NN NN O
nucleotide NN NN O
2595 NN NN O
deletion NN NN O
A NN NN O
was NN NN O
found NN NN O
in NN NN O
five NN NN O
families NN NN O
, NN NN O
the NN NN O
C NN NN O
1806 NN NN O
T NN NN O
nonsense NN NN O
mutation NN NN O
in NN NN O
three NN NN O
families NN NN O
, NN NN O
the NN NN O
3166 NN NN O
insertion NN NN O
TGAGA NN NN O
in NN NN O
three NN NN O
families NN NN O
, NN NN O
and NN NN O
the NN NN O
nucleotide NN NN O
1201 NN NN O
deletion NN NN O
11 NN NN O
in NN NN O
two NN NN O
families NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
the NN NN O
intragenic NN NN O
polymorphism NN NN O
D17S855 NN NN O
supports NN NN O
common NN NN O
origins NN NN O
of NN NN O
the NN NN O
mutations NN NN O
. NN NN O

Eleven NN NN O
of NN NN O
the NN NN O
15 NN NN O
kindreds NN NN O
manifesting NN NN O
BRCA1 NN NN O
mutations NN NN O
were NN NN O
breast-ovarian NN NN B-Modifier
cancer NN NN I-Modifier
families NN NN O
, NN NN O
several NN NN O
of NN NN O
them NN NN O
with NN NN O
a NN NN O
predominant NN NN O
ovarian NN NN B-Modifier
cancer NN NN I-Modifier
phenotype NN NN O
. NN NN O

The NN NN O
set NN NN O
of NN NN O
32 NN NN O
families NN NN O
in NN NN O
which NN NN O
no NN NN O
BRCA1 NN NN O
alterations NN NN O
were NN NN O
detected NN NN O
included NN NN O
1 NN NN O
breast-ovarian NN NN B-Modifier
cancer NN NN I-Modifier
kindred NN NN O
manifesting NN NN O
clear NN NN O
linkage NN NN O
to NN NN O
the NN NN O
BRCA1 NN NN O
region NN NN O
and NN NN O
loss NN NN O
of NN NN O
the NN NN O
wild-type NN NN O
chromosome NN NN O
in NN NN O
associated NN NN O
tumors NN NN B-DiseaseClass
. NN NN O

Other NN NN O
tumor NN NN B-Modifier
types NN NN O
found NN NN O
in NN NN O
BRCA1 NN NN O
mutation NN NN O
/ NN NN O
haplotype NN NN O
carriers NN NN O
included NN NN O
prostatic NN NN B-CompositeMention
, NN NN I-CompositeMention
pancreas NN NN I-CompositeMention
, NN NN I-CompositeMention
skin NN NN I-CompositeMention
, NN NN I-CompositeMention
and NN NN I-CompositeMention
lung NN NN I-CompositeMention
cancer NN NN I-CompositeMention
, NN NN O
a NN NN O
malignant NN NN B-SpecificDisease
melanoma NN NN I-SpecificDisease
, NN NN O
an NN NN O
oligodendroglioma NN NN B-SpecificDisease
, NN NN O
and NN NN O
a NN NN O
carcinosarcoma NN NN B-SpecificDisease
. NN NN O

In NN NN O
all NN NN O
, NN NN O
12 NN NN O
of NN NN O
16 NN NN O
kindreds NN NN O
manifesting NN NN O
BRCA1 NN NN O
mutation NN NN O
or NN NN O
linkage NN NN O
contained NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
as NN NN O
compared NN NN O
with NN NN O
only NN NN O
6 NN NN O
of NN NN O
the NN NN O
remaining NN NN O
31 NN NN O
families NN NN O
( NN NN O
P NN NN O
. NN NN O

001 NN NN O
) NN NN O
. NN NN O

The NN NN O
present NN NN O
study NN NN O
confirms NN NN O
the NN NN O
involvement NN NN O
of NN NN O
BRCA1 NN NN O
in NN NN O
disease NN NN O
predisposition NN NN O
for NN NN O
a NN NN O
subset NN NN O
of NN NN O
hereditary NN NN B-Modifier
breast NN NN I-Modifier
cancer NN NN I-Modifier
families NN NN O
often NN NN O
characterized NN NN O
by NN NN O
ovarian NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
. NN NN O

8644703 NN NN O
Rapid NN NN O
detection NN NN O
of NN NN O
regionally NN NN O
clustered NN NN O
germ-line NN NN O
BRCA1 NN NN O
mutations NN NN O
by NN NN O
multiplex NN NN O
heteroduplex NN NN O
analysis NN NN O
. NN NN O

UKCCCR NN NN O
Familial NN NN O
Ovarian NN NN B-Modifier
Cancer NN NN I-Modifier
Study NN NN O
Group NN NN O
. NN NN O

Germ-line NN NN O
mutations NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
are NN NN O
responsible NN NN O
for NN NN O
a NN NN O
substantial NN NN O
proportion NN NN O
of NN NN O
families NN NN O
with NN NN O
multiple NN NN O
cases NN NN O
of NN NN O
early-onset NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
/ NN NN I-CompositeMention
or NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

Since NN NN O
the NN NN O
isolation NN NN O
of NN NN O
BRCA1 NN NN O
last NN NN O
year NN NN O
, NN NN O
65 NN NN O
distinct NN NN O
mutations NN NN O
scattered NN NN O
throughout NN NN O
the NN NN O
coding NN NN O
region NN NN O
have NN NN O
been NN NN O
detected NN NN O
, NN NN O
making NN NN O
analysis NN NN O
of NN NN O
the NN NN O
gene NN NN O
time NN NN O
consuming NN NN O
and NN NN O
technically NN NN O
challenging NN NN O
. NN NN O

We NN NN O
have NN NN O
developed NN NN O
a NN NN O
multiplex NN NN O
heteroduplex NN NN O
analysis NN NN O
that NN NN O
is NN NN O
designed NN NN O
to NN NN O
analyze NN NN O
one-quarter NN NN O
of NN NN O
the NN NN O
coding NN NN O
sequence NN NN O
in NN NN O
a NN NN O
single-step NN NN O
screening NN NN O
procedure NN NN O
and NN NN O
that NN NN O
will NN NN O
detect NN NN O
approximately NN NN O
50 NN NN O
% NN NN O
of NN NN O
all NN NN O
BRCA1 NN NN O
mutations NN NN O
so NN NN O
far NN NN O
reported NN NN O
in NN NN O
breast NN NN B-Modifier
/ NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
families NN NN O
. NN NN O

We NN NN O
have NN NN O
used NN NN O
this NN NN O
technique NN NN O
to NN NN O
analyze NN NN O
BRCA1 NN NN O
in NN NN O
162 NN NN O
families NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
/ NN NN I-CompositeMention
or NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
and NN NN O
identified NN NN O
12 NN NN O
distinct NN NN O
mutations NN NN O
in NN NN O
35 NN NN O
families NN NN O
. NN NN O

. NN NN O

8649785 NN NN O
A NN NN O
previously NN NN O
undescribed NN NN O
mutation NN NN O
within NN NN O
the NN NN O
tetramerisation NN NN O
domain NN NN O
of NN NN O
TP53 NN NN O
in NN NN O
a NN NN O
family NN NN O
with NN NN O
Li-Fraumeni NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

We NN NN O
report NN NN O
details NN NN O
of NN NN O
a NN NN O
family NN NN O
with NN NN O
classic NN NN O
Li-Fraumeni NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
in NN NN O
which NN NN O
there NN NN O
is NN NN O
a NN NN O
mutation NN NN O
in NN NN O
codon NN NN O
344 NN NN O
of NN NN O
the NN NN O
tumour NN NN B-Modifier
suppressor NN NN O
gene NN NN O
TP53 NN NN O
. NN NN O

Codon NN NN O
344 NN NN O
is NN NN O
a NN NN O
key NN NN O
residue NN NN O
within NN NN O
the NN NN O
tetramerisation NN NN O
domain NN NN O
, NN NN O
and NN NN O
the NN NN O
amino NN NN O
acid NN NN O
substitution NN NN O
of NN NN O
a NN NN O
proline NN NN O
for NN NN O
a NN NN O
leucine NN NN O
is NN NN O
predicted NN NN O
to NN NN O
have NN NN O
profound NN NN O
implications NN NN O
for NN NN O
tetramerisation NN NN O
and NN NN O
potentially NN NN O
DNA NN NN O
binding NN NN O
. NN NN O

This NN NN O
is NN NN O
the NN NN O
first NN NN O
report NN NN O
of NN NN O
a NN NN O
mutation NN NN O
at NN NN O
this NN NN O
residue NN NN O
in NN NN O
either NN NN O
sporadic NN NN B-DiseaseClass
tumours NN NN I-DiseaseClass
or NN NN O
in NN NN O
the NN NN O
germline NN NN O
and NN NN O
the NN NN O
first NN NN O
report NN NN O
of NN NN O
a NN NN O
germline NN NN O
mutation NN NN O
within NN NN O
the NN NN O
tetramerisation NN NN O
domain NN NN O
. NN NN O

The NN NN O
family NN NN O
does NN NN O
not NN NN O
appear NN NN O
to NN NN O
be NN NN O
remarkable NN NN O
in NN NN O
the NN NN O
spectrum NN NN O
of NN NN O
tumours NN NN B-DiseaseClass
, NN NN O
and NN NN O
there NN NN O
is NN NN O
loss NN NN O
of NN NN O
the NN NN O
wild-type NN NN O
allele NN NN O
in NN NN O
a NN NN O
leiomyosarcoma NN NN B-SpecificDisease
from NN NN O
the NN NN O
proband NN NN O
. NN NN O

A NN NN O
cell NN NN O
line NN NN O
has NN NN O
been NN NN O
established NN NN O
from NN NN O
the NN NN O
tumour NN NN B-DiseaseClass
of NN NN O
the NN NN O
proband NN NN O
and NN NN O
cytogenetic NN NN O
and NN NN O
molecular NN NN O
studies NN NN O
carried NN NN O
out NN NN O
, NN NN O
providing NN NN O
an NN NN O
extensive NN NN O
analysis NN NN O
in NN NN O
this NN NN O
family NN NN O
. NN NN O

. NN NN O

8651278 NN NN O
The NN NN O
spectrum NN NN O
of NN NN O
RB1 NN NN O
germ-line NN NN O
mutations NN NN O
in NN NN O
hereditary NN NN B-SpecificDisease
retinoblastoma NN NN I-SpecificDisease
. NN NN O

We NN NN O
have NN NN O
searched NN NN O
for NN NN O
germ-line NN NN O
RB1 NN NN O
mutations NN NN O
in NN NN O
119 NN NN O
patients NN NN O
with NN NN O
hereditary NN NN B-SpecificDisease
retinoblastoma NN NN I-SpecificDisease
. NN NN O

Previous NN NN O
investigations NN NN O
by NN NN O
Southern NN NN O
blot NN NN O
hybridization NN NN O
and NN NN O
PCR NN NN O
fragment-length NN NN O
analysis NN NN O
had NN NN O
revealed NN NN O
mutations NN NN O
in NN NN O
48 NN NN O
patients NN NN O
. NN NN O

Here NN NN O
we NN NN O
report NN NN O
on NN NN O
the NN NN O
analysis NN NN O
of NN NN O
the NN NN O
remaining NN NN O
71 NN NN O
patients NN NN O
. NN NN O

By NN NN O
applying NN NN O
heteroduplex NN NN O
analysis NN NN O
, NN NN O
nonisotopic NN NN O
SSCP NN NN O
, NN NN O
and NN NN O
direct NN NN O
sequencing NN NN O
, NN NN O
we NN NN O
detected NN NN O
germ-line NN NN O
mutations NN NN O
resulting NN NN O
in NN NN O
premature NN NN O
termination NN NN O
codons NN NN O
or NN NN O
disruption NN NN O
of NN NN O
splice NN NN O
signals NN NN O
in NN NN O
51 NN NN O
( NN NN O
72 NN NN O
% NN NN O
) NN NN O
of NN NN O
the NN NN O
71 NN NN O
patients NN NN O
. NN NN O

Four NN NN O
patients NN NN O
also NN NN O
showed NN NN O
rare NN NN O
sequence NN NN O
variants NN NN O
. NN NN O

No NN NN O
region NN NN O
of NN NN O
the NN NN O
RB1 NN NN O
gene NN NN O
was NN NN O
preferentially NN NN O
involved NN NN O
in NN NN O
single NN NN O
base NN NN O
substitutions NN NN O
. NN NN O

Recurrent NN NN O
transitions NN NN O
were NN NN O
observed NN NN O
at NN NN O
most NN NN O
of NN NN O
the NN NN O
14 NN NN O
codons NN NN O
within NN NN O
the NN NN O
RB1 NN NN O
. NN NN O

No NN NN O
mutation NN NN O
was NN NN O
observed NN NN O
in NN NN O
exons NN NN O
25-27 NN NN O
, NN NN O
although NN NN O
this NN NN O
region NN NN O
contains NN NN O
two NN NN O
CGA NN NN O
codons NN NN O
. NN NN O

This NN NN O
suggests NN NN O
that NN NN O
mutations NN NN O
within NN NN O
the NN NN O
3-terminal NN NN O
region NN NN O
of NN NN O
the NN NN O
RB1 NN NN O
gene NN NN O
may NN NN O
not NN NN O
be NN NN O
oncogenic NN NN O
. NN NN O

When NN NN O
these NN NN O
data NN NN O
were NN NN O
combined NN NN O
with NN NN O
the NN NN O
results NN NN O
of NN NN O
our NN NN O
previous NN NN O
investigations NN NN O
, NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
in NN NN O
a NN NN O
total NN NN O
of NN NN O
99 NN NN O
( NN NN O
83 NN NN O
% NN NN O
) NN NN O
of NN NN O
119 NN NN O
patients NN NN O
. NN NN O

The NN NN O
spectrum NN NN O
comprises NN NN O
15 NN NN O
% NN NN O
large NN NN O
deletions NN NN O
, NN NN O
26 NN NN O
% NN NN O
small NN NN O
length NN NN O
alterations NN NN O
, NN NN O
and NN NN O
42 NN NN O
% NN NN O
base NN NN O
substitutions NN NN O
. NN NN O

No NN NN O
correlation NN NN O
between NN NN O
the NN NN O
location NN NN O
of NN NN O
frameshift NN NN O
or NN NN O
nonsense NN NN O
mutations NN NN O
and NN NN O
phenotypic NN NN O
features NN NN O
, NN NN O
including NN NN O
age NN NN O
at NN NN O
diagnosis NN NN O
, NN NN O
the NN NN O
number NN NN O
of NN NN O
tumor NN NN B-Modifier
foci NN NN O
, NN NN O
and NN NN O
manifestation NN NN O
of NN NN O
nonocular NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
was NN NN O
observed NN NN O
. NN NN O

. NN NN O

8659522 NN NN O
Phenotypic NN NN O
characterization NN NN O
of NN NN O
individuals NN NN O
with NN NN O
30-40 NN NN O
CAG NN NN O
repeats NN NN O
in NN NN O
the NN NN O
Huntington NN NN B-Modifier
disease NN NN I-Modifier
( NN NN O
HD NN NN B-Modifier
) NN NN O
gene NN NN O
reveals NN NN O
HD NN NN B-Modifier
cases NN NN O
with NN NN O
36 NN NN O
repeats NN NN O
and NN NN O
apparently NN NN O
normal NN NN O
elderly NN NN O
individuals NN NN O
with NN NN O
36-39 NN NN O
repeats NN NN O
. NN NN O

Abnormal NN NN O
CAG NN NN O
expansions NN NN O
in NN NN O
the NN NN O
IT-15 NN NN O
gene NN NN O
are NN NN O
associated NN NN O
with NN NN O
Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
HD NN NN B-SpecificDisease
) NN NN O
. NN NN O

In NN NN O
the NN NN O
diagnostic NN NN O
setting NN NN O
it NN NN O
is NN NN O
necessary NN NN O
to NN NN O
define NN NN O
the NN NN O
limits NN NN O
of NN NN O
the NN NN O
CAG NN NN O
size NN NN O
ranges NN NN O
on NN NN O
normal NN NN O
and NN NN O
HD NN NN B-Modifier
-associated NN NN O
chromosomes NN NN O
. NN NN O

Most NN NN O
large NN NN O
analyses NN NN O
that NN NN O
defined NN NN O
the NN NN O
limits NN NN O
of NN NN O
the NN NN O
normal NN NN O
and NN NN O
pathological NN NN O
size NN NN O
ranges NN NN O
employed NN NN O
PCR NN NN O
assays NN NN O
, NN NN O
which NN NN O
included NN NN O
the NN NN O
CAG NN NN O
repeats NN NN O
and NN NN O
a NN NN O
CCG NN NN O
repeat NN NN O
tract NN NN O
that NN NN O
was NN NN O
thought NN NN O
to NN NN O
be NN NN O
invariant NN NN O
. NN NN O

Many NN NN O
of NN NN O
these NN NN O
experiments NN NN O
found NN NN O
an NN NN O
overlap NN NN O
between NN NN O
the NN NN O
normal NN NN O
and NN NN O
disease NN NN O
size NN NN O
ranges NN NN O
. NN NN O

Subsequent NN NN O
findings NN NN O
that NN NN O
the NN NN O
CCG NN NN O
repeats NN NN O
vary NN NN O
by NN NN O
8 NN NN O
trinucleotide NN NN O
lengths NN NN O
suggested NN NN O
that NN NN O
the NN NN O
limits NN NN O
of NN NN O
the NN NN O
normal NN NN O
and NN NN O
disease NN NN O
size NN NN O
ranges NN NN O
should NN NN O
be NN NN O
reevaluated NN NN O
with NN NN O
assays NN NN O
that NN NN O
exclude NN NN O
the NN NN O
CCG NN NN O
polymorphism NN NN O
. NN NN O

Since NN NN O
patients NN NN O
with NN NN O
between NN NN O
30 NN NN O
and NN NN O
40 NN NN O
repeats NN NN O
are NN NN O
rare NN NN O
, NN NN O
a NN NN O
consortium NN NN O
was NN NN O
assembled NN NN O
to NN NN O
collect NN NN O
such NN NN O
individuals NN NN O
. NN NN O

All NN NN O
178 NN NN O
samples NN NN O
were NN NN O
reanalyzed NN NN O
in NN NN O
Cambridge NN NN O
by NN NN O
using NN NN O
assays NN NN O
specific NN NN O
for NN NN O
the NN NN O
CAG NN NN O
repeats NN NN O
. NN NN O

We NN NN O
have NN NN O
optimized NN NN O
methods NN NN O
for NN NN O
reliable NN NN O
sizing NN NN O
of NN NN O
CAG NN NN O
repeats NN NN O
and NN NN O
show NN NN O
cases NN NN O
that NN NN O
demonstrate NN NN O
the NN NN O
dangers NN NN O
of NN NN O
using NN NN O
PCR NN NN O
assays NN NN O
that NN NN O
include NN NN O
both NN NN O
the NN NN O
CAG NN NN O
and NN NN O
CCG NN NN O
polymorphisms NN NN O
. NN NN O

Seven NN NN O
HD NN NN B-Modifier
patients NN NN O
had NN NN O
36 NN NN O
repeats NN NN O
, NN NN O
which NN NN O
confirms NN NN O
that NN NN O
this NN NN O
allele NN NN O
is NN NN O
associated NN NN O
with NN NN O
disease NN NN O
. NN NN O

Individuals NN NN O
without NN NN O
apparent NN NN O
symptoms NN NN O
or NN NN O
signs NN NN O
of NN NN O
HD NN NN B-SpecificDisease
were NN NN O
found NN NN O
at NN NN O
36 NN NN O
repeats NN NN O
( NN NN O
aged NN NN O
74 NN NN O
, NN NN O
78 NN NN O
, NN NN O
79 NN NN O
, NN NN O
and NN NN O
87 NN NN O
years NN NN O
) NN NN O
, NN NN O
37 NN NN O
repeats NN NN O
( NN NN O
aged NN NN O
69 NN NN O
years NN NN O
) NN NN O
, NN NN O
38 NN NN O
repeats NN NN O
( NN NN O
aged NN NN O
69 NN NN O
and NN NN O
90 NN NN O
years NN NN O
) NN NN O
, NN NN O
and NN NN O
39 NN NN O
repeats NN NN O
( NN NN O
aged NN NN O
67 NN NN O
, NN NN O
90 NN NN O
, NN NN O
and NN NN O
95 NN NN O
years NN NN O
) NN NN O
. NN NN O

The NN NN O
detailed NN NN O
case NN NN O
histories NN NN O
of NN NN O
an NN NN O
exceptional NN NN O
case NN NN O
from NN NN O
this NN NN O
series NN NN O
will NN NN O
be NN NN O
presented NN NN O
a NN NN O
95-year-old NN NN O
man NN NN O
with NN NN O
39 NN NN O
repeats NN NN O
who NN NN O
did NN NN O
not NN NN O
have NN NN O
classical NN NN O
features NN NN O
of NN NN O
HD NN NN B-SpecificDisease
. NN NN O

The NN NN O
apparently NN NN O
healthy NN NN O
survival NN NN O
into NN NN O
old NN NN O
age NN NN O
of NN NN O
some NN NN O
individuals NN NN O
with NN NN O
36-39 NN NN O
repeats NN NN O
suggests NN NN O
that NN NN O
the NN NN O
HD NN NN B-Modifier
mutation NN NN O
may NN NN O
not NN NN O
always NN NN O
be NN NN O
fully NN NN O
penetrant NN NN O
. NN NN O

. NN NN O

8659549 NN NN O
Identification NN NN O
and NN NN O
expression NN NN O
of NN NN O
eight NN NN O
novel NN NN O
mutations NN NN O
among NN NN O
non-Jewish NN NN O
patients NN NN O
with NN NN O
Canavan NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Canavan NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
is NN NN O
inherited NN NN O
as NN NN O
an NN NN O
autosomal NN NN O
recessive NN NN O
trait NN NN O
that NN NN O
is NN NN O
caused NN NN O
by NN NN O
the NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
aspartoacylase NN NN I-SpecificDisease
( NN NN O
ASPA NN NN O
) NN NN O
. NN NN O

The NN NN O
majority NN NN O
of NN NN O
patients NN NN O
with NN NN O
Canavan NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
are NN NN O
from NN NN O
an NN NN O
Ashkenazi NN NN O
Jewish NN NN O
background NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
ASPA NN NN O
that NN NN O
lead NN NN O
to NN NN O
loss NN NN O
of NN NN O
enzymatic NN NN O
activity NN NN O
have NN NN O
been NN NN O
identified NN NN O
, NN NN O
and NN NN O
E285A NN NN O
and NN NN O
Y231X NN NN O
are NN NN O
the NN NN O
two NN NN O
predominant NN NN O
mutations NN NN O
that NN NN O
account NN NN O
for NN NN O
97 NN NN O
% NN NN O
of NN NN O
the NN NN O
mutant NN NN O
chromosomes NN NN O
in NN NN O
Ashkenazi NN NN O
Jewish NN NN O
patients NN NN O
. NN NN O

The NN NN O
current NN NN O
study NN NN O
was NN NN O
aimed NN NN O
at NN NN O
finding NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
Canavan NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
in NN NN O
25 NN NN O
independent NN NN O
patients NN NN O
of NN NN O
non-Jewish NN NN O
background NN NN O
. NN NN O

Eight NN NN O
novel NN NN O
and NN NN O
three NN NN O
previously NN NN O
characterized NN NN O
mutations NN NN O
accounted NN NN O
for NN NN O
80 NN NN O
% NN NN O
( NN NN O
40 NN NN O
/ NN NN O
50 NN NN O
) NN NN O
of NN NN O
mutant NN NN O
chromosomes NN NN O
. NN NN O

The NN NN O
A305E NN NN O
missense NN NN O
mutation NN NN O
accounted NN NN O
for NN NN O
48 NN NN O
% NN NN O
( NN NN O
24 NN NN O
/ NN NN O
50 NN NN O
) NN NN O
of NN NN O
mutant NN NN O
chromosomes NN NN O
in NN NN O
patients NN NN O
of NN NN O
western NN NN O
European NN NN O
descent NN NN O
, NN NN O
while NN NN O
the NN NN O
two NN NN O
predominant NN NN O
Jewish NN NN O
mutations NN NN O
each NN NN O
accounted NN NN O
for NN NN O
a NN NN O
single NN NN O
mutant NN NN O
chromosome NN NN O
. NN NN O

The NN NN O
eight NN NN O
novel NN NN O
mutations NN NN O
identified NN NN O
included NN NN O
1- NN NN O
and NN NN O
4-bp NN NN O
deletions NN NN O
( NN NN O
32 NN NN O
deltaT NN NN O
and NN NN O
876 NN NN O
deltaAGAA NN NN O
, NN NN O
respectively NN NN O
) NN NN O
and NN NN O
I16T NN NN O
, NN NN O
G27R NN NN O
, NN NN O
D114E NN NN O
, NN NN O
G123E NN NN O
, NN NN O
C152Y NN NN O
, NN NN O
and NN NN O
R168C NN NN O
missense NN NN O
mutations NN NN O
. NN NN O

The NN NN O
homozygous NN NN O
32 NN NN O
deltaT NN NN O
deletion NN NN O
was NN NN O
identified NN NN O
in NN NN O
the NN NN O
only NN NN O
known NN NN O
patient NN NN O
of NN NN O
African-American NN NN O
origin NN NN O
with NN NN O
Canavan NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

The NN NN O
heterozygosity NN NN O
for NN NN O
876 NN NN O
deltaAGAA NN NN O
mutation NN NN O
was NN NN O
identified NN NN O
in NN NN O
three NN NN O
independent NN NN O
patients NN NN O
from NN NN O
England NN NN O
. NN NN O

Six NN NN O
single-base NN NN O
changes NN NN O
leading NN NN O
to NN NN O
missense NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
in NN NN O
patients NN NN O
from NN NN O
Turkey NN NN O
( NN NN O
D114E NN NN O
, NN NN O
R168C NN NN O
) NN NN O
, NN NN O
The NN NN O
Netherlands NN NN O
( NN NN O
I16T NN NN O
) NN NN O
, NN NN O
Germany NN NN O
( NN NN O
G27R NN NN O
) NN NN O
, NN NN O
Ireland NN NN O
( NN NN O
C152Y NN NN O
) NN NN O
, NN NN O
and NN NN O
Canada NN NN O
( NN NN O
G123E NN NN O
) NN NN O
. NN NN O

A NN NN O
PCR-based NN NN O
protocol NN NN O
is NN NN O
described NN NN O
that NN NN O
was NN NN O
used NN NN O
to NN NN O
introduce NN NN O
mutations NN NN O
in NN NN O
wild-type NN NN O
cDNA NN NN O
. NN NN O

In NN NN O
vitro NN NN O
expression NN NN O
of NN NN O
mutant NN NN O
cDNA NN NN O
clones NN NN O
demonstrated NN NN O
that NN NN O
all NN NN O
of NN NN O
these NN NN O
mutations NN NN O
led NN NN O
to NN NN O
a NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
ASPA NN NN I-SpecificDisease
and NN NN O
should NN NN O
therefore NN NN O
result NN NN O
in NN NN O
Canavan NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

. NN NN O

8661102 NN NN O
Identification NN NN O
and NN NN O
chromosomal NN NN O
localization NN NN O
of NN NN O
Atm NN NN O
, NN NN O
the NN NN O
mouse NN NN O
homolog NN NN O
of NN NN O
the NN NN O
ataxia-telangiectasia NN NN B-Modifier
gene NN NN O
. NN NN O

Atm NN NN O
, NN NN O
the NN NN O
mouse NN NN O
homolog NN NN O
of NN NN O
the NN NN O
human NN NN O
ATM NN NN O
gene NN NN O
defective NN NN O
in NN NN O
ataxia-telangiectasia NN NN B-SpecificDisease
( NN NN O
A-T NN NN B-SpecificDisease
) NN NN O
, NN NN O
has NN NN O
been NN NN O
identified NN NN O
. NN NN O

The NN NN O
entire NN NN O
coding NN NN O
sequence NN NN O
of NN NN O
the NN NN O
Atm NN NN O
transcript NN NN O
was NN NN O
cloned NN NN O
and NN NN O
found NN NN O
to NN NN O
contain NN NN O
an NN NN O
open NN NN O
reading NN NN O
frame NN NN O
encoding NN NN O
a NN NN O
protein NN NN O
of NN NN O
3066 NN NN O
amino NN NN O
acids NN NN O
with NN NN O
84 NN NN O
% NN NN O
overall NN NN O
identity NN NN O
and NN NN O
91 NN NN O
% NN NN O
similarity NN NN O
to NN NN O
the NN NN O
human NN NN O
ATM NN NN O
protein NN NN O
. NN NN O

Variable NN NN O
levels NN NN O
of NN NN O
expression NN NN O
of NN NN O
Atm NN NN O
were NN NN O
observed NN NN O
in NN NN O
different NN NN O
tissues NN NN O
. NN NN O

Fluorescence NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
and NN NN O
linkage NN NN O
analysis NN NN O
located NN NN O
the NN NN O
Atm NN NN O
gene NN NN O
on NN NN O
mouse NN NN O
chromosome NN NN O
9 NN NN O
, NN NN O
band NN NN O
9C NN NN O
, NN NN O
in NN NN O
a NN NN O
region NN NN O
homologous NN NN O
to NN NN O
the NN NN O
ATM NN NN O
region NN NN O
on NN NN O
human NN NN O
chromosome NN NN O
11q22-q23 NN NN O
. NN NN O

. NN NN O

8666397 NN NN O
The NN NN O
mouse NN NN O
homolog NN NN O
of NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-Modifier
syndrome NN NN I-Modifier
protein NN NN O
( NN NN O
WASP NN NN O
) NN NN O
gene NN NN O
is NN NN O
highly NN NN O
conserved NN NN O
and NN NN O
maps NN NN O
near NN NN O
the NN NN O
scurfy NN NN O
( NN NN O
sf NN NN O
) NN NN O
mutation NN NN O
on NN NN O
the NN NN O
X NN NN O
chromosome NN NN O
. NN NN O

The NN NN O
mouse NN NN O
WASP NN NN O
gene NN NN O
, NN NN O
the NN NN O
homolog NN NN O
of NN NN O
the NN NN O
gene NN NN O
mutated NN NN O
in NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
has NN NN O
been NN NN O
isolated NN NN O
and NN NN O
sequenced NN NN O
. NN NN O

the NN NN O
predicted NN NN O
amino NN NN O
acid NN NN O
sequence NN NN O
is NN NN O
86 NN NN O
% NN NN O
identical NN NN O
to NN NN O
the NN NN O
human NN NN O
WASP NN NN O
sequence NN NN O
. NN NN O

A NN NN O
distinct NN NN O
feature NN NN O
of NN NN O
the NN NN O
mouse NN NN O
gene NN NN O
is NN NN O
an NN NN O
expanded NN NN O
polymorphic NN NN O
GGA NN NN O
trinucleotide NN NN O
repeat NN NN O
that NN NN O
codes NN NN O
for NN NN O
polyglycine NN NN O
and NN NN O
varies NN NN O
from NN NN O
15 NN NN O
to NN NN O
17 NN NN O
triplets NN NN O
in NN NN O
different NN NN O
Mus NN NN O
musculus NN NN O
strains NN NN O
. NN NN O

The NN NN O
genomic NN NN O
structure NN NN O
of NN NN O
the NN NN O
mouse NN NN O
WASP NN NN O
gene NN NN O
is NN NN O
expressed NN NN O
as NN NN O
an NN NN O
approximately NN NN O
2 NN NN O
. NN NN O

4-kb NN NN O
mRNA NN NN O
in NN NN O
thymus NN NN O
and NN NN O
spleen NN NN O
. NN NN O

Chromosomal NN NN O
mapping NN NN O
in NN NN O
an NN NN O
interspecific NN NN O
M NN NN O
. NN NN O

Musculus NN NN O
/ NN NN O
M NN NN O
. NN NN O

spretus NN NN O
backcross NN NN O
placed NN NN O
the NN NN O
Wasp NN NN O
locus NN NN O
near NN NN O
the NN NN O
centromere NN NN O
of NN NN O
the NN NN O
mouse NN NN O
X NN NN O
chromosome NN NN O
, NN NN O
inseparable NN NN O
from NN NN O
Gata1 NN NN O
, NN NN O
Tcfe3 NN NN O
, NN NN O
and NN NN O
scurfy NN NN O
( NN NN O
sf NN NN O
) NN NN O
. NN NN O

This NN NN O
localization NN NN O
makes NN NN O
Wasp NN NN O
a NN NN O
candidate NN NN O
for NN NN O
involvement NN NN O
in NN NN O
scurfy NN NN O
, NN NN O
a NN NN O
T NN NN O
cell-mediated NN NN O
fatal NN NN B-DiseaseClass
lymphoreticular NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
of NN NN O
mice NN NN O
that NN NN O
has NN NN O
previously NN NN O
been NN NN O
proposed NN NN O
as NN NN O
a NN NN O
mouse NN NN O
homolog NN NN O
of NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Northern NN NN O
analysis NN NN O
of NN NN O
sf NN NN O
tissue NN NN O
samples NN NN O
indicated NN NN O
the NN NN O
presence NN NN O
of NN NN O
WASP NN NN O
mRNA NN NN O
in NN NN O
liver NN NN O
and NN NN O
skin NN NN O
, NN NN O
presumably NN NN O
as NN NN O
a NN NN O
consequence NN NN O
of NN NN O
lymphocytic NN NN O
infiltration NN NN O
, NN NN O
but NN NN O
non NN NN O
abnormalities NN NN O
in NN NN O
the NN NN O
amount NN NN O
or NN NN O
size NN NN O
of NN NN O
mRNA NN NN O
present NN NN O
. NN NN O

8670333 NN NN O
Colchicine NN NN O
in NN NN O
breast NN NN O
milk NN NN O
of NN NN O
patients NN NN O
with NN NN O
familial NN NN B-SpecificDisease
Mediterranean NN NN I-SpecificDisease
fever NN NN I-SpecificDisease
. NN NN O

OBJECTIVE NN NN O
. NN NN O

To NN NN O
clarify NN NN O
whether NN NN O
colchicine NN NN O
is NN NN O
excreted NN NN O
in NN NN O
breast NN NN O
milk NN NN O
, NN NN O
and NN NN O
to NN NN O
compare NN NN O
its NN NN O
concentrations NN NN O
in NN NN O
the NN NN O
serum NN NN O
and NN NN O
breast NN NN O
milk NN NN O
of NN NN O
lactating NN NN O
women NN NN O
who NN NN O
have NN NN O
familial NN NN B-SpecificDisease
Mediterranean NN NN I-SpecificDisease
fever NN NN I-SpecificDisease
( NN NN O
FMF NN NN B-SpecificDisease
) NN NN O
. NN NN O

METHODS NN NN O
. NN NN O

Using NN NN O
a NN NN O
specific NN NN O
radioimmunoassay NN NN O
, NN NN O
we NN NN O
determined NN NN O
colchicine NN NN O
concentrations NN NN O
in NN NN O
the NN NN O
serum NN NN O
and NN NN O
breast NN NN O
milk NN NN O
of NN NN O
4 NN NN O
patients NN NN O
at NN NN O
various NN NN O
time NN NN O
points NN NN O
, NN NN O
following NN NN O
oral NN NN O
administration NN NN O
of NN NN O
the NN NN O
drug NN NN O
. NN NN O

The NN NN O
study NN NN O
evaluated NN NN O
4 NN NN O
patients NN NN O
with NN NN O
FMF NN NN B-SpecificDisease
who NN NN O
had NN NN O
been NN NN O
taking NN NN O
colchicine NN NN O
on NN NN O
a NN NN O
long-term NN NN O
basis NN NN O
. NN NN O

RESULTS NN NN O
. NN NN O

Colchicine NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
excreted NN NN O
in NN NN O
breast NN NN O
milk NN NN O
. NN NN O

Its NN NN O
levels NN NN O
ranged NN NN O
between NN NN O
1 NN NN O
. NN NN O

9 NN NN O
and NN NN O
8 NN NN O
. NN NN O

6 NN NN O
ng NN NN O
/ NN NN O
ml NN NN O
, NN NN O
which NN NN O
were NN NN O
similar NN NN O
to NN NN O
those NN NN O
found NN NN O
in NN NN O
the NN NN O
serum NN NN O
( NN NN O
parallel NN NN O
concentration NN NN O
time NN NN O
curves NN NN O
) NN NN O
. NN NN O

However NN NN O
, NN NN O
there NN NN O
appeared NN NN O
to NN NN O
be NN NN O
a NN NN O
considerable NN NN O
variation NN NN O
in NN NN O
colchicine NN NN O
milk NN NN O
concentration NN NN O
among NN NN O
the NN NN O
different NN NN O
patients NN NN O
, NN NN O
which NN NN O
might NN NN O
be NN NN O
related NN NN O
to NN NN O
individual NN NN O
breast NN NN O
milk NN NN O
composition NN NN O
and NN NN O
, NN NN O
possibly NN NN O
, NN NN O
to NN NN O
other NN NN O
nutritional NN NN O
or NN NN O
metabolic NN NN O
factors NN NN O
. NN NN O

CONCLUSION NN NN O
. NN NN O

The NN NN O
extensive NN NN O
peripheral NN NN O
tissue NN NN O
binding NN NN O
and NN NN O
relatively NN NN O
low NN NN O
concentration NN NN O
of NN NN O
colchicine NN NN O
in NN NN O
breast NN NN O
milk NN NN O
suggests NN NN O
that NN NN O
the NN NN O
amount NN NN O
ingested NN NN O
by NN NN O
the NN NN O
infant NN NN O
is NN NN O
small NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
based NN NN O
on NN NN O
our NN NN O
clinical NN NN O
experience NN NN O
, NN NN O
nursing NN NN O
appears NN NN O
to NN NN O
be NN NN O
safe NN NN O
for NN NN O
lactating NN NN O
women NN NN O
with NN NN O
FMF NN NN B-SpecificDisease
who NN NN O
continue NN NN O
to NN NN O
take NN NN O
colchicine NN NN O
. NN NN O

8673131 NN NN O
Abnormal NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
protein NN NN O
kinase NN NN O
levels NN NN O
produce NN NN O
only NN NN O
mild NN NN O
myopathy NN NN B-DiseaseClass
in NN NN O
mice NN NN O
. NN NN O

Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
is NN NN O
commonly NN NN O
associated NN NN O
with NN NN O
CTG NN NN O
repeat NN NN O
expansions NN NN O
within NN NN O
the NN NN O
gene NN NN O
for NN NN O
DM-protein NN NN O
kinase NN NN O
( NN NN O
DMPK NN NN O
) NN NN O
. NN NN O

The NN NN O
effect NN NN O
of NN NN O
altered NN NN O
expression NN NN O
levels NN NN O
of NN NN O
DMPK NN NN O
, NN NN O
which NN NN O
is NN NN O
ubiquitously NN NN O
expressed NN NN O
in NN NN O
all NN NN O
muscle NN NN O
cell NN NN O
lineages NN NN O
during NN NN O
development NN NN O
, NN NN O
was NN NN O
examined NN NN O
by NN NN O
disrupting NN NN O
the NN NN O
endogenous NN NN O
Dmpk NN NN O
gene NN NN O
and NN NN O
overexpressing NN NN O
a NN NN O
normal NN NN O
human NN NN O
DMPK NN NN O
transgene NN NN O
in NN NN O
mice NN NN O
. NN NN O

Nullizygous NN NN O
( NN NN O
- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
showed NN NN O
only NN NN O
inconsistent NN NN O
and NN NN O
minor NN NN O
size NN NN O
changes NN NN O
in NN NN O
head NN NN O
and NN NN O
neck NN NN O
muscle NN NN O
fibres NN NN O
at NN NN O
older NN NN O
age NN NN O
, NN NN O
animals NN NN O
with NN NN O
the NN NN O
highest NN NN O
DMPK NN NN O
transgene NN NN O
expression NN NN O
showed NN NN O
hypertrophic NN NN B-SpecificDisease
cardiomyopathy NN NN I-SpecificDisease
and NN NN O
enhanced NN NN O
neonatal NN NN O
mortality NN NN O
. NN NN O

However NN NN O
, NN NN O
both NN NN O
models NN NN O
lack NN NN O
other NN NN O
frequent NN NN O
DM NN NN B-Modifier
symptoms NN NN O
including NN NN O
the NN NN O
fibre-type NN NN O
dependent NN NN O
atrophy NN NN B-SpecificDisease
, NN NN O
myotonia NN NN B-SpecificDisease
, NN NN O
cataract NN NN B-SpecificDisease
and NN NN O
male-infertility NN NN B-SpecificDisease
. NN NN O

These NN NN O
results NN NN O
strengthen NN NN O
the NN NN O
contention NN NN O
that NN NN O
simple NN NN O
loss- NN NN O
or NN NN O
gain-of-expression NN NN O
of NN NN O
DMPK NN NN O
is NN NN O
not NN NN O
the NN NN O
only NN NN O
crucial NN NN O
requirement NN NN O
for NN NN O
development NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O

. NN NN O

8673132 NN NN O
Mice NN NN O
lacking NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
protein NN NN O
kinase NN NN O
develop NN NN O
a NN NN O
late NN NN O
onset NN NN O
progressive NN NN O
myopathy NN NN B-SpecificDisease
. NN NN O

Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
resulting NN NN O
from NN NN O
the NN NN O
expansion NN NN O
of NN NN O
a NN NN O
CTG NN NN O
repeat NN NN O
in NN NN O
the NN NN O
3 NN NN O
untranslated NN NN O
region NN NN O
of NN NN O
a NN NN O
putative NN NN O
protein NN NN O
kinase NN NN O
( NN NN O
DMPK NN NN O
) NN NN O
. NN NN O

To NN NN O
elucidate NN NN O
the NN NN O
role NN NN O
of NN NN O
DMPK NN NN O
in NN NN O
DM NN NN B-Modifier
pathogenesis NN NN O
we NN NN O
have NN NN O
developed NN NN O
Dmpk NN NN O
deficient NN NN O
( NN NN O
Dmpk- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
. NN NN O

Dmpk- NN NN O
/ NN NN O
-mice NN NN O
develop NN NN O
a NN NN O
late-onset NN NN O
, NN NN O
progressive NN NN B-SpecificDisease
skeletal NN NN I-SpecificDisease
myopathy NN NN I-SpecificDisease
that NN NN O
shares NN NN O
some NN NN O
pathological NN NN O
features NN NN O
with NN NN O
DM NN NN B-SpecificDisease
. NN NN O

Muscles NN NN O
from NN NN O
mature NN NN O
mice NN NN O
show NN NN O
variation NN NN O
in NN NN O
fibre NN NN O
size NN NN O
, NN NN O
increased NN NN O
fibre NN NN B-SpecificDisease
degeneration NN NN I-SpecificDisease
and NN NN O
fibrosis NN NN B-SpecificDisease
. NN NN O

Adult NN NN O
Dmpk- NN NN O
/ NN NN O
-mice NN NN O
show NN NN O
ultrastructural NN NN O
changes NN NN O
in NN NN O
muscle NN NN O
and NN NN O
a NN NN O
50 NN NN O
% NN NN O
decrease NN NN O
in NN NN O
force NN NN O
generation NN NN O
compared NN NN O
to NN NN O
young NN NN O
mice NN NN O
. NN NN O

Our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
DMPK NN NN O
may NN NN O
be NN NN O
necessary NN NN O
for NN NN O
the NN NN O
maintenance NN NN O
of NN NN O
skeletal NN NN O
muscle NN NN O
structure NN NN O
and NN NN O
function NN NN O
and NN NN O
suggest NN NN O
that NN NN O
a NN NN O
decrease NN NN O
in NN NN O
DMPK NN NN O
levels NN NN O
may NN NN O
contribute NN NN O
to NN NN O
DM NN NN B-Modifier
pathology NN NN O
. NN NN O

. NN NN O

8674108 NN NN O
The NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
gene NN NN O
Brca1 NN NN O
is NN NN O
required NN NN O
for NN NN O
embryonic NN NN O
cellular NN NN O
proliferation NN NN O
in NN NN O
the NN NN O
mouse NN NN O
. NN NN O

Mutations NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
gone NN NN O
in NN NN O
humans NN NN O
are NN NN O
associated NN NN O
with NN NN O
predisposition NN NN O
to NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancers NN NN I-CompositeMention
. NN NN O

We NN NN O
show NN NN O
here NN NN O
that NN NN O
Brca1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
mice NN NN O
are NN NN O
normal NN NN O
and NN NN O
fertile NN NN O
and NN NN O
lack NN NN O
tumors NN NN B-DiseaseClass
by NN NN O
age NN NN O
eleven NN NN O
months NN NN O
. NN NN O

Homozygous NN NN O
Brca1 NN NN O
( NN NN O
5-6 NN NN O
) NN NN O
mutant NN NN O
mice NN NN O
die NN NN O
before NN NN O
day NN NN O
7 NN NN O
. NN NN O

5 NN NN O
of NN NN O
embryogenesis NN NN O
. NN NN O

Mutant NN NN O
embryos NN NN O
are NN NN O
poorly NN NN O
developed NN NN O
, NN NN O
with NN NN O
no NN NN O
evidence NN NN O
of NN NN O
mesoderm NN NN O
formation NN NN O
. NN NN O

The NN NN O
extraembryonic NN NN O
region NN NN O
is NN NN O
abnormal NN NN O
, NN NN O
but NN NN O
aggregation NN NN O
with NN NN O
wild-type NN NN O
tetraploid NN NN O
embryos NN NN O
does NN NN O
not NN NN O
rescue NN NN O
the NN NN O
lethality NN NN O
. NN NN O

In NN NN O
vivo NN NN O
, NN NN O
mutant NN NN O
embryos NN NN O
do NN NN O
not NN NN O
exhibit NN NN O
increased NN NN O
apoptosis NN NN O
but NN NN O
show NN NN O
reduced NN NN O
cell NN NN O
proliferation NN NN O
accompanied NN NN O
by NN NN O
decreased NN NN O
expression NN NN O
of NN NN O
cyclin NN NN O
E NN NN O
and NN NN O
mdm-2 NN NN O
, NN NN O
a NN NN O
regulator NN NN O
of NN NN O
p53 NN NN O
activity NN NN O
. NN NN O

The NN NN O
expression NN NN O
of NN NN O
cyclin-dependent NN NN O
kinase NN NN O
inhibitor NN NN O
p21 NN NN O
is NN NN O
dramatically NN NN O
increased NN NN O
in NN NN O
the NN NN O
mutant NN NN O
embryos NN NN O
. NN NN O

Buttressing NN NN O
these NN NN O
in NN NN O
vivo NN NN O
observations NN NN O
is NN NN O
the NN NN O
fact NN NN O
that NN NN O
mutant NN NN O
blastocyst NN NN O
growth NN NN O
is NN NN O
grossly NN NN O
impaired NN NN O
in NN NN O
vitro NN NN O
. NN NN O

Thus NN NN O
, NN NN O
the NN NN O
death NN NN O
of NN NN O
Brca1 NN NN O
( NN NN O
5-6 NN NN O
) NN NN O
mutant NN NN O
embryos NN NN O
prior NN NN O
to NN NN O
gastrulation NN NN O
may NN NN O
be NN NN O
due NN NN O
to NN NN O
a NN NN O
failure NN NN O
of NN NN O
the NN NN O
proliferative NN NN O
burst NN NN O
required NN NN O
for NN NN O
the NN NN O
development NN NN O
of NN NN O
the NN NN O
different NN NN O
germ NN NN O
layers NN NN O
. NN NN O

8675707 NN NN O
Increased NN NN O
coronary NN NN B-SpecificDisease
heart NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
in NN NN O
Japanese-American NN NN O
men NN NN O
with NN NN O
mutation NN NN O
in NN NN O
the NN NN O
cholesteryl NN NN O
ester NN NN O
transfer NN NN O
protein NN NN O
gene NN NN O
despite NN NN O
increased NN NN O
HDL NN NN O
levels NN NN O
. NN NN O

Plasma NN NN O
high NN NN O
density NN NN O
lipoprotein NN NN O
( NN NN O
HDL NN NN O
) NN NN O
levels NN NN O
are NN NN O
strongly NN NN O
genetically NN NN O
determined NN NN O
and NN NN O
show NN NN O
a NN NN O
general NN NN O
inverse NN NN O
relationship NN NN O
with NN NN O
coronary NN NN B-SpecificDisease
heart NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
CHD NN NN B-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
cholesteryl NN NN O
ester NN NN O
transfer NN NN O
protein NN NN O
( NN NN O
CETP NN NN O
) NN NN O
mediates NN NN O
the NN NN O
transfer NN NN O
of NN NN O
cholesteryl NN NN O
esters NN NN O
from NN NN O
HDL NN NN O
to NN NN O
other NN NN O
lipoproteins NN NN O
and NN NN O
is NN NN O
a NN NN O
key NN NN O
participant NN NN O
in NN NN O
the NN NN O
reverse NN NN O
transport NN NN O
of NN NN O
cholesterol NN NN O
from NN NN O
the NN NN O
periphery NN NN O
to NN NN O
the NN NN O
liver NN NN O
. NN NN O

A NN NN O
high NN NN O
prevalence NN NN O
of NN NN O
two NN NN O
different NN NN O
CETP NN NN O
gene NN NN O
mutations NN NN O
( NN NN O
D442G NN NN O
, NN NN O
5 NN NN O
. NN NN O

1 NN NN O
% NN NN O
; NN NN O
intron NN NN O
14G NN NN O
A NN NN O
, NN NN O
0 NN NN O
. NN NN O

5 NN NN O
% NN NN O
) NN NN O
, NN NN O
was NN NN O
found NN NN O
in NN NN O
3 NN NN O
, NN NN O
469 NN NN O
men NN NN O
of NN NN O
Japanese NN NN O
ancestry NN NN O
in NN NN O
the NN NN O
Honolulu NN NN O
Heart NN NN O
Program NN NN O
and NN NN O
mutations NN NN O
were NN NN O
associated NN NN O
with NN NN O
decreased NN NN O
CETP NN NN O
( NN NN O
-35 NN NN O
% NN NN O
) NN NN O
and NN NN O
increased NN NN O
HDL NN NN O
chol NN NN O
levels NN NN O
( NN NN O
+ NN NN O
10 NN NN O
% NN NN O
for NN NN O
D442G NN NN O
) NN NN O
. NN NN O

However NN NN O
, NN NN O
the NN NN O
overall NN NN O
prevalence NN NN O
of NN NN O
definite NN NN O
CHD NN NN B-SpecificDisease
was NN NN O
21 NN NN O
% NN NN O
in NN NN O
men NN NN O
with NN NN O
mutations NN NN O
and NN NN O
16 NN NN O
% NN NN O
in NN NN O
men NN NN O
without NN NN O
mutations NN NN O
. NN NN O

The NN NN O
relative NN NN O
risk NN NN O
( NN NN O
RR NN NN O
) NN NN O
of NN NN O
CHD NN NN B-SpecificDisease
was NN NN O
1 NN NN O
. NN NN O

43 NN NN O
in NN NN O
men NN NN O
with NN NN O
mutations NN NN O
( NN NN O
P NN NN O
. NN NN O

05 NN NN O
) NN NN O
; NN NN O
after NN NN O
adjustment NN NN O
for NN NN O
CHD NN NN B-Modifier
risk NN NN O
factors NN NN O
, NN NN O
the NN NN O
RR NN NN O
was NN NN O
1 NN NN O
. NN NN O

55 NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O

02 NN NN O
) NN NN O
; NN NN O
after NN NN O
additional NN NN O
adjustment NN NN O
for NN NN O
HDL NN NN O
levels NN NN O
, NN NN O
the NN NN O
RR NN NN O
was NN NN O
1 NN NN O
. NN NN O

68 NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O

008 NN NN O
) NN NN O
. NN NN O

Similar NN NN O
RR NN NN O
values NN NN O
were NN NN O
obtained NN NN O
for NN NN O
the NN NN O
D442G NN NN O
mutation NN NN O
alone NN NN O
. NN NN O

Increased NN NN O
CHD NN NN B-SpecificDisease
in NN NN O
men NN NN O
with NN NN O
mutations NN NN O
was NN NN O
primarily NN NN O
observed NN NN O
for NN NN O
HDL NN NN O
chol NN NN O
41-60 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
; NN NN O
for NN NN O
HDL NN NN O
chol NN NN O
60 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
men NN NN O
with NN NN O
and NN NN O
without NN NN O
mutations NN NN O
had NN NN O
low NN NN O
CHD NN NN B-SpecificDisease
prevalence NN NN O
. NN NN O

Thus NN NN O
, NN NN O
genetic NN NN O
CETP NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
appears NN NN O
to NN NN O
be NN NN O
an NN NN O
independent NN NN O
risk NN NN O
factor NN NN O
for NN NN O
CHD NN NN B-SpecificDisease
, NN NN O
primarily NN NN O
due NN NN O
to NN NN O
increased NN NN O
CHD NN NN B-Modifier
prevalence NN NN O
in NN NN O
men NN NN O
with NN NN O
the NN NN O
D442G NN NN O
mutation NN NN O
and NN NN O
HDL NN NN O
cholesterol NN NN O
between NN NN O
41 NN NN O
and NN NN O
60 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
. NN NN O

The NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
both NN NN O
HDL NN NN O
concentration NN NN O
and NN NN O
the NN NN O
dynamics NN NN O
of NN NN O
cholesterol NN NN O
transport NN NN O
through NN NN O
HDL NN NN O
( NN NN O
i NN NN O
. NN NN O

e. NN NN O
, NN NN O
reverse NN NN O
cholesterol NN NN O
transport NN NN O
) NN NN O
determine NN NN O
the NN NN O
anti-atherogenicity NN NN O
of NN NN O
the NN NN O
HDL NN NN O
fraction NN NN O
. NN NN O

8678979 NN NN O
Mapping NN NN O
the NN NN O
homolog NN NN O
of NN NN O
the NN NN O
human NN NN O
Rb1 NN NN O
gene NN NN O
to NN NN O
chromosome NN NN O
14 NN NN O
of NN NN O
higher NN NN O
primates NN NN O
. NN NN O

The NN NN O
Rb1 NN NN O
gene NN NN O
has NN NN O
been NN NN O
implicated NN NN O
with NN NN O
retinoblastoma NN NN B-SpecificDisease
and NN NN O
is NN NN O
located NN NN O
on NN NN O
human NN NN O
Chromosome NN NN O
( NN NN O
Chr NN NN O
) NN NN O
13q14 NN NN O
. NN NN O

2 NN NN O
2 NN NN O
. NN NN O

A NN NN O
unique NN NN O
sequence NN NN O
human NN NN O
Rb1 NN NN O
cosmid NN NN O
DNA NN NN O
probe NN NN O
has NN NN O
been NN NN O
used NN NN O
to NN NN O
localize NN NN O
this NN NN O
region NN NN O
on NN NN O
apes NN NN O
Chr NN NN O
14 NN NN O
by NN NN O
the NN NN O
FISH NN NN O
technique NN NN O
. NN NN O

The NN NN O
conservation NN NN O
of NN NN O
the NN NN O
Rb1 NN NN O
gene NN NN O
in NN NN O
higher NN NN O
primates NN NN O
at NN NN O
the NN NN O
corresponding NN NN O
equivalent NN NN O
chromosome NN NN O
locus NN NN O
( NN NN O
14q14 NN NN O
) NN NN O
of NN NN O
the NN NN O
human NN NN O
may NN NN O
serve NN NN O
as NN NN O
a NN NN O
phylogenetic NN NN O
marker NN NN O
to NN NN O
further NN NN O
trace NN NN O
the NN NN O
evolutionary NN NN O
pathway NN NN O
of NN NN O
human NN NN O
descent NN NN O
. NN NN O

8682510 NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
: NN NN O
no NN NN O
strict NN NN O
genotype-phenotype NN NN O
correlations NN NN O
but NN NN O
clustering NN NN O
of NN NN O
missense NN NN O
mutations NN NN O
in NN NN O
the NN NN O
amino-terminal NN NN O
part NN NN O
of NN NN O
the NN NN O
WASP NN NN O
gene NN NN O
product NN NN O
. NN NN O

The NN NN O
Wiskott-Aldrich NN NN B-Modifier
syndrome NN NN I-Modifier
protein NN NN O
( NN NN O
WASP NN NN O
) NN NN O
gene NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
mutated NN NN O
in NN NN O
patients NN NN O
presenting NN NN O
with NN NN O
WAS NN NN B-SpecificDisease
and NN NN O
in NN NN O
patients NN NN O
showing NN NN O
X-linked NN NN B-SpecificDisease
thrombocytopenia NN NN I-SpecificDisease
. NN NN O

Mutation NN NN O
analysis NN NN O
in NN NN O
19 NN NN O
families NN NN O
of NN NN O
German NN NN O
, NN NN O
Swiss NN NN O
and NN NN O
Turkish NN NN O
descent NN NN O
by NN NN O
single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
and NN NN O
sequencing NN NN O
resulted NN NN O
in NN NN O
the NN NN O
detection NN NN O
of NN NN O
seven NN NN O
novel NN NN O
and NN NN O
10 NN NN O
known NN NN O
mutations NN NN O
. NN NN O

A NN NN O
striking NN NN O
clustering NN NN O
of NN NN O
missense NN NN O
mutations NN NN O
in NN NN O
the NN NN O
first NN NN O
four NN NN O
exons NN NN O
contrasted NN NN O
with NN NN O
a NN NN O
random NN NN O
distribution NN NN O
of NN NN O
nonsense NN NN O
mutations NN NN O
. NN NN O

More NN NN O
than NN NN O
85 NN NN O
% NN NN O
of NN NN O
all NN NN O
known NN NN O
missense NN NN O
mutations NN NN O
were NN NN O
localized NN NN O
in NN NN O
the NN NN O
amino-terminal NN NN O
stretch NN NN O
of NN NN O
the NN NN O
WASP NN NN O
gene NN NN O
product NN NN O
; NN NN O
this NN NN O
region NN NN O
contained NN NN O
a NN NN O
mutational NN NN O
hot NN NN O
spot NN NN O
at NN NN O
codon NN NN O
86 NN NN O
. NN NN O

No NN NN O
genotype-phenotype NN NN O
correlation NN NN O
emerged NN NN O
after NN NN O
a NN NN O
comparison NN NN O
of NN NN O
the NN NN O
identified NN NN O
mutations NN NN O
with NN NN O
the NN NN O
resulting NN NN O
clinical NN NN O
picture NN NN O
for NN NN O
a NN NN O
classical NN NN O
WAS NN NN B-Modifier
phenotype NN NN O
. NN NN O

A NN NN O
substitution NN NN O
at NN NN O
codon NN NN O
86 NN NN O
resulted NN NN O
in NN NN O
an NN NN O
extremely NN NN O
variable NN NN O
expression NN NN O
of NN NN O
the NN NN O
disease NN NN O
in NN NN O
a NN NN O
large NN NN O
Swiss NN NN O
family NN NN O
. NN NN O

An NN NN O
extended NN NN O
homology NN NN O
search NN NN O
revealed NN NN O
a NN NN O
distant NN NN O
relationship NN NN O
of NN NN O
this NN NN O
stretch NN NN O
to NN NN O
the NN NN O
vasodilator-stimulated NN NN O
phosphoprotein NN NN O
( NN NN O
VASP NN NN O
) NN NN O
, NN NN O
which NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
maintenance NN NN O
of NN NN O
cyto-architecture NN NN O
by NN NN O
interacting NN NN O
with NN NN O
actin-like NN NN O
filaments NN NN O
. NN NN O

. NN NN O

8689689 NN NN O
Influence NN NN O
of NN NN O
PAX6 NN NN O
gene NN NN O
dosage NN NN O
on NN NN O
development NN NN O
: NN NN O
overexpression NN NN O
causes NN NN O
severe NN NN O
eye NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
. NN NN O

Aniridia NN NN B-SpecificDisease
in NN NN O
man NN NN O
and NN NN O
Small NN NN O
eye NN NN O
in NN NN O
mice NN NN O
are NN NN O
semidominant NN NN B-DiseaseClass
developmental NN NN I-DiseaseClass
disorders NN NN I-DiseaseClass
caused NN NN O
by NN NN O
mutations NN NN O
within NN NN O
the NN NN O
paired NN NN O
box NN NN O
gene NN NN O
PAX6 NN NN O
. NN NN O

Whereas NN NN O
heterozygotes NN NN O
suffer NN NN O
from NN NN O
iris NN NN B-SpecificDisease
hypoplasia NN NN I-SpecificDisease
, NN NN O
homozygous NN NN O
mice NN NN O
lack NN NN O
eyes NN NN O
and NN NN O
nasal NN NN O
cavities NN NN O
and NN NN O
exhibit NN NN O
brain NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
. NN NN O

To NN NN O
investigate NN NN O
the NN NN O
role NN NN O
of NN NN O
gene NN NN O
dosage NN NN O
in NN NN O
more NN NN O
detail NN NN O
, NN NN O
we NN NN O
have NN NN O
generated NN NN O
yeast NN NN O
artificial NN NN O
chromosome NN NN O
transgenic NN NN O
mice NN NN O
carrying NN NN O
the NN NN O
human NN NN O
PAX6 NN NN O
locus NN NN O
. NN NN O

When NN NN O
crossed NN NN O
onto NN NN O
the NN NN O
Small NN NN O
eye NN NN O
background NN NN O
, NN NN O
the NN NN O
transgene NN NN O
rescues NN NN O
the NN NN O
mutant NN NN O
phenotype NN NN O
. NN NN O

Strikingly NN NN O
, NN NN O
mice NN NN O
carrying NN NN O
multiple NN NN O
copies NN NN O
on NN NN O
a NN NN O
wild-type NN NN O
background NN NN O
show NN NN O
specific NN NN O
developmental NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
of NN NN I-DiseaseClass
the NN NN I-DiseaseClass
eye NN NN I-DiseaseClass
, NN NN O
but NN NN O
not NN NN O
of NN NN O
other NN NN O
tissues NN NN O
expressing NN NN O
the NN NN O
gene NN NN O
. NN NN O

Thus NN NN O
, NN NN O
at NN NN O
least NN NN O
five NN NN O
different NN NN O
eye NN NN O
phenotypes NN NN O
are NN NN O
associated NN NN O
with NN NN O
changes NN NN O
in NN NN O
PAX6 NN NN O
expression NN NN O
. NN NN O

We NN NN O
provide NN NN O
evidence NN NN O
that NN NN O
not NN NN O
only NN NN O
reduced NN NN O
, NN NN O
but NN NN O
also NN NN O
increased NN NN O
levels NN NN O
of NN NN O
transcriptional NN NN O
regulators NN NN O
can NN NN O
cause NN NN O
developmental NN NN B-DiseaseClass
defects NN NN I-DiseaseClass
. NN NN O

. NN NN O

8692963 NN NN O
Heterodimer NN NN O
formation NN NN O
and NN NN O
activity NN NN O
in NN NN O
the NN NN O
human NN NN O
enzyme NN NN O
galactose-1-phosphate NN NN O
uridylyltransferase NN NN O
. NN NN O

One NN NN O
of NN NN O
the NN NN O
fundamental NN NN O
questions NN NN O
concerning NN NN O
expression NN NN O
and NN NN O
function NN NN O
of NN NN O
dimeric NN NN O
enzymes NN NN O
involves NN NN O
the NN NN O
impact NN NN O
of NN NN O
naturally NN NN O
occurring NN NN O
mutations NN NN O
on NN NN O
subunit NN NN O
assembly NN NN O
and NN NN O
heterodimer NN NN O
activity NN NN O
. NN NN O

This NN NN O
question NN NN O
is NN NN O
of NN NN O
particular NN NN O
interest NN NN O
for NN NN O
the NN NN O
human NN NN O
enzyme NN NN O
galactose-l-phosphate NN NN O
uridylyl-transferase NN NN O
( NN NN O
GALT NN NN O
) NN NN O
, NN NN O
impairment NN NN O
of NN NN O
which NN NN O
results NN NN O
in NN NN O
the NN NN O
inherited NN NN B-DiseaseClass
metabolic NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
galactosemia NN NN B-SpecificDisease
, NN NN O
because NN NN O
many NN NN O
if NN NN O
not NN NN O
most NN NN O
patients NN NN O
studied NN NN O
to NN NN O
date NN NN O
are NN NN O
compound NN NN O
heterozygotes NN NN O
rather NN NN O
than NN NN O
true NN NN O
molecular NN NN O
homozygotes NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
the NN NN O
broad NN NN O
range NN NN O
of NN NN O
phenotypic NN NN O
severity NN NN O
observed NN NN O
in NN NN O
these NN NN O
patients NN NN O
raises NN NN O
the NN NN O
possibility NN NN O
that NN NN O
allelic NN NN O
combination NN NN O
, NN NN O
not NN NN O
just NN NN O
allelic NN NN O
constitution NN NN O
, NN NN O
may NN NN O
play NN NN O
some NN NN O
role NN NN O
in NN NN O
determining NN NN O
outcome NN NN O
. NN NN O

In NN NN O
the NN NN O
work NN NN O
described NN NN O
herein NN NN O
, NN NN O
we NN NN O
have NN NN O
selected NN NN O
two NN NN O
distinct NN NN O
naturally NN NN O
occurring NN NN O
null NN NN O
mutations NN NN O
of NN NN O
GALT NN NN O
, NN NN O
Q188R NN NN O
and NN NN O
R333W NN NN O
, NN NN O
and NN NN O
asked NN NN O
the NN NN O
questions NN NN O
( NN NN O
i NN NN O
) NN NN O
what NN NN O
are NN NN O
the NN NN O
impacts NN NN O
of NN NN O
these NN NN O
mutations NN NN O
on NN NN O
subunit NN NN O
assembly NN NN O
, NN NN O
and NN NN O
( NN NN O
ii NN NN O
) NN NN O
if NN NN O
heterodimers NN NN O
do NN NN O
form NN NN O
, NN NN O
are NN NN O
they NN NN O
active NN NN O
? NN NN O

To NN NN O
answer NN NN O
these NN NN O
questions NN NN O
, NN NN O
we NN NN O
have NN NN O
established NN NN O
a NN NN O
yeast NN NN O
system NN NN O
for NN NN O
the NN NN O
coexpression NN NN O
of NN NN O
epitope-tagged NN NN O
alleles NN NN O
of NN NN O
human NN NN O
GALT NN NN O
and NN NN O
investigated NN NN O
both NN NN O
the NN NN O
extent NN NN O
of NN NN O
specific NN NN O
GALT NN NN O
subunit NN NN O
interactions NN NN O
and NN NN O
the NN NN O
activity NN NN O
of NN NN O
defined NN NN O
heterodimer NN NN O
pools NN NN O
. NN NN O

We NN NN O
have NN NN O
found NN NN O
that NN NN O
both NN NN O
homodimers NN NN O
and NN NN O
heterodimers NN NN O
do NN NN O
form NN NN O
involving NN NN O
each NN NN O
of NN NN O
the NN NN O
mutant NN NN O
subunits NN NN O
tested NN NN O
and NN NN O
that NN NN O
both NN NN O
heterodimer NN NN O
pools NN NN O
retain NN NN O
substantial NN NN O
enzymatic NN NN O
activity NN NN O
. NN NN O

These NN NN O
results NN NN O
are NN NN O
significant NN NN O
not NN NN O
only NN NN O
in NN NN O
terms NN NN O
of NN NN O
their NN NN O
implications NN NN O
for NN NN O
furthering NN NN O
our NN NN O
understanding NN NN O
of NN NN O
galactosemia NN NN B-SpecificDisease
and NN NN O
GALT NN NN O
holoenzyme NN NN O
structure-function NN NN O
relationships NN NN O
but NN NN O
also NN NN O
because NN NN O
the NN NN O
system NN NN O
described NN NN O
may NN NN O
serve NN NN O
as NN NN O
a NN NN O
model NN NN O
for NN NN O
similar NN NN O
studies NN NN O
of NN NN O
other NN NN O
complexes NN NN O
composed NN NN O
of NN NN O
multiple NN NN O
subunits NN NN O
. NN NN O

. NN NN O

8696339 NN NN O
Cleavage NN NN O
of NN NN O
huntingtin NN NN O
by NN NN O
apopain NN NN O
, NN NN O
a NN NN O
proapoptotic NN NN O
cysteine NN NN O
protease NN NN O
, NN NN O
is NN NN O
modulated NN NN O
by NN NN O
the NN NN O
polyglutamine NN NN O
tract NN NN O
. NN NN O

Apoptosis NN NN O
has NN NN O
recently NN NN O
been NN NN O
recognized NN NN O
as NN NN O
a NN NN O
mode NN NN O
of NN NN O
cell NN NN O
death NN NN O
in NN NN O
Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
HD NN NN B-SpecificDisease
) NN NN O
. NN NN O

Apopain NN NN O
, NN NN O
a NN NN O
human NN NN O
counterpart NN NN O
of NN NN O
the NN NN O
nematode NN NN O
cysteine NN NN O
protease NN NN O
death-gene NN NN O
product NN NN O
, NN NN O
CED-3 NN NN O
, NN NN O
has NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
proteolytic NN NN O
events NN NN O
leading NN NN O
to NN NN O
apoptosis NN NN O
. NN NN O

Here NN NN O
we NN NN O
show NN NN O
that NN NN O
apoptotic NN NN O
extracts NN NN O
and NN NN O
apopain NN NN O
itself NN NN O
specifically NN NN O
cleave NN NN O
the NN NN O
HD NN NN B-Modifier
gene NN NN O
product NN NN O
, NN NN O
huntingtin NN NN O
. NN NN O

The NN NN O
rate NN NN O
of NN NN O
cleavage NN NN O
increases NN NN O
with NN NN O
the NN NN O
length NN NN O
of NN NN O
the NN NN O
huntingtin NN NN O
polyglutamine NN NN O
tract NN NN O
, NN NN O
providing NN NN O
an NN NN O
explanation NN NN O
for NN NN O
the NN NN O
gain-of-function NN NN O
associated NN NN O
with NN NN O
CAG NN NN O
expansion NN NN O
. NN NN O

Our NN NN O
results NN NN O
show NN NN O
that NN NN O
huntingtin NN NN O
is NN NN O
cleaved NN NN O
by NN NN O
cysteine NN NN O
proteases NN NN O
and NN NN O
suggest NN NN O
that NN NN O
HD NN NN B-SpecificDisease
might NN NN O
be NN NN O
a NN NN O
disorder NN NN B-DiseaseClass
of NN NN I-DiseaseClass
inappropriate NN NN I-DiseaseClass
apoptosis NN NN I-DiseaseClass
. NN NN O

. NN NN O

8700509 NN NN O
The NN NN O
5 NN NN O
' NN NN O
end NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
lies NN NN O
within NN NN O
a NN NN O
duplicated NN NN O
region NN NN O
of NN NN O
human NN NN O
chromosome NN NN O
17q21 NN NN O
. NN NN O

To NN NN O
begin NN NN O
to NN NN O
address NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
abnormal NN NN O
regulation NN NN O
of NN NN O
the NN NN O
breast NN NN B-Modifier
/ NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
susceptibility NN NN O
gene NN NN O
BRCA1 NN NN O
is NN NN O
a NN NN O
critical NN NN O
step NN NN O
in NN NN O
sporadic NN NN O
breast NN NN O
/ NN NN O
ovarian NN NN O
tumorigenesis NN NN O
, NN NN O
we NN NN O
have NN NN O
determined NN NN O
the NN NN O
detailed NN NN O
structure NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
genomic NN NN O
region NN NN O
. NN NN O

We NN NN O
show NN NN O
that NN NN O
this NN NN O
region NN NN O
of NN NN O
the NN NN O
genome NN NN O
contains NN NN O
a NN NN O
tandem NN NN O
duplication NN NN O
of NN NN O
approximately NN NN O
30 NN NN O
kilobases NN NN O
, NN NN O
which NN NN O
results NN NN O
in NN NN O
two NN NN O
copies NN NN O
of NN NN O
BRCA1 NN NN O
exons NN NN O
1 NN NN O
and NN NN O
2 NN NN O
, NN NN O
of NN NN O
exons NN NN O
1 NN NN O
and NN NN O
3 NN NN O
of NN NN O
the NN NN O
adjacent NN NN O
1A1-3B NN NN O
gene NN NN O
and NN NN O
of NN NN O
the NN NN O
previously NN NN O
reported NN NN O
295 NN NN O
base NN NN O
pair NN NN O
intergenic NN NN O
region NN NN O
. NN NN O

Sequence NN NN O
analysis NN NN O
of NN NN O
the NN NN O
duplicated NN NN O
exons NN NN O
of NN NN O
BRCA1 NN NN O
and NN NN O
1A1-3B NN NN O
and NN NN O
flanking NN NN O
genomic NN NN O
DNA NN NN O
reveals NN NN O
maintenance NN NN O
of NN NN O
the NN NN O
intron-exon NN NN O
structure NN NN O
and NN NN O
a NN NN O
high NN NN O
degree NN NN O
of NN NN O
nucleotide NN NN O
sequence NN NN O
identity NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
these NN NN O
are NN NN O
non-processed NN NN O
pseudogenes NN NN O
and NN NN O
that NN NN O
the NN NN O
duplication NN NN O
is NN NN O
a NN NN O
recent NN NN O
event NN NN O
in NN NN O
evolutionary NN NN O
terms NN NN O
. NN NN O

We NN NN O
also NN NN O
show NN NN O
that NN NN O
a NN NN O
processed NN NN O
pseudogene NN NN O
of NN NN O
the NN NN O
acidic NN NN O
ribosomal NN NN O
phosphoprotein NN NN O
P1 NN NN O
( NN NN O
ARPP1 NN NN O
) NN NN O
is NN NN O
inserted NN NN O
directly NN NN O
upstream NN NN O
of NN NN O
pseudo-BRCA1 NN NN O
exon NN NN O
1A NN NN O
. NN NN O

We NN NN O
believe NN NN O
that NN NN O
these NN NN O
findings NN NN O
could NN NN O
not NN NN O
only NN NN O
confound NN NN O
BRCA1 NN NN O
mutation NN NN O
analysis NN NN O
, NN NN O
but NN NN O
could NN NN O
have NN NN O
implications NN NN O
for NN NN O
the NN NN O
normal NN NN O
and NN NN O
abnormal NN NN O
regulation NN NN O
of NN NN O
BRCA1 NN NN O
transcription NN NN O
, NN NN O
translation NN NN O
and NN NN O
function NN NN O
. NN NN O

. NN NN O

8723064 NN NN O
Deletion NN NN O
of NN NN O
small NN NN O
nuclear NN NN O
ribonucleoprotein NN NN O
polypeptide NN NN O
N NN NN O
( NN NN O
SNRPN NN NN O
) NN NN O
in NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
detected NN NN O
by NN NN O
fluorescence NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
: NN NN O
two NN NN O
sibs NN NN O
with NN NN O
the NN NN O
typical NN NN O
phenotype NN NN O
without NN NN O
a NN NN O
cytogenetic NN NN O
deletion NN NN O
in NN NN O
chromosome NN NN O
15q NN NN O
. NN NN O

The NN NN O
small NN NN O
nuclear NN NN O
ribonucleoprotein NN NN O
polypeptide NN NN O
N NN NN O
( NN NN O
SNRPN NN NN O
) NN NN O
gene NN NN O
is NN NN O
regarded NN NN O
as NN NN O
one NN NN O
of NN NN O
the NN NN O
candidates NN NN O
for NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
. NN NN O

We NN NN O
describe NN NN O
two NN NN O
sibs NN NN O
with NN NN O
typical NN NN O
PWS NN NN B-SpecificDisease
presenting NN NN O
deletion NN NN O
of NN NN O
SNRPN NN NN O
detected NN NN O
by NN NN O
fluorescence NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
( NN NN O
FISH NN NN O
) NN NN O
. NN NN O

Neither NN NN O
a NN NN O
cytogenetically NN NN O
detectable NN NN O
15q12 NN NN O
deletion NN NN O
nor NN NN O
a NN NN O
deletion NN NN O
for NN NN O
the NN NN O
D15S11 NN NN O
, NN NN O
D15S10 NN NN O
, NN NN O
and NN NN O
GABRB3 NN NN O
cosmid NN NN O
probes NN NN O
were NN NN O
found NN NN O
in NN NN O
either NN NN O
patient NN NN O
. NN NN O

This NN NN O
implies NN NN O
a NN NN O
smaller NN NN O
deletion NN NN O
limited NN NN O
to NN NN O
the NN NN O
PWS NN NN B-Modifier
critical NN NN O
region NN NN O
. NN NN O

FISH NN NN O
with NN NN O
a NN NN O
SNRPN NN NN O
probe NN NN O
will NN NN O
permit NN NN O
analysis NN NN O
of NN NN O
PWS NN NN B-Modifier
patients NN NN O
with NN NN O
limited NN NN O
deletions NN NN O
not NN NN O
detectable NN NN O
with NN NN O
other NN NN O
probes NN NN O
. NN NN O

. NN NN O

8733131 NN NN O
Expression NN NN O
of NN NN O
the NN NN O
von NN NN B-Modifier
Hippel-Lindau NN NN I-Modifier
disease NN NN I-Modifier
tumour NN NN I-Modifier
suppressor NN NN O
gene NN NN O
during NN NN O
human NN NN O
embryogenesis NN NN O
. NN NN O

The NN NN O
von NN NN B-Modifier
Hippel-Lindau NN NN I-Modifier
( NN NN I-Modifier
VHL NN NN I-Modifier
) NN NN I-Modifier
disease NN NN I-Modifier
product NN NN O
is NN NN O
thought NN NN O
to NN NN O
down-regulate NN NN O
transcription NN NN O
by NN NN O
antagonizing NN NN O
elongin-enhanced NN NN O
transcriptional NN NN O
elongation NN NN O
. NN NN O

Germline NN NN O
VHL NN NN B-Modifier
gene NN NN O
mutations NN NN O
predispose NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
retinal NN NN B-CompositeMention
, NN NN I-CompositeMention
cerebellar NN NN I-CompositeMention
and NN NN I-CompositeMention
spinal NN NN I-CompositeMention
haemangioblastomas NN NN I-CompositeMention
, NN NN O
renal NN NN B-SpecificDisease
cell NN NN I-SpecificDisease
carcinoma NN NN I-SpecificDisease
and NN NN O
phaeochromocytoma NN NN B-SpecificDisease
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
somatic NN NN O
Inactivation NN NN O
of NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
is NN NN O
frequent NN NN O
in NN NN O
sporadic NN NN B-SpecificDisease
renal NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
carcinoma NN NN I-SpecificDisease
and NN NN O
haemangioblastoma NN NN B-SpecificDisease
. NN NN O

Regulation NN NN O
of NN NN O
transcript NN NN O
elongation NN NN O
is NN NN O
an NN NN O
important NN NN O
control NN NN O
mechanism NN NN O
for NN NN O
gene NN NN O
expression NN NN O
and NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
might NN NN O
modify NN NN O
the NN NN O
expression NN NN O
of NN NN O
proto-oncogenes NN NN O
and NN NN O
growth NN NN O
suppressor NN NN O
genes NN NN O
during NN NN O
embryogenesis NN NN O
. NN NN O

We NN NN O
therefore NN NN O
investigated NN NN O
the NN NN O
expression NN NN O
of NN NN O
VHL NN NN B-Modifier
mRNA NN NN O
during NN NN O
human NN NN O
embryogenesis NN NN O
by NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
studies NN NN O
at NN NN O
4 NN NN O
, NN NN O
6 NN NN O
and NN NN O
10 NN NN O
weeks NN NN O
post NN NN O
conception NN NN O
. NN NN O

Although NN NN O
VHL NN NN B-Modifier
mRNA NN NN O
was NN NN O
expressed NN NN O
in NN NN O
all NN NN O
three NN NN O
germ NN NN O
layers NN NN O
, NN NN O
strong NN NN O
expression NN NN O
was NN NN O
noted NN NN O
in NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
, NN NN O
kidneys NN NN O
, NN NN O
testis NN NN O
and NN NN O
lung NN NN O
. NN NN O

Within NN NN O
the NN NN O
kidney NN NN O
, NN NN O
VHL NN NN B-Modifier
mRNA NN NN O
was NN NN O
differentially NN NN O
expressed NN NN O
within NN NN O
renal NN NN O
tubules NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
product NN NN O
may NN NN O
have NN NN O
a NN NN O
specific NN NN O
role NN NN O
in NN NN O
kidney NN NN O
development NN NN O
. NN NN O

Two NN NN O
alternatively NN NN O
spliced NN NN O
VHL NN NN B-Modifier
mRNAs NN NN O
characterized NN NN O
by NN NN O
inclusion NN NN O
( NN NN O
isoform NN NN O
I NN NN O
) NN NN O
or NN NN O
exclusion NN NN O
( NN NN O
isoform NN NN O
II NN NN O
) NN NN O
of NN NN O
exon NN NN O
2 NN NN O
are NN NN O
transcribed NN NN O
in NN NN O
adult NN NN O
tissues NN NN O
. NN NN O

To NN NN O
investigate NN NN O
if NN NN O
the NN NN O
two NN NN O
isoforms NN NN O
are NN NN O
differentially NN NN O
expressed NN NN O
during NN NN O
embryogenesis NN NN O
, NN NN O
VHL NN NN B-Modifier
mRNA NN NN O
was NN NN O
reverse NN NN O
transcribed NN NN O
from NN NN O
13 NN NN O
fetal NN NN O
tissues NN NN O
( NN NN O
8-10 NN NN O
weeks NN NN O
gestation NN NN O
) NN NN O
. NN NN O

The NN NN O
quantitative NN NN O
distribution NN NN O
of NN NN O
VHL NN NN B-Modifier
mRNA NN NN O
within NN NN O
fetal NN NN O
tissues NN NN O
reflected NN NN O
that NN NN O
seen NN NN O
by NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
and NN NN O
the NN NN O
ratio NN NN O
of NN NN O
the NN NN O
two NN NN O
VHL NN NN B-Modifier
isoforms NN NN O
was NN NN O
similar NN NN O
between NN NN O
tissues NN NN O
. NN NN O

Although NN NN O
the NN NN O
genes NN NN O
regulated NN NN O
by NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
product NN NN O
have NN NN O
not NN NN O
yet NN NN O
been NN NN O
identified NN NN O
, NN NN O
our NN NN O
findings NN NN O
are NN NN O
compatible NN NN O
with NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
VHL NN NN B-Modifier
-mediated NN NN O
control NN NN O
of NN NN O
transcriptional NN NN O
elongation NN NN O
may NN NN O
have NN NN O
a NN NN O
role NN NN O
in NN NN O
normal NN NN O
human NN NN O
development NN NN O
. NN NN O

. NN NN O

8751855 NN NN O
Genetic NN NN O
heterogeneity NN NN O
in NN NN O
hereditary NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
: NN NN O
role NN NN O
of NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
. NN NN O

The NN NN O
common NN NN O
hereditary NN NN O
forms NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
have NN NN O
been NN NN O
largely NN NN O
attributed NN NN O
to NN NN O
the NN NN O
inheritance NN NN O
of NN NN O
mutations NN NN O
in NN NN O
the NN NN O
BRCA1 NN NN O
or NN NN O
BRCA2 NN NN O
genes NN NN O
. NN NN O

However NN NN O
, NN NN O
it NN NN O
is NN NN O
not NN NN O
yet NN NN O
clear NN NN O
what NN NN O
proportion NN NN O
of NN NN O
hereditary NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
is NN NN O
explained NN NN O
by NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
or NN NN O
by NN NN O
some NN NN O
other NN NN O
unidentified NN NN O
susceptibility NN NN O
gene NN NN O
( NN NN O
s NN NN O
) NN NN O
. NN NN O

We NN NN O
describe NN NN O
the NN NN O
proportion NN NN O
of NN NN O
hereditary NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
explained NN NN O
by NN NN O
BRCA1 NN NN O
or NN NN O
BRCA2 NN NN O
in NN NN O
a NN NN O
sample NN NN O
of NN NN O
North NN NN O
American NN NN O
hereditary NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancers NN NN I-SpecificDisease
and NN NN O
assess NN NN O
the NN NN O
evidence NN NN O
for NN NN O
additional NN NN O
susceptibility NN NN O
genes NN NN O
that NN NN O
may NN NN O
confer NN NN O
hereditary NN NN B-Modifier
breast NN NN I-Modifier
or NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
risk NN NN O
. NN NN O

Twenty-three NN NN O
families NN NN O
were NN NN O
identified NN NN O
through NN NN O
two NN NN O
high-risk NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
research NN NN O
programs NN NN O
. NN NN O

Genetic NN NN O
analysis NN NN O
was NN NN O
undertaken NN NN O
to NN NN O
establish NN NN O
linkage NN NN O
between NN NN O
the NN NN O
breast NN NN B-Modifier
or NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
cases NN NN O
and NN NN O
markers NN NN O
on NN NN O
chromosomes NN NN O
17q NN NN O
( NN NN O
BRCA1 NN NN O
) NN NN O
and NN NN O
13q NN NN O
( NN NN O
BRCA2 NN NN O
) NN NN O
. NN NN O

Mutation NN NN O
analysis NN NN O
in NN NN O
the NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
genes NN NN O
was NN NN O
also NN NN O
undertaken NN NN O
in NN NN O
all NN NN O
families NN NN O
. NN NN O

The NN NN O
pattern NN NN O
of NN NN O
hereditary NN NN B-DiseaseClass
cancer NN NN I-DiseaseClass
in NN NN O
14 NN NN O
( NN NN O
61 NN NN O
% NN NN O
) NN NN O
of NN NN O
the NN NN O
23 NN NN O
families NN NN O
studied NN NN O
was NN NN O
attributed NN NN O
to NN NN O
BRCA1 NN NN O
by NN NN O
a NN NN O
combination NN NN O
of NN NN O
linkage NN NN O
and NN NN O
mutation NN NN O
analyses NN NN O
. NN NN O

No NN NN O
families NN NN O
were NN NN O
attributed NN NN O
to NN NN O
BRCA2 NN NN O
. NN NN O

Five NN NN O
families NN NN O
( NN NN O
22 NN NN O
% NN NN O
) NN NN O
provided NN NN O
evidence NN NN O
against NN NN O
linkage NN NN O
to NN NN O
both NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
. NN NN O

No NN NN O
BRCA1 NN NN O
or NN NN O
BRCA2 NN NN O
mutations NN NN O
were NN NN O
detected NN NN O
in NN NN O
these NN NN O
five NN NN O
families NN NN O
. NN NN O

The NN NN O
BRCA1 NN NN O
or NN NN O
BRCA2 NN NN O
status NN NN O
of NN NN O
four NN NN O
families NN NN O
( NN NN O
17 NN NN O
% NN NN O
) NN NN O
could NN NN O
not NN NN O
be NN NN O
determined NN NN O
. NN NN O

BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
probably NN NN O
explain NN NN O
the NN NN O
majority NN NN O
of NN NN O
hereditary NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
that NN NN O
exists NN NN O
in NN NN O
the NN NN O
North NN NN O
American NN NN O
population NN NN O
. NN NN O

However NN NN O
, NN NN O
one NN NN O
or NN NN O
more NN NN O
additional NN NN O
genes NN NN O
may NN NN O
yet NN NN O
be NN NN O
found NN NN O
that NN NN O
explain NN NN O
some NN NN O
proportion NN NN O
of NN NN O
hereditary NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

. NN NN O

8755645 NN NN O
An NN NN O
intronic NN NN O
mutation NN NN O
in NN NN O
a NN NN O
lariat NN NN O
branchpoint NN NN O
sequence NN NN O
is NN NN O
a NN NN O
direct NN NN O
cause NN NN O
of NN NN O
an NN NN O
inherited NN NN B-DiseaseClass
human NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
( NN NN O
fish-eye NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
first NN NN O
step NN NN O
in NN NN O
the NN NN O
splicing NN NN O
of NN NN O
an NN NN O
intron NN NN O
from NN NN O
nuclear NN NN O
precursors NN NN O
of NN NN O
mRNA NN NN O
results NN NN O
in NN NN O
the NN NN O
formation NN NN O
of NN NN O
a NN NN O
lariat NN NN O
structure NN NN O
. NN NN O

A NN NN O
distinct NN NN O
intronic NN NN O
nucleotide NN NN O
sequence NN NN O
, NN NN O
known NN NN O
as NN NN O
the NN NN O
branchpoint NN NN O
region NN NN O
, NN NN O
plays NN NN O
a NN NN O
central NN NN O
role NN NN O
in NN NN O
this NN NN O
process NN NN O
. NN NN O

We NN NN O
here NN NN O
describe NN NN O
a NN NN O
point NN NN O
mutation NN NN O
in NN NN O
such NN NN O
a NN NN O
sequence NN NN O
. NN NN O

Three NN NN O
sisters NN NN O
were NN NN O
shown NN NN O
to NN NN O
suffer NN NN O
from NN NN O
fish-eye NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
FED NN NN B-SpecificDisease
) NN NN O
, NN NN O
a NN NN O
disorder NN NN O
which NN NN O
is NN NN O
caused NN NN O
by NN NN O
mutations NN NN O
in NN NN O
the NN NN O
gene NN NN O
coding NN NN O
for NN NN O
lecithin NN NN O
cholesterol NN NN O
acyltransferase NN NN O
( NN NN O
LCAT NN NN O
) NN NN O
. NN NN O

Sequencing NN NN O
of NN NN O
the NN NN O
LCAT NN NN O
gene NN NN O
of NN NN O
all NN NN O
three NN NN O
probands NN NN O
revealed NN NN O
compound NN NN O
heterozygosity NN NN O
for NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
4 NN NN O
which NN NN O
is NN NN O
reported NN NN O
to NN NN O
underlie NN NN O
the NN NN O
FED NN NN B-Modifier
phenotype NN NN O
, NN NN O
and NN NN O
a NN NN O
point NN NN O
mutation NN NN O
located NN NN O
in NN NN O
intron NN NN O
4 NN NN O
( NN NN O
IVS4 NN NN O
T-22C NN NN O
) NN NN O
. NN NN O

By NN NN O
performing NN NN O
in NN NN O
vitro NN NN O
expression NN NN O
of NN NN O
LCAT NN NN O
minigenes NN NN O
and NN NN O
reverse NN NN O
transcriptase NN NN O
PCR NN NN O
on NN NN O
mRNA NN NN O
isolated NN NN O
from NN NN O
leukocytes NN NN O
of NN NN O
the NN NN O
patient NN NN O
, NN NN O
this NN NN O
gene NN NN O
defect NN NN O
was NN NN O
shown NN NN O
to NN NN O
cause NN NN O
a NN NN O
null NN NN O
allele NN NN O
as NN NN O
the NN NN O
result NN NN O
of NN NN O
complete NN NN O
intron NN NN O
retention NN NN O
. NN NN O

In NN NN O
conclusion NN NN O
, NN NN O
we NN NN O
demonstrated NN NN O
that NN NN O
a NN NN O
point NN NN O
mutation NN NN O
in NN NN O
a NN NN O
lariat NN NN O
branchpoint NN NN O
consensus NN NN O
sequence NN NN O
causes NN NN O
a NN NN O
null NN NN O
allele NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
FED NN NN B-SpecificDisease
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
our NN NN O
finding NN NN O
illustrates NN NN O
the NN NN O
importance NN NN O
of NN NN O
this NN NN O
sequence NN NN O
for NN NN O
normal NN NN O
human NN NN O
mRNA NN NN O
processing NN NN O
. NN NN O

Finally NN NN O
, NN NN O
this NN NN O
report NN NN O
provides NN NN O
a NN NN O
widely NN NN O
applicable NN NN O
strategy NN NN O
which NN NN O
ensures NN NN O
fast NN NN O
and NN NN O
effective NN NN O
screening NN NN O
for NN NN O
intronic NN NN O
defects NN NN O
that NN NN O
underlie NN NN O
differential NN NN O
gene NN NN O
expression NN NN O
. NN NN O

. NN NN O

8755918 NN NN O
Mutations NN NN O
associated NN NN O
with NN NN O
variant NN NN O
phenotypes NN NN O
in NN NN O
ataxia-telangiectasia NN NN B-SpecificDisease
. NN NN O

We NN NN O
have NN NN O
identified NN NN O
14 NN NN O
families NN NN O
with NN NN O
ataxia-telangiectasia NN NN B-SpecificDisease
( NN NN O
A-T NN NN B-SpecificDisease
) NN NN O
in NN NN O
which NN NN O
mutation NN NN O
of NN NN O
the NN NN O
ATM NN NN O
gene NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
less NN NN O
severe NN NN O
clinical NN NN O
and NN NN O
cellular NN NN O
phenotype NN NN O
( NN NN O
approximately NN NN O
10 NN NN O
% NN NN O
-15 NN NN O
% NN NN O
of NN NN O
A-T NN NN B-Modifier
families NN NN O
identified NN NN O
in NN NN O
the NN NN O
United NN NN O
Kingdom NN NN O
) NN NN O
. NN NN O

In NN NN O
10 NN NN O
of NN NN O
these NN NN O
families NN NN O
, NN NN O
all NN NN O
the NN NN O
homozygotes NN NN O
have NN NN O
a NN NN O
137-bp NN NN O
insertion NN NN O
in NN NN O
their NN NN O
cDNA NN NN O
caused NN NN O
by NN NN O
a NN NN O
point NN NN O
mutation NN NN O
in NN NN O
a NN NN O
sequence NN NN O
resembling NN NN O
a NN NN O
splice-donor NN NN O
site NN NN O
. NN NN O

The NN NN O
second NN NN O
A-T NN NN B-Modifier
allele NN NN O
has NN NN O
a NN NN O
different NN NN O
mutation NN NN O
in NN NN O
each NN NN O
patient NN NN O
. NN NN O

We NN NN O
show NN NN O
that NN NN O
the NN NN O
less NN NN O
severe NN NN O
phenotype NN NN O
in NN NN O
these NN NN O
patients NN NN O
is NN NN O
caused NN NN O
by NN NN O
some NN NN O
degree NN NN O
of NN NN O
normal NN NN O
splicing NN NN O
, NN NN O
which NN NN O
occurs NN NN O
as NN NN O
an NN NN O
alternative NN NN O
product NN NN O
from NN NN O
the NN NN O
insertion-containing NN NN O
allele NN NN O
. NN NN O

The NN NN O
level NN NN O
of NN NN O
the NN NN O
137-bp NN NN O
PCR NN NN O
product NN NN O
containing NN NN O
the NN NN O
insertion NN NN O
was NN NN O
lowest NN NN O
in NN NN O
two NN NN O
patients NN NN O
who NN NN O
showed NN NN O
a NN NN O
later NN NN O
onset NN NN O
of NN NN O
cerebellar NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
. NN NN O

A NN NN O
further NN NN O
four NN NN O
families NN NN O
who NN NN O
do NN NN O
not NN NN O
have NN NN O
this NN NN O
insertion NN NN O
have NN NN O
been NN NN O
identified NN NN O
. NN NN O

Mutations NN NN O
detected NN NN O
in NN NN O
two NN NN O
of NN NN O
four NN NN O
of NN NN O
these NN NN O
are NN NN O
missense NN NN O
mutations NN NN O
, NN NN O
normally NN NN O
rare NN NN O
in NN NN O
A-T NN NN B-Modifier
patients NN NN O
. NN NN O

The NN NN O
demonstration NN NN O
of NN NN O
mutations NN NN O
giving NN NN O
rise NN NN O
to NN NN O
a NN NN O
slightly NN NN O
milder NN NN O
phenotype NN NN O
in NN NN O
A-T NN NN B-SpecificDisease
raises NN NN O
the NN NN O
interesting NN NN O
question NN NN O
of NN NN O
what NN NN O
range NN NN O
of NN NN O
phenotypes NN NN O
might NN NN O
occur NN NN O
in NN NN O
individuals NN NN O
in NN NN O
whom NN NN O
both NN NN O
mutations NN NN O
are NN NN O
milder NN NN O
. NN NN O

One NN NN O
possibility NN NN O
might NN NN O
be NN NN O
that NN NN O
individuals NN NN O
who NN NN O
are NN NN O
compound NN NN O
heterozygotes NN NN O
for NN NN O
ATM NN NN O
mutations NN NN O
are NN NN O
more NN NN O
common NN NN O
than NN NN O
we NN NN O
realize NN NN O
. NN NN O

. NN NN O

8758207 NN NN O
Mutation NN NN O
of NN NN O
the NN NN O
VHL NN NN O
gene NN NN O
is NN NN O
associated NN NN O
exclusively NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
non-papillary NN NN B-SpecificDisease
renal NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
carcinomas NN NN I-SpecificDisease
. NN NN O

To NN NN O
define NN NN O
the NN NN O
possible NN NN O
role NN NN O
of NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
sporadic NN NN B-SpecificDisease
renal NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
carcinomas NN NN I-SpecificDisease
, NN NN O
91 NN NN O
different NN NN O
parenchymal NN NN B-DiseaseClass
tumours NN NN I-DiseaseClass
of NN NN I-DiseaseClass
the NN NN I-DiseaseClass
kidney NN NN I-DiseaseClass
have NN NN O
been NN NN O
investigated NN NN O
for NN NN O
mutation NN NN O
of NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
by NN NN O
single NN NN O
strand NN NN O
conformation NN NN O
polymorphism NN NN O
( NN NN O
SSCP NN NN O
) NN NN O
and NN NN O
/ NN NN O
or NN NN O
heteroduplex NN NN O
( NN NN O
HD NN NN O
) NN NN O
techniques NN NN O
. NN NN O

Chromosome NN NN O
3p NN NN O
deletion NN NN O
was NN NN O
detected NN NN O
in NN NN O
98 NN NN O
per NN NN O
cent NN NN O
of NN NN O
non-papillary NN NN B-SpecificDisease
renal NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
carcinomas NN NN I-SpecificDisease
and NN NN O
in NN NN O
25 NN NN O
per NN NN O
cent NN NN O
of NN NN O
chromophobe NN NN O
renal NN NN B-SpecificDisease
cell NN NN I-SpecificDisease
carcinomas NN NN I-SpecificDisease
. NN NN O

In NN NN O
22 NN NN O
of NN NN O
the NN NN O
43 NN NN O
non-papillary NN NN B-SpecificDisease
renal NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
carcinomas NN NN I-SpecificDisease
, NN NN O
abnormally NN NN O
migrating NN NN O
DNA NN NN O
bands NN NN O
were NN NN O
detected NN NN O
by NN NN O
SSCP NN NN O
and NN NN O
/ NN NN O
or NN NN O
HD NN NN O
analysis NN NN O
. NN NN O

No NN NN O
mobility NN NN O
shift NN NN O
was NN NN O
seen NN NN O
in NN NN O
any NN NN O
of NN NN O
the NN NN O
23 NN NN O
chromophobe NN NN O
renal NN NN B-SpecificDisease
cell NN NN I-SpecificDisease
carcinomas NN NN I-SpecificDisease
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
15 NN NN O
papillary NN NN B-SpecificDisease
renal NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
tumours NN NN I-SpecificDisease
and NN NN O
ten NN NN O
renal NN NN B-SpecificDisease
oncocytomas NN NN I-SpecificDisease
, NN NN O
which NN NN O
are NN NN O
characterized NN NN O
by NN NN O
genetic NN NN O
changes NN NN O
other NN NN O
than NN NN O
loss NN NN O
of NN NN O
chromosome NN NN O
3p NN NN O
sequences NN NN O
, NN NN O
were NN NN O
analysed NN NN O
for NN NN O
mutation NN NN O
of NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
. NN NN O

None NN NN O
of NN NN O
these NN NN O
tumours NN NN B-DiseaseClass
showed NN NN O
abnormal NN NN O
migration NN NN O
patterns NN NN O
. NN NN O

The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
mutation NN NN O
of NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
is NN NN O
associated NN NN O
exclusively NN NN O
with NN NN O
the NN NN O
development NN NN O
of NN NN O
non-papillary NN NN B-SpecificDisease
renal NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
carcinoma NN NN I-SpecificDisease
. NN NN O

. NN NN O

8776595 NN NN O
The NN NN O
Emery-Dreifuss NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
protein NN NN O
, NN NN O
emerin NN NN O
, NN NN O
is NN NN O
a NN NN O
nuclear NN NN O
membrane NN NN O
protein NN NN O
. NN NN O

A NN NN O
large NN NN O
fragment NN NN O
of NN NN O
emerin NN NN O
cDNA NN NN O
was NN NN O
prepared NN NN O
by NN NN O
PCR NN NN O
and NN NN O
expressed NN NN O
as NN NN O
a NN NN O
recombinant NN NN O
protein NN NN O
in NN NN O
Escherichia NN NN O
coli NN NN O
. NN NN O

Using NN NN O
this NN NN O
as NN NN O
immunogen NN NN O
, NN NN O
we NN NN O
prepared NN NN O
a NN NN O
panel NN NN O
of NN NN O
12 NN NN O
monoclonal NN NN O
antibodies NN NN O
which NN NN O
recognise NN NN O
at NN NN O
least NN NN O
four NN NN O
different NN NN O
epitopes NN NN O
on NN NN O
emerin NN NN O
in NN NN O
order NN NN O
to NN NN O
ensure NN NN O
that NN NN O
emerin NN NN O
can NN NN O
be NN NN O
distinguished NN NN O
from NN NN O
non-specific NN NN O
cross-reacting NN NN O
proteins NN NN O
. NN NN O

All NN NN O
the NN NN O
mAbs NN NN O
recognised NN NN O
a NN NN O
34 NN NN O
kDa NN NN O
protein NN NN O
in NN NN O
all NN NN O
tissues NN NN O
tested NN NN O
, NN NN O
though NN NN O
minor NN NN O
emerin-related NN NN O
bands NN NN O
were NN NN O
also NN NN O
detected NN NN O
in NN NN O
some NN NN O
tissues NN NN O
. NN NN O

Immunofluorescence NN NN O
microscopy NN NN O
showed NN NN O
that NN NN O
emerin NN NN O
is NN NN O
located NN NN O
at NN NN O
the NN NN O
nuclear NN NN O
rim NN NN O
in NN NN O
all NN NN O
tissues NN NN O
examined NN NN O
. NN NN O

A NN NN O
muscle NN NN O
biopsy NN NN O
from NN NN O
an NN NN O
Emery-Dreifuss NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
( NN NN O
EMDM NN NN B-Modifier
) NN NN O
patient NN NN O
showed NN NN O
complete NN NN O
absence NN NN O
of NN NN O
emerin NN NN O
by NN NN O
both NN NN O
Western NN NN O
blotting NN NN O
and NN NN O
immunohistochemistry NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
simple NN NN O
diagnostic NN NN O
antibody NN NN O
test NN NN O
for NN NN O
EDMD NN NN B-Modifier
families NN NN O
. NN NN O

Biochemical NN NN O
fractionation NN NN O
of NN NN O
brain NN NN O
and NN NN O
liver NN NN O
tissues NN NN O
showed NN NN O
that NN NN O
emerin NN NN O
was NN NN O
present NN NN O
in NN NN O
nuclei NN NN O
purified NN NN O
by NN NN O
centrifugation NN NN O
through NN NN O
65 NN NN O
% NN NN O
sucrose NN NN O
and NN NN O
was NN NN O
absent NN NN O
from NN NN O
soluble NN NN O
fractions NN NN O
( NN NN O
post-100 NN NN O
, NN NN O
000 NN NN O
g NN NN O
) NN NN O
. NN NN O

From NN NN O
these NN NN O
results NN NN O
, NN NN O
together NN NN O
with NN NN O
sequence NN NN O
and NN NN O
structural NN NN O
homologies NN NN O
between NN NN O
emerin NN NN O
, NN NN O
thymopoietins NN NN O
and NN NN O
the NN NN O
nuclear NN NN O
lamina-associated NN NN O
protein NN NN O
, NN NN O
LAP2 NN NN O
, NN NN O
we NN NN O
suggest NN NN O
that NN NN O
emerin NN NN O
will NN NN O
prove NN NN O
to NN NN O
be NN NN O
one NN NN O
member NN NN O
of NN NN O
a NN NN O
family NN NN O
of NN NN O
inner NN NN O
nuclear NN NN O
membrane NN NN O
proteins NN NN O
. NN NN O

. NN NN O

8782829 NN NN O
Mutation NN NN O
of NN NN O
MSH3 NN NN O
in NN NN O
endometrial NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
and NN NN O
evidence NN NN O
for NN NN O
its NN NN O
functional NN NN O
role NN NN O
in NN NN O
heteroduplex NN NN O
repair NN NN O
. NN NN O

Many NN NN O
human NN NN O
tumours NN NN B-DiseaseClass
have NN NN O
length NN NN O
alterations NN NN O
in NN NN O
repetitive NN NN O
sequence NN NN O
elements NN NN O
. NN NN O

Although NN NN O
this NN NN O
microsatellite NN NN O
instability NN NN O
has NN NN O
been NN NN O
attributed NN NN O
to NN NN O
mutations NN NN O
in NN NN O
four NN NN O
DNA NN NN O
mismatch NN NN O
repair NN NN O
genes NN NN O
in NN NN O
hereditary NN NN B-Modifier
nonpolyposis NN NN I-Modifier
colorectal NN NN I-Modifier
cancer NN NN I-Modifier
( NN NN O
HNPCC NN NN B-Modifier
) NN NN O
kindreds NN NN O
, NN NN O
many NN NN O
sporadic NN NN B-DiseaseClass
tumours NN NN I-DiseaseClass
exhibit NN NN O
instability NN NN O
but NN NN O
no NN NN O
detectable NN NN O
mutations NN NN O
in NN NN O
these NN NN O
genes NN NN O
. NN NN O

It NN NN O
is NN NN O
therefore NN NN O
of NN NN O
interest NN NN O
to NN NN O
identify NN NN O
other NN NN O
genes NN NN O
that NN NN O
contribute NN NN O
to NN NN O
this NN NN O
instability NN NN O
. NN NN O

In NN NN O
yeast NN NN O
, NN NN O
mutations NN NN O
in NN NN O
several NN NN O
genes NN NN O
, NN NN O
including NN NN O
RTH NN NN O
and NN NN O
MSH3 NN NN O
, NN NN O
cause NN NN O
microsatellite NN NN O
instability NN NN O
. NN NN O

Thus NN NN O
, NN NN O
we NN NN O
screened NN NN O
16 NN NN O
endometrial NN NN B-SpecificDisease
carcinomas NN NN I-SpecificDisease
with NN NN O
microsatellite NN NN O
instability NN NN O
for NN NN O
alterations NN NN O
in NN NN O
FEN1 NN NN O
( NN NN O
the NN NN O
human NN NN O
homolog NN NN O
of NN NN O
RTH NN NN O
) NN NN O
and NN NN O
in NN NN O
MSH3 NN NN O
( NN NN O
refs NN NN O
12-14 NN NN O
) NN NN O
. NN NN O

Although NN NN O
we NN NN O
found NN NN O
no NN NN O
FEN1 NN NN O
mutations NN NN O
, NN NN O
a NN NN O
frameshift NN NN O
mutation NN NN O
in NN NN O
MSH3 NN NN O
was NN NN O
observed NN NN O
in NN NN O
an NN NN O
endometrial NN NN B-SpecificDisease
carcinoma NN NN I-SpecificDisease
and NN NN O
in NN NN O
an NN NN O
endometrial NN NN B-Modifier
carcinoma NN NN I-Modifier
cell NN NN O
line NN NN O
. NN NN O

Extracts NN NN O
of NN NN O
the NN NN O
cell NN NN O
line NN NN O
were NN NN O
deficient NN NN O
in NN NN O
repair NN NN O
of NN NN O
DNA NN NN O
substrates NN NN O
containing NN NN O
mismatches NN NN O
or NN NN O
extra NN NN O
nucleotides NN NN O
. NN NN O

Introducing NN NN O
chromosome NN NN O
5 NN NN O
, NN NN O
encoding NN NN O
the NN NN O
MSH3 NN NN O
gene NN NN O
, NN NN O
into NN NN O
the NN NN O
mutant NN NN O
cell NN NN O
line NN NN O
increased NN NN O
the NN NN O
stability NN NN O
of NN NN O
some NN NN O
but NN NN O
not NN NN O
all NN NN O
microsatellites NN NN O
. NN NN O

Extracts NN NN O
of NN NN O
these NN NN O
cells NN NN O
repaired NN NN O
certain NN NN O
substrates NN NN O
containing NN NN O
extra NN NN O
nucleotides NN NN O
, NN NN O
but NN NN O
were NN NN O
deficient NN NN O
in NN NN O
repair NN NN O
of NN NN O
those NN NN O
containing NN NN O
mismatches NN NN O
or NN NN O
other NN NN O
extra NN NN O
nucleotides NN NN O
. NN NN O

A NN NN O
subsequent NN NN O
search NN NN O
revealed NN NN O
a NN NN O
second NN NN O
gene NN NN O
mutation NN NN O
in NN NN O
HHUA NN NN O
cells NN NN O
, NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
in NN NN O
the NN NN O
MSH6 NN NN O
gene NN NN O
. NN NN O

Together NN NN O
the NN NN O
data NN NN O
suggest NN NN O
that NN NN O
the NN NN O
MSH3 NN NN O
gene NN NN O
encodes NN NN O
a NN NN O
product NN NN O
that NN NN O
functions NN NN O
in NN NN O
repair NN NN O
of NN NN O
some NN NN O
but NN NN O
not NN NN O
all NN NN O
pre-mutational NN NN O
intermediates NN NN O
, NN NN O
its NN NN O
mutation NN NN O
in NN NN O
tumours NN NN B-DiseaseClass
can NN NN O
result NN NN O
in NN NN O
genomic NN NN O
instability NN NN O
and NN NN O
, NN NN O
as NN NN O
in NN NN O
yeast NN NN O
, NN NN O
MSH3 NN NN O
and NN NN O
MSH6 NN NN O
are NN NN O
partially NN NN O
redundant NN NN O
for NN NN O
mismatch NN NN O
repair NN NN O
. NN NN O

. NN NN O

8786135 NN NN O
Comparative NN NN O
genome NN NN O
mapping NN NN O
of NN NN O
the NN NN O
ataxia-telangiectasia NN NN B-Modifier
region NN NN O
in NN NN O
mouse NN NN O
, NN NN O
rat NN NN O
, NN NN O
and NN NN O
Syrian NN NN O
hamster NN NN O
. NN NN O

Chromosomal NN NN O
locations NN NN O
of NN NN O
the NN NN O
Atm NN NN O
( NN NN O
ataxia-telangiectasia NN NN B-Modifier
( NN NN O
AT NN NN B-Modifier
) NN NN O
-mutated NN NN O
) NN NN O
and NN NN O
Acat1 NN NN O
( NN NN O
mitochondrial NN NN O
acetoacetyl-CoA NN NN O
thiolase NN NN O
) NN NN O
genes NN NN O
in NN NN O
mouse NN NN O
, NN NN O
rat NN NN O
, NN NN O
and NN NN O
Syrian NN NN O
hamster NN NN O
were NN NN O
determined NN NN O
by NN NN O
direct NN NN O
R-banding NN NN O
FISH NN NN O
. NN NN O

Both NN NN O
genes NN NN O
were NN NN O
colocalized NN NN O
to NN NN O
the NN NN O
C-D NN NN O
band NN NN O
of NN NN O
mouse NN NN O
chromosome NN NN O
9 NN NN O
, NN NN O
the NN NN O
proximal NN NN O
end NN NN O
of NN NN O
q24 NN NN O
. NN NN O

1 NN NN O
of NN NN O
rat NN NN O
chromosome NN NN O
8 NN NN O
, NN NN O
and NN NN O
qa4-qa5 NN NN O
of NN NN O
Syrian NN NN O
hamster NN NN O
chromosome NN NN O
12 NN NN O
. NN NN O

The NN NN O
regions NN NN O
in NN NN O
the NN NN O
mouse NN NN O
and NN NN O
rat NN NN O
were NN NN O
homologous NN NN O
to NN NN O
human NN NN O
chromosome NN NN O
11q NN NN O
. NN NN O

Fine NN NN O
genetic NN NN O
linkage NN NN O
mapping NN NN O
of NN NN O
the NN NN O
mouse NN NN O
AT NN NN B-Modifier
region NN NN O
was NN NN O
performed NN NN O
using NN NN O
the NN NN O
interspecific NN NN O
backcross NN NN O
mice NN NN O
. NN NN O

Atm NN NN O
, NN NN O
Acat1 NN NN O
, NN NN O
and NN NN O
Npat NN NN O
, NN NN O
which NN NN O
is NN NN O
a NN NN O
new NN NN O
gene NN NN O
isolated NN NN O
from NN NN O
the NN NN O
AT NN NN O
region NN NN O
, NN NN O
and NN NN O
12 NN NN O
flanking NN NN O
microsatellite NN NN O
DNA NN NN O
markers NN NN O
were NN NN O
examined NN NN O
. NN NN O

No NN NN O
recombinations NN NN O
were NN NN O
found NN NN O
among NN NN O
the NN NN O
Atm NN NN O
, NN NN O
Npat NN NN O
, NN NN O
Acat1 NN NN O
, NN NN O
and NN NN O
D9Mit6 NN NN O
loci NN NN O
, NN NN O
and NN NN O
these NN NN O
loci NN NN O
were NN NN O
mapped NN NN O
2 NN NN O
. NN NN O

0 NN NN O
cM NN NN O
distal NN NN O
to NN NN O
D9Mit99 NN NN O
and NN NN O
1 NN NN O
. NN NN O

3 NN NN O
cM NN NN O
proximal NN NN O
to NN NN O
D9Mit102 NN NN O
. NN NN O

Comparison NN NN O
of NN NN O
the NN NN O
linkage NN NN O
map NN NN O
of NN NN O
mouse NN NN O
chromosome NN NN O
9 NN NN O
( NN NN O
MMU9 NN NN O
) NN NN O
and NN NN O
that NN NN O
of NN NN O
human NN NN O
chromosome NN NN O
11 NN NN O
( NN NN O
HSA11 NN NN O
) NN NN O
indicates NN NN O
that NN NN O
there NN NN O
is NN NN O
a NN NN O
chromosomal NN NN O
rearrangement NN NN O
due NN NN O
to NN NN O
an NN NN O
inversion NN NN O
between NN NN O
Ets1 NN NN O
and NN NN O
Atm-Npat-Acat1 NN NN O
and NN NN O
that NN NN O
the NN NN O
inversion NN NN O
of NN NN O
MMU9 NN NN O
originated NN NN O
from NN NN O
the NN NN O
chromosomal NN NN O
breakage NN NN O
at NN NN O
the NN NN O
boundary NN NN O
between NN NN O
Gria4 NN NN O
and NN NN O
Atm-Npat-Acat1 NN NN O
on NN NN O
HSA11 NN NN O
. NN NN O

This NN NN O
type NN NN O
of NN NN O
inversion NN NN O
appeared NN NN O
to NN NN O
be NN NN O
conserved NN NN O
in NN NN O
the NN NN O
three NN NN O
rodent NN NN O
species NN NN O
, NN NN O
mouse NN NN O
, NN NN O
rat NN NN O
, NN NN O
and NN NN O
Syrian NN NN O
hamster NN NN O
, NN NN O
using NN NN O
additional NN NN O
comparative NN NN O
mapping NN NN O
data NN NN O
with NN NN O
the NN NN O
Rck NN NN O
gene NN NN O

8789439 NN NN O
An NN NN O
animal NN NN O
model NN NN O
for NN NN O
Norrie NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
ND NN NN B-SpecificDisease
) NN NN O
: NN NN O
gene NN NN O
targeting NN NN O
of NN NN O
the NN NN O
mouse NN NN O
ND NN NN B-Modifier
gene NN NN O
. NN NN O

In NN NN O
order NN NN O
to NN NN O
elucidate NN NN O
the NN NN O
cellular NN NN O
and NN NN O
molecular NN NN O
processes NN NN O
which NN NN O
are NN NN O
involved NN NN O
in NN NN O
Norrie NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
ND NN NN B-SpecificDisease
) NN NN O
, NN NN O
we NN NN O
have NN NN O
used NN NN O
gene NN NN O
targeting NN NN O
technology NN NN O
to NN NN O
generate NN NN O
ND NN NN B-Modifier
mutant NN NN O
mice NN NN O
. NN NN O

The NN NN O
murine NN NN O
homologue NN NN O
of NN NN O
the NN NN O
ND NN NN B-Modifier
gene NN NN O
was NN NN O
cloned NN NN O
and NN NN O
shown NN NN O
to NN NN O
encode NN NN O
a NN NN O
polypeptide NN NN O
that NN NN O
shares NN NN O
94 NN NN O
% NN NN O
of NN NN O
the NN NN O
amino NN NN O
acid NN NN O
sequence NN NN O
with NN NN O
its NN NN O
human NN NN O
counterpart NN NN O
. NN NN O

RNA NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
revealed NN NN O
expression NN NN O
in NN NN O
retina NN NN O
, NN NN O
brain NN NN O
and NN NN O
the NN NN O
olfactory NN NN O
bulb NN NN O
and NN NN O
epithelium NN NN O
of NN NN O
2 NN NN O
week NN NN O
old NN NN O
mice NN NN O
. NN NN O

Hemizygous NN NN O
mice NN NN O
carrying NN NN O
a NN NN O
replacement NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
2 NN NN O
of NN NN O
the NN NN O
ND NN NN B-Modifier
gene NN NN O
developed NN NN O
retrolental NN NN O
structures NN NN O
in NN NN O
the NN NN O
vitreous NN NN O
body NN NN O
and NN NN O
showed NN NN O
an NN NN O
overall NN NN O
disorganization NN NN O
of NN NN O
the NN NN O
retinal NN NN O
ganglion NN NN O
cell NN NN O
layer NN NN O
. NN NN O

The NN NN O
outer NN NN O
plexiform NN NN O
layer NN NN O
disappears NN NN O
occasionally NN NN O
, NN NN O
resulting NN NN O
in NN NN O
a NN NN O
juxtaposed NN NN O
inner NN NN O
and NN NN O
outer NN NN O
nuclear NN NN O
layer NN NN O
. NN NN O

At NN NN O
the NN NN O
same NN NN O
regions NN NN O
, NN NN O
the NN NN O
outer NN NN O
segments NN NN O
of NN NN O
the NN NN O
photoreceptor NN NN O
cell NN NN O
layer NN NN O
are NN NN O
no NN NN O
longer NN NN O
present NN NN O
. NN NN O

These NN NN O
ocular NN NN O
findings NN NN O
are NN NN O
consistent NN NN O
with NN NN O
observations NN NN O
in NN NN O
ND NN NN B-Modifier
patients NN NN O
and NN NN O
the NN NN O
generated NN NN O
mouse NN NN O
line NN NN O
provides NN NN O
a NN NN O
faithful NN NN O
model NN NN O
for NN NN O
study NN NN O
of NN NN O
early NN NN O
pathogenic NN NN O
events NN NN O
in NN NN O
this NN NN O
severe NN NN O
X-linked NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
neurological NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
. NN NN O

. NN NN O

8790412 NN NN O
The NN NN O
hybrid NN NN O
PAX3-FKHR NN NN O
fusion NN NN O
protein NN NN O
of NN NN O
alveolar NN NN B-SpecificDisease
rhabdomyosarcoma NN NN I-SpecificDisease
transforms NN NN O
fibroblasts NN NN O
in NN NN O
culture NN NN O
. NN NN O

Pediatric NN NN B-SpecificDisease
alveolar NN NN I-SpecificDisease
rhabdomyosarcoma NN NN I-SpecificDisease
is NN NN O
characterized NN NN O
by NN NN O
a NN NN O
chromosomal NN NN O
translocation NN NN O
that NN NN O
fuses NN NN O
parts NN NN O
of NN NN O
the NN NN O
PAX3 NN NN O
and NN NN O
FKHR NN NN O
genes NN NN O
. NN NN O

PAX3 NN NN O
codes NN NN O
for NN NN O
a NN NN O
transcriptional NN NN O
regulator NN NN O
that NN NN O
controls NN NN O
developmental NN NN O
programs NN NN O
, NN NN O
and NN NN O
FKHR NN NN O
codes NN NN O
for NN NN O
a NN NN O
forkhead-winged NN NN O
helix NN NN O
protein NN NN O
, NN NN O
also NN NN O
a NN NN O
likely NN NN O
transcription NN NN O
factor NN NN O
. NN NN O

The NN NN O
PAX3-FKHR NN NN O
fusion NN NN O
product NN NN O
retains NN NN O
the NN NN O
DNA NN NN O
binding NN NN O
domains NN NN O
of NN NN O
the NN NN O
PAX3 NN NN O
protein NN NN O
and NN NN O
the NN NN O
putative NN NN O
activator NN NN O
domain NN NN O
of NN NN O
the NN NN O
FKHR NN NN O
protein NN NN O
. NN NN O

The NN NN O
PAX3-FKHR NN NN O
protein NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
function NN NN O
as NN NN O
a NN NN O
transcriptional NN NN O
activator NN NN O
. NN NN O

Using NN NN O
the NN NN O
RCAS NN NN O
retroviral NN NN O
vector NN NN O
, NN NN O
we NN NN O
have NN NN O
introduced NN NN O
the NN NN O
PAX3-FKHR NN NN O
gene NN NN O
into NN NN O
chicken NN NN O
embryo NN NN O
fibroblasts NN NN O
. NN NN O

Expression NN NN O
of NN NN O
the NN NN O
PAX3-FKHR NN NN O
protein NN NN O
in NN NN O
these NN NN O
cells NN NN O
leads NN NN O
to NN NN O
transformation NN NN O
the NN NN O
cells NN NN O
become NN NN O
enlarged NN NN O
, NN NN O
grow NN NN O
tightly NN NN O
packed NN NN O
and NN NN O
in NN NN O
multiple NN NN O
layers NN NN O
, NN NN O
and NN NN O
acquire NN NN O
the NN NN O
ability NN NN O
for NN NN O
anchorage-independent NN NN O
growth NN NN O
. NN NN O

This NN NN O
cellular NN NN O
transformation NN NN O
in NN NN O
vitro NN NN O
will NN NN O
facilitate NN NN O
studies NN NN O
on NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
PAX3-FKHR-induced NN NN O
oncogenesis NN NN O
. NN NN O

. NN NN O

8808605 NN NN O
Somatic-cell NN NN O
selection NN NN O
is NN NN O
a NN NN O
major NN NN O
determinant NN NN O
of NN NN O
the NN NN O
blood-cell NN NN O
phenotype NN NN O
in NN NN O
heterozygotes NN NN O
for NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
mutations NN NN O
causing NN NN O
severe NN NN O
enzyme NN NN B-DiseaseClass
deficiency NN NN I-DiseaseClass
. NN NN O

X-chromosome NN NN O
inactivation NN NN O
in NN NN O
mammals NN NN O
is NN NN O
regarded NN NN O
as NN NN O
an NN NN O
essentially NN NN O
random NN NN O
process NN NN O
, NN NN O
but NN NN O
the NN NN O
resulting NN NN O
somatic-cell NN NN O
mosaicism NN NN O
creates NN NN O
the NN NN O
opportunity NN NN O
for NN NN O
cell NN NN O
selection NN NN O
. NN NN O

In NN NN O
most NN NN O
people NN NN O
with NN NN O
red-blood-cell NN NN O
glucose-6-phosphate NN NN B-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
G6PD NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
the NN NN O
enzyme-deficient NN NN O
phenotype NN NN O
is NN NN O
only NN NN O
moderately NN NN O
expressed NN NN O
in NN NN O
nucleated NN NN O
cells NN NN O
. NN NN O

However NN NN O
, NN NN O
in NN NN O
a NN NN O
small NN NN O
subset NN NN O
of NN NN O
hemizygous NN NN O
males NN NN O
who NN NN O
suffer NN NN O
from NN NN O
chronic NN NN B-SpecificDisease
nonspherocytic NN NN I-SpecificDisease
hemolytic NN NN I-SpecificDisease
anemia NN NN I-SpecificDisease
, NN NN O
the NN NN O
underlying NN NN O
mutations NN NN O
( NN NN O
designated NN NN O
class NN NN O
I NN NN O
) NN NN O
cause NN NN O
more-severe NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
and NN NN O
this NN NN O
might NN NN O
provide NN NN O
an NN NN O
opportunity NN NN O
for NN NN O
selection NN NN O
in NN NN O
heterozygous NN NN O
females NN NN O
during NN NN O
development NN NN O
. NN NN O

In NN NN O
order NN NN O
to NN NN O
test NN NN O
this NN NN O
possibility NN NN O
we NN NN O
have NN NN O
analyzed NN NN O
four NN NN O
heterozygotes NN NN O
for NN NN O
class NN NN O
I NN NN O
G6PD NN NN O
mutations NN NN O
two NN NN O
with NN NN O
G6PD NN NN O
Portici NN NN O
( NN NN O
1178G NN NN O
-- NN NN O
A NN NN O
) NN NN O
and NN NN O
two NN NN O
with NN NN O
G6PD NN NN O
Bari NN NN O
( NN NN O
1187C NN NN O
-- NN NN O
T NN NN O
) NN NN O
. NN NN O

We NN NN O
found NN NN O
that NN NN O
in NN NN O
fractionated NN NN O
blood NN NN O
cell NN NN O
types NN NN O
( NN NN O
including NN NN O
erythroid NN NN O
, NN NN O
myeloid NN NN O
, NN NN O
and NN NN O
lymphoid NN NN O
cell NN NN O
lineages NN NN O
) NN NN O
there NN NN O
was NN NN O
a NN NN O
significant NN NN O
excess NN NN O
of NN NN O
G6PD-normal NN NN O
cells NN NN O
. NN NN O

The NN NN O
significant NN NN O
concordance NN NN O
that NN NN O
we NN NN O
have NN NN O
observed NN NN O
in NN NN O
the NN NN O
degree NN NN O
of NN NN O
imbalance NN NN O
in NN NN O
the NN NN O
different NN NN O
blood-cell NN NN O
lineages NN NN O
indicates NN NN O
that NN NN O
a NN NN O
selective NN NN O
mechanism NN NN O
is NN NN O
likely NN NN O
to NN NN O
operate NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
pluripotent NN NN O
blood NN NN O
stem NN NN O
cells NN NN O
. NN NN O

Thus NN NN O
, NN NN O
it NN NN O
appears NN NN O
that NN NN O
severe NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
affects NN NN O
adversely NN NN O
the NN NN O
proliferation NN NN O
or NN NN O
the NN NN O
survival NN NN O
of NN NN O
nucleated NN NN O
blood NN NN O
cells NN NN O
and NN NN O
that NN NN O
this NN NN O
phenotypic NN NN O
characteristic NN NN O
is NN NN O
critical NN NN O
during NN NN O
hematopoiesis NN NN O
. NN NN O

. NN NN O

8808606 NN NN O
Analysis NN NN O
of NN NN O
meiotic NN NN O
segregation NN NN O
, NN NN O
using NN NN O
single-sperm NN NN O
typing NN NN O
: NN NN O
meiotic NN NN O
drive NN NN O
at NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
locus NN NN O
. NN NN O

Meiotic NN NN O
drive NN NN O
at NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
( NN NN O
DM NN NN B-Modifier
) NN NN O
locus NN NN O
has NN NN O
recently NN NN O
been NN NN O
suggested NN NN O
as NN NN O
being NN NN O
responsible NN NN O
for NN NN O
maintaining NN NN O
the NN NN O
frequency NN NN O
, NN NN O
in NN NN O
the NN NN O
human NN NN O
population NN NN O
, NN NN O
of NN NN O
DM NN NN B-Modifier
chromosomes NN NN O
capable NN NN O
of NN NN O
expansion NN NN O
to NN NN O
the NN NN O
disease NN NN O
state NN NN O
. NN NN O

In NN NN O
order NN NN O
to NN NN O
test NN NN O
this NN NN O
hypothesis NN NN O
, NN NN O
we NN NN O
have NN NN O
studied NN NN O
samples NN NN O
of NN NN O
single NN NN O
sperm NN NN O
from NN NN O
three NN NN O
individuals NN NN O
heterozygous NN NN O
at NN NN O
the NN NN O
DM NN NN B-Modifier
locus NN NN O
, NN NN O
each NN NN O
with NN NN O
one NN NN O
allele NN NN O
larger NN NN O
and NN NN O
one NN NN O
allele NN NN O
smaller NN NN O
than NN NN O
19 NN NN O
CTG NN NN O
repeats NN NN O
. NN NN O

To NN NN O
guard NN NN O
against NN NN O
the NN NN O
possible NN NN O
problem NN NN O
of NN NN O
differential NN NN O
PCR NN NN O
amplification NN NN O
rates NN NN O
based NN NN O
on NN NN O
the NN NN O
lengths NN NN O
of NN NN O
the NN NN O
alleles NN NN O
, NN NN O
the NN NN O
sperm NN NN O
were NN NN O
also NN NN O
typed NN NN O
at NN NN O
another NN NN O
closely NN NN O
linked NN NN O
marker NN NN O
whose NN NN O
allele NN NN O
size NN NN O
was NN NN O
unrelated NN NN O
to NN NN O
the NN NN O
allele NN NN O
size NN NN O
at NN NN O
the NN NN O
DM NN NN B-Modifier
locus NN NN O
. NN NN O

Using NN NN O
statistical NN NN O
models NN NN O
specifically NN NN O
designed NN NN O
to NN NN O
study NN NN O
single-sperm NN NN O
segregation NN NN O
data NN NN O
, NN NN O
we NN NN O
find NN NN O
no NN NN O
evidence NN NN O
of NN NN O
meiotic NN NN O
segregation NN NN O
distortion NN NN O
. NN NN O

The NN NN O
upper NN NN O
limit NN NN O
of NN NN O
the NN NN O
two-sided NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
for NN NN O
the NN NN O
estimate NN NN O
of NN NN O
the NN NN O
common NN NN O
segregation NN NN O
probability NN NN O
for NN NN O
the NN NN O
three NN NN O
donors NN NN O
is NN NN O
at NN NN O
or NN NN O
below NN NN O
. NN NN O

515 NN NN O
for NN NN O
all NN NN O
models NN NN O
considered NN NN O
, NN NN O
and NN NN O
no NN NN O
statistically NN NN O
significant NN NN O
difference NN NN O
from NN NN O
. NN NN O

5 NN NN O
is NN NN O
detected NN NN O
in NN NN O
any NN NN O
of NN NN O
the NN NN O
models NN NN O
. NN NN O

This NN NN O
suggests NN NN O
that NN NN O
any NN NN O
greater NN NN O
amount NN NN O
of NN NN O
segregation NN NN O
distortion NN NN O
at NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
locus NN NN O
must NN NN O
result NN NN O
from NN NN O
events NN NN O
following NN NN O
sperm NN NN O
ejaculation NN NN O
. NN NN O

8812423 NN NN O
LPP NN NN O
, NN NN O
the NN NN O
preferred NN NN O
fusion NN NN O
partner NN NN O
gene NN NN O
of NN NN O
HMGIC NN NN O
in NN NN O
lipomas NN NN B-DiseaseClass
, NN NN O
is NN NN O
a NN NN O
novel NN NN O
member NN NN O
of NN NN O
the NN NN O
LIM NN NN O
protein NN NN O
gene NN NN O
family NN NN O
. NN NN O

A NN NN O
major NN NN O
cytogenetic NN NN O
subgroup NN NN O
of NN NN O
lipomas NN NN B-DiseaseClass
is NN NN O
characterized NN NN O
by NN NN O
recurrent NN NN O
chromosome NN NN O
aberrations NN NN O
, NN NN O
mainly NN NN O
translocations NN NN O
, NN NN O
that NN NN O
involve NN NN O
chromosome NN NN O
segment NN NN O
12q13-q15 NN NN O
. NN NN O

Multiple NN NN O
chromosomes NN NN O
have NN NN O
been NN NN O
found NN NN O
as NN NN O
the NN NN O
translocation NN NN O
partners NN NN O
of NN NN O
chromosome NN NN O
12 NN NN O
but NN NN O
3q27-q28 NN NN O
is NN NN O
preferentially NN NN O
involved NN NN O
. NN NN O

In NN NN O
previous NN NN O
studies NN NN O
, NN NN O
it NN NN O
has NN NN O
been NN NN O
shown NN NN O
that NN NN O
the NN NN O
high NN NN O
mobility NN NN O
group NN NN O
( NN NN O
HMG NN NN O
) NN NN O
protein NN NN O
gene NN NN O
HMGIC NN NN O
at NN NN O
12q15 NN NN O
is NN NN O
consistently NN NN O
rearranged NN NN O
as NN NN O
a NN NN O
consequence NN NN O
of NN NN O
these NN NN O
translocations NN NN O
. NN NN O

Here NN NN O
, NN NN O
we NN NN O
report NN NN O
the NN NN O
identification NN NN O
and NN NN O
characterization NN NN O
of NN NN O
the NN NN O
chromosome NN NN O
3-derived NN NN O
translocation NN NN O
partner NN NN O
gene NN NN O
, NN NN O
which NN NN O
we NN NN O
have NN NN O
designated NN NN O
LPP NN NN O
( NN NN O
lipoma NN NN B-Modifier
preferred NN NN O
partner NN NN O
gene NN NN O
) NN NN O
. NN NN O

Using NN NN O
3-RACE NN NN O
analysis NN NN O
of NN NN O
HMGIC NN NN O
fusion NN NN O
transcripts NN NN O
in NN NN O
lipoma NN NN B-Modifier
cell NN NN O
line NN NN O
Li-501 NN NN O
/ NN NN O
SV40 NN NN O
, NN NN O
ectopic NN NN O
genetic NN NN O
sequences NN NN O
were NN NN O
obtained NN NN O
, NN NN O
which NN NN O
by NN NN O
CASH NN NN O
( NN NN O
chromosome NN NN O
assignment NN NN O
using NN NN O
somatic NN NN O
cell NN NN O
hybrids NN NN O
) NN NN O
and NN NN O
FISH NN NN O
( NN NN O
fluorescence NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
) NN NN O
analysis NN NN O
were NN NN O
found NN NN O
to NN NN O
originate NN NN O
from NN NN O
chromosome NN NN O
segment NN NN O
3q27-q28 NN NN O
. NN NN O

In NN NN O
Northern NN NN O
blot NN NN O
analysis NN NN O
, NN NN O
an NN NN O
mRNA NN NN O
of NN NN O
over NN NN O
10 NN NN O
kb NN NN O
was NN NN O
detected NN NN O
by NN NN O
these NN NN O
ectopic NN NN O
sequences NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
human NN NN O
tissues NN NN O
but NN NN O
not NN NN O
in NN NN O
brain NN NN O
and NN NN O
peripheral NN NN O
blood NN NN O
leukocytes NN NN O
. NN NN O

Upon NN NN O
partial NN NN O
cDNA NN NN O
cloning NN NN O
, NN NN O
features NN NN O
of NN NN O
the NN NN O
genetic NN NN O
organization NN NN O
of NN NN O
LPP NN NN O
were NN NN O
established NN NN O
. NN NN O

The NN NN O
gene NN NN O
was NN NN O
found NN NN O
to NN NN O
span NN NN O
a NN NN O
genomic NN NN O
region NN NN O
of NN NN O
over NN NN O
400 NN NN O
kb NN NN O
. NN NN O

Nucleotide NN NN O
sequence NN NN O
analysis NN NN O
of NN NN O
a NN NN O
composite NN NN O
cDNA NN NN O
of NN NN O
LPP NN NN O
revealed NN NN O
an NN NN O
open NN NN O
reading NN NN O
frame NN NN O
of NN NN O
1836 NN NN O
nucleotides NN NN O
encoding NN NN O
a NN NN O
proline-rich NN NN O
protein NN NN O
containing NN NN O
a NN NN O
leucine-zipper NN NN O
motif NN NN O
in NN NN O
its NN NN O
amino-terminal NN NN O
region NN NN O
and NN NN O
three NN NN O
LIM NN NN O
domains NN NN O
in NN NN O
its NN NN O
carboxy-terminal NN NN O
region NN NN O
. NN NN O

The NN NN O
LPP-encoded NN NN O
protein NN NN O
should NN NN O
be NN NN O
classified NN NN O
as NN NN O
a NN NN O
novel NN NN O
member NN NN O
of NN NN O
the NN NN O
group NN NN O
3 NN NN O
proteins NN NN O
of NN NN O
the NN NN O
LIM NN NN O
protein NN NN O
gene NN NN O
family NN NN O
. NN NN O

Using NN NN O
reverse NN NN O
transcriptase NN NN O
combined NN NN O
with NN NN O
polymerase NN NN O
chain NN NN O
reactions NN NN O
in NN NN O
the NN NN O
analysis NN NN O
of NN NN O
a NN NN O
number NN NN O
of NN NN O
lipoma NN NN B-Modifier
cell NN NN O
lines NN NN O
and NN NN O
primary NN NN B-DiseaseClass
lipomas NN NN I-DiseaseClass
, NN NN O
it NN NN O
appeared NN NN O
that NN NN O
LPP NN NN O
is NN NN O
frequently NN NN O
rearranged NN NN O
also NN NN O
in NN NN O
cases NN NN O
without NN NN O
a NN NN O
cytogenetically NN NN O
detectable NN NN O
involvement NN NN O
of NN NN O
3q27-q28 NN NN O
. NN NN O

Two NN NN O
alternative NN NN O
HMGIC NN NN O
/ NN NN O
LPP NN NN O
hybrid NN NN O
transcripts NN NN O
have NN NN O
been NN NN O
detected NN NN O
; NN NN O
the NN NN O
difference NN NN O
between NN NN O
them NN NN O
is NN NN O
mainly NN NN O
the NN NN O
presence NN NN O
of NN NN O
either NN NN O
two NN NN O
or NN NN O
three NN NN O
LIM NN NN O
domains NN NN O
in NN NN O
the NN NN O
predicted NN NN O
HMGI-C NN NN O
/ NN NN O
LPP NN NN O
fusion NN NN O
proteins NN NN O
. NN NN O

. NN NN O

8824873 NN NN O
Absence NN NN O
of NN NN O
disease NN NN O
phenotype NN NN O
and NN NN O
intergenerational NN NN O
stability NN NN O
of NN NN O
the NN NN O
CAG NN NN O
repeat NN NN O
in NN NN O
transgenic NN NN O
mice NN NN O
expressing NN NN O
the NN NN O
human NN NN O
Huntington NN NN B-Modifier
disease NN NN I-Modifier
transcript NN NN O
. NN NN O

The NN NN O
mutation NN NN O
underlying NN NN O
Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
HD NN NN B-SpecificDisease
) NN NN O
is NN NN O
CAG NN NN O
expansion NN NN O
in NN NN O
the NN NN O
first NN NN O
exon NN NN O
of NN NN O
the NN NN O
HD NN NN B-Modifier
gene NN NN O
. NN NN O

In NN NN O
order NN NN O
to NN NN O
investigate NN NN O
the NN NN O
role NN NN O
of NN NN O
CAG NN NN O
expansion NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
HD NN NN B-SpecificDisease
, NN NN O
we NN NN O
have NN NN O
produced NN NN O
transgenic NN NN O
mice NN NN O
containing NN NN O
the NN NN O
full NN NN O
length NN NN O
human NN NN O
HD NN NN B-Modifier
cDNA NN NN O
with NN NN O
44 NN NN O
CAG NN NN O
repeats NN NN O
. NN NN O

By NN NN O
1 NN NN O
year NN NN O
, NN NN O
these NN NN O
mice NN NN O
have NN NN O
no NN NN O
behavioral NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
and NN NN O
morphometric NN NN O
analysis NN NN O
at NN NN O
6 NN NN O
( NN NN O
one NN NN O
animal NN NN O
) NN NN O
and NN NN O
9 NN NN O
( NN NN O
two NN NN O
animals NN NN O
) NN NN O
months NN NN O
age NN NN O
revealed NN NN O
no NN NN O
changes NN NN O
. NN NN O

Despite NN NN O
high NN NN O
levels NN NN O
of NN NN O
mRNA NN NN O
expression NN NN O
, NN NN O
there NN NN O
was NN NN O
no NN NN O
evidence NN NN O
of NN NN O
the NN NN O
HD NN NN B-Modifier
gene NN NN O
product NN NN O
in NN NN O
any NN NN O
of NN NN O
these NN NN O
transgenic NN NN O
mice NN NN O
. NN NN O

In NN NN O
vitro NN NN O
transfection NN NN O
studies NN NN O
indicated NN NN O
that NN NN O
the NN NN O
inclusion NN NN O
of NN NN O
120 NN NN O
bp NN NN O
of NN NN O
the NN NN O
5 NN NN O
UTR NN NN O
in NN NN O
the NN NN O
cDNA NN NN O
construct NN NN O
and NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
frameshift NN NN O
mutation NN NN O
at NN NN O
nucleotide NN NN O
2349 NN NN O
prevented NN NN O
expression NN NN O
of NN NN O
the NN NN O
HD NN NN B-Modifier
cDNA NN NN O
. NN NN O

These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
HD NN NN B-SpecificDisease
is NN NN O
not NN NN O
mediated NN NN O
through NN NN O
DNA-protein NN NN O
interaction NN NN O
and NN NN O
that NN NN O
presence NN NN O
of NN NN O
the NN NN O
RNA NN NN O
transcript NN NN O
with NN NN O
an NN NN O
expanded NN NN O
CAG NN NN O
repeat NN NN O
is NN NN O
insufficient NN NN O
to NN NN O
cause NN NN O
the NN NN O
disease NN NN O
. NN NN O

Rather NN NN O
, NN NN O
translation NN NN O
of NN NN O
the NN NN O
CAG NN NN O
is NN NN O
crucial NN NN O
for NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
HD NN NN B-SpecificDisease
. NN NN O

In NN NN O
contrast NN NN O
to NN NN O
that NN NN O
seen NN NN O
in NN NN O
humans NN NN O
, NN NN O
the NN NN O
CAG NN NN O
repeat NN NN O
in NN NN O
these NN NN O
mice NN NN O
was NN NN O
remarkably NN NN O
stable NN NN O
in NN NN O
97 NN NN O
meioses NN NN O
. NN NN O

This NN NN O
suggests NN NN O
that NN NN O
genomic NN NN O
sequences NN NN O
may NN NN O
play NN NN O
a NN NN O
critical NN NN O
role NN NN O
in NN NN O
influencing NN NN O
repeat NN NN O
instability NN NN O
. NN NN O

. NN NN O

8825052 NN NN O
FISH NN NN O
studies NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
sporadic NN NN B-SpecificDisease
aniridia NN NN I-SpecificDisease
and NN NN O
t NN NN O
( NN NN O
7 NN NN O
; NN NN O
11 NN NN O
) NN NN O
( NN NN O
q31.2 NN NN O
; NN NN O
p13 NN NN O
) NN NN O
. NN NN O

A NN NN O
2 NN NN O
year NN NN O
old NN NN O
female NN NN O
presenting NN NN O
with NN NN O
bilateral NN NN B-SpecificDisease
sporadic NN NN I-SpecificDisease
aniridia NN NN I-SpecificDisease
was NN NN O
found NN NN O
to NN NN O
have NN NN O
an NN NN O
apparently NN NN O
balanced NN NN O
reciprocal NN NN O
translocation NN NN O
with NN NN O
a NN NN O
chromosome NN NN O
11 NN NN O
breakpoint NN NN O
within NN NN O
band NN NN O
p13 NN NN O
. NN NN O

Fluorescence NN NN O
in NN NN O
situ NN NN O
hybridisation NN NN O
( NN NN O
FISH NN NN O
) NN NN O
studies NN NN O
with NN NN O
distal NN NN O
11p13 NN NN O
specific NN NN O
cosmids NN NN O
showed NN NN O
that NN NN O
the NN NN O
chromosome NN NN O
11 NN NN O
breakpoint NN NN O
lay NN NN O
between NN NN O
the NN NN O
aniridia NN NN B-SpecificDisease
( NN NN O
PAX6 NN NN O
) NN NN O
locus NN NN O
and NN NN O
a NN NN O
region NN NN O
approximately NN NN O
100 NN NN O
kb NN NN O
distal NN NN O
to NN NN O
PAX6 NN NN O
defined NN NN O
by NN NN O
the NN NN O
cosmid NN NN O
FO2121 NN NN O
. NN NN O

Although NN NN O
this NN NN O
patient NN NN O
did NN NN O
not NN NN O
have NN NN O
a NN NN O
detectable NN NN O
deletion NN NN O
within NN NN O
PAX6 NN NN O
, NN NN O
her NN NN O
aniridia NN NN B-SpecificDisease
may NN NN O
have NN NN O
resulted NN NN O
from NN NN O
a NN NN O
disruption NN NN O
of NN NN O
the NN NN O
distal NN NN O
chromatin NN NN O
domain NN NN O
containing NN NN O
either NN NN O
enhancers NN NN O
or NN NN O
regulators NN NN O
for NN NN O
PAX6 NN NN O
. NN NN O

This NN NN O
case NN NN O
may NN NN O
therefore NN NN O
be NN NN O
another NN NN O
example NN NN O
of NN NN O
aniridia NN NN B-SpecificDisease
caused NN NN O
by NN NN O
a NN NN O
position NN NN O
effect NN NN O
as NN NN O
recently NN NN O
described NN NN O
in NN NN O
two NN NN O
familial NN NN B-Modifier
aniridia NN NN I-Modifier
patients NN NN O
in NN NN O
which NN NN O
the NN NN O
phenotype NN NN O
cosegregated NN NN O
with NN NN O
chromosome NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
with NN NN O
11p13 NN NN O
breakpoints NN NN O
. NN NN O

. NN NN O

8825599 NN NN O
Muscle NN NN O
expression NN NN O
of NN NN O
glucose-6-phosphate NN NN B-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
different NN NN O
variants NN NN O
. NN NN O

Muscle NN NN O
expression NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
has NN NN O
been NN NN O
investigated NN NN O
in NN NN O
Mediterranean NN NN O
, NN NN O
Seattle-like NN NN O
and NN NN O
A-variants NN NN O
. NN NN O

G6PD NN NN O
activity NN NN O
was NN NN O
detected NN NN O
in NN NN O
samples NN NN O
obtained NN NN O
from NN NN O
biopsies NN NN O
on NN NN O
the NN NN O
quadriceps NN NN O
muscle NN NN O
of NN NN O
seven NN NN O
males NN NN O
and NN NN O
one NN NN O
female NN NN O
. NN NN O

The NN NN O
type NN NN O
of NN NN O
genetic NN NN O
variant NN NN O
was NN NN O
determined NN NN O
by NN NN O
molecular NN NN O
analysis NN NN O
of NN NN O
DNA NN NN O
, NN NN O
extracted NN NN O
from NN NN O
blood NN NN O
samples NN NN O
. NN NN O

All NN NN O
variants NN NN O
showed NN NN O
the NN NN O
enzyme NN NN O
defect NN NN O
in NN NN O
muscle NN NN O
. NN NN O

A NN NN O
statistically NN NN O
significant NN NN O
relationship NN NN O
was NN NN O
found NN NN O
in NN NN O
the NN NN O
activity NN NN O
of NN NN O
G6PD NN NN O
between NN NN O
erythrocytes NN NN O
and NN NN O
muscle NN NN O
of NN NN O
the NN NN O
male NN NN O
subjects NN NN O
( NN NN O
r NN NN O
= NN NN O
0 NN NN O
. NN NN O

968 NN NN O
; NN NN O
p NN NN O
= NN NN O
0 NN NN O
. NN NN O

00008 NN NN O
) NN NN O
. NN NN O

The NN NN O
equation NN NN O
for NN NN O
the NN NN O
best NN NN O
fit NN NN O
line NN NN O
was NN NN O
Y NN NN O
= NN NN O
0 NN NN O
. NN NN O

390X NN NN O
+ NN NN O
0 NN NN O
. NN NN O

198 NN NN O
198 NN NN O
. NN NN O

The NN NN O
results NN NN O
suggest NN NN O
that NN NN O
, NN NN O
for NN NN O
a NN NN O
given NN NN O
variant NN NN O
, NN NN O
the NN NN O
extent NN NN O
of NN NN O
the NN NN O
enzyme NN NN O
defect NN NN O
in NN NN O
muscle NN NN O
may NN NN O
be NN NN O
determined NN NN O
, NN NN O
using NN NN O
this NN NN O
equation NN NN O
, NN NN O
from NN NN O
the NN NN O
G6PD NN NN O
activity NN NN O
of NN NN O
erythrocytes NN NN O

8828602 NN NN O
Gene NN NN O
therapy NN NN O
for NN NN O
phenylketonuria NN NN B-SpecificDisease
. NN NN O

Classical NN NN O
phenylketonuria NN NN B-SpecificDisease
( NN NN O
PKU NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
caused NN NN O
by NN NN O
a NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
hepatic NN NN I-SpecificDisease
phenylalanine NN NN I-SpecificDisease
hydroxylase NN NN I-SpecificDisease
( NN NN O
PAH NN NN O
) NN NN O
. NN NN O

Limitations NN NN O
of NN NN O
the NN NN O
current NN NN O
dietary NN NN O
treatment NN NN O
for NN NN O
PKU NN NN B-SpecificDisease
have NN NN O
led NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
potential NN NN O
treatments NN NN O
based NN NN O
on NN NN O
somatic NN NN O
gene NN NN O
transfer NN NN O
. NN NN O

Three NN NN O
different NN NN O
vector NN NN O
systems NN NN O
have NN NN O
been NN NN O
examined NN NN O
. NN NN O

Vectors NN NN O
derived NN NN O
from NN NN O
a NN NN O
recombinant NN NN O
retrovirus NN NN O
or NN NN O
a NN NN O
DNA NN NN O
/ NN NN O
protein NN NN O
complex NN NN O
can NN NN O
efficiently NN NN O
transduce NN NN O
the NN NN O
PAH NN NN O
cDNA NN NN O
into NN NN O
PAH-deficient NN NN B-Modifier
hepatocytes NN NN O
in NN NN O
vitro NN NN O
, NN NN O
but NN NN O
the NN NN O
application NN NN O
of NN NN O
these NN NN O
vector NN NN O
systems NN NN O
is NN NN O
presently NN NN O
limited NN NN O
by NN NN O
their NN NN O
low NN NN O
transduction NN NN O
efficiency NN NN O
in NN NN O
vivo NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
a NN NN O
vector NN NN O
derived NN NN O
from NN NN O
a NN NN O
recombinant NN NN O
adenovirus NN NN O
can NN NN O
restore NN NN O
10 NN NN O
% NN NN O
-80 NN NN O
% NN NN O
of NN NN O
normal NN NN O
hepatic NN NN O
PAH NN NN O
activity NN NN O
into NN NN O
PAH-deficient NN NN B-Modifier
mice NN NN O
, NN NN O
which NN NN O
completely NN NN O
normalizes NN NN O
serum NN NN O
phenylalanine NN NN O
levels NN NN O
. NN NN O

This NN NN O
treatment NN NN O
is NN NN O
transient NN NN O
and NN NN O
can NN NN O
not NN NN O
be NN NN O
effectively NN NN O
re-administered NN NN O
due NN NN O
to NN NN O
the NN NN O
presence NN NN O
of NN NN O
neutralizing NN NN O
antibodies NN NN O
directed NN NN O
against NN NN O
the NN NN O
recombinant NN NN O
adenoviral NN NN O
vector NN NN O
. NN NN O

However NN NN O
, NN NN O
these NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
PKU NN NN B-SpecificDisease
can NN NN O
be NN NN O
completely NN NN O
corrected NN NN O
by NN NN O
somatic NN NN O
gene NN NN O
therapy NN NN O
, NN NN O
and NN NN O
provide NN NN O
some NN NN O
direction NN NN O
for NN NN O
the NN NN O
future NN NN O
development NN NN O
of NN NN O
adenoviral NN NN O
vectors NN NN O
. NN NN O

. NN NN O

8833159 NN NN O
Exon-intron NN NN O
structure NN NN O
of NN NN O
the NN NN O
human NN NN O
neuronal NN NN O
nicotinic NN NN O
acetylcholine NN NN O
receptor NN NN O
alpha NN NN O
4 NN NN O
subunit NN NN O
( NN NN O
CHRNA4 NN NN O
) NN NN O
. NN NN O

The NN NN O
human NN NN O
neuronal NN NN O
nicotinic NN NN O
acetylcholine NN NN O
receptor NN NN O
alpha NN NN O
4 NN NN O
subunit NN NN O
gene NN NN O
( NN NN O
CHRNA4 NN NN O
) NN NN O
is NN NN O
located NN NN O
in NN NN O
the NN NN O
candidate NN NN O
region NN NN O
for NN NN O
three NN NN O
different NN NN O
phenotypes NN NN O
benign NN NN B-SpecificDisease
familial NN NN I-SpecificDisease
neonatal NN NN I-SpecificDisease
convulsions NN NN I-SpecificDisease
, NN NN O
autosomal NN NN B-SpecificDisease
dominant NN NN I-SpecificDisease
nocturnal NN NN I-SpecificDisease
frontal NN NN I-SpecificDisease
lobe NN NN I-SpecificDisease
epilepsy NN NN I-SpecificDisease
, NN NN O
and NN NN O
low-voltage NN NN O
EEG NN NN O
. NN NN O

Recently NN NN O
, NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
in NN NN O
transmembrane NN NN O
domain NN NN O
2 NN NN O
of NN NN O
CHRNA4 NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
autosomal NN NN B-SpecificDisease
dominant NN NN I-SpecificDisease
nocturnal NN NN I-SpecificDisease
frontal NN NN I-SpecificDisease
lobe NN NN I-SpecificDisease
epilepsy NN NN I-SpecificDisease
in NN NN O
one NN NN O
extended NN NN O
pedigree NN NN O
. NN NN O

We NN NN O
have NN NN O
determined NN NN O
the NN NN O
genomic NN NN O
organization NN NN O
of NN NN O
CHRNA4 NN NN O
, NN NN O
which NN NN O
consists NN NN O
of NN NN O
six NN NN O
exons NN NN O
distributed NN NN O
over NN NN O
approximately NN NN O
17 NN NN O
kb NN NN O
of NN NN O
genomic NN NN O
DNA NN NN O
. NN NN O

The NN NN O
nucleotide NN NN O
sequence NN NN O
obtained NN NN O
from NN NN O
the NN NN O
genomic NN NN O
regions NN NN O
adjacent NN NN O
to NN NN O
the NN NN O
exon NN NN O
boundaries NN NN O
enabled NN NN O
us NN NN O
to NN NN O
develop NN NN O
a NN NN O
set NN NN O
of NN NN O
primer NN NN O
pairs NN NN O
for NN NN O
PCR NN NN O
amplification NN NN O
of NN NN O
the NN NN O
complete NN NN O
coding NN NN O
region NN NN O
. NN NN O

The NN NN O
sequence NN NN O
analysis NN NN O
provides NN NN O
the NN NN O
basis NN NN O
for NN NN O
a NN NN O
comprehensive NN NN O
mutation NN NN O
screening NN NN O
of NN NN O
CHRNA4 NN NN O
in NN NN O
the NN NN O
above-mentioned NN NN O
phenotypes NN NN O
and NN NN O
possibly NN NN O
in NN NN O
other NN NN O
types NN NN O
of NN NN O
idiopathic NN NN B-DiseaseClass
epilepsies NN NN I-DiseaseClass
. NN NN O

. NN NN O

8841191 NN NN O
Ashkenazi NN NN O
Jewish NN NN O
population NN NN O
frequencies NN NN O
for NN NN O
common NN NN O
mutations NN NN O
in NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
. NN NN O

BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
are NN NN O
the NN NN O
two NN NN O
major NN NN O
identified NN NN O
causes NN NN O
of NN NN O
inherited NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
with NN NN O
mutations NN NN O
in NN NN O
either NN NN O
gene NN NN O
conferring NN NN O
up NN NN O
to NN NN O
80-90 NN NN O
% NN NN O
lifetime NN NN O
risk NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
in NN NN O
carrier NN NN O
females NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
BRCA1 NN NN O
account NN NN O
for NN NN O
approximately NN NN O
45 NN NN O
% NN NN O
of NN NN O
familial NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
and NN NN O
90 NN NN O
% NN NN O
of NN NN O
inherited NN NN B-CompositeMention
breast NN NN I-CompositeMention
/ NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
, NN NN O
whereas NN NN O
mutations NN NN O
in NN NN O
BRCA2 NN NN O
account NN NN O
for NN NN O
a NN NN O
comparable NN NN O
percentage NN NN O
of NN NN O
inherited NN NN B-Modifier
breast NN NN I-Modifier
cancer NN NN I-Modifier
cases NN NN O
. NN NN O

Over NN NN O
85 NN NN O
distinct NN NN O
BRCA1 NN NN O
mutations NN NN O
and NN NN O
a NN NN O
growing NN NN O
list NN NN O
of NN NN O
BRCA2 NN NN O
mutations NN NN O
have NN NN O
been NN NN O
identified NN NN O
, NN NN O
with NN NN O
the NN NN O
majority NN NN O
resulting NN NN O
in NN NN O
protein NN NN O
truncation NN NN O
. NN NN O

A NN NN O
specific NN NN O
BRCA1 NN NN O
mutation NN NN O
, NN NN O
185delAG NN NN O
, NN NN O
has NN NN O
a NN NN O
reported NN NN O
increased NN NN O
carrier NN NN O
frequency NN NN O
of NN NN O
approximately NN NN O
0 NN NN O
. NN NN O

9 NN NN O
% NN NN O
in NN NN O
the NN NN O
Ashkenazi NN NN O
Jewish NN NN O
population NN NN O
, NN NN O
but NN NN O
is NN NN O
also NN NN O
found NN NN O
in NN NN O
rare NN NN O
non-Jewish NN NN O
patients NN NN O
with NN NN O
a NN NN O
different NN NN O
haplotype NN NN O
. NN NN O

The NN NN O
6174delT NN NN O
mutation NN NN O
in NN NN O
BRCA2 NN NN O
was NN NN O
recently NN NN O
identified NN NN O
as NN NN O
a NN NN O
frequent NN NN O
mutation NN NN O
in NN NN O
8 NN NN O
out NN NN O
of NN NN O
107 NN NN O
Ashkenazi NN NN O
Jewish NN NN O
women NN NN O
diagnosed NN NN O
with NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
by NN NN O
age NN NN O
50 NN NN O
( NN NN O
ref NN NN O
. NN NN O

8 NN NN O
) NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
three NN NN O
Ashkenazi NN NN O
male NN NN B-Modifier
breast NN NN I-Modifier
cancer NN NN I-Modifier
patients NN NN O
. NN NN O

We NN NN O
have NN NN O
conducted NN NN O
a NN NN O
large-scale NN NN O
population NN NN O
study NN NN O
to NN NN O
investigate NN NN O
the NN NN O
prevalence NN NN O
of NN NN O
specific NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
mutations NN NN O
in NN NN O
Ashkenazi NN NN O
Jewish NN NN O
individuals NN NN O
who NN NN O
were NN NN O
unselected NN NN O
for NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

BRCA1 NN NN O
mutation NN NN O
screening NN NN O
on NN NN O
approximately NN NN O
3 NN NN O
, NN NN O
000 NN NN O
Ashkenazi NN NN O
Jewish NN NN O
samples NN NN O
determined NN NN O
a NN NN O
carrier NN NN O
frequency NN NN O
of NN NN O
1 NN NN O
. NN NN O

09 NN NN O
% NN NN O
for NN NN O
the NN NN O
185delAG NN NN O
mutation NN NN O
and NN NN O
0 NN NN O
. NN NN O

13 NN NN O
% NN NN O
for NN NN O
the NN NN O
5382insC NN NN O
mutation NN NN O
. NN NN O

BRCA2 NN NN O
analysis NN NN O
on NN NN O
3 NN NN O
, NN NN O
085 NN NN O
individuals NN NN O
from NN NN O
the NN NN O
same NN NN O
population NN NN O
showed NN NN O
a NN NN O
carrier NN NN O
frequency NN NN O
of NN NN O
1 NN NN O
. NN NN O

52 NN NN O
% NN NN O
for NN NN O
the NN NN O
6174delT NN NN O
mutation NN NN O
. NN NN O

This NN NN O
expanded NN NN O
population-based NN NN O
study NN NN O
confirms NN NN O
that NN NN O
the NN NN O
BRCA1 NN NN O
185delAG NN NN O
mutation NN NN O
and NN NN O
the NN NN O
BRCA2 NN NN O
6174delT NN NN O
mutation NN NN O
constitute NN NN O
the NN NN O
two NN NN O
most NN NN O
frequent NN NN O
mutation NN NN O
alleles NN NN O
predisposing NN NN O
to NN NN O
hereditary NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
among NN NN O
the NN NN O
Ashkenazim NN NN O
, NN NN O
and NN NN O
suggests NN NN O
a NN NN O
relatively NN NN O
lower NN NN O
penetrance NN NN O
for NN NN O
the NN NN O
6174delT NN NN O
mutation NN NN O
in NN NN O
BRCA2 NN NN O

8843193 NN NN O
Dual NN NN O
roles NN NN O
of NN NN O
ATM NN NN O
in NN NN O
the NN NN O
cellular NN NN O
response NN NN O
to NN NN O
radiation NN NN O
and NN NN O
in NN NN O
cell NN NN O
growth NN NN O
control NN NN O
. NN NN O

The NN NN O
gene NN NN O
mutated NN NN O
in NN NN O
ataxia-telangiectasia NN NN B-Modifier
( NN NN O
AT NN NN B-Modifier
) NN NN O
patients NN NN O
, NN NN O
denoted NN NN O
ATM NN NN O
, NN NN O
encodes NN NN O
a NN NN O
putative NN NN O
protein NN NN O
or NN NN O
lipid NN NN O
kinase NN NN O
. NN NN O

To NN NN O
elucidate NN NN O
the NN NN O
functions NN NN O
of NN NN O
ATM NN NN O
, NN NN O
we NN NN O
disrupted NN NN O
the NN NN O
mouse NN NN O
ATM NN NN O
gene NN NN O
through NN NN O
homologous NN NN O
recombination NN NN O
in NN NN O
mice NN NN O
. NN NN O

Consistent NN NN O
with NN NN O
cellular NN NN O
defects NN NN O
of NN NN O
AT NN NN B-Modifier
patients NN NN O
, NN NN O
the NN NN O
ATM- NN NN O
/ NN NN O
- NN NN O
cells NN NN O
are NN NN O
hypersensitive NN NN O
to NN NN O
gamma-irradiation NN NN O
and NN NN O
defective NN NN O
in NN NN O
cell-cycle NN NN O
arrest NN NN O
following NN NN O
radiation NN NN O
, NN NN O
correlating NN NN O
with NN NN O
a NN NN O
defective NN NN O
up-regulation NN NN O
of NN NN O
p53 NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
ATM- NN NN O
/ NN NN O
- NN NN O
mouse NN NN O
thymocytes NN NN O
are NN NN O
more NN NN O
resistant NN NN O
to NN NN O
apoptosis NN NN O
induced NN NN O
by NN NN O
gamma-irradiation NN NN O
than NN NN O
normal NN NN O
thymocytes NN NN O
. NN NN O

ATM- NN NN O
/ NN NN O
- NN NN O
fibroblasts NN NN O
are NN NN O
inefficient NN NN O
in NN NN O
G1 NN NN O
to NN NN O
S-phase NN NN O
progression NN NN O
following NN NN O
serum NN NN O
stimulation NN NN O
and NN NN O
senesce NN NN O
after NN NN O
only NN NN O
a NN NN O
few NN NN O
passages NN NN O
in NN NN O
culture NN NN O
. NN NN O

They NN NN O
have NN NN O
an NN NN O
increased NN NN O
constitutive NN NN O
level NN NN O
of NN NN O
p21CP1 NN NN O
/ NN NN O
WAF1 NN NN O
. NN NN O

The NN NN O
ATM NN NN O
protein NN NN O
is NN NN O
therefore NN NN O
critical NN NN O
both NN NN O
for NN NN O
cellular NN NN O
responses NN NN O
to NN NN O
ionizing NN NN O
radiation NN NN O
and NN NN O
for NN NN O
normal NN NN O
cell-cycle NN NN O
progression NN NN O
. NN NN O

ATM NN NN O
+ NN NN O
/ NN NN O
- NN NN O
fibroblasts NN NN O
and NN NN O
thymocytes NN NN O
showed NN NN O
intermediately NN NN O
defective NN NN O
responses NN NN O
to NN NN O
irradiation NN NN O
but NN NN O
no NN NN O
growth NN NN O
defect NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
increased NN NN O
cancer NN NN B-Modifier
risk NN NN O
of NN NN O
AT NN NN B-Modifier
heterozygotes NN NN O
could NN NN O
be NN NN O
attributable NN NN O
to NN NN O
poor NN NN O
checkpoint NN NN O
function NN NN O
. NN NN O

. NN NN O

8843194 NN NN O
Targeted NN NN O
disruption NN NN O
of NN NN O
ATM NN NN O
leads NN NN O
to NN NN O
growth NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
, NN NN O
chromosomal NN NN B-SpecificDisease
fragmentation NN NN I-SpecificDisease
during NN NN I-SpecificDisease
meiosis NN NN I-SpecificDisease
, NN NN O
immune NN NN B-DiseaseClass
defects NN NN I-DiseaseClass
, NN NN O
and NN NN O
thymic NN NN B-SpecificDisease
lymphoma NN NN I-SpecificDisease
. NN NN O

ATM NN NN O
, NN NN O
the NN NN O
gene NN NN O
mutated NN NN O
in NN NN O
the NN NN O
inherited NN NN B-DiseaseClass
human NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
ataxia-telangiectasia NN NN B-SpecificDisease
, NN NN O
is NN NN O
a NN NN O
member NN NN O
of NN NN O
a NN NN O
family NN NN O
of NN NN O
kinases NN NN O
involved NN NN O
in NN NN O
DNA NN NN O
metabolism NN NN O
and NN NN O
cell-cycle NN NN O
checkpoint NN NN O
control NN NN O
. NN NN O

To NN NN O
help NN NN O
clarify NN NN O
the NN NN O
physiological NN NN O
roles NN NN O
of NN NN O
the NN NN O
ATM NN NN O
protein NN NN O
, NN NN O
we NN NN O
disrupted NN NN O
the NN NN O
ATM NN NN O
gene NN NN O
in NN NN O
mice NN NN O
through NN NN O
homologous NN NN O
recombination NN NN O
. NN NN O

Initial NN NN O
evaluation NN NN O
of NN NN O
the NN NN O
ATM NN NN O
knockout NN NN O
animals NN NN O
indicates NN NN O
that NN NN O
inactivation NN NN O
of NN NN O
the NN NN O
mouse NN NN O
ATM NN NN O
gene NN NN O
recreates NN NN O
much NN NN O
of NN NN O
the NN NN O
phenotype NN NN O
of NN NN O
ataxia-telangiectasia NN NN B-SpecificDisease
. NN NN O

The NN NN O
homozygous NN NN O
mutant NN NN O
( NN NN O
ATM- NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
are NN NN O
viable NN NN O
, NN NN O
growth-retarded NN NN O
, NN NN O
and NN NN O
infertile NN NN O
. NN NN O

The NN NN O
infertility NN NN B-SpecificDisease
of NN NN O
ATM- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
results NN NN O
from NN NN O
meiotic NN NN O
failure NN NN O
. NN NN O

Meiosis NN NN O
is NN NN O
arrested NN NN O
at NN NN O
the NN NN O
zygotene NN NN O
/ NN NN O
pachytene NN NN O
stage NN NN O
of NN NN O
prophase NN NN O
I NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
abnormal NN NN O
chromosomal NN NN O
synapsis NN NN O
and NN NN O
subsequent NN NN O
chromosome NN NN O
fragmentation NN NN O
. NN NN O

Immune NN NN B-DiseaseClass
defects NN NN I-DiseaseClass
also NN NN O
are NN NN O
evident NN NN O
in NN NN O
ATM- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
, NN NN O
including NN NN O
reduced NN NN O
numbers NN NN O
of NN NN O
B220 NN NN O
+ NN NN O
CD43- NN NN O
pre-B NN NN O
cells NN NN O
, NN NN O
thymocytes NN NN O
, NN NN O
and NN NN O
peripheral NN NN O
T NN NN O
cells NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
functional NN NN O
impairment NN NN O
of NN NN O
T-cell-dependent NN NN O
immune NN NN O
responses NN NN O
. NN NN O

The NN NN O
cerebella NN NN O
of NN NN O
ATM- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
appear NN NN O
normal NN NN O
by NN NN O
histologic NN NN O
examination NN NN O
at NN NN O
3 NN NN O
to NN NN O
4 NN NN O
months NN NN O
and NN NN O
the NN NN O
mice NN NN O
have NN NN O
no NN NN O
gross NN NN O
behavioral NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
. NN NN O

The NN NN O
majority NN NN O
of NN NN O
mutant NN NN O
mice NN NN O
rapidly NN NN O
develop NN NN O
thymic NN NN B-SpecificDisease
lymphomas NN NN I-SpecificDisease
and NN NN O
die NN NN O
before NN NN O
4 NN NN O
months NN NN O
of NN NN O
age NN NN O
. NN NN O

These NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
the NN NN O
ATM NN NN O
gene NN NN O
product NN NN O
plays NN NN O
an NN NN O
essential NN NN O
role NN NN O
in NN NN O
a NN NN O
diverse NN NN O
group NN NN O
of NN NN O
cellular NN NN O
processes NN NN O
, NN NN O
including NN NN O
meiosis NN NN O
, NN NN O
the NN NN O
normal NN NN O
growth NN NN O
of NN NN O
somatic NN NN O
tissues NN NN O
, NN NN O
immune NN NN O
development NN NN O
, NN NN O
and NN NN O
tumor NN NN B-Modifier
suppression NN NN O
. NN NN O

. NN NN O

8845838 NN NN O
Cloning NN NN O
and NN NN O
characterization NN NN O
of NN NN O
human NN NN O
very-long-chain NN NN O
acyl-CoA NN NN O
dehydrogenase NN NN O
cDNA NN NN O
, NN NN O
chromosomal NN NN O
assignment NN NN O
of NN NN O
the NN NN O
gene NN NN O
and NN NN O
identification NN NN O
in NN NN O
four NN NN O
patients NN NN O
of NN NN O
nine NN NN O
different NN NN O
mutations NN NN O
within NN NN O
the NN NN O
VLCAD NN NN O
gene NN NN O
. NN NN O

Very-long-chain NN NN O
acyl-CoA NN NN O
dehydrogenase NN NN O
( NN NN O
VLCAD NN NN O
) NN NN O
is NN NN O
one NN NN O
of NN NN O
four NN NN O
straight-chain NN NN O
acyl-CoA NN NN O
dehydrogenase NN NN O
( NN NN O
ACD NN NN O
) NN NN O
enzymes NN NN O
, NN NN O
which NN NN O
are NN NN O
all NN NN O
nuclear NN NN O
encoded NN NN O
mitochondrial NN NN O
flavoproteins NN NN O
catalyzing NN NN O
the NN NN O
initial NN NN O
step NN NN O
in NN NN O
fatty NN NN O
acid NN NN O
beta-oxidation NN NN O
. NN NN O

We NN NN O
have NN NN O
used NN NN O
the NN NN O
very NN NN O
fast NN NN O
, NN NN O
Rapid NN NN O
Amplification NN NN O
of NN NN O
cDNA NN NN O
Ends NN NN O
( NN NN O
RACE NN NN O
) NN NN O
based NN NN O
strategy NN NN O
to NN NN O
obtain NN NN O
the NN NN O
sequence NN NN O
of NN NN O
cDNAs NN NN O
encoding NN NN O
human NN NN O
VLCAD NN NN O
from NN NN O
placenta NN NN O
and NN NN O
fibroblasts NN NN O
. NN NN O

Alignment NN NN O
of NN NN O
the NN NN O
predicted NN NN O
amino NN NN O
acid NN NN O
sequence NN NN O
of NN NN O
human NN NN O
VLCAD NN NN O
with NN NN O
those NN NN O
of NN NN O
the NN NN O
other NN NN O
human NN NN O
ACD NN NN O
enzymes NN NN O
revealed NN NN O
extensive NN NN O
sequence NN NN O
homology NN NN O
. NN NN O

Moreover NN NN O
, NN NN O
human NN NN O
VLCAD NN NN O
and NN NN O
human NN NN O
acyl-CoA NN NN O
oxidase NN NN O
showed NN NN O
extensive NN NN O
sequence NN NN O
homology NN NN O
corroborating NN NN O
the NN NN O
notion NN NN O
that NN NN O
these NN NN O
genes NN NN O
are NN NN O
evolutionarily NN NN O
related NN NN O
. NN NN O

Southern NN NN O
blot NN NN O
analysis NN NN O
of NN NN O
genomic NN NN O
DNA NN NN O
from NN NN O
hybrid NN NN O
cell NN NN O
lines NN NN O
was NN NN O
used NN NN O
to NN NN O
localize NN NN O
the NN NN O
VLCAD NN NN O
gene NN NN O
to NN NN O
human NN NN O
chromosome NN NN O
17p11 NN NN O
. NN NN O

2-p11 NN NN O
2-p11 NN NN O
. NN NN O

13105 NN NN O
13105 NN NN O
. NN NN O

Using NN NN O
Northern NN NN O
and NN NN O
Western NN NN O
blot NN NN O
analysis NN NN O
to NN NN O
investigate NN NN O
the NN NN O
tissue NN NN O
specific NN NN O
distribution NN NN O
of NN NN O
VLCAD NN NN O
mRNA NN NN O
and NN NN O
protein NN NN O
in NN NN O
several NN NN O
human NN NN O
tissues NN NN O
we NN NN O
showed NN NN O
that NN NN O
VLCAD NN NN O
is NN NN O
most NN NN O
abundant NN NN O
in NN NN O
heart NN NN O
and NN NN O
skeletal NN NN O
muscle NN NN O
. NN NN O

This NN NN O
agrees NN NN O
well NN NN O
with NN NN O
the NN NN O
fact NN NN O
that NN NN O
cardiac NN NN O
and NN NN O
muscle NN NN O
symptoms NN NN O
are NN NN O
characteristic NN NN O
for NN NN O
patients NN NN O
with NN NN O
VLCAD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Northern NN NN O
blot NN NN O
analysis NN NN O
and NN NN O
sequencing NN NN O
of NN NN O
cloned NN NN O
PCR NN NN O
amplified NN NN O
VLCAD NN NN O
cDNA NN NN O
from NN NN O
four NN NN O
unrelated NN NN O
patients NN NN O
with NN NN O
VLCAD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
showed NN NN O
that NN NN O
VLCAD NN NN O
mRNA NN NN O
was NN NN O
undetectable NN NN O
in NN NN O
one NN NN O
patient NN NN O
and NN NN O
that NN NN O
the NN NN O
other NN NN O
three NN NN O
have NN NN O
mutations NN NN O
in NN NN O
both NN NN O
VLCAD NN NN O
alleles NN NN O
. NN NN O

Western NN NN O
blot NN NN O
analysis NN NN O
of NN NN O
patient NN NN O
fibroblasts NN NN O
showed NN NN O
that NN NN O
the NN NN O
identified NN NN O
mutations NN NN O
result NN NN O
in NN NN O
severely NN NN O
reduced NN NN O
amounts NN NN O
of NN NN O
VLCAD NN NN O
protein NN NN O
. NN NN O

8871666 NN NN O
Molecular NN NN O
bases NN NN O
of NN NN O
combined NN NN B-SpecificDisease
subtotal NN NN I-SpecificDisease
deficiencies NN NN I-SpecificDisease
of NN NN I-SpecificDisease
C6 NN NN I-SpecificDisease
and NN NN I-SpecificDisease
C7 NN NN I-SpecificDisease
: NN NN O
their NN NN O
effects NN NN O
in NN NN O
combination NN NN O
with NN NN O
other NN NN O
C6 NN NN B-CompositeMention
and NN NN I-CompositeMention
C7 NN NN I-CompositeMention
deficiencies NN NN I-CompositeMention
. NN NN O

Combined NN NN B-SpecificDisease
subtotal NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
of NN NN I-SpecificDisease
C6 NN NN I-SpecificDisease
and NN NN I-SpecificDisease
C7 NN NN I-SpecificDisease
, NN NN O
in NN NN O
which NN NN O
both NN NN O
proteins NN NN O
are NN NN O
expressed NN NN O
at NN NN O
very NN NN O
low NN NN O
levels NN NN O
, NN NN O
has NN NN O
been NN NN O
observed NN NN O
in NN NN O
homozygous NN NN O
form NN NN O
in NN NN O
two NN NN O
families NN NN O
. NN NN O

A NN NN O
defect NN NN O
at NN NN O
the NN NN O
5 NN NN O
splice NN NN O
donor NN NN O
site NN NN O
of NN NN O
intron NN NN O
15 NN NN O
of NN NN O
the NN NN O
C6 NN NN O
gene NN NN O
explains NN NN O
the NN NN O
low NN NN O
molecular NN NN O
weight NN NN O
of NN NN O
the NN NN O
C6 NN NN O
protein NN NN O
and NN NN O
is NN NN O
probably NN NN O
responsible NN NN O
for NN NN O
its NN NN O
low NN NN O
expressed NN NN O
concentration NN NN O
. NN NN O

The NN NN O
C7 NN NN O
defect NN NN O
is NN NN O
more NN NN O
enigmatic NN NN O
the NN NN O
protein NN NN O
is NN NN O
of NN NN O
normal NN NN O
molecular NN NN O
weight NN NN O
, NN NN O
low NN NN O
circulating NN NN O
concentration NN NN O
, NN NN O
and NN NN O
altered NN NN O
isoelectric NN NN O
point NN NN O
. NN NN O

An NN NN O
Arg NN NN O
Ser NN NN O
codon NN NN O
substitution NN NN O
in NN NN O
exon NN NN O
11 NN NN O
is NN NN O
the NN NN O
only NN NN O
molecular NN NN O
alteration NN NN O
within NN NN O
the NN NN O
mature NN NN O
C7 NN NN O
protein NN NN O
. NN NN O

These NN NN O
defects NN NN O
are NN NN O
associated NN NN O
with NN NN O
a NN NN O
characteristic NN NN O
set NN NN O
of NN NN O
polymorphic NN NN O
DNA NN NN O
markers NN NN O
in NN NN O
the NN NN O
C6 NN NN O
/ NN NN O
C7 NN NN O
region NN NN O
, NN NN O
forming NN NN O
a NN NN O
distinct NN NN O
haplotype NN NN O
. NN NN O

The NN NN O
haplotype NN NN O
has NN NN O
been NN NN O
found NN NN O
in NN NN O
combination NN NN O
with NN NN O
a NN NN O
number NN NN O
of NN NN O
other NN NN O
haplotypes NN NN O
containing NN NN O
defective NN NN O
genes NN NN O
that NN NN O
lead NN NN O
either NN NN O
to NN NN O
C6 NN NN B-CompositeMention
or NN NN I-CompositeMention
C7 NN NN B-CompositeMention
deficiency NN NN I-CompositeMention
, NN NN O
but NN NN O
with NN NN O
different NN NN O
consequences NN NN O
. NN NN O

Where NN NN O
it NN NN O
is NN NN O
combined NN NN O
with NN NN O
a NN NN O
C6-deficient NN NN B-Modifier
gene NN NN O
, NN NN O
the NN NN O
serum NN NN O
C7 NN NN O
levels NN NN O
can NN NN O
be NN NN O
surprisingly NN NN O
high NN NN O
, NN NN O
possibly NN NN O
because NN NN O
there NN NN O
is NN NN O
no NN NN O
C6 NN NN O
generating NN NN O
C56 NN NN O
to NN NN O
consume NN NN O
the NN NN O
C7 NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
where NN NN O
the NN NN O
C7 NN NN O
genes NN NN O
are NN NN O
both NN NN O
defective NN NN O
( NN NN O
but NN NN O
still NN NN O
partially NN NN O
functional NN NN O
) NN NN O
, NN NN O
there NN NN O
may NN NN O
be NN NN O
a NN NN O
profound NN NN O
deficit NN NN O
of NN NN O
circulating NN NN O
C7 NN NN O
because NN NN O
there NN NN O
is NN NN O
ample NN NN O
C6 NN NN O
to NN NN O
produce NN NN O
C56 NN NN O
and NN NN O
consume NN NN O
the NN NN O
already NN NN O
small NN NN O
amount NN NN O
of NN NN O
C7 NN NN O
. NN NN O

Each NN NN O
molecular NN NN O
defect NN NN O
has NN NN O
also NN NN O
been NN NN O
found NN NN O
in NN NN O
isolation NN NN O
and NN NN O
has NN NN O
the NN NN O
expected NN NN O
effect NN NN O
. NN NN O

. NN NN O

8892662 NN NN O
Genetic NN NN O
bases NN NN O
of NN NN O
human NN NN O
complement NN NN B-SpecificDisease
C7 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Complement NN NN B-SpecificDisease
C7 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
( NN NN O
C7D NN NN B-SpecificDisease
) NN NN O
is NN NN O
associated NN NN O
frequently NN NN O
with NN NN O
recurrent NN NN O
bacterial NN NN B-DiseaseClass
infections NN NN I-DiseaseClass
, NN NN O
especially NN NN O
meningitis NN NN B-DiseaseClass
caused NN NN O
by NN NN O
Neisseria NN NN B-SpecificDisease
meningitidis NN NN I-SpecificDisease
. NN NN O

We NN NN O
report NN NN O
in NN NN O
this NN NN O
work NN NN O
the NN NN O
molecular NN NN O
bases NN NN O
of NN NN O
C7D NN NN B-SpecificDisease
in NN NN O
two NN NN O
unrelated NN NN O
Japanese NN NN O
males NN NN O
. NN NN O

We NN NN O
used NN NN O
exon-specific NN NN O
PCR NN NN O
/ NN NN O
single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
analysis NN NN O
as NN NN O
a NN NN O
screening NN NN O
step NN NN O
for NN NN O
mutations NN NN O
. NN NN O

Subsequent NN NN O
direct NN NN O
sequencing NN NN O
of NN NN O
the NN NN O
target NN NN O
exons NN NN O
identified NN NN O
homozygous NN NN O
mutations NN NN O
in NN NN O
exon NN NN O
16 NN NN O
of NN NN O
case NN NN O
1 NN NN O
and NN NN O
in NN NN O
exon NN NN O
15 NN NN O
of NN NN O
case NN NN O
2 NN NN O
. NN NN O

The NN NN O
mutation NN NN O
of NN NN O
case NN NN O
1 NN NN O
was NN NN O
a NN NN O
homozygous NN NN O
T NN NN O
to NN NN O
A NN NN O
transversion NN NN O
at NN NN O
nucleotide NN NN O
2250 NN NN O
, NN NN O
the NN NN O
third NN NN O
nucleotide NN NN O
of NN NN O
the NN NN O
codon NN NN O
TGT NN NN O
for NN NN O
Cys728 NN NN O
, NN NN O
leading NN NN O
to NN NN O
a NN NN O
stop NN NN O
codon NN NN O
TGA NN NN O
( NN NN O
C728X NN NN O
) NN NN O
. NN NN O

In NN NN O
case NN NN O
2 NN NN O
, NN NN O
a NN NN O
homozygous NN NN O
2-bp NN NN O
deletion NN NN O
( NN NN O
2137delTG NN NN O
/ NN NN O
2138delGT NN NN O
/ NN NN O
2139delTG NN NN O
) NN NN O
caused NN NN O
a NN NN O
frameshift NN NN O
, NN NN O
generating NN NN O
a NN NN O
premature NN NN O
termination NN NN O
codon NN NN O
4 NN NN O
to NN NN O
6 NN NN O
nucleotides NN NN O
downstream NN NN O
. NN NN O

Family NN NN O
study NN NN O
in NN NN O
case NN NN O
1 NN NN O
confirmed NN NN O
the NN NN O
genetic NN NN O
nature NN NN O
of NN NN O
the NN NN O
defect NN NN O
. NN NN O

Moreover NN NN O
, NN NN O
we NN NN O
detected NN NN O
a NN NN O
novel NN NN O
polymorphism NN NN O
in NN NN O
intron NN NN O
11 NN NN O
that NN NN O
presumably NN NN O
is NN NN O
linked NN NN O
to NN NN O
the NN NN O
mutation NN NN O
responsible NN NN O
for NN NN O
C7D NN NN B-SpecificDisease
in NN NN O
case NN NN O
1 NN NN O
. NN NN O

Our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
C7D NN NN B-SpecificDisease
is NN NN O
heterogeneous NN NN O
like NN NN O
most NN NN O
of NN NN O
the NN NN O
other NN NN O
deficiencies NN NN B-DiseaseClass
of NN NN I-DiseaseClass
complement NN NN I-DiseaseClass
components NN NN I-DiseaseClass
. NN NN O

. NN NN O

8894695 NN NN O
HPRT-APRT-deficient NN NN B-Modifier
mice NN NN O
are NN NN O
not NN NN O
a NN NN O
model NN NN O
for NN NN O
lesch-nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Complete NN NN B-SpecificDisease
hypoxanthine-guanine NN NN I-SpecificDisease
phosphoribosyl-transferase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
HPRT NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
humans NN NN O
results NN NN O
in NN NN O
the NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
which NN NN O
is NN NN O
characterized NN NN O
, NN NN O
among NN NN O
other NN NN O
features NN NN O
, NN NN O
by NN NN O
compulsive NN NN O
self-injurious NN NN O
behavior NN NN O
. NN NN O

HPRT-deficient NN NN B-Modifier
mice NN NN O
generated NN NN O
using NN NN O
mouse NN NN O
embryonic NN NN O
stem NN NN O
cells NN NN O
exhibit NN NN O
none NN NN O
of NN NN O
the NN NN O
behavioral NN NN O
symptoms NN NN O
associated NN NN O
with NN NN O
the NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Administration NN NN O
of NN NN O
drugs NN NN O
that NN NN O
inhibit NN NN O
adenine NN NN O
phosphoribosyltransferase NN NN O
( NN NN O
APRT NN NN O
) NN NN O
in NN NN O
HPRT-deficient NN NN B-Modifier
mice NN NN O
has NN NN O
produced NN NN O
the NN NN O
suggestion NN NN O
that NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
APRT NN NN I-SpecificDisease
in NN NN O
combination NN NN O
with NN NN O
HPRT-deficiency NN NN B-SpecificDisease
in NN NN O
mice NN NN O
may NN NN O
lead NN NN O
to NN NN O
self-mutilation NN NN O
behavior NN NN O
[ NN NN O
C NN NN O
. NN NN O

L NN NN O
. NN NN O

Wu NN NN O
and NN NN O
D NN NN O
. NN NN O

W NN NN O
. NN NN O

Melton NN NN O
( NN NN O
1993 NN NN O
) NN NN O
Nature NN NN O
Genet NN NN O
. NN NN O

3 NN NN O
, NN NN O
235-240 NN NN O
] NN NN O
. NN NN O

To NN NN O
test NN NN O
this NN NN O
proposition NN NN O
, NN NN O
we NN NN O
bred NN NN O
HPRT-APRT-deficient NN NN B-Modifier
mice NN NN O
. NN NN O

Although NN NN O
the NN NN O
doubly-deficient NN NN O
mice NN NN O
excrete NN NN O
adenine NN NN O
and NN NN O
its NN NN O
highly NN NN O
insoluble NN NN O
derivative NN NN O
, NN NN O
2 NN NN O
, NN NN O
8-dihydroxyadenine NN NN O
, NN NN O
which NN NN O
are NN NN O
also NN NN O
associated NN NN O
with NN NN O
human NN NN O
APRT NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
additional NN NN O
abnormalities NN NN O
or NN NN O
any NN NN O
self-injurious NN NN O
behavior NN NN O
were NN NN O
not NN NN O
detected NN NN O
. NN NN O

Thus NN NN O
, NN NN O
APRT-HPRT-deficient NN NN B-Modifier
mice NN NN O
, NN NN O
which NN NN O
are NN NN O
devoid NN NN O
of NN NN O
any NN NN O
purine NN NN O
salvage NN NN O
pathways NN NN O
, NN NN O
show NN NN O
no NN NN O
novel NN NN O
phenotype NN NN O
and NN NN O
are NN NN O
not NN NN O
a NN NN O
model NN NN O
for NN NN O
the NN NN O
behavioral NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
associated NN NN O
with NN NN O
the NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
as NN NN O
previously NN NN O
suggested NN NN O

8898652 NN NN O
Somatic NN NN O
alterations NN NN O
of NN NN O
the NN NN O
DPC4 NN NN O
gene NN NN O
in NN NN O
human NN NN O
colorectal NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
in NN NN O
vivo NN NN O
. NN NN O

BACKGROUND NN NN O
& NN NN O
AIMS NN NN O
The NN NN O
chromosome NN NN O
region NN NN O
18q21 NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
frequently NN NN O
deleted NN NN O
in NN NN O
colorectal NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
, NN NN O
and NN NN O
such NN NN O
frequent NN NN O
allelic NN NN O
loss NN NN O
is NN NN O
a NN NN O
hallmark NN NN O
of NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
tumor-suppressor NN NN O
gene NN NN O
. NN NN O

The NN NN O
DPC4 NN NN O
gene NN NN O
, NN NN O
which NN NN O
is NN NN O
located NN NN O
at NN NN O
18q21 NN NN O
, NN NN O
has NN NN O
been NN NN O
identified NN NN O
as NN NN O
a NN NN O
tumor-suppressor NN NN O
gene NN NN O
from NN NN O
examination NN NN O
of NN NN O
pancreatic NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
. NN NN O

The NN NN O
aim NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
was NN NN O
to NN NN O
determine NN NN O
if NN NN O
it NN NN O
might NN NN O
also NN NN O
be NN NN O
altered NN NN O
in NN NN O
colorectal NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
. NN NN O

METHODS NN NN O
Mutation NN NN O
analyses NN NN O
of NN NN O
the NN NN O
DPC4 NN NN O
gene NN NN O
were NN NN O
performed NN NN O
on NN NN O
complementary NN NN O
DNA NN NN O
samples NN NN O
from NN NN O
31 NN NN O
primary NN NN O
colorectal NN NN B-Modifier
cancer NN NN I-Modifier
specimens NN NN O
using NN NN O
a NN NN O
combination NN NN O
of NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
, NN NN O
single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
, NN NN O
and NN NN O
DNA NN NN O
sequencing NN NN O
. NN NN O

RESULTS NN NN O
Four NN NN O
missense NN NN O
mutations NN NN O
producing NN NN O
amino NN NN O
acid NN NN O
substitutions NN NN O
and NN NN O
a NN NN O
somatic NN NN O
12-base NN NN O
pair NN NN O
deletion NN NN O
in NN NN O
the NN NN O
coding NN NN O
region NN NN O
of NN NN O
the NN NN O
DPC4 NN NN O
gene NN NN O
were NN NN O
detected NN NN O
in NN NN O
the NN NN O
31 NN NN O
cancers NN NN B-DiseaseClass
( NN NN O
16 NN NN O
% NN NN O
; NN NN O
5 NN NN O
of NN NN O
31 NN NN O
) NN NN O
. NN NN O

CONCLUSIONS NN NN O
The NN NN O
DPC4 NN NN O
gene NN NN O
may NN NN O
play NN NN O
a NN NN O
role NN NN O
as NN NN O
a NN NN O
tumor-suppressor NN NN O
gene NN NN O
in NN NN O
a NN NN O
fraction NN NN O
of NN NN O
colorectal NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
; NN NN O
however NN NN O
, NN NN O
while NN NN O
allelic NN NN O
loss NN NN O
at NN NN O
18q21 NN NN O
is NN NN O
very NN NN O
often NN NN O
seen NN NN O
in NN NN O
colorectal NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
, NN NN O
only NN NN O
a NN NN O
minority NN NN O
show NN NN O
DPC4 NN NN O
mutations NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
there NN NN O
might NN NN O
be NN NN O
another NN NN O
tumor-suppressor NN NN O
gene NN NN O
in NN NN O
this NN NN O
chromosome NN NN O
region NN NN O
. NN NN O

. NN NN O

8917548 NN NN O
Pleiotropic NN NN O
defects NN NN O
in NN NN O
ataxia-telangiectasia NN NN B-Modifier
protein-deficient NN NN O
mice NN NN O
. NN NN O

We NN NN O
have NN NN O
generated NN NN O
a NN NN O
mouse NN NN O
model NN NN O
for NN NN O
ataxia-telangiectasia NN NN B-SpecificDisease
by NN NN O
using NN NN O
gene NN NN O
targeting NN NN O
to NN NN O
generate NN NN O
mice NN NN O
that NN NN O
do NN NN O
not NN NN O
express NN NN O
the NN NN O
Atm NN NN O
protein NN NN O
. NN NN O

Atm-deficient NN NN B-Modifier
mice NN NN O
are NN NN O
retarded NN NN O
in NN NN O
growth NN NN O
, NN NN O
do NN NN O
not NN NN O
produce NN NN O
mature NN NN O
sperm NN NN O
, NN NN O
and NN NN O
exhibit NN NN O
severe NN NN O
defects NN NN O
in NN NN O
T NN NN O
cell NN NN O
maturation NN NN O
while NN NN O
going NN NN O
on NN NN O
to NN NN O
develop NN NN O
thymomas NN NN B-SpecificDisease
. NN NN O

Atm-deficient NN NN B-Modifier
fibroblasts NN NN O
grow NN NN O
poorly NN NN O
in NN NN O
culture NN NN O
and NN NN O
display NN NN O
a NN NN O
high NN NN O
level NN NN O
of NN NN O
double-stranded NN NN O
chromosome NN NN O
breaks NN NN O
. NN NN O

Atm-deficient NN NN B-Modifier
thymocytes NN NN O
undergo NN NN O
spontaneous NN NN O
apoptosis NN NN O
in NN NN O
vitro NN NN O
significantly NN NN O
more NN NN O
than NN NN O
controls NN NN O
. NN NN O

Atm-deficient NN NN B-Modifier
mice NN NN O
then NN NN O
exhibit NN NN O
many NN NN O
of NN NN O
the NN NN O
same NN NN O
symptoms NN NN O
found NN NN O
in NN NN O
ataxia-telangiectasia NN NN B-Modifier
patients NN NN O
and NN NN O
in NN NN O
cells NN NN O
derived NN NN O
from NN NN O
them NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
Atm NN NN O
protein NN NN O
exists NN NN O
as NN NN O
two NN NN O
discrete NN NN O
molecular NN NN O
species NN NN O
, NN NN O
and NN NN O
that NN NN O
loss NN NN O
of NN NN O
one NN NN O
or NN NN O
of NN NN O
both NN NN O
of NN NN O
these NN NN O
can NN NN O
lead NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O

. NN NN O

8929264 NN NN O
The NN NN O
DCC NN NN O
protein NN NN O
and NN NN O
prognosis NN NN O
in NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

BACKGROUND NN NN O
Allelic NN NN O
loss NN NN O
of NN NN O
chromosome NN NN O
18q NN NN O
predicts NN NN O
a NN NN O
poor NN NN O
outcome NN NN O
in NN NN O
patients NN NN O
with NN NN O
stage NN NN B-SpecificDisease
II NN NN I-SpecificDisease
colorectal NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Although NN NN O
the NN NN O
specific NN NN O
gene NN NN O
inactivated NN NN O
by NN NN O
this NN NN O
allelic NN NN O
loss NN NN O
has NN NN O
not NN NN O
been NN NN O
elucidated NN NN O
, NN NN O
the NN NN O
DCC NN NN O
( NN NN O
deleted NN NN O
in NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
) NN NN O
gene NN NN O
is NN NN O
a NN NN O
candidate NN NN O
. NN NN O

We NN NN O
investigated NN NN O
whether NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
DCC NN NN O
protein NN NN O
in NN NN O
tumor NN NN B-Modifier
cells NN NN O
is NN NN O
a NN NN O
prognostic NN NN O
marker NN NN O
in NN NN O
colorectal NN NN B-SpecificDisease
carcinoma NN NN I-SpecificDisease
. NN NN O

METHODS NN NN O
The NN NN O
expression NN NN O
of NN NN O
DCC NN NN O
was NN NN O
evaluated NN NN O
immunohistochemically NN NN O
in NN NN O
132 NN NN O
paraffin-embedded NN NN O
samples NN NN O
from NN NN O
patients NN NN O
with NN NN O
curatively NN NN O
resected NN NN O
stage NN NN B-CompositeMention
II NN NN I-CompositeMention
and NN NN I-CompositeMention
III NN NN I-CompositeMention
colorectal NN NN I-CompositeMention
carcinomas NN NN I-CompositeMention
. NN NN O

The NN NN O
Cox NN NN O
proportional-hazards NN NN O
model NN NN O
was NN NN O
used NN NN O
to NN NN O
adjust NN NN O
for NN NN O
covariates NN NN O
including NN NN O
age NN NN O
, NN NN O
sex NN NN O
, NN NN O
tumor NN NN B-Modifier
site NN NN O
, NN NN O
degree NN NN O
of NN NN O
tumor NN NN B-Modifier
differentiation NN NN O
, NN NN O
and NN NN O
use NN NN O
of NN NN O
adjuvant NN NN O
therapy NN NN O
. NN NN O

RESULTS NN NN O
The NN NN O
expression NN NN O
of NN NN O
DCC NN NN O
was NN NN O
a NN NN O
strong NN NN O
positive NN NN O
predictive NN NN O
factor NN NN O
for NN NN O
survival NN NN O
in NN NN O
both NN NN O
stage NN NN B-CompositeMention
II NN NN I-CompositeMention
and NN NN I-CompositeMention
stage NN NN I-CompositeMention
III NN NN I-CompositeMention
colorectal NN NN I-CompositeMention
carcinomas NN NN I-CompositeMention
. NN NN O

In NN NN O
patients NN NN O
with NN NN O
stage NN NN O
II NN NN O
disease NN NN O
whose NN NN O
tumors NN NN B-DiseaseClass
expressed NN NN O
DCC NN NN O
, NN NN O
the NN NN O
five-year NN NN O
survival NN NN O
rate NN NN O
was NN NN O
94 NN NN O
. NN NN O

3 NN NN O
percent NN NN O
, NN NN O
whereas NN NN O
in NN NN O
patients NN NN O
with NN NN O
DCC-negative NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
, NN NN O
the NN NN O
survival NN NN O
rate NN NN O
was NN NN O
61 NN NN O
. NN NN O

6 NN NN O
percent NN NN O
( NN NN O
P NN NN O
0 NN NN O
. NN NN O

001 NN NN O
) NN NN O
. NN NN O

In NN NN O
patients NN NN O
with NN NN O
stage NN NN B-SpecificDisease
III NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN O
the NN NN O
respective NN NN O
survival NN NN O
rates NN NN O
were NN NN O
59 NN NN O
. NN NN O

3 NN NN O
percent NN NN O
and NN NN O
33 NN NN O
. NN NN O

2 NN NN O
percent NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O

03 NN NN O
) NN NN O
. NN NN O

CONCLUSIONS NN NN O
DCC NN NN O
is NN NN O
a NN NN O
prognostic NN NN O
marker NN NN O
in NN NN O
patients NN NN O
with NN NN O
stage NN NN B-CompositeMention
II NN NN I-CompositeMention
or NN NN I-CompositeMention
stage NN NN I-CompositeMention
III NN NN I-CompositeMention
colorectal NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

In NN NN O
stage NN NN B-SpecificDisease
II NN NN I-SpecificDisease
colorectal NN NN I-SpecificDisease
carcinomas NN NN I-SpecificDisease
, NN NN O
the NN NN O
absence NN NN O
of NN NN O
DCC NN NN O
identifies NN NN O
a NN NN O
subgroup NN NN O
of NN NN O
patients NN NN O
with NN NN O
lesions NN NN O
that NN NN O
behave NN NN O
like NN NN O
stage NN NN B-DiseaseClass
III NN NN I-DiseaseClass
cancers NN NN I-DiseaseClass
. NN NN O

These NN NN O
findings NN NN O
may NN NN O
thus NN NN O
have NN NN O
therapeutic NN NN O
implications NN NN O
in NN NN O
this NN NN O
group NN NN O
of NN NN O
patients NN NN O

8929413 NN NN O
Association NN NN O
of NN NN O
anxiety-related NN NN B-DiseaseClass
traits NN NN I-DiseaseClass
with NN NN O
a NN NN O
polymorphism NN NN O
in NN NN O
the NN NN O
serotonin NN NN O
transporter NN NN O
gene NN NN O
regulatory NN NN O
region NN NN O
. NN NN O

Transporter-facilitated NN NN O
uptake NN NN O
of NN NN O
serotonin NN NN O
( NN NN O
5-hydroxytryptamine NN NN O
or NN NN O
5-HT NN NN O
) NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
anxiety NN NN B-DiseaseClass
in NN NN O
humans NN NN O
and NN NN O
animal NN NN O
models NN NN O
and NN NN O
is NN NN O
the NN NN O
site NN NN O
of NN NN O
action NN NN O
of NN NN O
widely NN NN O
used NN NN O
uptake-inhibiting NN NN O
antidepressant NN NN O
and NN NN O
antianxiety NN NN O
drugs NN NN O
. NN NN O

Human NN NN O
5-HT NN NN O
transporter NN NN O
( NN NN O
5-HTT NN NN O
) NN NN O
gene NN NN O
transcription NN NN O
is NN NN O
modulated NN NN O
by NN NN O
a NN NN O
common NN NN O
polymorphism NN NN O
in NN NN O
its NN NN O
upstream NN NN O
regulatory NN NN O
region NN NN O
. NN NN O

The NN NN O
short NN NN O
variant NN NN O
of NN NN O
the NN NN O
polymorphism NN NN O
reduces NN NN O
the NN NN O
transcriptional NN NN O
efficiency NN NN O
of NN NN O
the NN NN O
5-HTT NN NN O
gene NN NN O
promoter NN NN O
, NN NN O
resulting NN NN O
in NN NN O
decreased NN NN O
5-HTT NN NN O
expression NN NN O
and NN NN O
5-HT NN NN O
uptake NN NN O
in NN NN O
lymphoblasts NN NN O
. NN NN O

Association NN NN O
studies NN NN O
in NN NN O
two NN NN O
independent NN NN O
samples NN NN O
totaling NN NN O
505 NN NN O
individuals NN NN O
revealed NN NN O
that NN NN O
the NN NN O
5-HTT NN NN O
polymorphism NN NN O
accounts NN NN O
for NN NN O
3 NN NN O
to NN NN O
4 NN NN O
percent NN NN O
of NN NN O
total NN NN O
variation NN NN O
and NN NN O
7 NN NN O
to NN NN O
9 NN NN O
percent NN NN O
of NN NN O
inherited NN NN O
variance NN NN O
in NN NN O
anxiety-related NN NN B-DiseaseClass
personality NN NN I-DiseaseClass
traits NN NN I-DiseaseClass
in NN NN O
individuals NN NN O
as NN NN O
well NN NN O
as NN NN O
sibships NN NN O
. NN NN O

. NN NN O

8931695 NN NN O
Phenotypic NN NN O
and NN NN O
genotypic NN NN O
overlap NN NN O
between NN NN O
atelosteogenesis NN NN B-SpecificDisease
type NN NN I-SpecificDisease
2 NN NN I-SpecificDisease
and NN NN O
diastrophic NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
diastrophic NN NN B-Modifier
dysplasia NN NN I-Modifier
sulfate NN NN O
transporter NN NN O
gene NN NN O
DTDST NN NN O
have NN NN O
been NN NN O
associated NN NN O
with NN NN O
a NN NN O
family NN NN O
of NN NN O
chondrodysplasias NN NN B-DiseaseClass
that NN NN O
comprises NN NN O
, NN NN O
in NN NN O
order NN NN O
of NN NN O
increasing NN NN O
severity NN NN O
, NN NN O
diastrophic NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
( NN NN O
DTD NN NN B-SpecificDisease
) NN NN O
, NN NN O
atelosteogenesis NN NN B-SpecificDisease
type NN NN I-SpecificDisease
2 NN NN I-SpecificDisease
( NN NN O
AO2 NN NN B-SpecificDisease
) NN NN O
, NN NN O
and NN NN O
achondrogenesis NN NN B-SpecificDisease
type NN NN I-SpecificDisease
1B NN NN I-SpecificDisease
( NN NN O
ACG1B NN NN B-SpecificDisease
) NN NN O
. NN NN O

To NN NN O
learn NN NN O
more NN NN O
about NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
DTDST NN NN B-SpecificDisease
chondrodysplasias NN NN I-SpecificDisease
and NN NN O
about NN NN O
genotype-phenotype NN NN O
correlations NN NN O
, NN NN O
we NN NN O
studied NN NN O
fibroblast NN NN O
cultures NN NN O
of NN NN O
three NN NN O
new NN NN O
patients NN NN O
one NN NN O
with NN NN O
AO-2 NN NN B-SpecificDisease
, NN NN O
one NN NN O
with NN NN O
DTD NN NN B-SpecificDisease
, NN NN O
and NN NN O
one NN NN O
with NN NN O
an NN NN O
intermediate NN NN O
phenotype NN NN O
( NN NN O
AO2 NN NN B-SpecificDisease
/ NN NN O
DTD NN NN B-SpecificDisease
) NN NN O
. NN NN O

Reduced NN NN O
incorporation NN NN O
of NN NN O
inorganic NN NN O
sulfate NN NN O
into NN NN O
macromolecules NN NN O
was NN NN O
found NN NN O
in NN NN O
all NN NN O
three NN NN O
. NN NN O

Each NN NN O
of NN NN O
the NN NN O
three NN NN O
patients NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
heterozygous NN NN O
for NN NN O
a NN NN O
c862t NN NN O
transition NN NN O
predicting NN NN O
a NN NN O
R279W NN NN O
substitution NN NN O
in NN NN O
the NN NN O
third NN NN O
extracellular NN NN O
loop NN NN O
of NN NN O
DTDST NN NN O
. NN NN O

In NN NN O
two NN NN O
patients NN NN O
( NN NN O
DTD NN NN B-SpecificDisease
and NN NN O
AO2 NN NN B-SpecificDisease
/ NN NN O
DTD NN NN B-SpecificDisease
) NN NN O
, NN NN O
no NN NN O
other NN NN O
structural NN NN O
mutation NN NN O
was NN NN O
found NN NN O
, NN NN O
but NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
amplification NN NN O
and NN NN O
single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
analysis NN NN O
of NN NN O
fibroblast NN NN O
cDNA NN NN O
showed NN NN O
reduced NN NN O
mRNA NN NN O
levels NN NN O
of NN NN O
the NN NN O
wild-type NN NN O
DTDST NN NN O
allele NN NN O
these NN NN O
two NN NN O
patients NN NN O
may NN NN O
be NN NN O
compound NN NN O
heterozygotes NN NN O
for NN NN O
the NN NN O
`` NN NN O
Finnish NN NN O
`` NN NN O
mutation NN NN O
( NN NN O
as NN NN O
yet NN NN O
uncharacterized NN NN O
at NN NN O
the NN NN O
DNA NN NN O
level NN NN O
) NN NN O
, NN NN O
which NN NN O
causes NN NN O
reduced NN NN O
expression NN NN O
of NN NN O
DTDST NN NN O
. NN NN O

The NN NN O
third NN NN O
patient NN NN O
( NN NN O
with NN NN O
AO2 NN NN B-SpecificDisease
) NN NN O
had NN NN O
the NN NN O
R279W NN NN O
mutation NN NN O
compounded NN NN O
with NN NN O
a NN NN O
novel NN NN O
mutation NN NN O
, NN NN O
the NN NN O
deletion NN NN O
of NN NN O
cytosine NN NN O
418 NN NN O
( NN NN O
delta NN NN O
c418 NN NN O
) NN NN O
, NN NN O
predicting NN NN O
a NN NN O
frameshift NN NN O
with NN NN O
premature NN NN O
termination NN NN O
. NN NN O

Also NN NN O
the NN NN O
delta NN NN O
c418 NN NN O
allele NN NN O
was NN NN O
underrepresented NN NN O
in NN NN O
the NN NN O
cDNA NN NN O
, NN NN O
in NN NN O
accordance NN NN O
with NN NN O
previous NN NN O
observations NN NN O
that NN NN O
premature NN NN O
stop NN NN O
codons NN NN O
reduce NN NN O
mRNA NN NN O
levels NN NN O
. NN NN O

The NN NN O
presence NN NN O
of NN NN O
the NN NN O
DTDST NN NN O
R279W NN NN O
mutation NN NN O
in NN NN O
a NN NN O
total NN NN O
of NN NN O
11 NN NN O
patients NN NN O
with NN NN O
AO2 NN NN B-SpecificDisease
or NN NN O
DTD NN NN B-SpecificDisease
emphasizes NN NN O
the NN NN O
overlap NN NN O
between NN NN O
these NN NN O
conditions NN NN O
. NN NN O

This NN NN O
mutation NN NN O
has NN NN O
not NN NN O
been NN NN O
found NN NN O
so NN NN O
far NN NN O
in NN NN O
8 NN NN O
analyzed NN NN O
ACG1B NN NN B-Modifier
patients NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
it NN NN O
allows NN NN O
some NN NN O
residual NN NN O
activity NN NN O
of NN NN O
the NN NN O
sulfate NN NN O
transporter NN NN O
. NN NN O

. NN NN O

8931701 NN NN O
Identification NN NN O
of NN NN O
WASP NN NN O
mutations NN NN O
, NN NN O
mutation NN NN O
hotspots NN NN O
and NN NN O
genotype-phenotype NN NN O
disparities NN NN O
in NN NN O
24 NN NN O
patients NN NN O
with NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

The NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
WAS NN NN B-SpecificDisease
) NN NN O
, NN NN O
an NN NN O
X-linked NN NN B-DiseaseClass
immunodeficiency NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
caused NN NN O
by NN NN O
mutation NN NN O
in NN NN O
the NN NN O
recently NN NN O
isolated NN NN O
gene NN NN O
encoding NN NN O
WAS NN NN B-Modifier
protein NN NN O
( NN NN O
WASP NN NN O
) NN NN O
, NN NN O
is NN NN O
known NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
extensive NN NN O
clinical NN NN O
heterogeneity NN NN O
. NN NN O

Cumulative NN NN O
mutation NN NN O
data NN NN O
have NN NN O
revealed NN NN O
that NN NN O
WASP NN NN O
genotypes NN NN O
are NN NN O
also NN NN O
highly NN NN O
variable NN NN O
among NN NN O
WAS NN NN B-Modifier
patients NN NN O
, NN NN O
but NN NN O
the NN NN O
relationship NN NN O
of NN NN O
phenotype NN NN O
with NN NN O
genotype NN NN O
in NN NN O
this NN NN O
disease NN NN O
remains NN NN O
unclear NN NN O
. NN NN O

To NN NN O
address NN NN O
this NN NN O
issue NN NN O
we NN NN O
characterized NN NN O
WASP NN NN O
mutations NN NN O
in NN NN O
24 NN NN O
unrelated NN NN O
WAS NN NN B-Modifier
patients NN NN O
, NN NN O
including NN NN O
18 NN NN O
boys NN NN O
with NN NN O
severe NN NN O
classical NN NN O
WAS NN NN B-SpecificDisease
and NN NN O
6 NN NN O
boys NN NN O
expressing NN NN O
mild NN NN O
forms NN NN O
of NN NN O
the NN NN O
disease NN NN O
, NN NN O
and NN NN O
then NN NN O
examined NN NN O
the NN NN O
degree NN NN O
of NN NN O
correlation NN NN O
of NN NN O
these NN NN O
as NN NN O
well NN NN O
as NN NN O
all NN NN O
previously NN NN O
published NN NN O
WASP NN NN O
mutations NN NN O
with NN NN O
disease NN NN O
severity NN NN O
. NN NN O

By NN NN O
analysis NN NN O
of NN NN O
these NN NN O
compiled NN NN O
mutation NN NN O
data NN NN O
, NN NN O
we NN NN O
demonstrated NN NN O
clustering NN NN O
of NN NN O
WASP NN NN O
mutations NN NN O
within NN NN O
the NN NN O
four NN NN O
most NN NN O
N-terminal NN NN O
exons NN NN O
of NN NN O
the NN NN O
gene NN NN O
and NN NN O
also NN NN O
identified NN NN O
several NN NN O
sites NN NN O
within NN NN O
this NN NN O
region NN NN O
as NN NN O
hotspots NN NN O
for NN NN O
WASP NN NN O
mutation NN NN O
. NN NN O

These NN NN O
characteristics NN NN O
were NN NN O
observed NN NN O
, NN NN O
however NN NN O
, NN NN O
in NN NN O
both NN NN O
severe NN NN O
and NN NN O
mild NN NN O
cases NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O

Similarly NN NN O
, NN NN O
while NN NN O
the NN NN O
cumulative NN NN O
data NN NN O
revealed NN NN O
a NN NN O
predominance NN NN O
of NN NN O
missense NN NN O
mutations NN NN O
among NN NN O
the NN NN O
WASP NN NN O
gene NN NN O
lesions NN NN O
observed NN NN O
in NN NN O
boys NN NN O
with NN NN O
isolated NN NN B-SpecificDisease
thrombocytopenia NN NN I-SpecificDisease
, NN NN O
missense NN NN O
mutations NN NN O
were NN NN O
not NN NN O
exclusively NN NN O
associated NN NN O
with NN NN O
milder NN NN O
WAS NN NN B-Modifier
phenotypes NN NN O
, NN NN O
but NN NN O
also NN NN O
comprised NN NN O
a NN NN O
substantial NN NN O
portion NN NN O
( NN NN O
38 NN NN O
% NN NN O
) NN NN O
of NN NN O
the NN NN O
WASP NN NN O
gene NN NN O
defects NN NN O
found NN NN O
in NN NN O
patients NN NN O
with NN NN O
severe NN NN O
disease NN NN O
. NN NN O

These NN NN O
findings NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
detection NN NN O
of NN NN O
identical NN NN O
WASP NN NN O
mutations NN NN O
in NN NN O
patients NN NN O
with NN NN O
disparate NN NN O
phenotypes NN NN O
, NN NN O
reveal NN NN O
a NN NN O
lack NN NN O
of NN NN O
phenotype NN NN O
concordance NN NN O
with NN NN O
genotype NN NN O
in NN NN O
WAS NN NN B-SpecificDisease
and NN NN O
thus NN NN O
imply NN NN O
that NN NN O
phenotypic NN NN O
outcome NN NN O
in NN NN O
this NN NN O
disease NN NN O
can NN NN O
not NN NN O
be NN NN O
reliably NN NN O
predicted NN NN O
solely NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
WASP NN NN O
genotypes NN NN O
. NN NN O

. NN NN O

8931709 NN NN O
Germline NN NN O
mutations NN NN O
in NN NN O
the NN NN O
3 NN NN O
' NN NN O
part NN NN O
of NN NN O
APC NN NN B-Modifier
exon NN NN O
15 NN NN O
do NN NN O
not NN NN O
result NN NN O
in NN NN O
truncated NN NN O
proteins NN NN O
and NN NN O
are NN NN O
associated NN NN O
with NN NN O
attenuated NN NN O
adenomatous NN NN B-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
. NN NN O

Familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
( NN NN O
FAP NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
inherited NN NN O
predisposition NN NN O
to NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
characterized NN NN O
by NN NN O
the NN NN O
development NN NN O
of NN NN O
numerous NN NN O
adenomatous NN NN B-DiseaseClass
polyps NN NN I-DiseaseClass
predominantly NN NN O
in NN NN O
the NN NN O
colorectal NN NN O
region NN NN O
. NN NN O

Germline NN NN O
mutations NN NN O
in NN NN O
the NN NN O
adenomatous NN NN B-Modifier
polyposis NN NN I-Modifier
coli NN NN I-Modifier
( NN NN O
APC NN NN B-Modifier
) NN NN O
gene NN NN O
are NN NN O
responsible NN NN O
for NN NN O
most NN NN O
cases NN NN O
of NN NN O
FAP NN NN B-SpecificDisease
. NN NN O

Mutations NN NN O
at NN NN O
the NN NN O
5 NN NN O
end NN NN O
of NN NN O
APC NN NN B-SpecificDisease
are NN NN O
known NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
a NN NN O
relatively NN NN O
mild NN NN O
form NN NN O
of NN NN O
the NN NN O
disease NN NN O
, NN NN O
called NN NN O
attenuated NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
( NN NN O
AAPC NN NN B-SpecificDisease
) NN NN O
. NN NN O

We NN NN O
identified NN NN O
a NN NN O
frameshift NN NN O
mutation NN NN O
in NN NN O
the NN NN O
3 NN NN O
part NN NN O
of NN NN O
exon NN NN O
15 NN NN O
, NN NN O
resulting NN NN O
in NN NN O
a NN NN O
stop NN NN O
codon NN NN O
at NN NN O
1862 NN NN O
, NN NN O
in NN NN O
a NN NN O
large NN NN O
Dutch NN NN O
kindred NN NN O
with NN NN O
AAPC NN NN B-SpecificDisease
. NN NN O

Western NN NN O
blot NN NN O
analysis NN NN O
of NN NN O
lymphoblastoid NN NN O
cell NN NN O
lines NN NN O
derived NN NN O
from NN NN O
affected NN NN O
family NN NN O
members NN NN O
from NN NN O
this NN NN O
kindred NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
from NN NN O
a NN NN O
previously NN NN O
reported NN NN O
Swiss NN NN O
family NN NN O
carrying NN NN O
a NN NN O
frameshift NN NN O
mutation NN NN O
at NN NN O
codon NN NN O
1987 NN NN O
and NN NN O
displaying NN NN O
a NN NN O
similar NN NN O
attenuated NN NN O
phenotype NN NN O
, NN NN O
showed NN NN O
only NN NN O
the NN NN O
wild-type NN NN O
APC NN NN B-Modifier
protein NN NN O
. NN NN O

Our NN NN O
study NN NN O
indicates NN NN O
that NN NN O
chain-terminating NN NN O
mutations NN NN O
located NN NN O
in NN NN O
the NN NN O
3 NN NN O
part NN NN O
of NN NN O
APC NN NN B-SpecificDisease
do NN NN O
not NN NN O
result NN NN O
in NN NN O
detectable NN NN O
truncated NN NN O
polypeptides NN NN O
and NN NN O
we NN NN O
hypothesize NN NN O
that NN NN O
this NN NN O
is NN NN O
likely NN NN O
to NN NN O
be NN NN O
the NN NN O
basis NN NN O
for NN NN O
the NN NN O
observed NN NN O
AAPC NN NN B-Modifier
phenotype NN NN O
. NN NN O

. NN NN O

8938427 NN NN O
Complete NN NN O
genomic NN NN O
sequence NN NN O
and NN NN O
analysis NN NN O
of NN NN O
117 NN NN O
kb NN NN O
of NN NN O
human NN NN O
DNA NN NN O
containing NN NN O
the NN NN O
gene NN NN O
BRCA1 NN NN O
. NN NN O

Over NN NN O
100 NN NN O
distinct NN NN O
disease-associated NN NN O
mutations NN NN O
have NN NN O
been NN NN O
identified NN NN O
in NN NN O
the NN NN O
breast-ovarian NN NN B-Modifier
cancer NN NN I-Modifier
susceptibility NN NN O
gene NN NN O
BRCA1 NN NN O
. NN NN O

Loss NN NN O
of NN NN O
the NN NN O
wild-type NN NN O
allele NN NN O
in NN NN O
90 NN NN O
% NN NN O
of NN NN O
tumors NN NN B-DiseaseClass
from NN NN O
patients NN NN O
with NN NN O
inherited NN NN O
BRCA1 NN NN O
mutations NN NN O
indicates NN NN O
tumor NN NN B-Modifier
suppressive NN NN O
function NN NN O
. NN NN O

The NN NN O
low NN NN O
incidence NN NN O
of NN NN O
somatic NN NN O
mutations NN NN O
suggests NN NN O
that NN NN O
BRCA1 NN NN O
inactivation NN NN O
in NN NN O
sporadic NN NN O
tumors NN NN B-DiseaseClass
occurs NN NN O
by NN NN O
alternative NN NN O
mechanisms NN NN O
, NN NN O
such NN NN O
as NN NN O
interstitial NN NN O
chromosomal NN NN O
deletion NN NN O
or NN NN O
reduced NN NN O
transcription NN NN O
. NN NN O

To NN NN O
identify NN NN O
possible NN NN O
features NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
genomic NN NN O
region NN NN O
that NN NN O
may NN NN O
contribute NN NN O
to NN NN O
chromosomal NN NN O
instability NN NN O
as NN NN O
well NN NN O
as NN NN O
potential NN NN O
transcriptional NN NN O
regulatory NN NN O
elements NN NN O
, NN NN O
a NN NN O
117 NN NN O
, NN NN O
143-bp NN NN O
DNA NN NN O
sequence NN NN O
encompassing NN NN O
BRCA1 NN NN O
was NN NN O
obtained NN NN O
by NN NN O
random NN NN O
sequencing NN NN O
of NN NN O
four NN NN O
cosmids NN NN O
identified NN NN O
from NN NN O
a NN NN O
human NN NN O
chromosome NN NN O
17 NN NN O
specific NN NN O
library NN NN O
. NN NN O

The NN NN O
24 NN NN O
exons NN NN O
of NN NN O
BRCA1 NN NN O
span NN NN O
an NN NN O
81-kb NN NN O
region NN NN O
that NN NN O
has NN NN O
an NN NN O
unusually NN NN O
high NN NN O
density NN NN O
of NN NN O
Alu NN NN O
repetitive NN NN O
DNA NN NN O
( NN NN O
41 NN NN O
. NN NN O

5 NN NN O
% NN NN O
) NN NN O
, NN NN O
but NN NN O
relatively NN NN O
low NN NN O
density NN NN O
( NN NN O
4 NN NN O
. NN NN O

8 NN NN O
% NN NN O
) NN NN O
of NN NN O
other NN NN O
repetitive NN NN O
sequences NN NN O
. NN NN O

BRCA1 NN NN O
intron NN NN O
lengths NN NN O
range NN NN O
in NN NN O
size NN NN O
from NN NN O
403 NN NN O
bp NN NN O
to NN NN O
9 NN NN O
. NN NN O

2 NN NN O
kb NN NN O
and NN NN O
contain NN NN O
the NN NN O
intragenic NN NN O
microsatellite NN NN O
markers NN NN O
D17S1323 NN NN O
, NN NN O
D17S1322 NN NN O
, NN NN O
and NN NN O
D17S855 NN NN O
, NN NN O
which NN NN O
localize NN NN O
to NN NN O
introns NN NN O
12 NN NN O
, NN NN O
19 NN NN O
, NN NN O
and NN NN O
20 NN NN O
, NN NN O
respectively NN NN O
. NN NN O

In NN NN O
addition NN NN O
to NN NN O
BRCA1 NN NN O
, NN NN O
the NN NN O
contig NN NN O
contains NN NN O
two NN NN O
complete NN NN O
genes NN NN O
Rho7 NN NN O
, NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
rho NN NN O
family NN NN O
of NN NN O
GTP NN NN O
binding NN NN O
proteins NN NN O
, NN NN O
and NN NN O
VAT1 NN NN O
, NN NN O
an NN NN O
abundant NN NN O
membrane NN NN O
protein NN NN O
of NN NN O
cholinergic NN NN O
synaptic NN NN O
vesicles NN NN O
. NN NN O

Partial NN NN O
sequences NN NN O
of NN NN O
the NN NN O
1A1-3B NN NN O
B-box NN NN O
protein NN NN O
pseudogene NN NN O
and NN NN O
IFP NN NN O
35 NN NN O
, NN NN O
an NN NN O
interferon NN NN O
induced NN NN O
leucine NN NN O
zipper NN NN O
protein NN NN O
, NN NN O
reside NN NN O
within NN NN O
the NN NN O
contig NN NN O
. NN NN O

An NN NN O
L21 NN NN O
ribosomal NN NN O
protein NN NN O
pseudogene NN NN O
is NN NN O
embedded NN NN O
in NN NN O
BRCA1 NN NN O
intron NN NN O
13 NN NN O
. NN NN O

The NN NN O
order NN NN O
of NN NN O
genes NN NN O
on NN NN O
the NN NN O
chromosome NN NN O
is NN NN O
centromere-1FP NN NN O
35-VAT1-Rho7-BRCA1-1A1-3B-telomere NN NN O

8944023 NN NN O
Identification NN NN O
of NN NN O
a NN NN O
RING NN NN O
protein NN NN O
that NN NN O
can NN NN O
interact NN NN O
in NN NN O
vivo NN NN O
with NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
product NN NN O
. NN NN O

The NN NN O
hereditary NN NN B-Modifier
breast NN NN I-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
gene NN NN O
, NN NN O
BRCA1 NN NN O
, NN NN O
encodes NN NN O
a NN NN O
large NN NN O
polypeptide NN NN O
that NN NN O
contains NN NN O
the NN NN O
cysteine-rich NN NN O
RING NN NN O
motif NN NN O
, NN NN O
a NN NN O
zinc-binding NN NN O
domain NN NN O
found NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
regulatory NN NN O
proteins NN NN O
. NN NN O

Here NN NN O
we NN NN O
describe NN NN O
a NN NN O
novel NN NN O
protein NN NN O
that NN NN O
interacts NN NN O
in NN NN O
vivo NN NN O
with NN NN O
the NN NN O
N-terminal NN NN O
region NN NN O
of NN NN O
BRCA1 NN NN O
. NN NN O

This NN NN O
BRCA1-associated NN NN O
RING NN NN O
domain NN NN O
( NN NN O
BARD1 NN NN O
) NN NN O
protein NN NN O
contains NN NN O
an NN NN O
N-terminal NN NN O
RING NN NN O
motif NN NN O
, NN NN O
three NN NN O
tandem NN NN O
ankyrin NN NN O
repeats NN NN O
, NN NN O
and NN NN O
a NN NN O
C-terminal NN NN O
sequence NN NN O
with NN NN O
significant NN NN O
homology NN NN O
to NN NN O
the NN NN O
phylogenetically NN NN O
conserved NN NN O
BRCT NN NN O
domains NN NN O
that NN NN O
lie NN NN O
near NN NN O
the NN NN O
C NN NN O
terminus NN NN O
of NN NN O
BRCA1 NN NN O
. NN NN O

The NN NN O
BARD1 NN NN O
/ NN NN O
BRCA1 NN NN O
interaction NN NN O
is NN NN O
disrupted NN NN O
by NN NN O
BRCA1 NN NN O
missense NN NN O
mutations NN NN O
that NN NN O
segregate NN NN O
with NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
susceptibility NN NN O
, NN NN O
indicating NN NN O
that NN NN O
BARD1 NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
mediating NN NN O
tumour NN NN B-Modifier
suppression NN NN O
by NN NN O
BRCA1 NN NN O
. NN NN O

. NN NN O

8944024 NN NN O
Detection NN NN O
of NN NN O
heterozygous NN NN O
mutations NN NN O
in NN NN O
BRCA1 NN NN O
using NN NN O
high NN NN O
density NN NN O
oligonucleotide NN NN O
arrays NN NN O
and NN NN O
two-colour NN NN O
fluorescence NN NN O
analysis NN NN O
. NN NN O

The NN NN O
ability NN NN O
to NN NN O
scan NN NN O
a NN NN O
large NN NN O
gene NN NN O
rapidly NN NN O
and NN NN O
accurately NN NN O
for NN NN O
all NN NN O
possible NN NN O
heterozygous NN NN O
mutations NN NN O
in NN NN O
large NN NN O
numbers NN NN O
of NN NN O
patient NN NN O
samples NN NN O
will NN NN O
be NN NN O
critical NN NN O
for NN NN O
the NN NN O
future NN NN O
of NN NN O
medicine NN NN O
. NN NN O

We NN NN O
have NN NN O
designed NN NN O
high-density NN NN O
arrays NN NN O
consisting NN NN O
of NN NN O
over NN NN O
96 NN NN O
, NN NN O
600 NN NN O
oligonucleotides NN NN O
20-nucleotides NN NN O
( NN NN O
nt NN NN O
) NN NN O
in NN NN O
length NN NN O
to NN NN O
screen NN NN O
for NN NN O
a NN NN O
wide NN NN O
range NN NN O
of NN NN O
heterozygous NN NN O
mutations NN NN O
in NN NN O
the NN NN O
3 NN NN O
. NN NN O

45-kilobases NN NN O
( NN NN O
kb NN NN O
) NN NN O
exon NN NN O
11 NN NN O
of NN NN O
the NN NN O
hereditary NN NN B-Modifier
breast NN NN I-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
gene NN NN O
BRCA1 NN NN O
. NN NN O

Reference NN NN O
and NN NN O
test NN NN O
samples NN NN O
were NN NN O
co-hybridized NN NN O
to NN NN O
these NN NN O
arrays NN NN O
and NN NN O
differences NN NN O
in NN NN O
hybridization NN NN O
patterns NN NN O
quantitated NN NN O
by NN NN O
two-colour NN NN O
analysis NN NN O
. NN NN O

Fourteen NN NN O
of NN NN O
fifteen NN NN O
patient NN NN O
samples NN NN O
with NN NN O
known NN NN O
mutations NN NN O
were NN NN O
accurately NN NN O
diagnosed NN NN O
, NN NN O
and NN NN O
no NN NN O
false NN NN O
positive NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
in NN NN O
20 NN NN O
control NN NN O
samples NN NN O
. NN NN O

Eight NN NN O
single NN NN O
nucleotide NN NN O
polymorphisms NN NN O
were NN NN O
also NN NN O
readily NN NN O
detected NN NN O
. NN NN O

DNA NN NN O
chip-based NN NN O
assays NN NN O
may NN NN O
provide NN NN O
a NN NN O
valuable NN NN O
new NN NN O
technology NN NN O
for NN NN O
high-throughput NN NN O
cost-efficient NN NN O
detection NN NN O
of NN NN O
genetic NN NN O
alterations NN NN O
. NN NN O

8954016 NN NN O
Autosomal NN NN B-SpecificDisease
dominant NN NN I-SpecificDisease
primary NN NN I-SpecificDisease
hyperparathyroidism NN NN I-SpecificDisease
and NN NN I-SpecificDisease
jaw NN NN I-SpecificDisease
tumor NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
associated NN NN O
with NN NN O
renal NN NN B-SpecificDisease
hamartomas NN NN I-SpecificDisease
and NN NN O
cystic NN NN B-DiseaseClass
kidney NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
: NN NN O
linkage NN NN O
to NN NN O
1q21-q32 NN NN O
and NN NN O
loss NN NN O
of NN NN O
the NN NN O
wild NN NN O
type NN NN O
allele NN NN O
in NN NN O
renal NN NN B-SpecificDisease
hamartomas NN NN I-SpecificDisease
. NN NN O

Hereditary NN NN B-SpecificDisease
hyperparathyroidism-jaw NN NN I-SpecificDisease
tumor NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
HPT-JT NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
( NN NN O
OMIM NN NN O
145001 NN NN O
) NN NN O
that NN NN O
has NN NN O
recently NN NN O
been NN NN O
mapped NN NN O
to NN NN O
chromosomal NN NN O
region NN NN O
1q21-q32 NN NN O
( NN NN O
HRPT2 NN NN O
) NN NN O
. NN NN O

Here NN NN O
we NN NN O
report NN NN O
two NN NN O
families NN NN O
with NN NN O
HPT-JT NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
in NN NN O
which NN NN O
adult NN NN B-SpecificDisease
renal NN NN I-SpecificDisease
hamartomas NN NN I-SpecificDisease
or NN NN O
cystic NN NN B-DiseaseClass
kidney NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
were NN NN O
prominent NN NN O
associated NN NN O
features NN NN O
, NN NN O
possibly NN NN O
representing NN NN O
a NN NN O
new NN NN O
phenotypic NN NN O
variant NN NN O
of NN NN O
the NN NN O
HPT-JT NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

In NN NN O
the NN NN O
first NN NN O
family NN NN O
, NN NN O
renal NN NN B-DiseaseClass
lesions NN NN I-DiseaseClass
were NN NN O
present NN NN O
in NN NN O
five NN NN O
out NN NN O
of NN NN O
six NN NN O
affected NN NN O
individuals NN NN O
, NN NN O
whereas NN NN O
HPT NN NN B-SpecificDisease
and NN NN O
JT NN NN B-SpecificDisease
were NN NN O
seen NN NN O
in NN NN O
four NN NN O
and NN NN O
two NN NN O
cases NN NN O
, NN NN O
respectively NN NN O
. NN NN O

In NN NN O
the NN NN O
second NN NN O
family NN NN O
, NN NN O
JT NN NN B-SpecificDisease
was NN NN O
found NN NN O
in NN NN O
three NN NN O
of NN NN O
the NN NN O
five NN NN O
affected NN NN O
individuals NN NN O
and NN NN O
two NN NN O
affected NN NN O
members NN NN O
also NN NN O
exhibited NN NN O
polycystic NN NN B-SpecificDisease
kidney NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

The NN NN O
possibility NN NN O
of NN NN O
the NN NN O
latter NN NN O
cosegregating NN NN O
as NN NN O
a NN NN O
separate NN NN O
autosomal NN NN O
dominant NN NN O
gene NN NN O
can NN NN O
not NN NN O
be NN NN O
ruled NN NN O
out NN NN O
. NN NN O

A NN NN O
sex-dependent NN NN O
penetrance NN NN O
of NN NN O
primary NN NN B-SpecificDisease
HPT NN NN I-SpecificDisease
, NN NN O
resulting NN NN O
in NN NN O
predominantly NN NN O
male-affected NN NN O
cases NN NN O
was NN NN O
evident NN NN O
in NN NN O
the NN NN O
two NN NN O
families NN NN O
. NN NN O

Twenty NN NN O
microsatellite NN NN O
markers NN NN O
in NN NN O
the NN NN O
HRPT2 NN NN O
region NN NN O
were NN NN O
typed NN NN O
, NN NN O
in NN NN O
addition NN NN O
to NN NN O
markers NN NN O
in NN NN O
the NN NN O
multiple NN NN B-Modifier
endocrine NN NN I-Modifier
neoplasia NN NN I-Modifier
( NN NN I-Modifier
MEN NN NN I-Modifier
) NN NN I-Modifier
types NN NN I-Modifier
1 NN NN I-Modifier
and NN NN I-Modifier
2 NN NN I-Modifier
regions NN NN O
at NN NN O
11q13 NN NN O
and NN NN O
10q11 NN NN O
. NN NN O

The NN NN O
disease NN NN O
in NN NN O
these NN NN O
two NN NN O
kindreds NN NN O
was NN NN O
linked NN NN O
to NN NN O
five NN NN O
markers NN NN O
in NN NN O
the NN NN O
1q21-q32 NN NN O
region NN NN O
( NN NN O
logarithm-of-odds NN NN O
scores NN NN O
3 NN NN O
. NN NN O

2-4 NN NN O
2-4 NN NN O
. NN NN O

2 NN NN O
) NN NN O
, NN NN O
whereas NN NN O
linkage NN NN O
to NN NN O
the NN NN O
MEN1 NN NN B-Modifier
and NN NN O
MEN2 NN NN B-Modifier
regions NN NN O
was NN NN O
excluded NN NN O
. NN NN O

Meiotic NN NN O
recombinations NN NN O
detected NN NN O
in NN NN O
affected NN NN O
individuals NN NN O
placed NN NN O
the NN NN O
locus NN NN O
telomeric NN NN O
of NN NN O
D1S215 NN NN O
, NN NN O
thus NN NN O
narrowing NN NN O
the NN NN O
HRPT2 NN NN O
region NN NN O
from NN NN O
60 NN NN O
to NN NN O
approximately NN NN O
34 NN NN O
centimorgans NN NN O
. NN NN O

Loss NN NN O
of NN NN O
heterozygosity NN NN O
was NN NN O
studied NN NN O
in NN NN O
seven NN NN O
renal NN NN B-SpecificDisease
hamartomas NN NN I-SpecificDisease
from NN NN O
two NN NN O
affected NN NN O
individuals NN NN O
in NN NN O
the NN NN O
first NN NN O
family NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
a NN NN O
jaw NN NN B-SpecificDisease
tumor NN NN I-SpecificDisease
and NN NN O
a NN NN O
parathyroid NN NN B-SpecificDisease
tumor NN NN I-SpecificDisease
from NN NN O
the NN NN O
second NN NN O
family NN NN O
. NN NN O

All NN NN O
renal NN NN B-SpecificDisease
hamartomas NN NN I-SpecificDisease
showed NN NN O
loss NN NN O
of NN NN O
heterozygosity NN NN O
at NN NN O
the NN NN O
1q21-q32 NN NN O
region NN NN O
. NN NN O

The NN NN O
losses NN NN O
invariably NN NN O
involved NN NN O
the NN NN O
wild NN NN O
type NN NN O
allele NN NN O
derived NN NN O
from NN NN O
the NN NN O
unaffected NN NN O
parent NN NN O
, NN NN O
suggesting NN NN O
the NN NN O
inactivation NN NN O
of NN NN O
a NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
gene NN NN O
in NN NN O
this NN NN O
region NN NN O

8956035 NN NN O
Independent NN NN O
origin NN NN O
of NN NN O
single NN NN O
and NN NN O
double NN NN O
mutations NN NN O
in NN NN O
the NN NN O
human NN NN O
glucose NN NN O
6-phosphate NN NN O
dehydrogenase NN NN O
gene NN NN O
. NN NN O

The NN NN O
vast NN NN O
majority NN NN O
of NN NN O
both NN NN O
polymorphic NN NN O
and NN NN O
sporadic NN NN O
G6PD NN NN O
variants NN NN O
are NN NN O
due NN NN O
to NN NN O
single NN NN O
missense NN NN O
mutations NN NN O
. NN NN O

In NN NN O
the NN NN O
four NN NN O
polymorphic NN NN O
variants NN NN O
that NN NN O
have NN NN O
two NN NN O
point NN NN O
mutations NN NN O
, NN NN O
one NN NN O
of NN NN O
the NN NN O
mutations NN NN O
is NN NN O
always NN NN O
376 NN NN O
A NN NN O
-- NN NN O
G NN NN O
( NN NN O
126 NN NN O
Asn NN NN O
-- NN NN O
Asp NN NN O
) NN NN O
, NN NN O
which NN NN O
on NN NN O
its NN NN O
own NN NN O
gives NN NN O
rise NN NN O
to NN NN O
the NN NN O
nondeficient NN NN O
polymorphic NN NN O
variant NN NN O
, NN NN O
G6PD NN NN O
A NN NN O
. NN NN O

In NN NN O
a NN NN O
study NN NN O
of NN NN O
G6PD NN NN B-Modifier
deficient NN NN I-Modifier
patients NN NN O
who NN NN O
presented NN NN O
with NN NN O
clinical NN NN O
favism NN NN B-SpecificDisease
in NN NN O
Spain NN NN O
, NN NN O
we NN NN O
have NN NN O
found NN NN O
a NN NN O
new NN NN O
polymorphic NN NN O
variant NN NN O
that NN NN O
we NN NN O
have NN NN O
called NN NN O
G6PD NN NN O
Malaga NN NN O
, NN NN O
whose NN NN O
only NN NN O
abnormality NN NN O
is NN NN O
a NN NN O
542 NN NN O
A NN NN O
-- NN NN O
T NN NN O
( NN NN O
181 NN NN O
Asp NN NN O
-- NN NN O
Val NN NN O
) NN NN O
mutation NN NN O
. NN NN O

This NN NN O
is NN NN O
the NN NN O
same NN NN O
mutation NN NN O
as NN NN O
previously NN NN O
found NN NN O
in NN NN O
association NN NN O
with NN NN O
the NN NN O
mutation NN NN O
of NN NN O
G6PD NN NN O
A NN NN O
in NN NN O
the NN NN O
double NN NN O
mutant NN NN O
, NN NN O
G6PD NN NN O
Santamaria NN NN O
. NN NN O

G6PD NN NN O
Malaga NN NN O
is NN NN O
associated NN NN O
with NN NN O
enzyme NN NN B-DiseaseClass
deficiency NN NN I-DiseaseClass
( NN NN O
class NN NN O
III NN NN O
) NN NN O
, NN NN O
and NN NN O
the NN NN O
enzymic NN NN O
properties NN NN O
of NN NN O
G6PD NN NN O
Malaga NN NN O
and NN NN O
G6PD NN NN O
Santamaria NN NN O
are NN NN O
quite NN NN O
similar NN NN O
, NN NN O
indicating NN NN O
that NN NN O
in NN NN O
this NN NN O
case NN NN O
the NN NN O
effects NN NN O
of NN NN O
the NN NN O
two NN NN O
mutations NN NN O
are NN NN O
additive NN NN O
rather NN NN O
than NN NN O
synergistic NN NN O
. NN NN O

G6PD NN NN O
Santamaria NN NN O
might NN NN O
have NN NN O
been NN NN O
produced NN NN O
by NN NN O
recombination NN NN O
between NN NN O
G6PD NN NN O
A NN NN O
and NN NN O
G6PD NN NN O
Malaga NN NN O
; NN NN O
however NN NN O
haplotype NN NN O
analysis NN NN O
, NN NN O
including NN NN O
the NN NN O
use NN NN O
of NN NN O
a NN NN O
new NN NN O
silent NN NN O
polymorphism NN NN O
, NN NN O
suggests NN NN O
that NN NN O
the NN NN O
same NN NN O
542 NN NN O
A NN NN O
-- NN NN O
T NN NN O
mutation NN NN O
has NN NN O
taken NN NN O
place NN NN O
independently NN NN O
in NN NN O
a NN NN O
G6PD NN NN O
B NN NN O
gene NN NN O
to NN NN O
give NN NN O
G6PD NN NN O
Malaga NN NN O
and NN NN O
in NN NN O
a NN NN O
G6PD NN NN O
A NN NN O
gene NN NN O
to NN NN O
give NN NN O
G6PD NN NN O
Santamaria NN NN O
. NN NN O

These NN NN O
findings NN NN O
help NN NN O
to NN NN O
outline NN NN O
the NN NN O
relationship NN NN O
and NN NN O
evolution NN NN O
of NN NN O
mutations NN NN O
in NN NN O
the NN NN O
human NN NN O
G6PD NN NN O
locus NN NN O
. NN NN O

. NN NN O

8968716 NN NN O
BRCA1 NN NN O
R841W NN NN O
: NN NN O
a NN NN O
strong NN NN O
candidate NN NN O
for NN NN O
a NN NN O
common NN NN O
mutation NN NN O
with NN NN O
moderate NN NN O
phenotype NN NN O
. NN NN O

BRCA1 NN NN O
mutations NN NN O
cause NN NN O
increased NN NN O
risk NN NN O
for NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
, NN NN O
frequently NN NN O
of NN NN O
early NN NN O
onset NN NN O
. NN NN O

Many NN NN O
different NN NN O
mutations NN NN O
occur NN NN O
in NN NN O
BRCA1 NN NN O
, NN NN O
including NN NN O
several NN NN O
examples NN NN O
of NN NN O
recurrent NN NN O
mutations NN NN O
, NN NN O
each NN NN O
of NN NN O
which NN NN O
accounts NN NN O
for NN NN O
a NN NN O
significant NN NN O
number NN NN O
of NN NN O
families NN NN O
with NN NN O
heritable NN NN O
cancer NN NN B-Modifier
predisposition NN NN O
. NN NN O

These NN NN O
common NN NN O
mutations NN NN O
have NN NN O
an NN NN O
etiological NN NN O
role NN NN O
in NN NN O
many NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
cases NN NN O
and NN NN O
provide NN NN O
the NN NN O
opportunity NN NN O
to NN NN O
examine NN NN O
genotype-phenotype NN NN O
correlations NN NN O
and NN NN O
genotype-environment NN NN O
interactions NN NN O
in NN NN O
individuals NN NN O
with NN NN O
the NN NN O
identical NN NN O
BRCA1 NN NN O
lesion NN NN O
. NN NN O

We NN NN O
report NN NN O
a NN NN O
novel NN NN O
missense NN NN O
change NN NN O
in NN NN O
BRCA1 NN NN O
, NN NN O
2640 NN NN O
C NN NN O
-- NN NN O
T NN NN O
( NN NN O
R841W NN NN O
) NN NN O
, NN NN O
found NN NN O
in NN NN O
3 NN NN O
cases NN NN O
from NN NN O
a NN NN O
subject NN NN O
group NN NN O
of NN NN O
305 NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
79 NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
cases NN NN O
from NN NN O
Orange NN NN O
County NN NN O
, NN NN O
CA NN NN O
. NN NN O

These NN NN O
are NN NN O
consecutive NN NN O
, NN NN O
population-based NN NN O
cases NN NN O
not NN NN O
selected NN NN O
for NN NN O
age NN NN O
or NN NN O
family NN NN O
history NN NN O
. NN NN O

In NN NN O
all NN NN O
three NN NN O
cases NN NN O
, NN NN O
there NN NN O
is NN NN O
a NN NN O
strong NN NN O
family NN NN O
history NN NN O
of NN NN O
breast NN NN B-CompositeMention
, NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
, NN NN I-CompositeMention
or NN NN I-CompositeMention
other NN NN I-CompositeMention
cancers NN NN I-CompositeMention
possibly NN NN O
related NN NN O
to NN NN O
a NN NN O
BRCA1 NN NN O
defect NN NN O
and NN NN O
family NN NN O
members NN NN O
showed NN NN O
a NN NN O
high NN NN O
concordance NN NN O
of NN NN O
cancer NN NN B-Modifier
incidence NN NN O
with NN NN O
the NN NN O
presence NN NN O
of NN NN O
R841W NN NN O
. NN NN O

The NN NN O
age NN NN O
of NN NN O
cancer NN NN B-Modifier
onset NN NN O
was NN NN O
not NN NN O
always NN NN O
distinct NN NN O
from NN NN O
typical NN NN O
sporadic NN NN O
cases NN NN O
. NN NN O

Testing NN NN O
of NN NN O
a NN NN O
sample NN NN O
of NN NN O
413 NN NN O
unrelated NN NN O
individuals NN NN O
to NN NN O
examine NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
R841W NN NN O
might NN NN O
be NN NN O
a NN NN O
rare NN NN O
polymorphism NN NN O
detected NN NN O
one NN NN O
additional NN NN O
instance NN NN O
in NN NN O
a NN NN O
woman NN NN O
with NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
diagnosed NN NN O
at NN NN O
age NN NN O
77 NN NN O
years NN NN O
, NN NN O
and NN NN O
cancer NN NN B-DiseaseClass
in NN NN O
one NN NN O
parent NN NN O
. NN NN O

R841W NN NN O
is NN NN O
likely NN NN O
to NN NN O
be NN NN O
an NN NN O
etiologically NN NN O
significant NN NN O
lesion NN NN O
with NN NN O
involvement NN NN O
in NN NN O
close NN NN O
to NN NN O
1 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
of NN NN O
0-1 NN NN O
. NN NN O

7 NN NN O
% NN NN O
) NN NN O
of NN NN O
all NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancers NN NN I-CompositeMention
in NN NN O
this NN NN O
population NN NN O
. NN NN O

8968760 NN NN O
Ataxia-telangiectasia NN NN B-SpecificDisease
: NN NN O
founder NN NN O
effect NN NN O
among NN NN O
north NN NN O
African NN NN O
Jews NN NN O
. NN NN O

The NN NN O
ATM NN NN O
gene NN NN O
is NN NN O
responsible NN NN O
for NN NN O
the NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
ataxia-telangiectasia NN NN B-SpecificDisease
( NN NN O
A-T NN NN B-SpecificDisease
) NN NN O
, NN NN O
characterized NN NN O
by NN NN O
cerebellar NN NN B-DiseaseClass
degeneration NN NN I-DiseaseClass
, NN NN O
immunodeficiency NN NN B-DiseaseClass
and NN NN O
cancer NN NN B-DiseaseClass
predisposition NN NN I-DiseaseClass
. NN NN O

A-T NN NN B-Modifier
carriers NN NN O
were NN NN O
reported NN NN O
to NN NN O
be NN NN O
moderately NN NN O
cancer-prone NN NN B-DiseaseClass
. NN NN O

A NN NN O
wide NN NN O
variety NN NN O
of NN NN O
A-T NN NN B-Modifier
mutations NN NN O
, NN NN O
most NN NN O
of NN NN O
which NN NN O
are NN NN O
unique NN NN O
to NN NN O
single NN NN O
families NN NN O
, NN NN O
were NN NN O
identified NN NN O
in NN NN O
various NN NN O
ethnic NN NN O
groups NN NN O
, NN NN O
precluding NN NN O
carrier NN NN O
screening NN NN O
with NN NN O
mutation-specific NN NN O
assays NN NN O
. NN NN O

However NN NN O
, NN NN O
a NN NN O
single NN NN O
mutation NN NN O
was NN NN O
observed NN NN O
in NN NN O
32 NN NN O
/ NN NN O
33 NN NN O
defective NN NN O
ATM NN NN O
alleles NN NN O
in NN NN O
Jewish NN NN O
A-T NN NN B-Modifier
families NN NN O
of NN NN O
North NN NN O
African NN NN O
origin NN NN O
, NN NN O
coming NN NN O
from NN NN O
various NN NN O
regions NN NN O
of NN NN O
Morocco NN NN O
and NN NN O
Tunisia NN NN O
. NN NN O

This NN NN O
mutation NN NN O
, NN NN O
103C NN NN O
-- NN NN O
T NN NN O
, NN NN O
results NN NN O
in NN NN O
a NN NN O
stop NN NN O
codon NN NN O
at NN NN O
position NN NN O
35 NN NN O
of NN NN O
the NN NN O
ATM NN NN O
protein NN NN O
. NN NN O

In NN NN O
keeping NN NN O
with NN NN O
the NN NN O
nature NN NN O
of NN NN O
this NN NN O
mutation NN NN O
, NN NN O
various NN NN O
antibodies NN NN O
directed NN NN O
against NN NN O
the NN NN O
ATM NN NN O
protein NN NN O
failed NN NN O
to NN NN O
defect NN NN O
this NN NN O
protein NN NN O
in NN NN O
patient NN NN O
cells NN NN O
. NN NN O

A NN NN O
rapid NN NN O
carrier NN NN O
detection NN NN O
assay NN NN O
detected NN NN O
this NN NN O
mutation NN NN O
in NN NN O
three NN NN O
out NN NN O
of NN NN O
488 NN NN O
ATM NN NN O
alleles NN NN O
of NN NN O
Jewish NN NN O
Moroccan NN NN O
or NN NN O
Tunisian NN NN O
origin NN NN O
. NN NN O

This NN NN O
founder NN NN O
effect NN NN O
provides NN NN O
a NN NN O
unique NN NN O
opportunity NN NN O
for NN NN O
population-based NN NN O
screening NN NN O
for NN NN O
A-T NN NN B-Modifier
carriers NN NN O
in NN NN O
a NN NN O
large NN NN O
Jewish NN NN O
community NN NN O
. NN NN O

. NN NN O

9012404 NN NN O
Mutation NN NN O
analysis NN NN O
of NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
in NN NN O
a NN NN O
male NN NN B-Modifier
breast NN NN I-Modifier
cancer NN NN I-Modifier
population NN NN O
. NN NN O

A NN NN O
population-based NN NN O
series NN NN O
of NN NN O
54 NN NN O
male NN NN B-Modifier
breast NN NN I-Modifier
cancer NN NN I-Modifier
cases NN NN O
from NN NN O
Southern NN NN O
California NN NN O
were NN NN O
analyzed NN NN O
for NN NN O
germ-line NN NN O
mutations NN NN O
in NN NN O
the NN NN O
inherited NN NN B-Modifier
breast NN NN I-Modifier
/ NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
genes NN NN O
, NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
. NN NN O

Nine NN NN O
( NN NN O
17 NN NN O
% NN NN O
) NN NN O
of NN NN O
the NN NN O
patients NN NN O
had NN NN O
a NN NN O
family NN NN O
history NN NN O
of NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
/ NN NN I-CompositeMention
or NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
in NN NN O
at NN NN O
least NN NN O
one NN NN O
first-degree NN NN O
relative NN NN O
. NN NN O

A NN NN O
further NN NN O
seven NN NN O
( NN NN O
13 NN NN O
% NN NN O
) NN NN O
of NN NN O
the NN NN O
patients NN NN O
reported NN NN O
breast NN NN B-CompositeMention
/ NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
in NN NN O
at NN NN O
least NN NN O
one NN NN O
second-degree NN NN O
relative NN NN O
and NN NN O
in NN NN O
no NN NN O
first-degree NN NN O
relatives NN NN O
. NN NN O

No NN NN O
germ-line NN NN O
BRCA1 NN NN O
mutations NN NN O
were NN NN O
found NN NN O
. NN NN O

Two NN NN O
male NN NN B-Modifier
breast NN NN I-Modifier
cancer NN NN I-Modifier
patients NN NN O
( NN NN O
4 NN NN O
% NN NN O
of NN NN O
the NN NN O
total NN NN O
) NN NN O
were NN NN O
found NN NN O
to NN NN O
carry NN NN O
novel NN NN O
truncating NN NN O
mutations NN NN O
in NN NN O
the NN NN O
BRCA2 NN NN O
gene NN NN O
. NN NN O

Only NN NN O
one NN NN O
of NN NN O
the NN NN O
two NN NN O
male NN NN B-Modifier
breast NN NN I-Modifier
cancer NN NN I-Modifier
patients NN NN O
carrying NN NN O
a NN NN O
BRCA2 NN NN O
mutation NN NN O
had NN NN O
a NN NN O
family NN NN O
history NN NN O
of NN NN O
cancer NN NN B-DiseaseClass
, NN NN O
with NN NN O
one NN NN O
case NN NN O
of NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
in NN NN O
a NN NN O
first-degree NN NN O
relative NN NN O
. NN NN O

The NN NN O
remaining NN NN O
eight NN NN O
cases NN NN O
( NN NN O
89 NN NN O
% NN NN O
) NN NN O
of NN NN O
male NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
with NN NN O
a NN NN O
family NN NN O
history NN NN O
of NN NN O
breast NN NN B-CompositeMention
/ NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
in NN NN O
first-degree NN NN O
relatives NN NN O
remain NN NN O
unaccounted NN NN O
for NN NN O
by NN NN O
mutations NN NN O
in NN NN O
either NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
or NN NN O
the NN NN O
BRCA2 NN NN O
gene NN NN O
. NN NN O

. NN NN O

9012409 NN NN O
Molecular NN NN O
basis NN NN O
for NN NN O
Duarte NN NN B-CompositeMention
and NN NN I-CompositeMention
Los NN NN I-CompositeMention
Angeles NN NN I-CompositeMention
variant NN NN I-CompositeMention
galactosemia NN NN I-CompositeMention
. NN NN O

Human NN NN O
orythrocytes NN NN O
that NN NN O
are NN NN O
homozygous NN NN O
for NN NN O
the NN NN O
Duarte NN NN B-SpecificDisease
enzyme NN NN I-SpecificDisease
variant NN NN I-SpecificDisease
of NN NN I-SpecificDisease
galactosemia NN NN I-SpecificDisease
( NN NN O
D NN NN O
/ NN NN O
D NN NN O
) NN NN O
have NN NN O
a NN NN O
characteristic NN NN O
isoform NN NN O
on NN NN O
isoelectric NN NN O
focusing NN NN O
and NN NN O
50 NN NN O
% NN NN O
reduction NN NN O
in NN NN O
galactose-1-phosphate NN NN O
uridyltransferase NN NN O
( NN NN O
GALT NN NN O
) NN NN O
enzyme NN NN O
activity NN NN O
. NN NN O

The NN NN O
Duarte NN NN O
biochemical NN NN O
phenotype NN NN O
has NN NN O
a NN NN O
molecular NN NN O
genotype NN NN O
of NN NN O
N314D NN NN O
/ NN NN O
N314D NN NN O
. NN NN O

The NN NN O
characteristic NN NN O
Duarte NN NN O
isoform NN NN O
is NN NN O
also NN NN O
associated NN NN O
with NN NN O
a NN NN O
variant NN NN O
called NN NN O
the NN NN O
`` NN NN O
Los NN NN O
Angeles NN NN O
( NN NN O
LA NN NN O
) NN NN O
phenotype NN NN O
, NN NN O
`` NN NN O
which NN NN O
has NN NN O
increased NN NN O
GALT NN NN O
enzyme NN NN O
activity NN NN O
. NN NN O

We NN NN O
evaluated NN NN O
GALT NN NN O
enzyme NN NN O
activity NN NN O
and NN NN O
screened NN NN O
the NN NN O
GALT NN NN O
genes NN NN O
of NN NN O
145 NN NN O
patients NN NN O
with NN NN O
one NN NN O
or NN NN O
more NN NN O
N314D-containing NN NN O
alleles NN NN O
. NN NN O

We NN NN O
found NN NN O
seven NN NN O
with NN NN O
the NN NN O
LA NN NN O
biochemical NN NN O
phenotype NN NN O
, NN NN O
and NN NN O
all NN NN O
had NN NN O
a NN NN O
1721C NN NN O
-- NN NN O
T NN NN O
transition NN NN O
in NN NN O
exon NN NN O
7 NN NN O
in NN NN O
cis NN NN O
with NN NN O
the NN NN O
N314D NN NN O
missense NN NN O
mutation NN NN O
. NN NN O

The NN NN O
1721C NN NN O
-- NN NN O
T NN NN O
transition NN NN O
is NN NN O
a NN NN O
neutral NN NN O
polymorphism NN NN O
for NN NN O
leucine NN NN O
at NN NN O
amino NN NN O
acid NN NN O
218 NN NN O
( NN NN O
L218L NN NN O
) NN NN O
. NN NN O

In NN NN O
pedigree NN NN O
analyses NN NN O
, NN NN O
this NN NN O
1721C NN NN O
-- NN NN O
T NN NN O
transition NN NN O
segregated NN NN O
with NN NN O
the NN NN O
LA NN NN O
phenotype NN NN O
of NN NN O
increased NN NN O
GALT NN NN O
activity NN NN O
in NN NN O
three NN NN O
different NN NN O
biochemical NN NN O
phenotypes NN NN O
( NN NN O
LA NN NN O
/ NN NN O
N NN NN O
, NN NN O
LA NN NN O
/ NN NN O
G NN NN O
, NN NN O
and NN NN O
LA NN NN O
/ NN NN O
D NN NN O
) NN NN O
. NN NN O

To NN NN O
determine NN NN O
the NN NN O
mechanism NN NN O
for NN NN O
increased NN NN O
activity NN NN O
of NN NN O
the NN NN O
LA NN NN O
variant NN NN O
, NN NN O
we NN NN O
compared NN NN O
GALT NN NN O
mRNA NN NN O
, NN NN O
protein NN NN O
abundance NN NN O
, NN NN O
and NN NN O
enzyme NN NN O
thermal NN NN O
stability NN NN O
in NN NN O
lymphoblast NN NN O
cell NN NN O
lines NN NN O
of NN NN O
D NN NN O
and NN NN O
LA NN NN O
phenotypes NN NN O
with NN NN O
comparable NN NN O
genotypes NN NN O
. NN NN O

GALT NN NN O
protein NN NN O
abundance NN NN O
was NN NN O
increased NN NN O
in NN NN O
LA NN NN O
compared NN NN O
to NN NN O
D NN NN O
alleles NN NN O
, NN NN O
but NN NN O
mRNA NN NN O
was NN NN O
similar NN NN O
among NN NN O
all NN NN O
genotypes NN NN O
. NN NN O

When NN NN O
LA NN NN O
/ NN NN O
D NN NN O
and NN NN O
D NN NN O
/ NN NN O
D NN NN O
GALT NN NN O
biochemical NN NN O
phenotypes NN NN O
were NN NN O
compared NN NN O
to NN NN O
N NN NN O
/ NN NN O
N NN NN O
GALT NN NN O
phenotypes NN NN O
, NN NN O
both NN NN O
had NN NN O
50 NN NN O
% NN NN O
, NN NN O
as NN NN O
compared NN NN O
to NN NN O
21 NN NN O
% NN NN O
, NN NN O
reduction NN NN O
in NN NN O
GALT NN NN O
activity NN NN O
in NN NN O
the NN NN O
wild NN NN O
type NN NN O
( NN NN O
N NN NN O
/ NN NN O
N NN NN O
) NN NN O
after NN NN O
exposure NN NN O
at NN NN O
identical NN NN O
initial NN NN O
enzyme NN NN O
activity NN NN O
to NN NN O
50 NN NN O
degrees NN NN O
C NN NN O
for NN NN O
15 NN NN O
min NN NN O
. NN NN O

We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
codon NN NN O
change NN NN O
N314D NN NN O
in NN NN O
cis NN NN O
with NN NN O
the NN NN O
base-pair NN NN O
transition NN NN O
1721C NN NN O
-- NN NN O
T NN NN O
produces NN NN O
the NN NN O
LA NN NN B-SpecificDisease
variant NN NN I-SpecificDisease
of NN NN I-SpecificDisease
galactosemia NN NN I-SpecificDisease
and NN NN O
that NN NN O
this NN NN O
nucleotide NN NN O
change NN NN O
increases NN NN O
GALT NN NN O
activity NN NN O
by NN NN O
increasing NN NN O
GALT NN NN O
protein NN NN O
abundance NN NN O
without NN NN O
increasing NN NN O
transcription NN NN O
or NN NN O
decreasing NN NN O
thermal NN NN O
lability NN NN O
. NN NN O

A NN NN O
favorable NN NN O
codon NN NN O
bias NN NN O
for NN NN O
the NN NN O
mutated NN NN O
codon NN NN O
with NN NN O
consequently NN NN O
increased NN NN O
translation NN NN O
rates NN NN O
is NN NN O
postulated NN NN O
as NN NN O
the NN NN O
mechanism NN NN O
. NN NN O

. NN NN O

9019400 NN NN O
The NN NN O
TSG101 NN NN O
tumor NN NN B-Modifier
susceptibility NN NN O
gene NN NN O
is NN NN O
located NN NN O
in NN NN O
chromosome NN NN O
11 NN NN O
band NN NN O
p15 NN NN O
and NN NN O
is NN NN O
mutated NN NN O
in NN NN O
human NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Recent NN NN O
work NN NN O
has NN NN O
identified NN NN O
a NN NN O
mouse NN NN O
gene NN NN O
( NN NN O
tsg101 NN NN O
) NN NN O
whose NN NN O
inactivation NN NN O
in NN NN O
fibroblasts NN NN O
results NN NN O
in NN NN O
cellular NN NN O
transformation NN NN O
and NN NN O
the NN NN O
ability NN NN O
to NN NN O
produce NN NN O
metastatic NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
in NN NN O
nude NN NN O
mice NN NN O
. NN NN O

Here NN NN O
, NN NN O
we NN NN O
report NN NN O
that NN NN O
the NN NN O
human NN NN O
homolog NN NN O
, NN NN O
TSG101 NN NN O
, NN NN O
which NN NN O
we NN NN O
isolated NN NN O
and NN NN O
mapped NN NN O
to NN NN O
chromosome NN NN O
11 NN NN O
, NN NN O
bands NN NN O
15 NN NN O
. NN NN O

1-15 NN NN O
1-15 NN NN O
. NN NN O

2 NN NN O
, NN NN O
a NN NN O
region NN NN O
proposed NN NN O
to NN NN O
contain NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
gene NN NN O
( NN NN O
s NN NN O
) NN NN O
, NN NN O
is NN NN O
mutated NN NN O
at NN NN O
high NN NN O
frequency NN NN O
in NN NN O
human NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

In NN NN O
7 NN NN O
of NN NN O
15 NN NN O
uncultured NN NN O
primary NN NN O
human NN NN O
breast NN NN B-SpecificDisease
carcinomas NN NN I-SpecificDisease
, NN NN O
intragenic NN NN O
deletions NN NN O
were NN NN O
shown NN NN O
in NN NN O
TSG101 NN NN O
genomic NN NN O
DNA NN NN O
and NN NN O
transcripts NN NN O
by NN NN O
gel NN NN O
and NN NN O
sequence NN NN O
analysis NN NN O
, NN NN O
and NN NN O
mutations NN NN O
affecting NN NN O
two NN NN O
TSG101 NN NN O
alleles NN NN O
were NN NN O
identified NN NN O
in NN NN O
four NN NN O
of NN NN O
these NN NN O
cancers NN NN B-DiseaseClass
. NN NN O

No NN NN O
TSG101 NN NN O
defects NN NN O
were NN NN O
found NN NN O
in NN NN O
matched NN NN O
normal NN NN O
breast NN NN O
tissue NN NN O
from NN NN O
the NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
patients NN NN O
. NN NN O

These NN NN O
findings NN NN O
strongly NN NN O
implicate NN NN O
TSG101 NN NN O
mutations NN NN O
in NN NN O
human NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease

9020847 NN NN O
Moderate NN NN O
intergenerational NN NN O
and NN NN O
somatic NN NN O
instability NN NN O
of NN NN O
a NN NN O
55-CTG NN NN O
repeat NN NN O
in NN NN O
transgenic NN NN O
mice NN NN O
. NN NN O

Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
is NN NN O
associated NN NN O
with NN NN O
the NN NN O
expansion NN NN O
of NN NN O
a NN NN O
( NN NN O
CTG NN NN O
) NN NN O
n NN NN O
trinucleotide NN NN O
repeat NN NN O
in NN NN O
the NN NN O
3 NN NN O
untranslated NN NN O
region NN NN O
( NN NN O
UTR NN NN O
) NN NN O
of NN NN O
the NN NN O
DM NN NN B-Modifier
protein NN NN O
kinase NN NN O
gene NN NN O
( NN NN O
DMPK NN NN O
) NN NN O
. NN NN O

The NN NN O
( NN NN O
CTG NN NN O
) NN NN O
n NN NN O
repeat NN NN O
is NN NN O
polymorphic NN NN O
and NN NN O
varies NN NN O
in NN NN O
size NN NN O
between NN NN O
5 NN NN O
and NN NN O
37 NN NN O
repeats NN NN O
in NN NN O
unaffected NN NN O
individuals NN NN O
whereas NN NN O
in NN NN O
affected NN NN O
patients NN NN O
there NN NN O
are NN NN O
between NN NN O
50 NN NN O
and NN NN O
4 NN NN O
, NN NN O
000 NN NN O
CTGs NN NN O
. NN NN O

The NN NN O
size NN NN O
of NN NN O
the NN NN O
( NN NN O
CTG NN NN O
) NN NN O
n NN NN O
repeat NN NN O
, NN NN O
which NN NN O
increases NN NN O
through NN NN O
generations NN NN O
, NN NN O
generally NN NN O
correlates NN NN O
with NN NN O
clinical NN NN O
severity NN NN O
and NN NN O
age NN NN O
of NN NN O
onset NN NN O
. NN NN O

The NN NN O
instability NN NN O
of NN NN O
the NN NN O
CTG NN NN O
repeat NN NN O
appears NN NN O
to NN NN O
depend NN NN O
on NN NN O
its NN NN O
size NN NN O
as NN NN O
well NN NN O
as NN NN O
on NN NN O
the NN NN O
sex NN NN O
of NN NN O
the NN NN O
transmitting NN NN O
parent NN NN O
. NN NN O

Moreover NN NN O
, NN NN O
mitotic NN NN O
instability NN NN O
analysis NN NN O
of NN NN O
different NN NN O
human NN NN O
DM NN NN B-Modifier
tissues NN NN O
shows NN NN O
length NN NN O
mosaicism NN NN O
between NN NN O
different NN NN O
cell NN NN O
lineages NN NN O
. NN NN O

The NN NN O
molecular NN NN O
mechanisms NN NN O
of NN NN O
triplet NN NN O
instability NN NN O
remain NN NN O
elusive NN NN O
. NN NN O

To NN NN O
investigate NN NN O
the NN NN O
role NN NN O
of NN NN O
genomic NN NN O
sequences NN NN O
in NN NN O
instability NN NN O
, NN NN O
we NN NN O
produced NN NN O
transgenic NN NN O
mice NN NN O
containing NN NN O
a NN NN O
45-kb NN NN O
genomic NN NN O
segment NN NN O
with NN NN O
a NN NN O
55-CTG NN NN O
repeat NN NN O
cloned NN NN O
from NN NN O
a NN NN O
mildly NN NN O
affected NN NN O
patient NN NN O
. NN NN O

In NN NN O
contrast NN NN O
to NN NN O
other NN NN O
mouse NN NN O
models NN NN O
containing NN NN O
CAG NN NN O
repeats NN NN O
within NN NN O
cDNAs NN NN O
, NN NN O
these NN NN O
mice NN NN O
showed NN NN O
both NN NN O
intergenerational NN NN O
and NN NN O
somatic NN NN O
repeat NN NN O
instability NN NN O
. NN NN O

. NN NN O

9028321 NN NN O
Missense NN NN O
mutations NN NN O
in NN NN O
the NN NN O
Fas NN NN O
gene NN NN O
resulting NN NN O
in NN NN O
autoimmune NN NN B-SpecificDisease
lymphoproliferative NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
: NN NN O
a NN NN O
molecular NN NN O
and NN NN O
immunological NN NN O
analysis NN NN O
. NN NN O

Programmed NN NN O
cell NN NN O
death NN NN O
( NN NN O
or NN NN O
apoptosis NN NN O
) NN NN O
is NN NN O
a NN NN O
physiological NN NN O
process NN NN O
essential NN NN O
to NN NN O
the NN NN O
normal NN NN O
development NN NN O
and NN NN O
homeostatic NN NN O
maintenance NN NN O
of NN NN O
the NN NN O
immune NN NN O
system NN NN O
. NN NN O

The NN NN O
Fas NN NN O
/ NN NN O
Apo-1 NN NN O
receptor NN NN O
plays NN NN O
a NN NN O
crucial NN NN O
role NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
apoptosis NN NN O
, NN NN O
as NN NN O
demonstrated NN NN O
by NN NN O
lymphoproliferation NN NN O
in NN NN O
MRL-lpr NN NN O
/ NN NN O
lpr NN NN O
mice NN NN O
and NN NN O
by NN NN O
the NN NN O
recently NN NN O
described NN NN O
autoimmune NN NN B-SpecificDisease
lymphoproliferative NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
ALPS NN NN B-SpecificDisease
) NN NN O
in NN NN O
humans NN NN O
, NN NN O
both NN NN O
of NN NN O
which NN NN O
are NN NN O
due NN NN O
to NN NN O
mutations NN NN O
in NN NN O
the NN NN O
Fas NN NN O
gene NN NN O
. NN NN O

We NN NN O
describe NN NN O
a NN NN O
novel NN NN O
family NN NN O
with NN NN O
ALPS NN NN B-SpecificDisease
in NN NN O
which NN NN O
three NN NN O
affected NN NN O
siblings NN NN O
carry NN NN O
two NN NN O
distinct NN NN O
missense NN NN O
mutations NN NN O
on NN NN O
both NN NN O
the NN NN O
Fas NN NN O
gene NN NN O
alleles NN NN O
and NN NN O
show NN NN O
lack NN NN O
of NN NN O
Fas-induced NN NN O
apoptosis NN NN O
. NN NN O

The NN NN O
children NN NN O
share NN NN O
common NN NN O
clinical NN NN O
features NN NN O
including NN NN O
splenomegaly NN NN B-DiseaseClass
and NN NN O
lymphadenopathy NN NN B-DiseaseClass
, NN NN O
but NN NN O
only NN NN O
one NN NN O
developed NN NN O
severe NN NN O
autoimmune NN NN B-DiseaseClass
manifestations NN NN I-DiseaseClass
. NN NN O

In NN NN O
all NN NN O
three NN NN O
siblings NN NN O
, NN NN O
we NN NN O
demonstrated NN NN O
the NN NN O
presence NN NN O
of NN NN O
anergic NN NN O
CD3 NN NN O
+ NN NN O
CD4-CD8- NN NN O
( NN NN O
double NN NN O
negative NN NN O
, NN NN O
[ NN NN O
DN NN NN O
] NN NN O
) NN NN O
T NN NN O
cells NN NN O
; NN NN O
moreover NN NN O
, NN NN O
a NN NN O
chronic NN NN O
lymphocyte NN NN O
activation NN NN O
was NN NN O
found NN NN O
, NN NN O
as NN NN O
demonstrated NN NN O
by NN NN O
the NN NN O
presence NN NN O
of NN NN O
high NN NN O
levels NN NN O
of NN NN O
HLA-DR NN NN O
expression NN NN O
on NN NN O
peripheral NN NN O
CD3 NN NN O
+ NN NN O
cells NN NN O
and NN NN O
by NN NN O
the NN NN O
presence NN NN O
of NN NN O
high NN NN O
levels NN NN O
of NN NN O
serum NN NN O
activation NN NN O
markers NN NN O
such NN NN O
as NN NN O
soluble NN NN O
interleukin-2 NN NN O
receptor NN NN O
( NN NN O
slL-2R NN NN O
) NN NN O
and NN NN O
soluble NN NN O
CD30 NN NN O
( NN NN O
sCD30 NN NN O
) NN NN O
. NN NN O

. NN NN O

9050866 NN NN O
The NN NN O
ataxia-telangiectasia NN NN B-Modifier
gene NN NN O
product NN NN O
, NN NN O
a NN NN O
constitutively NN NN O
expressed NN NN O
nuclear NN NN O
protein NN NN O
that NN NN O
is NN NN O
not NN NN O
up-regulated NN NN O
following NN NN O
genome NN NN O
damage NN NN O
. NN NN O

The NN NN O
product NN NN O
of NN NN O
the NN NN O
ataxia-telangiectasia NN NN B-Modifier
gene NN NN O
( NN NN O
ATM NN NN O
) NN NN O
was NN NN O
identified NN NN O
by NN NN O
using NN NN O
an NN NN O
antiserum NN NN O
developed NN NN O
to NN NN O
a NN NN O
peptide NN NN O
corresponding NN NN O
to NN NN O
the NN NN O
deduced NN NN O
amino NN NN O
acid NN NN O
sequence NN NN O
. NN NN O

The NN NN O
ATM NN NN O
protein NN NN O
is NN NN O
a NN NN O
single NN NN O
, NN NN O
high-molecular NN NN O
weight NN NN O
protein NN NN O
predominantly NN NN O
confined NN NN O
to NN NN O
the NN NN O
nucleus NN NN O
of NN NN O
human NN NN O
fibroblasts NN NN O
, NN NN O
but NN NN O
is NN NN O
present NN NN O
in NN NN O
both NN NN O
nuclear NN NN O
and NN NN O
microsomal NN NN O
fractions NN NN O
from NN NN O
human NN NN O
lymphoblast NN NN O
cells NN NN O
and NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
. NN NN O

ATM NN NN O
protein NN NN O
levels NN NN O
and NN NN O
localization NN NN O
remain NN NN O
constant NN NN O
throughout NN NN O
all NN NN O
stages NN NN O
of NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
. NN NN O

Truncated NN NN O
ATM NN NN O
protein NN NN O
was NN NN O
not NN NN O
detected NN NN O
in NN NN O
lymphoblasts NN NN O
from NN NN O
ataxia-telangiectasia NN NN B-Modifier
patients NN NN O
homozygous NN NN O
for NN NN O
mutations NN NN O
leading NN NN O
to NN NN O
premature NN NN O
protein NN NN O
termination NN NN O
. NN NN O

Exposure NN NN O
of NN NN O
normal NN NN O
human NN NN O
cells NN NN O
to NN NN O
gamma-irradiation NN NN O
and NN NN O
the NN NN O
radiomimetic NN NN O
drug NN NN O
neocarzinostatin NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
ATM NN NN O
protein NN NN O
levels NN NN O
, NN NN O
in NN NN O
contrast NN NN O
to NN NN O
a NN NN O
noted NN NN O
rise NN NN O
in NN NN O
p53 NN NN O
levels NN NN O
over NN NN O
the NN NN O
same NN NN O
time NN NN O
interval NN NN O
. NN NN O

These NN NN O
findings NN NN O
are NN NN O
consistent NN NN O
with NN NN O
a NN NN O
role NN NN O
for NN NN O
the NN NN O
ATM NN NN O
protein NN NN O
in NN NN O
ensuring NN NN O
the NN NN O
fidelity NN NN O
of NN NN O
DNA NN NN O
repair NN NN O
and NN NN O
cell NN NN O
cycle NN NN O
regulation NN NN O
following NN NN O
genome NN NN O
damage NN NN O
. NN NN O

. NN NN O

9050868 NN NN O
Type NN NN O
III NN NN O
collagen NN NN O
is NN NN O
crucial NN NN O
for NN NN O
collagen NN NN O
I NN NN O
fibrillogenesis NN NN O
and NN NN O
for NN NN O
normal NN NN O
cardiovascular NN NN O
development NN NN O
. NN NN O

Type NN NN O
III NN NN O
collagen NN NN O
is NN NN O
a NN NN O
fibrillar NN NN O
forming NN NN O
collagen NN NN O
comprising NN NN O
three NN NN O
alpha1 NN NN O
( NN NN O
III NN NN O
) NN NN O
chains NN NN O
and NN NN O
is NN NN O
expressed NN NN O
in NN NN O
early NN NN O
embryos NN NN O
and NN NN O
throughout NN NN O
embryogenesis NN NN O
. NN NN O

In NN NN O
the NN NN O
adult NN NN O
, NN NN O
type NN NN O
III NN NN O
collagen NN NN O
is NN NN O
a NN NN O
major NN NN O
component NN NN O
of NN NN O
the NN NN O
extracellular NN NN O
matrix NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
internal NN NN O
organs NN NN O
and NN NN O
skin NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
COL3A1 NN NN O
gene NN NN O
have NN NN O
been NN NN O
implicated NN NN O
as NN NN O
a NN NN O
cause NN NN O
of NN NN O
type NN NN B-SpecificDisease
IV NN NN I-SpecificDisease
Ehlers-Danlos NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
a NN NN O
disease NN NN O
leading NN NN O
to NN NN O
aortic NN NN O
rupture NN NN O
in NN NN O
early NN NN O
adult NN NN O
life NN NN O
. NN NN O

To NN NN O
directly NN NN O
study NN NN O
the NN NN O
role NN NN O
of NN NN O
Col3a1 NN NN O
in NN NN O
development NN NN O
and NN NN O
disease NN NN O
, NN NN O
we NN NN O
have NN NN O
inactivated NN NN O
the NN NN O
Col3a1 NN NN O
gene NN NN O
in NN NN O
embryonic NN NN O
stem NN NN O
cells NN NN O
by NN NN O
homologous NN NN O
recombination NN NN O
. NN NN O

The NN NN O
mutated NN NN O
allele NN NN O
was NN NN O
transmitted NN NN O
through NN NN O
the NN NN O
mouse NN NN O
germ NN NN O
line NN NN O
and NN NN O
homozygous NN NN O
mutant NN NN O
animals NN NN O
were NN NN O
derived NN NN O
from NN NN O
heterozygous NN NN O
intercrosses NN NN O
. NN NN O

About NN NN O
10 NN NN O
% NN NN O
of NN NN O
the NN NN O
homozygous NN NN O
mutant NN NN O
animals NN NN O
survived NN NN O
to NN NN O
adulthood NN NN O
but NN NN O
have NN NN O
a NN NN O
much NN NN O
shorter NN NN O
life NN NN O
span NN NN O
compared NN NN O
with NN NN O
wild-type NN NN O
mice NN NN O
. NN NN O

The NN NN O
major NN NN O
cause NN NN O
of NN NN O
death NN NN O
of NN NN O
mutant NN NN O
mice NN NN O
was NN NN O
rupture NN NN O
of NN NN O
the NN NN O
major NN NN O
blood NN NN O
vessels NN NN O
, NN NN O
similar NN NN O
to NN NN O
patients NN NN O
with NN NN O
type NN NN B-SpecificDisease
IV NN NN I-SpecificDisease
Ehlers-Danlos NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Ultrastructural NN NN O
analysis NN NN O
of NN NN O
tissues NN NN O
from NN NN O
mutant NN NN O
mice NN NN O
revealed NN NN O
that NN NN O
type NN NN O
III NN NN O
collagen NN NN O
is NN NN O
essential NN NN O
for NN NN O
normal NN NN O
collagen NN NN O
I NN NN O
fibrillogenesis NN NN O
in NN NN O
the NN NN O
cardiovascular NN NN O
system NN NN O
and NN NN O
other NN NN O
organs NN NN O
. NN NN O

. NN NN O

9056547 NN NN O
Nonsense NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
3 NN NN O
of NN NN O
the NN NN O
proteolipid NN NN O
protein NN NN O
gene NN NN O
( NN NN O
PLP NN NN O
) NN NN O
in NN NN O
a NN NN O
family NN NN O
with NN NN O
an NN NN O
unusual NN NN O
form NN NN O
of NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

We NN NN O
report NN NN O
a NN NN O
G NN NN O
-- NN NN O
A NN NN O
transition NN NN O
at NN NN O
nucleotide NN NN O
431 NN NN O
of NN NN O
the NN NN O
proteolipid NN NN O
protein NN NN O
gene NN NN O
( NN NN O
PLP NN NN O
) NN NN O
results NN NN O
in NN NN O
a NN NN O
nonsense NN NN O
codon NN NN O
in NN NN O
a NN NN O
family NN NN O
with NN NN O
an NN NN O
unusual NN NN O
form NN NN O
of NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
PMD NN NN B-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
mutation NN NN O
, NN NN O
which NN NN O
creates NN NN O
a NN NN O
second NN NN O
AluI NN NN O
restriction NN NN O
site NN NN O
, NN NN O
results NN NN O
in NN NN O
a NN NN O
nonsense NN NN O
mutation NN NN O
in NN NN O
PLP NN NN O
. NN NN O

The NN NN O
clinical NN NN O
picture NN NN O
resembles NN NN O
somewhat NN NN O
that NN NN O
of NN NN O
X-linked NN NN B-SpecificDisease
spastic NN NN I-SpecificDisease
paraplegia NN NN I-SpecificDisease
( NN NN O
SPG NN NN B-SpecificDisease
) NN NN O
. NN NN O

It NN NN O
differs NN NN O
from NN NN O
this NN NN O
and NN NN O
both NN NN O
the NN NN O
classical NN NN O
and NN NN O
connatal NN NN O
forms NN NN O
of NN NN O
PMD NN NN B-SpecificDisease
in NN NN O
that NN NN O
it NN NN O
is NN NN O
relatively NN NN O
mild NN NN O
in NN NN O
form NN NN O
, NN NN O
onset NN NN O
is NN NN O
delayed NN NN O
beyond NN NN O
age NN NN O
2 NN NN O
years NN NN O
, NN NN O
nystagmus NN NN B-DiseaseClass
is NN NN O
absent NN NN O
, NN NN O
tremors NN NN B-DiseaseClass
are NN NN O
prominent NN NN O
, NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
is NN NN O
not NN NN O
severe NN NN O
, NN NN O
some NN NN O
patients NN NN O
show NN NN O
dementia NN NN B-DiseaseClass
or NN NN O
personality NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
, NN NN O
the NN NN O
disease NN NN O
is NN NN O
progressive NN NN O
rather NN NN O
than NN NN O
static NN NN O
in NN NN O
some NN NN O
, NN NN O
and NN NN O
several NN NN O
females NN NN O
show NN NN O
signs NN NN O
of NN NN O
disease NN NN O
. NN NN O

The NN NN O
nonsense NN NN O
mutation NN NN O
, NN NN O
which NN NN O
is NN NN O
in NN NN O
exon NN NN O
3B NN NN O
, NN NN O
should NN NN O
block NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
normal NN NN O
PLP NN NN O
but NN NN O
spare NN NN O
DM20 NN NN O
, NN NN O
the NN NN O
isoform NN NN O
whose NN NN O
persistence NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
mild NN NN O
forms NN NN O
of NN NN O
PLP-associated NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
in NN NN O
both NN NN O
humans NN NN O
and NN NN O
mice NN NN O
. NN NN O

. NN NN O

9063749 NN NN O
Common NN NN O
BRCA1 NN NN O
variants NN NN O
and NN NN O
susceptibility NN NN O
to NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
in NN NN O
the NN NN O
general NN NN O
population NN NN O
. NN NN O

Most NN NN O
multiple NN NN O
case NN NN O
families NN NN O
of NN NN O
young NN NN O
onset NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
and NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
are NN NN O
thought NN NN O
to NN NN O
be NN NN O
due NN NN O
to NN NN O
highly NN NN O
penetrant NN NN O
mutations NN NN O
in NN NN O
the NN NN O
predisposing NN NN O
genes NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
. NN NN O

However NN NN O
, NN NN O
these NN NN O
mutations NN NN O
are NN NN O
uncommon NN NN O
in NN NN O
the NN NN O
population NN NN O
and NN NN O
they NN NN O
probably NN NN O
account NN NN O
for NN NN O
only NN NN O
a NN NN O
few NN NN O
percent NN NN O
of NN NN O
all NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
incidence NN NN O
. NN NN O

A NN NN O
much NN NN O
larger NN NN O
fraction NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
might NN NN O
, NN NN O
in NN NN O
principle NN NN O
, NN NN O
be NN NN O
due NN NN O
to NN NN O
common NN NN O
variants NN NN O
which NN NN O
confer NN NN O
more NN NN O
modest NN NN O
individual NN NN O
risks NN NN O
. NN NN O

There NN NN O
are NN NN O
several NN NN O
common NN NN O
polymorphisms NN NN O
in NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
which NN NN O
generate NN NN O
amino NN NN O
acid NN NN O
substitutions NN NN O
. NN NN O

We NN NN O
have NN NN O
examined NN NN O
the NN NN O
frequency NN NN O
of NN NN O
four NN NN O
of NN NN O
these NN NN O
polymorphisms NN NN O
Gln356Arg NN NN O
, NN NN O
Pro871Leu NN NN O
, NN NN O
Glu1038Gly NN NN O
and NN NN O
Ser1613Gly NN NN O
in NN NN O
large NN NN O
series NN NN O
of NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
cases NN NN O
and NN NN O
matched NN NN O
controls NN NN O
. NN NN O

Due NN NN O
to NN NN O
strong NN NN O
linkage NN NN O
disequilibrium NN NN O
, NN NN O
these NN NN O
four NN NN O
sites NN NN O
generate NN NN O
only NN NN O
three NN NN O
haplotypes NN NN O
with NN NN O
a NN NN O
frequency NN NN O
1 NN NN O
. NN NN O

3 NN NN O
% NN NN O
. NN NN O

The NN NN O
most NN NN O
common NN NN O
haplotypes NN NN O
, NN NN O
defined NN NN O
by NN NN O
the NN NN O
alleles NN NN O
Gln356Pro871Glu1038Ser1613 NN NN O
and NN NN O
Gln356Leu871Gly1038Gly1613 NN NN O
, NN NN O
have NN NN O
frequencies NN NN O
of NN NN O
0 NN NN O
. NN NN O

57 NN NN O
and NN NN O
0 NN NN O
. NN NN O

32 NN NN O
respectively NN NN O
, NN NN O
and NN NN O
these NN NN O
frequencies NN NN O
do NN NN O
not NN NN O
differ NN NN O
significantly NN NN O
between NN NN O
patient NN NN O
and NN NN O
control NN NN O
groups NN NN O
. NN NN O

Thus NN NN O
the NN NN O
most NN NN O
common NN NN O
polymorphisms NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
do NN NN O
not NN NN O
make NN NN O
a NN NN O
significant NN NN O
contribution NN NN O
to NN NN O
breast NN NN B-Modifier
or NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
risk NN NN O
. NN NN O

However NN NN O
, NN NN O
our NN NN O
data NN NN O
suggest NN NN O
that NN NN O
the NN NN O
Arg356 NN NN O
allele NN NN O
may NN NN O
have NN NN O
a NN NN O
different NN NN O
genotype NN NN O
distribution NN NN O
in NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
patients NN NN O
from NN NN O
that NN NN O
in NN NN O
controls NN NN O
( NN NN O
Arg356 NN NN O
homozygotes NN NN O
are NN NN O
more NN NN O
frequent NN NN O
in NN NN O
the NN NN O
control NN NN O
groups NN NN O
, NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O

01 NN NN O
) NN NN O
, NN NN O
indicating NN NN O
that NN NN O
it NN NN O
may NN NN O
be NN NN O
protective NN NN O
against NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

If NN NN O
this NN NN O
finding NN NN O
can NN NN O
be NN NN O
confirmed NN NN O
, NN NN O
it NN NN O
may NN NN O
provide NN NN O
an NN NN O
insight NN NN O
into NN NN O
the NN NN O
structural NN NN O
features NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
protein NN NN O
that NN NN O
are NN NN O
important NN NN O
for NN NN O
its NN NN O
function NN NN O
. NN NN O

9066888 NN NN O
Kniest NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
: NN NN O
Dr. NN NN O
W. NN NN O
Kniest NN NN O
, NN NN O
his NN NN O
patient NN NN O
, NN NN O
the NN NN O
molecular NN NN O
defect NN NN O
. NN NN O

Kniest NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
is NN NN O
a NN NN O
severe NN NN O
chondrodysplasia NN NN B-DiseaseClass
caused NN NN O
by NN NN O
the NN NN O
defective NN NN B-DiseaseClass
formation NN NN I-DiseaseClass
of NN NN I-DiseaseClass
type NN NN I-DiseaseClass
II NN NN I-DiseaseClass
collagen NN NN I-DiseaseClass
. NN NN O

We NN NN O
report NN NN O
about NN NN O
Dr NN NN O
. NN NN O

Kniest NN NN O
, NN NN O
who NN NN O
first NN NN O
described NN NN O
the NN NN O
condition NN NN O
in NN NN O
1952 NN NN O
, NN NN O
and NN NN O
his NN NN O
patient NN NN O
, NN NN O
who NN NN O
, NN NN O
at NN NN O
the NN NN O
age NN NN O
of NN NN O
50 NN NN O
years NN NN O
is NN NN O
severely NN NN B-DiseaseClass
handicapped NN NN I-DiseaseClass
with NN NN O
short NN NN B-DiseaseClass
stature NN NN I-DiseaseClass
, NN NN O
restricted NN NN B-DiseaseClass
joint NN NN I-DiseaseClass
mobility NN NN I-DiseaseClass
, NN NN O
and NN NN O
blindness NN NN B-DiseaseClass
but NN NN O
is NN NN O
mentally NN NN O
alert NN NN O
and NN NN O
leads NN NN O
an NN NN O
active NN NN O
life NN NN O
. NN NN O

Molecular NN NN O
analysis NN NN O
of NN NN O
the NN NN O
patients NN NN O
DNA NN NN O
showed NN NN O
a NN NN O
single NN NN O
base NN NN O
( NN NN O
G NN NN O
) NN NN O
deletion NN NN O
involving NN NN O
the NN NN O
GT NN NN O
dinucleotide NN NN O
at NN NN O
the NN NN O
start NN NN O
of NN NN O
intron NN NN O
18 NN NN O
destroying NN NN O
a NN NN O
splice NN NN O
site NN NN O
of NN NN O
the NN NN O
COL2A1 NN NN O
gene NN NN O
. NN NN O

This NN NN O
is NN NN O
in NN NN O
accordance NN NN O
with NN NN O
molecular NN NN O
findings NN NN O
in NN NN O
other NN NN O
patients NN NN O
with NN NN O
Kniest NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
and NN NN O
confirms NN NN O
, NN NN O
in NN NN O
the NN NN O
original NN NN O
patient NN NN O
, NN NN O
that NN NN O
the NN NN O
disorder NN NN O
is NN NN O
caused NN NN O
by NN NN O
small NN NN O
inframe NN NN O
deletions NN NN O
often NN NN O
due NN NN O
to NN NN O
exon NN NN O
skipping NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
COL2A1 NN NN O
splice NN NN O
site NN NN O
mutations NN NN O
. NN NN O

. NN NN O

9069115 NN NN O
Cloning NN NN O
of NN NN O
the NN NN O
homogentisate NN NN O
1,2-dioxygenase NN NN O
gene NN NN O
, NN NN O
the NN NN O
key NN NN O
enzyme NN NN O
of NN NN O
alkaptonuria NN NN B-SpecificDisease
in NN NN O
mouse NN NN O
. NN NN O

We NN NN O
determined NN NN O
48 NN NN O
amino NN NN O
acid NN NN O
residues NN NN O
from NN NN O
five NN NN O
peptides NN NN O
from NN NN O
the NN NN O
homogeneous NN NN O
monomer NN NN O
of NN NN O
homogentisate NN NN O
1 NN NN O
, NN NN O
2-dioxygenase NN NN O
( NN NN O
HGO NN NN O
; NN NN O
E NN NN O
. NN NN O

C NN NN O
. NN NN O

1 NN NN O
. NN NN O

13 NN NN O
. NN NN O

11 NN NN O
. NN NN O

15 NN NN O
) NN NN O
of NN NN O
mouse NN NN O
liver NN NN O
. NN NN O

After NN NN O
digestion NN NN O
with NN NN O
trypsin NN NN O
, NN NN O
peptides NN NN O
were NN NN O
separated NN NN O
by NN NN O
reversed NN NN O
phase NN NN O
chromatography NN NN O
and NN NN O
amino NN NN O
acid NN NN O
sequenced NN NN O
. NN NN O

The NN NN O
deduced NN NN O
codon NN NN O
sequence NN NN O
of NN NN O
three NN NN O
peptides NN NN O
was NN NN O
used NN NN O
to NN NN O
derive NN NN O
degenerated NN NN O
oligomeres NN NN O
. NN NN O

By NN NN O
combining NN NN O
these NN NN O
oligos NN NN O
, NN NN O
we NN NN O
were NN NN O
able NN NN O
to NN NN O
amplify NN NN O
fragments NN NN O
from NN NN O
100 NN NN O
to NN NN O
300 NN NN O
bases NN NN O
( NN NN O
b NN NN O
) NN NN O
from NN NN O
mouse NN NN O
liver NN NN O
cDNA NN NN O
by NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
after NN NN O
reverse NN NN O
transcription NN NN O
( NN NN O
RT-PCR NN NN O
) NN NN O
. NN NN O

A NN NN O
fragment NN NN O
of NN NN O
200 NN NN O
b NN NN O
was NN NN O
cloned NN NN O
and NN NN O
used NN NN O
as NN NN O
a NN NN O
probe NN NN O
to NN NN O
screen NN NN O
a NN NN O
mouse NN NN O
liver NN NN O
cDNA NN NN O
library NN NN O
. NN NN O

One NN NN O
clone NN NN O
from NN NN O
this NN NN O
library NN NN O
contained NN NN O
the NN NN O
complete NN NN O
cDNA-insert NN NN O
for NN NN O
HGO NN NN O
as NN NN O
determined NN NN O
by NN NN O
sequencing NN NN O
. NN NN O

The NN NN O
cDNA NN NN O
encodes NN NN O
for NN NN O
a NN NN O
protein NN NN O
of NN NN O
50 NN NN O
kDa NN NN O
, NN NN O
as NN NN O
predicted NN NN O
. NN NN O

The NN NN O
cDNA NN NN O
of NN NN O
mouse NN NN O
HGO NN NN O
has NN NN O
an NN NN O
overall NN NN O
identity NN NN O
of NN NN O
41 NN NN O
% NN NN O
to NN NN O
the NN NN O
corresponding NN NN O
gene NN NN O
hmgA NN NN O
from NN NN O
Aspergillus NN NN O
. NN NN O

Sequence NN NN O
similarities NN NN O
to NN NN O
human NN NN O
expressed NN NN O
sequence NN NN O
tags NN NN O
( NN NN O
EST NN NN O
) NN NN O
clones NN NN O
ranged NN NN O
from NN NN O
70 NN NN O
% NN NN O
to NN NN O
20 NN NN O
% NN NN O
. NN NN O

The NN NN O
positions NN NN O
of NN NN O
122 NN NN O
conserved NN NN O
amino NN NN O
acids NN NN O
could NN NN O
be NN NN O
determined NN NN O
by NN NN O
multiple NN NN O
sequence NN NN O
alignment NN NN O
. NN NN O

We NN NN O
identified NN NN O
one NN NN O
first NN NN O
intron NN NN O
of NN NN O
928 NN NN O
b NN NN O
in NN NN O
the NN NN O
mouse NN NN O
gene NN NN O
. NN NN O

The NN NN O
gene NN NN O
for NN NN O
HGO NN NN O
seems NN NN O
to NN NN O
be NN NN O
expressed NN NN O
in NN NN O
various NN NN O
tissues NN NN O
, NN NN O
as NN NN O
shown NN NN O
by NN NN O
RT-PCR NN NN O
on NN NN O
different NN NN O
cDNAs NN NN O
. NN NN O

FISH NN NN O
experiments NN NN O
with NN NN O
the NN NN O
whole NN NN O
murine NN NN O
cDNA NN NN O
as NN NN O
probe NN NN O
clearly NN NN O
revealed NN NN O
signals NN NN O
at NN NN O
the NN NN O
human NN NN O
chromosomal NN NN O
band NN NN O
3q13 NN NN O
. NN NN O

3-q21 NN NN O
. NN NN O

This NN NN O
corresponds NN NN O
well NN NN O
to NN NN O
the NN NN O
previous NN NN O
assignment NN NN O
of NN NN O
the NN NN O
locus NN NN O
for NN NN O
the NN NN O
human NN NN O
alkaptonuria NN NN B-Modifier
gene NN NN O
( NN NN O
AKU NN NN O
) NN NN O
to NN NN O
the NN NN O
same NN NN O
chromosomal NN NN O
region NN NN O
by NN NN O
multipoint NN NN O
linkage NN NN O
analysis NN NN O
. NN NN O

We NN NN O
therefore NN NN O
conclude NN NN O
that NN NN O
the NN NN O
HGO NN NN O
cDNA NN NN O
encodes NN NN O
the NN NN O
gene NN NN O
responsible NN NN O
for NN NN O
alkaptonuria NN NN B-SpecificDisease
. NN NN O

9072974 NN NN O
PTEN NN NN O
, NN NN O
a NN NN O
putative NN NN O
protein NN NN O
tyrosine NN NN O
phosphatase NN NN O
gene NN NN O
mutated NN NN O
in NN NN O
human NN NN O
brain NN NN B-CompositeMention
, NN NN I-CompositeMention
breast NN NN I-CompositeMention
, NN NN I-CompositeMention
and NN NN I-CompositeMention
prostate NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

Mapping NN NN O
of NN NN O
homozygous NN NN O
deletions NN NN O
on NN NN O
human NN NN O
chromosome NN NN O
10q23 NN NN O
has NN NN O
led NN NN O
to NN NN O
the NN NN O
isolation NN NN O
of NN NN O
a NN NN O
candidate NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
gene NN NN O
, NN NN O
PTEN NN NN O
, NN NN O
that NN NN O
appears NN NN O
to NN NN O
be NN NN O
mutated NN NN O
at NN NN O
considerable NN NN O
frequency NN NN O
in NN NN O
human NN NN O
cancers NN NN B-DiseaseClass
. NN NN O

In NN NN O
preliminary NN NN O
screens NN NN O
, NN NN O
mutations NN NN O
of NN NN O
PTEN NN NN O
were NN NN O
detected NN NN O
in NN NN O
31 NN NN O
% NN NN O
( NN NN O
13 NN NN O
/ NN NN O
42 NN NN O
) NN NN O
of NN NN O
glioblastoma NN NN B-Modifier
cell NN NN O
lines NN NN O
and NN NN O
xenografts NN NN O
, NN NN O
100 NN NN O
% NN NN O
( NN NN O
4 NN NN O
/ NN NN O
4 NN NN O
) NN NN O
of NN NN O
prostate NN NN B-Modifier
cancer NN NN I-Modifier
cell NN NN O
lines NN NN O
, NN NN O
6 NN NN O
% NN NN O
( NN NN O
4 NN NN O
/ NN NN O
65 NN NN O
) NN NN O
of NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
cell NN NN O
lines NN NN O
and NN NN O
xenografts NN NN O
, NN NN O
and NN NN O
17 NN NN O
% NN NN O
( NN NN O
3 NN NN O
/ NN NN O
18 NN NN O
) NN NN O
of NN NN O
primary NN NN B-SpecificDisease
glioblastomas NN NN I-SpecificDisease
. NN NN O

The NN NN O
predicted NN NN O
PTEN NN NN O
product NN NN O
has NN NN O
a NN NN O
protein NN NN O
tyrosine NN NN O
phosphatase NN NN O
domain NN NN O
and NN NN O
extensive NN NN O
homology NN NN O
to NN NN O
tensin NN NN O
, NN NN O
a NN NN O
protein NN NN O
that NN NN O
interacts NN NN O
with NN NN O
actin NN NN O
filaments NN NN O
at NN NN O
focal NN NN O
adhesions NN NN O
. NN NN O

These NN NN O
homologies NN NN O
suggest NN NN O
that NN NN O
PTEN NN NN O
may NN NN O
suppress NN NN O
tumor NN NN B-Modifier
cell NN NN O
growth NN NN O
by NN NN O
antagonizing NN NN O
protein NN NN O
tyrosine NN NN O
kinases NN NN O
and NN NN O
may NN NN O
regulate NN NN O
tumor NN NN B-Modifier
cell NN NN O
invasion NN NN O
and NN NN O
metastasis NN NN B-DiseaseClass
through NN NN O
interactions NN NN O
at NN NN O
focal NN NN O
adhesions NN NN O
. NN NN O

. NN NN O

9083764 NN NN O
Heterogeneity NN NN O
in NN NN O
Schwartz-Jampel NN NN B-SpecificDisease
chondrodystrophic NN NN I-SpecificDisease
myotonia NN NN I-SpecificDisease
. NN NN O

The NN NN O
Schwartz-Jampel NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
SJS NN NN B-SpecificDisease
; NN NN O
chondrodystrophic NN NN B-SpecificDisease
myotonia NN NN I-SpecificDisease
; NN NN O
McK NN NN O
255 NN NN O
, NN NN O
800 NN NN O
) NN NN O
is NN NN O
a NN NN O
recessively NN NN B-DiseaseClass
inherited NN NN I-DiseaseClass
condition NN NN I-DiseaseClass
defined NN NN O
by NN NN O
myotonia NN NN B-DiseaseClass
, NN NN O
short NN NN B-DiseaseClass
stature NN NN I-DiseaseClass
, NN NN O
and NN NN O
bone NN NN B-DiseaseClass
dysplasia NN NN I-DiseaseClass
. NN NN O

Genetic NN NN O
linkage NN NN O
between NN NN O
SJS NN NN B-SpecificDisease
and NN NN O
chromosomal NN NN O
region NN NN O
1q36-34 NN NN O
has NN NN O
been NN NN O
observed NN NN O
in NN NN O
several NN NN O
families NN NN O
, NN NN O
but NN NN O
the NN NN O
gene NN NN O
has NN NN O
not NN NN O
yet NN NN O
been NN NN O
identified NN NN O
. NN NN O

We NN NN O
studied NN NN O
the NN NN O
clinical NN NN O
and NN NN O
radiological NN NN O
features NN NN O
in NN NN O
81 NN NN O
patients NN NN O
from NN NN O
the NN NN O
literature NN NN O
and NN NN O
5 NN NN O
own NN NN O
patients NN NN O
trying NN NN O
to NN NN O
identify NN NN O
distinct NN NN O
subgroups NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
we NN NN O
tested NN NN O
genetic NN NN O
linkage NN NN O
to NN NN O
the NN NN O
SJS NN NN B-Modifier
locus NN NN O
on NN NN O
chromosome NN NN O
1 NN NN O
in NN NN O
one NN NN O
family NN NN O
with NN NN O
two NN NN O
affected NN NN O
sibs NN NN O
. NN NN O

We NN NN O
found NN NN O
that NN NN O
a NN NN O
group NN NN O
of NN NN O
patients NN NN O
have NN NN O
mild NN NN O
skeletal NN NN O
changes NN NN O
which NN NN O
may NN NN O
be NN NN O
secondary NN NN O
consequences NN NN O
of NN NN O
myotonia NN NN B-DiseaseClass
, NN NN O
while NN NN O
another NN NN O
group NN NN O
of NN NN O
patients NN NN O
appear NN NN O
to NN NN O
have NN NN O
primary NN NN O
bone NN NN B-DiseaseClass
dysplasia NN NN I-DiseaseClass
with NN NN O
myotonia NN NN B-DiseaseClass
. NN NN O

Within NN NN O
this NN NN O
latter NN NN O
group NN NN O
, NN NN O
there NN NN O
are NN NN O
differences NN NN O
in NN NN O
age NN NN O
of NN NN O
manifestation NN NN O
, NN NN O
clinical NN NN O
course NN NN O
and NN NN O
pattern NN NN O
of NN NN O
bone NN NN O
changes NN NN O
. NN NN O

We NN NN O
tentatively NN NN O
isolate NN NN O
three NN NN O
different NN NN O
types NN NN O
of NN NN O
SJS NN NN B-SpecificDisease
type NN NN I-SpecificDisease
1A NN NN I-SpecificDisease
, NN NN O
usually NN NN O
recognized NN NN O
in NN NN O
childhood NN NN O
, NN NN O
with NN NN O
moderate NN NN O
bone NN NN B-DiseaseClass
dysplasia NN NN I-DiseaseClass
, NN NN O
corresponding NN NN O
to NN NN O
the NN NN O
original NN NN O
descriptions NN NN O
of NN NN O
Schwartz NN NN O
, NN NN O
Jampel NN NN O
and NN NN O
Aberfeld NN NN O
; NN NN O
type NN NN O
1B NN NN O
, NN NN O
similar NN NN O
to NN NN O
type NN NN O
1A NN NN O
but NN NN O
recognizable NN NN O
at NN NN O
birth NN NN O
, NN NN O
with NN NN O
more NN NN O
pronounced NN NN O
bone NN NN B-DiseaseClass
dysplasia NN NN I-DiseaseClass
resembling NN NN O
Kniest NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
; NN NN O
and NN NN O
type NN NN O
2 NN NN O
, NN NN O
manifest NN NN O
at NN NN O
birth NN NN O
, NN NN O
with NN NN O
increased NN NN O
mortality NN NN O
and NN NN O
bone NN NN B-DiseaseClass
dysplasia NN NN I-DiseaseClass
resembling NN NN O
Pyle NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Genetic NN NN O
analysis NN NN O
of NN NN O
the NN NN O
family NN NN O
with NN NN O
two NN NN O
sibs NN NN O
affected NN NN O
by NN NN O
SJS NN NN B-SpecificDisease
type NN NN I-SpecificDisease
2 NN NN I-SpecificDisease
showed NN NN O
evidence NN NN O
against NN NN O
linkage NN NN O
to NN NN O
chromosome NN NN O
1p36-34 NN NN O
. NN NN O

CONCLUSIONS NN NN O
SJS NN NN B-SpecificDisease
is NN NN O
clinically NN NN O
and NN NN O
radiologically NN NN O
heterogeneous NN NN O
. NN NN O

The NN NN O
causes NN NN O
of NN NN O
heterogeneity NN NN O
are NN NN O
not NN NN O
known NN NN O
yet NN NN O
but NN NN O
are NN NN O
likely NN NN O
to NN NN O
include NN NN O
both NN NN O
different NN NN O
mutations NN NN O
at NN NN O
the NN NN O
SJS NN NN B-Modifier
locus NN NN O
on NN NN O
chromosome NN NN O
1 NN NN O
and NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
second NN NN O
SJS NN NN B-Modifier
locus NN NN O
. NN NN O

A NN NN O
tentative NN NN O
clinico-radiological NN NN O
classification NN NN O
can NN NN O
be NN NN O
useful NN NN O
for NN NN O
the NN NN O
characterization NN NN O
of NN NN O
patients NN NN O
and NN NN O
the NN NN O
development NN NN O
of NN NN O
genotype-phenotype NN NN O
correlations NN NN O
. NN NN O

. NN NN O

9090524 NN NN O
A NN NN O
clinical NN NN O
overview NN NN O
of NN NN O
WT1 NN NN O
gene NN NN O
mutations NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
WT1 NN NN O
gene NN NN O
were NN NN O
anticipated NN NN O
to NN NN O
explain NN NN O
the NN NN O
genetic NN NN O
basis NN NN O
of NN NN O
the NN NN O
childhood NN NN O
kidney NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
Wilms NN NN B-SpecificDisease
tumour NN NN I-SpecificDisease
( NN NN O
WT NN NN B-SpecificDisease
) NN NN O
. NN NN O

Six NN NN O
years NN NN O
on NN NN O
, NN NN O
we NN NN O
review NN NN O
100 NN NN O
reports NN NN O
of NN NN O
intragenic NN NN O
WT1 NN NN O
mutations NN NN O
and NN NN O
examine NN NN O
the NN NN O
accompanying NN NN O
clinical NN NN O
phenotypes NN NN O
. NN NN O

While NN NN O
only NN NN O
5 NN NN O
% NN NN O
of NN NN O
sporadic NN NN B-SpecificDisease
Wilms NN NN I-SpecificDisease
tumours NN NN I-SpecificDisease
have NN NN O
intragenic NN NN O
WT1 NN NN O
mutations NN NN O
, NN NN O
90 NN NN O
% NN NN O
of NN NN O
patients NN NN O
with NN NN O
the NN NN O
Denys-Drash NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
renal NN NN B-DiseaseClass
nephropathy NN NN I-DiseaseClass
, NN NN O
gonadal NN NN B-DiseaseClass
anomaly NN NN I-DiseaseClass
, NN NN O
predisposition NN NN B-DiseaseClass
to NN NN I-DiseaseClass
WT NN NN I-DiseaseClass
) NN NN O
carry NN NN O
constitutional NN NN O
intragenic NN NN O
WT1 NN NN O
mutations NN NN O
. NN NN O

WT1 NN NN O
mutations NN NN O
have NN NN O
also NN NN O
been NN NN O
reported NN NN O
in NN NN O
juvenile NN NN B-SpecificDisease
granulosa NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
tumour NN NN I-SpecificDisease
, NN NN O
non-asbestos NN NN B-SpecificDisease
related NN NN I-SpecificDisease
mesothelioma NN NN I-SpecificDisease
, NN NN O
desmoplastic NN NN B-SpecificDisease
small NN NN I-SpecificDisease
round NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
tumour NN NN I-SpecificDisease
and NN NN O
, NN NN O
most NN NN O
recently NN NN O
, NN NN O
acute NN NN B-SpecificDisease
myeloid NN NN I-SpecificDisease
leukemia NN NN I-SpecificDisease
. NN NN O

. NN NN O

9122265 NN NN O
A NN NN O
mutation NN NN O
in NN NN O
autosomal NN NN B-SpecificDisease
dominant NN NN I-SpecificDisease
myotonia NN NN I-SpecificDisease
congenita NN NN I-SpecificDisease
affects NN NN O
pore NN NN O
properties NN NN O
of NN NN O
the NN NN O
muscle NN NN O
chloride NN NN O
channel NN NN O
. NN NN O

Autosomal NN NN B-SpecificDisease
dominant NN NN I-SpecificDisease
myotonia NN NN I-SpecificDisease
congenita NN NN I-SpecificDisease
is NN NN O
an NN NN O
inherited NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
of NN NN I-DiseaseClass
skeletal NN NN I-DiseaseClass
muscle NN NN I-DiseaseClass
caused NN NN O
by NN NN O
mutations NN NN O
in NN NN O
a NN NN O
voltage-gated NN NN O
Cl- NN NN O
channel NN NN O
gene NN NN O
( NN NN O
CLCN1 NN NN O
, NN NN O
7q35 NN NN O
) NN NN O
. NN NN O

Here NN NN O
, NN NN O
we NN NN O
report NN NN O
that NN NN O
a NN NN O
mutation NN NN O
predicting NN NN O
the NN NN O
substitution NN NN O
of NN NN O
Gly NN NN O
230 NN NN O
by NN NN O
glutamic NN NN O
acid NN NN O
( NN NN O
G230E NN NN O
) NN NN O
between NN NN O
segments NN NN O
D3 NN NN O
and NN NN O
D4 NN NN O
dramatically NN NN O
alters NN NN O
the NN NN O
pore NN NN O
properties NN NN O
of NN NN O
a NN NN O
recombinant NN NN O
human NN NN O
muscle NN NN O
Cl- NN NN O
channel NN NN O
( NN NN O
hCIC-1 NN NN O
) NN NN O
expressed NN NN O
in NN NN O
a NN NN O
mammalian NN NN O
cell NN NN O
line NN NN O
( NN NN O
tsA201 NN NN O
) NN NN O
. NN NN O

The NN NN O
G230E NN NN O
mutation NN NN O
causes NN NN O
substantial NN NN O
changes NN NN O
in NN NN O
anion NN NN O
and NN NN O
cation NN NN O
selectivity NN NN O
as NN NN O
well NN NN O
as NN NN O
a NN NN O
fundamental NN NN O
change NN NN O
in NN NN O
rectification NN NN O
of NN NN O
the NN NN O
current-voltage NN NN O
relationship NN NN O
. NN NN O

Whereas NN NN O
wild-type NN NN O
channels NN NN O
are NN NN O
characterized NN NN O
by NN NN O
pronounced NN NN O
inward NN NN O
rectification NN NN O
and NN NN O
a NN NN O
Cl NN NN O
thiocyanate NN NN O
Br NN NN O
NO NN NN O
( NN NN O
3 NN NN O
) NN NN O
I NN NN O
CH NN NN O
( NN NN O
3 NN NN O
) NN NN O
SO NN NN O
( NN NN O
3 NN NN O
) NN NN O
selectivity NN NN O
, NN NN O
G230E NN NN O
exhibits NN NN O
outward NN NN O
rectification NN NN O
at NN NN O
positive NN NN O
potentials NN NN O
and NN NN O
a NN NN O
thiocyanate NN NN O
NO NN NN O
( NN NN O
3 NN NN O
) NN NN O
I NN NN O
Br NN NN O
Cl NN NN O
CH NN NN O
( NN NN O
3 NN NN O
) NN NN O
SO NN NN O
( NN NN O
3 NN NN O
) NN NN O
selectivity NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
the NN NN O
cation-to-anion NN NN O
permeability NN NN O
ratio NN NN O
of NN NN O
the NN NN O
mutant NN NN O
is NN NN O
much NN NN O
greater NN NN O
than NN NN O
that NN NN O
of NN NN O
the NN NN O
wild-type NN NN O
channel NN NN O
. NN NN O

Voltage-dependent NN NN O
blocks NN NN O
by NN NN O
intracellular NN NN O
and NN NN O
extracellular NN NN O
iodide NN NN O
help NN NN O
to NN NN O
distinguish NN NN O
two NN NN O
distinct NN NN O
ion NN NN O
binding NN NN O
sites NN NN O
within NN NN O
the NN NN O
hClC-1 NN NN O
conduction NN NN O
pathway NN NN O
. NN NN O

Both NN NN O
binding NN NN O
sites NN NN O
are NN NN O
preserved NN NN O
in NN NN O
the NN NN O
mutant NN NN O
but NN NN O
have NN NN O
decreased NN NN O
affinities NN NN O
for NN NN O
iodide NN NN O
. NN NN O

These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
Gly NN NN O
230 NN NN O
is NN NN O
critical NN NN O
for NN NN O
normal NN NN O
ion NN NN O
conductance NN NN O
in NN NN O
hClC-1 NN NN O
and NN NN O
that NN NN O
this NN NN O
residue NN NN O
resides NN NN O
within NN NN O
the NN NN O
channel NN NN O
pore NN NN O
. NN NN O

. NN NN O

9138149 NN NN O
The NN NN O
incidence NN NN O
of NN NN O
PAX6 NN NN O
mutation NN NN O
in NN NN O
patients NN NN O
with NN NN O
simple NN NN O
aniridia NN NN B-SpecificDisease
: NN NN O
an NN NN O
evaluation NN NN O
of NN NN O
mutation NN NN O
detection NN NN O
in NN NN O
12 NN NN O
cases NN NN O
. NN NN O

Twelve NN NN O
aniridia NN NN B-Modifier
patients NN NN O
, NN NN O
five NN NN O
with NN NN O
a NN NN O
family NN NN O
history NN NN O
and NN NN O
seven NN NN O
presumed NN NN O
to NN NN O
be NN NN O
sporadic NN NN O
, NN NN O
were NN NN O
exhaustively NN NN O
screened NN NN O
in NN NN O
order NN NN O
to NN NN O
test NN NN O
what NN NN O
proportion NN NN O
of NN NN O
people NN NN O
with NN NN O
aniridia NN NN B-SpecificDisease
, NN NN O
uncomplicated NN NN O
by NN NN O
associated NN NN O
anomalies NN NN O
, NN NN O
carry NN NN O
mutations NN NN O
in NN NN O
the NN NN O
human NN NN O
PAX6 NN NN O
gene NN NN O
. NN NN O

Mutations NN NN O
were NN NN O
detected NN NN O
in NN NN O
90 NN NN O
% NN NN O
of NN NN O
the NN NN O
cases NN NN O
. NN NN O

Three NN NN O
mutation NN NN O
detection NN NN O
techniques NN NN O
were NN NN O
used NN NN O
to NN NN O
determine NN NN O
if NN NN O
one NN NN O
method NN NN O
was NN NN O
superior NN NN O
for NN NN O
this NN NN O
gene NN NN O
. NN NN O

The NN NN O
protein NN NN O
truncation NN NN O
test NN NN O
( NN NN O
PTT NN NN O
) NN NN O
was NN NN O
used NN NN O
on NN NN O
RT-PCR NN NN O
products NN NN O
, NN NN O
SSCP NN NN O
on NN NN O
genomic NN NN O
PCR NN NN O
amplifications NN NN O
, NN NN O
and NN NN O
chemical NN NN O
cleavage NN NN O
of NN NN O
mismatch NN NN O
on NN NN O
both NN NN O
RT-PCR NN NN O
and NN NN O
genomic NN NN O
amplifications NN NN O
. NN NN O

For NN NN O
RT-PCR NN NN O
products NN NN O
, NN NN O
only NN NN O
the NN NN O
translated NN NN O
portion NN NN O
of NN NN O
the NN NN O
gene NN NN O
was NN NN O
screened NN NN O
. NN NN O

On NN NN O
genomic NN NN O
products NN NN O
exons NN NN O
1 NN NN O
to NN NN O
13 NN NN O
( NN NN O
including NN NN O
740 NN NN O
bp NN NN O
of NN NN O
the NN NN O
3 NN NN O
untranslated NN NN O
sequence NN NN O
and NN NN O
all NN NN O
intron NN NN O
/ NN NN O
exon NN NN O
boundaries NN NN O
) NN NN O
were NN NN O
screened NN NN O
, NN NN O
as NN NN O
was NN NN O
a NN NN O
neuroretina NN NN O
specific NN NN O
enhancer NN NN O
in NN NN O
intron NN NN O
4 NN NN O
. NN NN O

Ten NN NN O
of NN NN O
the NN NN O
possible NN NN O
12 NN NN O
mutations NN NN O
in NN NN O
the NN NN O
five NN NN O
familial NN NN O
cases NN NN O
and NN NN O
five NN NN O
of NN NN O
the NN NN O
sporadic NN NN O
patients NN NN O
were NN NN O
found NN NN O
, NN NN O
all NN NN O
of NN NN O
which NN NN O
conformed NN NN O
to NN NN O
a NN NN O
functional NN NN O
outcome NN NN O
of NN NN O
haploinsufficiency NN NN O
. NN NN O

Five NN NN O
were NN NN O
splice NN NN O
site NN NN O
mutations NN NN O
( NN NN O
one NN NN O
in NN NN O
the NN NN O
donor NN NN O
site NN NN O
of NN NN O
intron NN NN O
4 NN NN O
, NN NN O
two NN NN O
in NN NN O
the NN NN O
donor NN NN O
site NN NN O
of NN NN O
intron NN NN O
6 NN NN O
, NN NN O
one NN NN O
in NN NN O
each NN NN O
of NN NN O
the NN NN O
acceptor NN NN O
sites NN NN O
of NN NN O
introns NN NN O
8 NN NN O
and NN NN O
9 NN NN O
) NN NN O
and NN NN O
five NN NN O
were NN NN O
nonsense NN NN O
mutations NN NN O
in NN NN O
exons NN NN O
8 NN NN O
, NN NN O
9 NN NN O
, NN NN O
10 NN NN O
, NN NN O
11 NN NN O
, NN NN O
and NN NN O
12 NN NN O
. NN NN O

SSCP NN NN O
analysis NN NN O
of NN NN O
individually NN NN O
amplified NN NN O
exons NN NN O
, NN NN O
with NN NN O
which NN NN O
nine NN NN O
of NN NN O
the NN NN O
10 NN NN O
mutations NN NN O
were NN NN O
seen NN NN O
, NN NN O
was NN NN O
the NN NN O
most NN NN O
useful NN NN O
detection NN NN O
method NN NN O
for NN NN O
PAX6 NN NN O
. NN NN O

. NN NN O

9144439 NN NN O
Insulin NN NN O
gene NN NN O
region NN NN O
contributes NN NN O
to NN NN O
genetic NN NN O
susceptibility NN NN O
to NN NN O
, NN NN O
but NN NN O
may NN NN O
not NN NN O
to NN NN O
low NN NN O
incidence NN NN O
of NN NN O
, NN NN O
insulin-dependent NN NN B-SpecificDisease
diabetes NN NN I-SpecificDisease
mellitus NN NN I-SpecificDisease
in NN NN O
Japanese NN NN O
. NN NN O

In NN NN O
the NN NN O
Caucasian NN NN O
population NN NN O
, NN NN O
it NN NN O
has NN NN O
been NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
insulin NN NN O
gene NN NN O
( NN NN O
INS NN NN O
) NN NN O
region NN NN O
contains NN NN O
the NN NN O
insulin-dependent NN NN B-Modifier
diabetes NN NN I-Modifier
mellitus NN NN I-Modifier
locus NN NN O
( NN NN O
IDDM2 NN NN O
) NN NN O
. NN NN O

In NN NN O
the NN NN O
Japanese NN NN O
population NN NN O
, NN NN O
however NN NN O
, NN NN O
there NN NN O
has NN NN O
been NN NN O
no NN NN O
report NN NN O
demonstrating NN NN O
the NN NN O
contribution NN NN O
of NN NN O
IDDM2 NN NN O
to NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
IDDM NN NN B-SpecificDisease
. NN NN O

We NN NN O
conducted NN NN O
an NN NN O
association NN NN O
study NN NN O
of NN NN O
IDDM NN NN B-SpecificDisease
in NN NN O
a NN NN O
large NN NN O
number NN NN O
of NN NN O
Japanese NN NN O
subjects NN NN O
with NN NN O
multiple NN NN O
polymorphisms NN NN O
in NN NN O
INS NN NN O
region NN NN O
. NN NN O

We NN NN O
found NN NN O
a NN NN O
significant NN NN O
association NN NN O
of NN NN O
the NN NN O
INS NN NN O
region NN NN O
with NN NN O
IDDM NN NN B-SpecificDisease
. NN NN O

Alleles NN NN O
positively NN NN O
associated NN NN O
with NN NN O
IDDM NN NN B-SpecificDisease
in NN NN O
INS NN NN O
region NN NN O
were NN NN O
the NN NN O
same NN NN O
as NN NN O
those NN NN O
positively-associated NN NN O
with NN NN O
IDDM NN NN B-SpecificDisease
in NN NN O
Caucasian NN NN O
population NN NN O
, NN NN O
although NN NN O
positively-associated NN NN O
alleles NN NN O
are NN NN O
very NN NN O
common NN NN O
( NN NN O
allele NN NN O
frequencies NN NN O
0 NN NN O
. NN NN O

9 NN NN O
) NN NN O
in NN NN O
the NN NN O
Japanese NN NN O
general NN NN O
population NN NN O
. NN NN O

These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
IDDM2 NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
genetic NN NN O
susceptibility NN NN O
to NN NN O
IDDM NN NN B-SpecificDisease
in NN NN O
Japanese NN NN O
. NN NN O

The NN NN O
high NN NN O
frequencies NN NN O
of NN NN O
disease-associated NN NN O
alleles NN NN O
in NN NN O
the NN NN O
general NN NN O
population NN NN O
suggest NN NN O
that NN NN O
IDDM2 NN NN O
locus NN NN O
is NN NN O
not NN NN O
responsible NN NN O
for NN NN O
the NN NN O
low NN NN O
incidence NN NN O
of NN NN O
IDDM NN NN B-SpecificDisease
in NN NN O
Japanese NN NN O
. NN NN O

9144525 NN NN O
The NN NN O
human NN NN O
complement NN NN O
C9 NN NN O
gene NN NN O
: NN NN O
identification NN NN O
of NN NN O
two NN NN O
mutations NN NN O
causing NN NN O
deficiency NN NN O
and NN NN O
revision NN NN O
of NN NN O
the NN NN O
gene NN NN O
structure NN NN O
. NN NN O

The NN NN O
ninth NN NN O
component NN NN O
of NN NN O
human NN NN O
complement NN NN O
( NN NN O
C9 NN NN O
) NN NN O
is NN NN O
the NN NN O
last NN NN O
of NN NN O
the NN NN O
terminal NN NN O
complement NN NN O
components NN NN O
creating NN NN O
the NN NN O
membrane NN NN O
attack NN NN O
complex NN NN O
. NN NN O

C9 NN NN O
is NN NN O
a NN NN O
single-chain NN NN O
serum NN NN O
protein NN NN O
that NN NN O
is NN NN O
encoded NN NN O
by NN NN O
a NN NN O
gene NN NN O
located NN NN O
on NN NN O
chromosome NN NN O
5p NN NN O
. NN NN O

Deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
terminal NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
components NN NN I-SpecificDisease
is NN NN O
generally NN NN O
associated NN NN O
with NN NN O
recurrent NN NN O
neisseria NN NN B-SpecificDisease
infections NN NN I-SpecificDisease
. NN NN O

We NN NN O
studied NN NN O
a NN NN O
previously NN NN O
described NN NN O
Swiss NN NN O
family NN NN O
with NN NN O
inherited NN NN B-SpecificDisease
C9 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

To NN NN O
identify NN NN O
the NN NN O
genetic NN NN O
basis NN NN O
of NN NN O
C9 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
we NN NN O
developed NN NN O
an NN NN O
approach NN NN O
using NN NN O
exon-specific NN NN O
PCR NN NN O
and NN NN O
direct NN NN O
DNA NN NN O
sequencing NN NN O
. NN NN O

As NN NN O
a NN NN O
cause NN NN O
of NN NN O
C9 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
we NN NN O
found NN NN O
two NN NN O
different NN NN O
point NN NN O
mutations NN NN O
, NN NN O
both NN NN O
generating NN NN O
TGA NN NN O
stop NN NN O
codons NN NN O
in NN NN O
the NN NN O
coding NN NN O
sequence NN NN O
. NN NN O

One NN NN O
mutation NN NN O
, NN NN O
a NN NN O
C NN NN O
to NN NN O
A NN NN O
exchange NN NN O
, NN NN O
was NN NN O
detected NN NN O
in NN NN O
exon NN NN O
2 NN NN O
at NN NN O
cDNA NN NN O
position NN NN O
166 NN NN O
, NN NN O
the NN NN O
other NN NN O
, NN NN O
a NN NN O
C NN NN O
to NN NN O
T NN NN O
exchange NN NN O
, NN NN O
was NN NN O
located NN NN O
in NN NN O
exon NN NN O
4 NN NN O
( NN NN O
cDNA NN NN O
position NN NN O
464 NN NN O
) NN NN O
. NN NN O

In NN NN O
family NN NN O
studies NN NN O
of NN NN O
three NN NN O
first-degree NN NN O
relatives NN NN O
with NN NN O
heterozygous NN NN O
C9 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
we NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
two NN NN O
mutations NN NN O
are NN NN O
segregating NN NN O
independently NN NN O
. NN NN O

Therefore NN NN O
, NN NN O
these NN NN O
mutations NN NN O
are NN NN O
sufficient NN NN O
to NN NN O
explain NN NN O
the NN NN O
complete NN NN O
deficiency NN NN O
of NN NN O
both NN NN O
the NN NN O
probands NN NN O
studied NN NN O
. NN NN O

DNA NN NN O
sequencing NN NN O
of NN NN O
the NN NN O
exon-intron NN NN O
junctions NN NN O
revealed NN NN O
a NN NN O
number NN NN O
of NN NN O
revisions NN NN O
regarding NN NN O
the NN NN O
boundaries NN NN O
between NN NN O
exons NN NN O
4 NN NN O
, NN NN O
5 NN NN O
, NN NN O
and NN NN O
6 NN NN O
as NN NN O
well NN NN O
as NN NN O
between NN NN O
exons NN NN O
10 NN NN O
and NN NN O
11 NN NN O
. NN NN O

No NN NN O
additional NN NN O
introns NN NN O
were NN NN O
detected NN NN O
in NN NN O
exons NN NN O
6 NN NN O
and NN NN O
10 NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
DNA NN NN O
marker NN NN O
studies NN NN O
were NN NN O
conducted NN NN O
using NN NN O
known NN NN O
polymorphisms NN NN O
of NN NN O
the NN NN O
C6 NN NN O
, NN NN O
C7 NN NN O
, NN NN O
and NN NN O
C9 NN NN O
genes NN NN O
, NN NN O
confirming NN NN O
the NN NN O
linkage NN NN O
of NN NN O
the NN NN O
observed NN NN O
C9 NN NN O
mutations NN NN O
with NN NN O
defined NN NN O
haplotypes NN NN O
. NN NN O

. NN NN O

9145677 NN NN O
BRCA1 NN NN O
mutations NN NN O
in NN NN O
women NN NN O
attending NN NN O
clinics NN NN O
that NN NN O
evaluate NN NN O
the NN NN O
risk NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

BACKGROUND NN NN O
To NN NN O
define NN NN O
the NN NN O
incidence NN NN O
of NN NN O
BRCA1 NN NN O
mutations NN NN O
among NN NN O
patients NN NN O
seen NN NN O
in NN NN O
clinics NN NN O
that NN NN O
evaluate NN NN O
the NN NN O
risk NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
we NN NN O
analyzed NN NN O
DNA NN NN O
samples NN NN O
from NN NN O
women NN NN O
seen NN NN O
in NN NN O
this NN NN O
setting NN NN O
and NN NN O
constructed NN NN O
probability NN NN O
tables NN NN O
to NN NN O
provide NN NN O
estimates NN NN O
of NN NN O
the NN NN O
likelihood NN NN O
of NN NN O
finding NN NN O
a NN NN O
BRCA1 NN NN O
mutation NN NN O
in NN NN O
individual NN NN O
families NN NN O
. NN NN O

METHODS NN NN O
Clinical NN NN O
information NN NN O
, NN NN O
family NN NN O
histories NN NN O
, NN NN O
and NN NN O
blood NN NN O
for NN NN O
DNA NN NN O
analysis NN NN O
were NN NN O
obtained NN NN O
from NN NN O
263 NN NN O
women NN NN O
with NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Conformation-sensitive NN NN O
gel NN NN O
electrophoresis NN NN O
and NN NN O
DNA NN NN O
sequencing NN NN O
were NN NN O
used NN NN O
to NN NN O
identify NN NN O
BRCA1 NN NN O
mutations NN NN O
. NN NN O

RESULTS NN NN O
BRCA1 NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
in NN NN O
16 NN NN O
percent NN NN O
of NN NN O
women NN NN O
with NN NN O
a NN NN O
family NN NN O
history NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Only NN NN O
7 NN NN O
percent NN NN O
of NN NN O
women NN NN O
from NN NN O
families NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
but NN NN O
not NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
had NN NN O
BRCA1 NN NN O
mutations NN NN O
. NN NN O

The NN NN O
rates NN NN O
were NN NN O
higher NN NN O
among NN NN O
women NN NN O
from NN NN O
families NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
both NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

Among NN NN O
family NN NN O
members NN NN O
, NN NN O
an NN NN O
average NN NN O
age NN NN O
of NN NN O
less NN NN O
than NN NN O
55 NN NN O
years NN NN O
at NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
the NN NN O
presence NN NN O
of NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
the NN NN O
presence NN NN O
of NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
in NN NN O
the NN NN O
same NN NN O
woman NN NN O
, NN NN O
and NN NN O
Ashkenazi NN NN O
Jewish NN NN O
ancestry NN NN O
were NN NN O
all NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
detecting NN NN O
a NN NN O
BRCA1 NN NN O
mutation NN NN O
. NN NN O

No NN NN O
association NN NN O
was NN NN O
found NN NN O
between NN NN O
the NN NN O
presence NN NN O
of NN NN O
bilateral NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
or NN NN O
the NN NN O
number NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
in NN NN O
a NN NN O
family NN NN O
and NN NN O
the NN NN O
detection NN NN O
of NN NN O
a NN NN O
BRCA1 NN NN O
mutation NN NN O
, NN NN O
or NN NN O
between NN NN O
the NN NN O
position NN NN O
of NN NN O
the NN NN O
mutation NN NN O
in NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
and NN NN O
the NN NN O
presence NN NN O
of NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
in NN NN O
a NN NN O
family NN NN O
. NN NN O

CONCLUSIONS NN NN O
Among NN NN O
women NN NN O
with NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
and NN NN O
a NN NN O
family NN NN O
history NN NN O
of NN NN O
the NN NN O
disease NN NN O
, NN NN O
the NN NN O
percentage NN NN O
with NN NN O
BRCA1 NN NN O
coding-region NN NN O
mutations NN NN O
is NN NN O
less NN NN O
than NN NN O
the NN NN O
45 NN NN O
percent NN NN O
predicted NN NN O
by NN NN O
genetic-linkage NN NN O
analysis NN NN O
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
even NN NN O
in NN NN O
a NN NN O
referral NN NN O
clinic NN NN O
specializing NN NN O
in NN NN O
screening NN NN O
women NN NN O
from NN NN O
high-risk NN NN O
families NN NN O
, NN NN O
the NN NN O
majority NN NN O
of NN NN O
tests NN NN O
for NN NN O
BRCA1 NN NN O
mutations NN NN O
will NN NN O
be NN NN O
negative NN NN O
and NN NN O
therefore NN NN O
uninformative NN NN O
. NN NN O

. NN NN O

9174057 NN NN O
Mutations NN NN O
in NN NN O
the NN NN O
arginine-rich NN NN O
protein NN NN O
gene NN NN O
( NN NN O
ARP NN NN O
) NN NN O
in NN NN O
pancreatic NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

The NN NN O
ARP NN NN O
gene NN NN O
encodes NN NN O
a NN NN O
highly NN NN O
conserved NN NN O
arginine-rich NN NN O
protein NN NN O
from NN NN O
chromosomal NN NN O
band NN NN O
3p21 NN NN O
. NN NN O

1 NN NN O
1 NN NN O
. NN NN O

At NN NN O
the NN NN O
cytogenetic NN NN O
level NN NN O
this NN NN O
region NN NN O
is NN NN O
frequently NN NN O
deleted NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
different NN NN O
solid NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
, NN NN O
although NN NN O
not NN NN O
in NN NN O
pancreatic NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

We NN NN O
have NN NN O
reported NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
specific NN NN O
mutation NN NN O
( NN NN O
ATG50 NN NN O
-- NN NN O
AGG NN NN O
) NN NN O
or NN NN O
deletion NN NN O
of NN NN O
codon NN NN O
50 NN NN O
of NN NN O
the NN NN O
ARP NN NN O
gene NN NN O
in NN NN O
different NN NN O
tumor NN NN B-DiseaseClass
types NN NN I-DiseaseClass
( NN NN O
Shridhar NN NN O
et NN NN O
al NN NN O
. NN NN O

, NN NN O
1996 NN NN O
, NN NN O
1996a NN NN O
) NN NN O
. NN NN O

In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
have NN NN O
observed NN NN O
mutations NN NN O
involving NN NN O
codon NN NN O
50 NN NN O
in NN NN O
11 NN NN O
of NN NN O
37 NN NN O
pancreatic NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
. NN NN O

The NN NN O
frequency NN NN O
of NN NN O
codon NN NN O
50 NN NN O
mutation NN NN O
is NN NN O
roughly NN NN O
the NN NN O
same NN NN O
in NN NN O
pancreatic NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
as NN NN O
in NN NN O
the NN NN O
other NN NN O
types NN NN O
of NN NN O
tumors NN NN B-DiseaseClass
previously NN NN O
examined NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
we NN NN O
have NN NN O
detected NN NN O
mutations NN NN O
at NN NN O
codon NN NN O
51 NN NN O
in NN NN O
multiple NN NN O
PCR NN NN O
subclones NN NN O
in NN NN O
two NN NN O
other NN NN O
pancreatic NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
ARP NN NN O
gene NN NN O
are NN NN O
thus NN NN O
commonly NN NN O
observed NN NN O
in NN NN O
pancreatic NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
as NN NN O
well NN NN O
as NN NN O
many NN NN O
other NN NN O
cancers NN NN B-DiseaseClass
. NN NN O

9182899 NN NN O
Difficulties NN NN O
in NN NN O
the NN NN O
ascertainment NN NN O
of NN NN O
C9 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
: NN NN O
lessons NN NN O
to NN NN O
be NN NN O
drawn NN NN O
from NN NN O
a NN NN O
compound NN NN O
heterozygote NN NN O
C9-deficient NN NN B-Modifier
subject NN NN O
. NN NN O

A NN NN O
group NN NN O
of NN NN O
patients NN NN O
with NN NN O
long-surviving NN NN O
mismatched NN NN O
kidney NN NN O
allografts NN NN O
were NN NN O
investigated NN NN O
for NN NN O
complement NN NN O
function NN NN O
using NN NN O
haemolytic NN NN O
assays NN NN O
in NN NN O
agarose NN NN O
gels NN NN O
. NN NN O

One NN NN O
patient NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
no NN NN O
alternative NN NN O
pathway NN NN O
activity NN NN O
but NN NN O
a NN NN O
low NN NN O
normal NN NN O
classical NN NN O
pathway NN NN O
. NN NN O

Surprisingly NN NN O
, NN NN O
investigation NN NN O
revealed NN NN O
that NN NN O
the NN NN O
patients NN NN O
complement NN NN O
was NN NN O
normal NN NN O
for NN NN O
all NN NN O
components NN NN O
except NN NN O
C9 NN NN O
, NN NN O
which NN NN O
was NN NN O
functionally NN NN O
absent NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
shown NN NN O
to NN NN O
be NN NN O
heterozygous NN NN O
for NN NN O
DNA NN NN O
markers NN NN O
in NN NN O
the NN NN O
C6 NN NN O
, NN NN O
C7 NN NN O
and NN NN O
C9 NN NN O
region NN NN O
of NN NN O
chromosome NN NN O
5 NN NN O
and NN NN O
therefore NN NN O
appears NN NN O
to NN NN O
be NN NN O
a NN NN O
compound NN NN O
heterozygote NN NN O
for NN NN O
two NN NN O
uncharacterized NN NN O
C9 NN NN B-Modifier
deficiency NN NN I-Modifier
genes NN NN O
. NN NN O

Serological NN NN O
analysis NN NN O
by NN NN O
ELISA NN NN O
revealed NN NN O
that NN NN O
he NN NN O
has NN NN O
trace NN NN O
concentrations NN NN O
of NN NN O
a NN NN O
non-functional NN NN O
C9 NN NN O
molecule NN NN O
. NN NN O

Western NN NN O
blot NN NN O
analysis NN NN O
was NN NN O
not NN NN O
sufficiently NN NN O
sensitive NN NN O
to NN NN O
permit NN NN O
detection NN NN O
of NN NN O
this NN NN O
molecule NN NN O
. NN NN O

We NN NN O
hypothesize NN NN O
that NN NN O
the NN NN O
patient NN NN O
is NN NN O
heterozygous NN NN O
for NN NN O
a NN NN O
complete NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
of NN NN I-SpecificDisease
C9 NN NN I-SpecificDisease
and NN NN O
for NN NN O
a NN NN O
gene NN NN O
directing NN NN O
hyposynthesis NN NN O
of NN NN O
a NN NN O
defective NN NN O
C9 NN NN O
. NN NN O

We NN NN O
also NN NN O
suggest NN NN O
that NN NN O
C9 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
may NN NN O
be NN NN O
more NN NN O
common NN NN O
among NN NN O
Caucasians NN NN O
than NN NN O
has NN NN O
been NN NN O
reported NN NN O
. NN NN O

. NN NN O

9195227 NN NN O
Screening NN NN O
for NN NN O
ESR NN NN O
mutations NN NN O
in NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
patients NN NN O
. NN NN O

In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
leukocyte NN NN O
DNA NN NN O
from NN NN O
143 NN NN O
patients NN NN O
with NN NN O
familial NN NN O
clustering NN NN O
of NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
/ NN NN I-CompositeMention
or NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
and NN NN O
tumour NN NN B-Modifier
DNA NN NN O
from NN NN O
96 NN NN O
breast NN NN B-SpecificDisease
carcinomas NN NN I-SpecificDisease
were NN NN O
screened NN NN O
for NN NN O
base NN NN O
mutations NN NN O
in NN NN O
the NN NN O
estrogen NN NN O
receptor NN NN O
gene NN NN O
( NN NN O
ESR NN NN O
) NN NN O
. NN NN O

Three NN NN O
patients NN NN O
with NN NN O
a NN NN O
family NN NN O
history NN NN O
of NN NN O
cancer NN NN B-DiseaseClass
were NN NN O
carrying NN NN O
a NN NN O
Gly160Cys NN NN O
germline NN NN O
substitution NN NN O
. NN NN O

This NN NN O
alteration NN NN O
was NN NN O
also NN NN O
detected NN NN O
in NN NN O
eight NN NN O
( NN NN O
four NN NN O
females NN NN O
and NN NN O
four NN NN O
males NN NN O
) NN NN O
of NN NN O
729 NN NN O
controls NN NN O
( NN NN O
366 NN NN O
female NN NN O
, NN NN O
363 NN NN O
males NN NN O
) NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
substitution NN NN O
probably NN NN O
represents NN NN O
a NN NN O
polymorphism NN NN O
. NN NN O

However NN NN O
, NN NN O
in NN NN O
the NN NN O
229 NN NN O
female NN NN O
controls NN NN O
in NN NN O
whom NN NN O
family NN NN O
history NN NN O
of NN NN O
cancer NN NN B-DiseaseClass
was NN NN O
known NN NN O
, NN NN O
one NN NN O
of NN NN O
two NN NN O
who NN NN O
had NN NN O
a NN NN O
sister NN NN O
with NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
was NN NN O
carrying NN NN O
the NN NN O
variant NN NN O
allele NN NN O
. NN NN O

Hence NN NN O
, NN NN O
a NN NN O
possible NN NN O
clinical NN NN O
significance NN NN O
of NN NN O
the NN NN O
glycine NN NN O
into NN NN O
cysteine NN NN O
can NN NN O
not NN NN O
be NN NN O
completely NN NN O
ruled NN NN O
out NN NN O
and NN NN O
should NN NN O
be NN NN O
further NN NN O
investigated NN NN O
. NN NN O

Somatic NN NN O
mutations NN NN O
were NN NN O
not NN NN O
detected NN NN O
in NN NN O
any NN NN O
of NN NN O
the NN NN O
tumours NN NN B-DiseaseClass
studied NN NN O
, NN NN O
and NN NN O
the NN NN O
present NN NN O
data NN NN O
do NN NN O
not NN NN O
provide NN NN O
support NN NN O
for NN NN O
somatic NN NN O
ESR NN NN O
base NN NN O
mutations NN NN O
as NN NN O
an NN NN O
important NN NN O
mechanism NN NN O
for NN NN O
hormonal NN NN O
therapy NN NN O
resistance NN NN O
in NN NN O
estrogen NN NN B-SpecificDisease
receptor-positive NN NN I-SpecificDisease
breast NN NN I-SpecificDisease
carcinomas NN NN I-SpecificDisease
. NN NN O

. NN NN O

9218625 NN NN O
Molecular NN NN O
bases NN NN O
of NN NN O
C7 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
: NN NN O
three NN NN O
different NN NN O
defects NN NN O
. NN NN O

The NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
C7 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
has NN NN O
been NN NN O
investigated NN NN O
in NN NN O
two NN NN O
Irish NN NN O
families NN NN O
and NN NN O
a NN NN O
number NN NN O
of NN NN O
Israeli NN NN O
families NN NN O
of NN NN O
Moroccan NN NN O
Sephardic NN NN O
Jewish NN NN O
origin NN NN O
. NN NN O

Exon NN NN O
PCR NN NN O
and NN NN O
sequencing NN NN O
revealed NN NN O
a NN NN O
heterozygous NN NN O
point NN NN O
mutation NN NN O
at NN NN O
the NN NN O
3 NN NN O
splice NN NN O
acceptor NN NN O
site NN NN O
of NN NN O
intron NN NN O
1 NN NN O
in NN NN O
one NN NN O
Irish NN NN O
family NN NN O
. NN NN O

In NN NN O
the NN NN O
other NN NN O
Irish NN NN O
family NN NN O
, NN NN O
exons NN NN O
7 NN NN O
and NN NN O
8 NN NN O
failed NN NN O
to NN NN O
amplify NN NN O
and NN NN O
they NN NN O
were NN NN O
shown NN NN O
to NN NN O
be NN NN O
deleted NN NN O
. NN NN O

Marker NN NN O
haplotype NN NN O
studies NN NN O
of NN NN O
the NN NN O
C6 NN NN O
and NN NN O
C7 NN NN O
gene NN NN O
region NN NN O
and NN NN O
Southern NN NN O
blots NN NN O
show NN NN O
that NN NN O
the NN NN O
Irish NN NN O
family NN NN O
with NN NN O
the NN NN O
splice NN NN O
defect NN NN O
also NN NN O
segregate NN NN O
for NN NN O
the NN NN O
deletion NN NN O
, NN NN O
which NN NN O
is NN NN O
not NN NN O
easily NN NN O
detected NN NN O
in NN NN O
heterozygotes NN NN O
. NN NN O

The NN NN O
Israeli NN NN O
C7-deficient NN NN B-Modifier
cases NN NN O
all NN NN O
share NN NN O
a NN NN O
C7 NN NN O
haplotype NN NN O
and NN NN O
are NN NN O
homozygous NN NN O
for NN NN O
a NN NN O
mis-sense NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
9 NN NN O
. NN NN O

However NN NN O
, NN NN O
one NN NN O
individual NN NN O
is NN NN O
heterozygous NN NN O
for NN NN O
markers NN NN O
at NN NN O
adjacent NN NN O
C6 NN NN O
loci NN NN O
, NN NN O
showing NN NN O
that NN NN O
there NN NN O
has NN NN O
been NN NN O
an NN NN O
intergenic NN NN O
recombination NN NN O
and NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
deficiency NN NN O
mutation NN NN O
is NN NN O
of NN NN O
appreciable NN NN O
antiquity NN NN O
. NN NN O

. NN NN O

9222760 NN NN O
Molecular NN NN O
heterogeneity NN NN O
of NN NN O
classical NN NN B-CompositeMention
and NN NN I-CompositeMention
Duarte NN NN I-CompositeMention
galactosemia NN NN I-CompositeMention
: NN NN O
mutation NN NN O
analysis NN NN O
by NN NN O
denaturing NN NN O
gradient NN NN O
gel NN NN O
electrophoresis NN NN O
. NN NN O

Classical NN NN B-SpecificDisease
galactosemia NN NN I-SpecificDisease
is NN NN O
caused NN NN O
by NN NN O
one NN NN O
common NN NN O
missense NN NN O
mutation NN NN O
( NN NN O
Q188R NN NN O
) NN NN O
and NN NN O
by NN NN O
several NN NN O
rare NN NN O
mutations NN NN O
in NN NN O
the NN NN O
galactose-1-phosphate NN NN O
uridyltransferase NN NN O
( NN NN O
GALT NN NN O
) NN NN O
gene NN NN O
. NN NN O

The NN NN O
most NN NN O
common NN NN O
variant NN NN O
of NN NN O
GALT NN NN O
, NN NN O
the NN NN O
Duarte NN NN O
variant NN NN O
, NN NN O
occurs NN NN O
as NN NN O
two NN NN O
types NN NN O
, NN NN O
Duarte-1 NN NN O
( NN NN O
D-1 NN NN O
) NN NN O
and NN NN O
Duarte-2 NN NN O
( NN NN O
D-2 NN NN O
) NN NN O
, NN NN O
both NN NN O
of NN NN O
which NN NN O
carry NN NN O
the NN NN O
sequence NN NN O
change NN NN O
N314D NN NN O
. NN NN O

D-1 NN NN O
increases NN NN O
, NN NN O
whereas NN NN O
D-2 NN NN O
decreases NN NN O
GALT NN NN O
activity NN NN O
. NN NN O

To NN NN O
study NN NN O
the NN NN O
molecular NN NN O
genetics NN NN O
of NN NN O
classical NN NN B-CompositeMention
and NN NN I-CompositeMention
Duarte NN NN B-CompositeMention
galactosemia NN NN I-CompositeMention
, NN NN O
we NN NN O
analyzed NN NN O
the NN NN O
GALT NN NN O
mutations NN NN O
in NN NN O
30 NN NN O
families NN NN O
with NN NN O
classical NN NN B-SpecificDisease
galactosemia NN NN I-SpecificDisease
, NN NN O
in NN NN O
10 NN NN O
families NN NN O
with NN NN O
the NN NN O
D-2 NN NN O
variant NN NN O
and NN NN O
in NN NN O
3 NN NN O
individuals NN NN O
carrying NN NN O
the NN NN O
D-1 NN NN O
allele NN NN O
by NN NN O
denaturing NN NN O
gradient NN NN O
gel NN NN O
electrophoresis NN NN O
( NN NN O
DGGE NN NN O
) NN NN O
. NN NN O

DGGE NN NN O
detected NN NN O
59 NN NN O
of NN NN O
the NN NN O
60 NN NN O
classical NN NN O
galactosemia NN NN B-Modifier
alleles NN NN O
. NN NN O

Q188R NN NN O
accounted NN NN O
for NN NN O
60 NN NN O
% NN NN O
, NN NN O
K285N NN NN O
accounted NN NN O
for NN NN O
28 NN NN O
% NN NN O
of NN NN O
these NN NN O
alleles NN NN O
. NN NN O

Eight NN NN O
novel NN NN O
candidate NN NN O
galactosemia NN NN B-Modifier
mutations NN NN O
were NN NN O
found NN NN O
. NN NN O

On NN NN O
all NN NN O
D-2 NN NN O
alleles NN NN O
N314D NN NN O
occurred NN NN O
in NN NN O
cis NN NN O
with NN NN O
two NN NN O
intronic NN NN O
sequence NN NN O
changes NN NN O
, NN NN O
on NN NN O
the NN NN O
D-1 NN NN O
alleles NN NN O
in NN NN O
cis NN NN O
with NN NN O
a NN NN O
neutral NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
7 NN NN O
. NN NN O

We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
mutations NN NN O
causing NN NN O
galactosemia NN NN B-SpecificDisease
are NN NN O
highly NN NN O
heterogeneous NN NN O
and NN NN O
that NN NN O
K285N NN NN O
is NN NN O
a NN NN O
second NN NN O
common NN NN O
galactosemia NN NN B-Modifier
mutation NN NN O
in NN NN O
our NN NN O
population NN NN O
. NN NN O

. NN NN O

9223307 NN NN O
Isolation NN NN O
of NN NN O
full-length NN NN O
ATM NN NN O
cDNA NN NN O
and NN NN O
correction NN NN O
of NN NN O
the NN NN O
ataxia-telangiectasia NN NN B-Modifier
cellular NN NN O
phenotype NN NN O
. NN NN O

A NN NN O
gene NN NN O
mutated NN NN O
in NN NN O
the NN NN O
human NN NN O
genetic NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
ataxia-telangiectasia NN NN B-SpecificDisease
( NN NN O
A-T NN NN B-SpecificDisease
) NN NN O
, NN NN O
ATM NN NN O
, NN NN O
was NN NN O
recently NN NN O
identified NN NN O
by NN NN O
positional NN NN O
cloning NN NN O
. NN NN O

ATM NN NN O
is NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
phosphatidylinositol-3-kinase NN NN O
superfamily NN NN O
, NN NN O
some NN NN O
of NN NN O
which NN NN O
are NN NN O
protein NN NN O
kinases NN NN O
and NN NN O
appear NN NN O
to NN NN O
have NN NN O
important NN NN O
roles NN NN O
in NN NN O
cell NN NN O
cycle NN NN O
control NN NN O
and NN NN O
radiation NN NN O
signal NN NN O
transduction NN NN O
. NN NN O

We NN NN O
describe NN NN O
herein NN NN O
, NN NN O
to NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
for NN NN O
the NN NN O
first NN NN O
time NN NN O
, NN NN O
the NN NN O
cloning NN NN O
of NN NN O
a NN NN O
full-length NN NN O
cDNA NN NN O
for NN NN O
ATM NN NN O
and NN NN O
correction NN NN O
of NN NN O
multiple NN NN O
aspects NN NN O
of NN NN O
the NN NN O
radio-sensitive NN NN O
phenotype NN NN O
of NN NN O
A-T NN NN B-Modifier
cells NN NN O
by NN NN O
transfection NN NN O
with NN NN O
this NN NN O
cDNA NN NN O
. NN NN O

Overexpression NN NN O
of NN NN O
ATM NN NN O
cDNA NN NN O
in NN NN O
A-T NN NN B-Modifier
cells NN NN O
enhanced NN NN O
the NN NN O
survival NN NN O
of NN NN O
these NN NN O
cells NN NN O
in NN NN O
response NN NN O
to NN NN O
radiation NN NN O
exposure NN NN O
, NN NN O
decreased NN NN O
radiation-induced NN NN O
chromosome NN NN O
aberrations NN NN O
, NN NN O
reduced NN NN O
radio-resistant NN NN O
DNA NN NN O
synthesis NN NN O
, NN NN O
and NN NN O
partially NN NN O
corrected NN NN O
defective NN NN O
cell NN NN O
cycle NN NN O
checkpoints NN NN O
and NN NN O
induction NN NN O
of NN NN O
stress-activated NN NN O
protein NN NN O
kinase NN NN O
. NN NN O

This NN NN O
correction NN NN O
of NN NN O
the NN NN O
defects NN NN O
in NN NN O
A-T NN NN B-Modifier
cells NN NN O
provides NN NN O
further NN NN O
evidence NN NN O
of NN NN O
the NN NN O
multiplicity NN NN O
of NN NN O
effector NN NN O
functions NN NN O
of NN NN O
the NN NN O
ATM NN NN O
protein NN NN O
and NN NN O
suggests NN NN O
possible NN NN O
approaches NN NN O
to NN NN O
gene NN NN O
therapy NN NN O
. NN NN O

. NN NN O

9223312 NN NN O
Fusion NN NN O
genes NN NN O
resulting NN NN O
from NN NN O
alternative NN NN O
chromosomal NN NN O
translocations NN NN O
are NN NN O
overexpressed NN NN O
by NN NN O
gene-specific NN NN O
mechanisms NN NN O
in NN NN O
alveolar NN NN B-SpecificDisease
rhabdomyosarcoma NN NN I-SpecificDisease
. NN NN O

Chromosomal NN NN O
translocations NN NN O
identified NN NN O
in NN NN O
hematopoietic NN NN B-CompositeMention
and NN NN I-CompositeMention
solid NN NN I-CompositeMention
tumors NN NN I-CompositeMention
result NN NN O
in NN NN O
deregulated NN NN O
expression NN NN O
of NN NN O
protooncogenes NN NN O
or NN NN O
creation NN NN O
of NN NN O
chimeric NN NN O
proteins NN NN O
with NN NN O
tumorigenic NN NN O
potential NN NN O
. NN NN O

In NN NN O
the NN NN O
pediatric NN NN O
solid NN NN B-DiseaseClass
tumor NN NN I-DiseaseClass
alveolar NN NN B-SpecificDisease
rhabdomyosarcoma NN NN I-SpecificDisease
, NN NN O
a NN NN O
consistent NN NN O
t NN NN O
( NN NN O
2 NN NN O
; NN NN O
13 NN NN O
) NN NN O
( NN NN O
q35 NN NN O
; NN NN O
q14 NN NN O
) NN NN O
or NN NN O
variant NN NN O
t NN NN O
( NN NN O
1 NN NN O
; NN NN O
13 NN NN O
) NN NN O
( NN NN O
p36 NN NN O
; NN NN O
q14 NN NN O
) NN NN O
translocation NN NN O
generates NN NN O
PAX3-FKHR NN NN O
or NN NN O
PAX7-FKHR NN NN O
fusion NN NN O
proteins NN NN O
, NN NN O
respectively NN NN O
. NN NN O

In NN NN O
this NN NN O
report NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
in NN NN O
addition NN NN O
to NN NN O
functional NN NN O
alterations NN NN O
these NN NN O
translocations NN NN O
are NN NN O
associated NN NN O
with NN NN O
fusion NN NN O
product NN NN O
overexpression NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
PAX3-FKHR NN NN O
and NN NN O
PAX7-FKHR NN NN O
overexpression NN NN O
occurs NN NN O
by NN NN O
distinct NN NN O
mechanisms NN NN O
. NN NN O

Transcription NN NN O
of NN NN O
PAX3-FKHR NN NN O
is NN NN O
increased NN NN O
relative NN NN O
to NN NN O
wild-type NN NN O
PAX3 NN NN O
by NN NN O
a NN NN O
copy NN NN O
number-independent NN NN O
process NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
PAX7-FKHR NN NN O
overexpression NN NN O
results NN NN O
from NN NN O
fusion NN NN O
gene NN NN O
amplification NN NN O
. NN NN O

Thus NN NN O
, NN NN O
gene-specific NN NN O
mechanisms NN NN O
were NN NN O
selected NN NN O
to NN NN O
overexpress NN NN O
PAX3-FKHR NN NN O
and NN NN O
PAX7-FKHR NN NN O
in NN NN O
alveolar NN NN B-SpecificDisease
rhabdomyosarcoma NN NN I-SpecificDisease
, NN NN O
presumably NN NN O
due NN NN O
to NN NN O
differences NN NN O
in NN NN O
regulation NN NN O
between NN NN O
the NN NN O
wild-type NN NN O
loci NN NN O
. NN NN O

We NN NN O
postulate NN NN O
that NN NN O
these NN NN O
overexpression NN NN O
mechanisms NN NN O
ensure NN NN O
a NN NN O
critical NN NN O
level NN NN O
of NN NN O
gene NN NN O
product NN NN O
for NN NN O
the NN NN O
oncogenic NN NN O
effects NN NN O
of NN NN O
these NN NN O
fusions NN NN O
. NN NN O

. NN NN O

9241281 NN NN O
atm NN NN O
and NN NN O
p53 NN NN O
cooperate NN NN O
in NN NN O
apoptosis NN NN O
and NN NN O
suppression NN NN O
of NN NN O
tumorigenesis NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
resistance NN NN O
to NN NN O
acute NN NN B-SpecificDisease
radiation NN NN I-SpecificDisease
toxicity NN NN I-SpecificDisease
. NN NN O

Mutations NN NN O
in NN NN O
atm NN NN O
and NN NN O
p53 NN NN O
cause NN NN O
the NN NN O
human NN NN O
cancer-associated NN NN B-DiseaseClass
diseases NN NN I-DiseaseClass
ataxia-telangiectasia NN NN B-SpecificDisease
and NN NN O
Li-Fraumeni NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
respectively NN NN O
. NN NN O

The NN NN O
two NN NN O
genes NN NN O
are NN NN O
believed NN NN O
to NN NN O
interact NN NN O
in NN NN O
a NN NN O
number NN NN O
of NN NN O
pathways NN NN O
, NN NN O
including NN NN O
regulation NN NN O
of NN NN O
DNA NN NN O
damage-induced NN NN O
cell-cycle NN NN O
checkpoints NN NN O
, NN NN O
apoptosis NN NN O
and NN NN O
radiation NN NN O
sensitivity NN NN O
, NN NN O
and NN NN O
cellular NN NN O
proliferation NN NN O
. NN NN O

Atm-null NN NN O
mice NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
those NN NN O
null NN NN O
for NN NN O
p53 NN NN O
, NN NN O
develop NN NN O
mainly NN NN O
T-cell NN NN B-SpecificDisease
lymphomas NN NN I-SpecificDisease
, NN NN O
supporting NN NN O
the NN NN O
view NN NN O
that NN NN O
these NN NN O
genes NN NN O
have NN NN O
similar NN NN O
roles NN NN O
in NN NN O
thymocyte NN NN O
development NN NN O
. NN NN O

To NN NN O
study NN NN O
the NN NN O
interactions NN NN O
of NN NN O
these NN NN O
two NN NN O
genes NN NN O
on NN NN O
an NN NN O
organismal NN NN O
level NN NN O
, NN NN O
we NN NN O
bred NN NN O
mice NN NN O
heterozygous NN NN O
for NN NN O
null NN NN O
alleles NN NN O
of NN NN O
both NN NN O
atm NN NN O
and NN NN O
p53 NN NN O
to NN NN O
produce NN NN O
all NN NN O
genotypic NN NN O
combinations NN NN O
. NN NN O

Mice NN NN O
doubly NN NN O
null NN NN O
for NN NN O
atm NN NN O
and NN NN O
p53 NN NN O
exhibited NN NN O
a NN NN O
dramatic NN NN O
acceleration NN NN O
of NN NN O
tumour NN NN B-Modifier
formation NN NN O
relative NN NN O
to NN NN O
singly NN NN O
null NN NN O
mice NN NN O
, NN NN O
indicating NN NN O
that NN NN O
both NN NN O
genes NN NN O
collaborate NN NN O
in NN NN O
a NN NN O
significant NN NN O
manner NN NN O
to NN NN O
prevent NN NN O
tumorigenesis NN NN O
. NN NN O

With NN NN O
respect NN NN O
to NN NN O
their NN NN O
roles NN NN O
in NN NN O
apoptosis NN NN O
, NN NN O
loss NN NN O
of NN NN O
atm NN NN O
rendered NN NN O
thymocytes NN NN O
only NN NN O
partly NN NN O
resistant NN NN O
to NN NN O
irradiation-induced NN NN O
apoptosis NN NN O
, NN NN O
whereas NN NN O
additional NN NN O
loss NN NN O
of NN NN O
p53 NN NN O
engendered NN NN O
complete NN NN O
resistance NN NN O
. NN NN O

This NN NN O
implies NN NN O
that NN NN O
the NN NN O
irradiation-induced NN NN O
atm NN NN O
and NN NN O
p53 NN NN O
apoptotic NN NN O
pathways NN NN O
are NN NN O
not NN NN O
completely NN NN O
congruent NN NN O
. NN NN O

Finally-and NN NN O
in NN NN O
contrast NN NN O
to NN NN O
prior NN NN O
predictions-atm NN NN O
and NN NN O
p53 NN NN O
do NN NN O
not NN NN O
appear NN NN O
to NN NN O
interact NN NN O
in NN NN O
acute NN NN B-SpecificDisease
radiation NN NN I-SpecificDisease
toxicity NN NN I-SpecificDisease
, NN NN O
suggesting NN NN O
a NN NN O
separate NN NN O
atm NN NN O
effector NN NN O
pathway NN NN O
for NN NN O
this NN NN O
DNA NN NN O
damage NN NN O
response NN NN O
and NN NN O
having NN NN O
implications NN NN O
for NN NN O
the NN NN O
prognosis NN NN O
and NN NN O
treatment NN NN O
of NN NN O
human NN NN O
tumours NN NN B-DiseaseClass
. NN NN O

. NN NN O

9241282 NN NN O
Trinucleotide NN NN O
repeat NN NN O
expansion NN NN O
at NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
locus NN NN O
reduces NN NN O
expression NN NN O
of NN NN O
DMAHP NN NN O
. NN NN O

Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
, NN NN O
or NN NN O
dystrophia NN NN B-SpecificDisease
myotonica NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
, NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
multisystem NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
caused NN NN O
by NN NN O
the NN NN O
expansion NN NN O
of NN NN O
a NN NN O
CTG NN NN O
trinucleotide NN NN O
repeat NN NN O
in NN NN O
the NN NN O
3 NN NN O
untranslated NN NN O
region NN NN O
of NN NN O
the NN NN O
DMPK NN NN O
protein NN NN O
kinase NN NN O
gene NN NN O
on NN NN O
chromosome NN NN O
19q13 NN NN O
. NN NN O

3 NN NN O
( NN NN O
refs NN NN O
1-3 NN NN O
) NN NN O
. NN NN O

Although NN NN O
the NN NN O
DM NN NN B-Modifier
mutation NN NN O
was NN NN O
identified NN NN O
more NN NN O
than NN NN O
five NN NN O
years NN NN O
ago NN NN O
, NN NN O
the NN NN O
pathogenic NN NN O
mechanisms NN NN O
underlying NN NN O
this NN NN O
most NN NN O
prevalent NN NN O
form NN NN O
of NN NN O
hereditary NN NN O
adult NN NN O
neuromuscular NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
remain NN NN O
elusive NN NN O
. NN NN O

Previous NN NN O
work NN NN O
from NN NN O
our NN NN O
laboratory NN NN O
demonstrated NN NN O
that NN NN O
a NN NN O
DNase NN NN O
l-hypersensitive NN NN O
site NN NN O
located NN NN O
adjacent NN NN O
to NN NN O
the NN NN O
repeats NN NN O
on NN NN O
the NN NN O
wild-type NN NN O
allele NN NN O
is NN NN O
eliminated NN NN O
by NN NN O
repeat NN NN O
expansion NN NN O
, NN NN O
indicating NN NN O
that NN NN O
large NN NN O
CTG-repeat NN NN O
arrays NN NN O
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
a NN NN O
local NN NN O
chromatin NN NN O
environment NN NN O
that NN NN O
represses NN NN O
gene NN NN O
expression NN NN O
. NN NN O

Here NN NN O
we NN NN O
report NN NN O
that NN NN O
the NN NN O
hypersensitive NN NN O
site NN NN O
contains NN NN O
an NN NN O
enhancer NN NN O
element NN NN O
that NN NN O
regulates NN NN O
transcription NN NN O
of NN NN O
the NN NN O
adjacent NN NN O
DMAHP NN NN O
homeobox NN NN O
gene NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
DMAHP NN NN O
expression NN NN O
in NN NN O
the NN NN O
cells NN NN O
of NN NN O
DM NN NN B-Modifier
patients NN NN O
with NN NN O
loss NN NN O
of NN NN O
the NN NN O
hypersensitive NN NN O
site NN NN O
revealed NN NN O
a NN NN O
two- NN NN O
to NN NN O
fourfold NN NN O
reduction NN NN O
in NN NN O
steady-state NN NN O
DMAHP NN NN O
transcript NN NN O
levels NN NN O
relative NN NN O
to NN NN O
wild-type NN NN O
controls NN NN O
. NN NN O

Allele-specific NN NN O
analysis NN NN O
of NN NN O
DMAHP NN NN O
expression NN NN O
showed NN NN O
that NN NN O
steady-state NN NN O
transcript NN NN O
levels NN NN O
from NN NN O
the NN NN O
expanded NN NN O
allele NN NN O
were NN NN O
greatly NN NN O
reduced NN NN O
in NN NN O
comparison NN NN O
to NN NN O
those NN NN O
from NN NN O
the NN NN O
wild-type NN NN O
allele NN NN O
. NN NN O

Together NN NN O
, NN NN O
these NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
CTG-repeat NN NN O
expansions NN NN O
can NN NN O
suppress NN NN O
local NN NN O
gene NN NN O
expression NN NN O
and NN NN O
implicate NN NN O
DMAHP NN NN O
in NN NN O
DM NN NN B-Modifier
pathogenesis NN NN O
. NN NN O

9245987 NN NN O
Constitutively NN NN O
methylated NN NN O
CpG NN NN O
dinucleotides NN NN O
as NN NN O
mutation NN NN O
hot NN NN O
spots NN NN O
in NN NN O
the NN NN O
retinoblastoma NN NN B-Modifier
gene NN NN O
( NN NN O
RB1 NN NN O
) NN NN O
. NN NN O

A NN NN O
wide NN NN O
spectrum NN NN O
of NN NN O
mutations NN NN O
, NN NN O
ranging NN NN O
from NN NN O
point NN NN O
mutations NN NN O
to NN NN O
large NN NN O
deletions NN NN O
, NN NN O
have NN NN O
been NN NN O
described NN NN O
in NN NN O
the NN NN O
retinoblastoma NN NN B-Modifier
gene NN NN O
( NN NN O
RB1 NN NN O
) NN NN O
. NN NN O

Mutations NN NN O
have NN NN O
been NN NN O
found NN NN O
throughout NN NN O
the NN NN O
gene NN NN O
; NN NN O
however NN NN O
, NN NN O
these NN NN O
genetic NN NN O
alterations NN NN O
do NN NN O
not NN NN O
appear NN NN O
to NN NN O
be NN NN O
homogeneously NN NN O
distributed NN NN O
. NN NN O

In NN NN O
particular NN NN O
, NN NN O
a NN NN O
significant NN NN O
proportion NN NN O
of NN NN O
disease-causing NN NN O
mutations NN NN O
results NN NN O
in NN NN O
the NN NN O
premature NN NN O
termination NN NN O
of NN NN O
protein NN NN O
synthesis NN NN O
, NN NN O
and NN NN O
the NN NN O
majority NN NN O
of NN NN O
these NN NN O
mutations NN NN O
occur NN NN O
as NN NN O
C NN NN O
-- NN NN O
T NN NN O
transitions NN NN O
at NN NN O
CpG NN NN O
dinucleotides NN NN O
( NN NN O
CpGs NN NN O
) NN NN O
. NN NN O

Such NN NN O
recurrent NN NN O
CpG NN NN O
mutations NN NN O
, NN NN O
including NN NN O
those NN NN O
found NN NN O
in NN NN O
RB1 NN NN O
, NN NN O
are NN NN O
likely NN NN O
the NN NN O
result NN NN O
of NN NN O
the NN NN O
deamination NN NN O
of NN NN O
5-methylcytosine NN NN O
within NN NN O
these NN NN O
CpGs NN NN O
. NN NN O

In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
used NN NN O
the NN NN O
sodiumbisulfite NN NN O
conversion NN NN O
method NN NN O
to NN NN O
detect NN NN O
cytosine NN NN O
methylation NN NN O
in NN NN O
representative NN NN O
exons NN NN O
of NN NN O
RB1 NN NN O
. NN NN O

We NN NN O
analyzed NN NN O
DNA NN NN O
from NN NN O
a NN NN O
variety NN NN O
of NN NN O
tissues NN NN O
and NN NN O
specifically NN NN O
targeted NN NN O
CGA NN NN O
codons NN NN O
in NN NN O
RB1 NN NN O
, NN NN O
where NN NN O
recurrent NN NN O
premature NN NN O
termination NN NN O
mutations NN NN O
have NN NN O
been NN NN O
reported NN NN O
. NN NN O

We NN NN O
found NN NN O
that NN NN O
DNA NN NN O
methylation NN NN O
within NN NN O
RB1 NN NN O
exons NN NN O
8 NN NN O
, NN NN O
14 NN NN O
, NN NN O
25 NN NN O
, NN NN O
and NN NN O
27 NN NN O
appeared NN NN O
to NN NN O
be NN NN O
restricted NN NN O
to NN NN O
CpGs NN NN O
, NN NN O
including NN NN O
six NN NN O
CGA NN NN O
codons NN NN O
. NN NN O

Other NN NN O
codons NN NN O
containing NN NN O
methylated NN NN O
cytosines NN NN O
have NN NN O
not NN NN O
been NN NN O
reported NN NN O
to NN NN O
be NN NN O
mutated NN NN O
. NN NN O

Therefore NN NN O
, NN NN O
disease-causing NN NN O
mutations NN NN O
at NN NN O
CpGs NN NN O
in NN NN O
RB1 NN NN O
appear NN NN O
to NN NN O
be NN NN O
determined NN NN O
by NN NN O
several NN NN O
factors NN NN O
, NN NN O
including NN NN O
the NN NN O
constitutive NN NN O
presence NN NN O
of NN NN O
DNA NN NN O
methylation NN NN O
at NN NN O
cytosines NN NN O
within NN NN O
CpGs NN NN O
, NN NN O
the NN NN O
specific NN NN O
codon NN NN O
within NN NN O
which NN NN O
the NN NN O
methylated NN NN O
cytosine NN NN O
is NN NN O
located NN NN O
, NN NN O
and NN NN O
the NN NN O
particular NN NN O
region NN NN O
of NN NN O
the NN NN O
gene NN NN O
within NN NN O
which NN NN O
that NN NN O
codon NN NN O
resides NN NN O
. NN NN O

. NN NN O

9271438 NN NN O
The NN NN O
von NN NN B-Modifier
Hippel-Lindau NN NN I-Modifier
tumor NN NN I-Modifier
suppressor NN NN O
gene NN NN O
product NN NN O
interacts NN NN O
with NN NN O
Sp1 NN NN O
to NN NN O
repress NN NN O
vascular NN NN O
endothelial NN NN O
growth NN NN O
factor NN NN O
promoter NN NN O
activity NN NN O
. NN NN O

The NN NN O
von NN NN B-Modifier
Hippel-Lindau NN NN I-Modifier
tumor NN NN I-Modifier
suppressor NN NN O
gene NN NN O
( NN NN O
VHL NN NN O
) NN NN O
has NN NN O
a NN NN O
critical NN NN O
role NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
clear-cell NN NN B-SpecificDisease
renal NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
carcinoma NN NN I-SpecificDisease
( NN NN O
RCC NN NN B-SpecificDisease
) NN NN O
, NN NN O
as NN NN O
VHL NN NN O
mutations NN NN O
have NN NN O
been NN NN O
found NN NN O
in NN NN O
both NN NN O
von NN NN B-CompositeMention
Hippel-Lindau NN NN I-CompositeMention
disease-associated NN NN I-CompositeMention
and NN NN I-CompositeMention
sporadic NN NN I-CompositeMention
RCCs NN NN I-CompositeMention
. NN NN O

Recent NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
vascular NN NN O
endothelial NN NN O
growth NN NN O
factor NN NN O
( NN NN O
VEGF NN NN O
) NN NN O
mRNA NN NN O
is NN NN O
upregulated NN NN O
in NN NN O
RCC- NN NN B-CompositeMention
and NN NN I-CompositeMention
von NN NN I-CompositeMention
Hippel-Lindau NN NN I-CompositeMention
disease-associated NN NN I-CompositeMention
tumors NN NN I-CompositeMention
. NN NN O

We NN NN O
have NN NN O
therefore NN NN O
assessed NN NN O
the NN NN O
effect NN NN O
of NN NN O
the NN NN O
VHL NN NN O
gene NN NN O
product NN NN O
on NN NN O
VEGF NN NN O
expression NN NN O
. NN NN O

VEGF NN NN O
promoter-luciferase NN NN O
constructs NN NN O
were NN NN O
transiently NN NN O
cotransfected NN NN O
with NN NN O
a NN NN O
wild-type NN NN O
VHL NN NN O
( NN NN O
wt-VHL NN NN O
) NN NN O
vector NN NN O
in NN NN O
several NN NN O
cell NN NN O
lines NN NN O
, NN NN O
including NN NN O
293 NN NN O
embryonic NN NN O
kidney NN NN O
and NN NN O
RCC NN NN B-Modifier
cell NN NN O
lines NN NN O
. NN NN O

wt-VHL NN NN O
protein NN NN O
inhibited NN NN O
VEGF NN NN O
promoter NN NN O
activity NN NN O
in NN NN O
a NN NN O
dose-dependent NN NN O
manner NN NN O
up NN NN O
to NN NN O
5- NN NN O
to NN NN O
10-fold NN NN O
. NN NN O

Deletion NN NN O
analysis NN NN O
defined NN NN O
a NN NN O
144-bp NN NN O
region NN NN O
of NN NN O
the NN NN O
VEGF NN NN O
promoter NN NN O
necessary NN NN O
for NN NN O
VHL NN NN O
repression NN NN O
. NN NN O

This NN NN O
VHL-responsive NN NN O
element NN NN O
is NN NN O
GC NN NN O
rich NN NN O
and NN NN O
specifically NN NN O
binds NN NN O
the NN NN O
transcription NN NN O
factor NN NN O
Sp1 NN NN O
in NN NN O
crude NN NN O
nuclear NN NN O
extracts NN NN O
. NN NN O

In NN NN O
Drosophila NN NN O
cells NN NN O
, NN NN O
cotransfected NN NN O
VHL NN NN O
represses NN NN O
Sp1-mediated NN NN O
activation NN NN O
but NN NN O
not NN NN O
basal NN NN O
activity NN NN O
of NN NN O
the NN NN O
VEGF NN NN O
promoter NN NN O
. NN NN O

We NN NN O
next NN NN O
demonstrated NN NN O
in NN NN O
coimmunoprecipitates NN NN O
that NN NN O
VHL NN NN O
and NN NN O
Sp1 NN NN O
were NN NN O
part NN NN O
of NN NN O
the NN NN O
same NN NN O
complex NN NN O
and NN NN O
, NN NN O
by NN NN O
using NN NN O
a NN NN O
glutathione-S-transferase-VHL NN NN O
fusion NN NN O
protein NN NN O
and NN NN O
purified NN NN O
Sp1 NN NN O
, NN NN O
that NN NN O
VHL NN NN O
and NN NN O
Sp1 NN NN O
directly NN NN O
interact NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
endogenous NN NN O
VEGF NN NN O
mRNA NN NN O
levels NN NN O
were NN NN O
suppressed NN NN O
in NN NN O
permanent NN NN O
RCC NN NN B-Modifier
cell NN NN O
lines NN NN O
expressing NN NN O
wt-VHL NN NN O
, NN NN O
and NN NN O
nuclear NN NN O
run-on NN NN O
studies NN NN O
indicated NN NN O
that NN NN O
VHL NN NN O
regulation NN NN O
of NN NN O
VEGF NN NN O
occurs NN NN O
at NN NN O
least NN NN O
partly NN NN O
at NN NN O
the NN NN O
transcriptional NN NN O
level NN NN O
. NN NN O

These NN NN O
observations NN NN O
support NN NN O
a NN NN O
new NN NN O
mechanism NN NN O
for NN NN O
VHL-mediated NN NN O
transcriptional NN NN O
repression NN NN O
via NN NN O
a NN NN O
direct NN NN O
inhibitory NN NN O
action NN NN O
on NN NN O
Sp1 NN NN O
and NN NN O
suggest NN NN O
that NN NN O
loss NN NN O
of NN NN O
Sp1 NN NN O
inhibition NN NN O
may NN NN O
be NN NN O
important NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
von NN NN B-SpecificDisease
Hippel-Lindau NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
and NN NN O
RCC NN NN B-SpecificDisease
. NN NN O

. NN NN O

9272171 NN NN O
Adult NN NN B-SpecificDisease
onset NN NN I-SpecificDisease
globoid NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
leukodystrophy NN NN I-SpecificDisease
( NN NN O
Krabbe NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
) NN NN O
: NN NN O
analysis NN NN O
of NN NN O
galactosylceramidase NN NN O
cDNA NN NN O
from NN NN O
four NN NN O
Japanese NN NN O
patients NN NN O
. NN NN O

We NN NN O
examined NN NN O
galactosylceramidase NN NN O
( NN NN O
GALC NN NN O
) NN NN O
cDNA NN NN O
in NN NN O
four NN NN O
Japanese NN NN O
patients NN NN O
with NN NN O
adult NN NN B-SpecificDisease
onset NN NN I-SpecificDisease
globoid NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
leukodystrophy NN NN I-SpecificDisease
( NN NN O
Krabbe NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
; NN NN O
AO-GLD NN NN B-SpecificDisease
) NN NN O
by NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
/ NN NN O
single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
( NN NN O
PCR-SSCP NN NN O
) NN NN O
analysis NN NN O
, NN NN O
subsequent NN NN O
sequence NN NN O
determination NN NN O
, NN NN O
and NN NN O
restriction NN NN O
enzyme NN NN O
digestion NN NN O
of NN NN O
PCR NN NN O
products NN NN O
, NN NN O
initial NN NN O
symptoms NN NN O
were NN NN O
the NN NN O
onset NN NN O
of NN NN O
slowly NN NN O
progressive NN NN O
spastic NN NN B-DiseaseClass
paraplegia NN NN I-DiseaseClass
from NN NN O
the NN NN O
middle NN NN O
of NN NN O
the NN NN O
second NN NN O
decade NN NN O
, NN NN O
and NN NN O
all NN NN O
patients NN NN O
had NN NN O
diminished NN NN B-DiseaseClass
GALC NN NN I-DiseaseClass
activity NN NN I-DiseaseClass
in NN NN O
their NN NN O
leukocytes NN NN O
. NN NN O

We NN NN O
identified NN NN O
three NN NN O
missense NN NN O
mutations NN NN O
( NN NN O
I66M NN NN O
, NN NN O
G270D NN NN O
, NN NN O
L618S NN NN O
) NN NN O
and NN NN O
one NN NN O
exon-6 NN NN O
skipping NN NN O
( NN NN O
535-573del NN NN O
) NN NN O
. NN NN O

Two NN NN O
of NN NN O
the NN NN O
patients NN NN O
had NN NN O
only NN NN O
the NN NN O
I66M NN NN O
mutant NN NN O
mRNA NN NN O
, NN NN O
and NN NN O
one NN NN O
only NN NN O
the NN NN O
G27OD NN NN O
mutant NN NN O
mRNA NN NN O
. NN NN O

The NN NN O
fourth NN NN O
patient NN NN O
carried NN NN O
a NN NN O
compound NN NN O
heterozygous NN NN O
mutation NN NN O
of NN NN O
535-573del NN NN O
and NN NN O
L618S NN NN O
. NN NN O

To NN NN O
determine NN NN O
the NN NN O
enzymatic NN NN O
activities NN NN O
produced NN NN O
by NN NN O
these NN NN O
mutations NN NN O
, NN NN O
we NN NN O
constructed NN NN O
mutated NN NN O
GALC NN NN O
cDNAs NN NN O
and NN NN O
expressed NN NN O
them NN NN O
in NN NN O
COS-1 NN NN O
cells NN NN O
. NN NN O

Three NN NN O
mutations NN NN O
, NN NN O
viz NN NN O
. NN NN O

, NN NN O
G270D NN NN O
, NN NN O
L618S NN NN O
, NN NN O
and NN NN O
exon-6 NN NN O
skipping NN NN O
( NN NN O
535-573del NN NN O
) NN NN O
, NN NN O
produced NN NN O
diminished NN NN B-DiseaseClass
GALC NN NN I-DiseaseClass
activity NN NN I-DiseaseClass
as NN NN O
expected NN NN O
. NN NN O

The NN NN O
I66M NN NN O
mutation NN NN O
in NN NN O
the NN NN O
wild-type NN NN O
GALC NN NN O
cDNA NN NN O
( NN NN O
I289 NN NN O
) NN NN O
had NN NN O
normal NN NN O
activity NN NN O
, NN NN O
but NN NN O
when NN NN O
this NN NN O
mutation NN NN O
and NN NN O
the NN NN O
V289 NN NN O
polymorphism NN NN O
were NN NN O
introduced NN NN O
into NN NN O
the NN NN O
same NN NN O
allele NN NN O
, NN NN O
it NN NN O
had NN NN O
decreased NN NN O
activity NN NN O
. NN NN O

Thus NN NN O
, NN NN O
the NN NN O
combination NN NN O
of NN NN O
a NN NN O
unique NN NN O
mutation NN NN O
and NN NN O
polymorphism NN NN O
causes NN NN O
conformational NN NN O
change NN NN O
in NN NN O
the NN NN O
GALC NN NN O
enzyme NN NN O
, NN NN O
resulting NN NN O
in NN NN O
low NN NN O
enzymatic NN NN O
activity NN NN O
. NN NN O

AO-GLD NN NN B-Modifier
mutations NN NN O
, NN NN O
including NN NN O
those NN NN O
found NN NN O
here NN NN O
, NN NN O
are NN NN O
located NN NN O
in NN NN O
the NN NN O
N-terminus NN NN O
( NN NN O
I66M NN NN O
, NN NN O
G270D NN NN O
, NN NN O
535-573del NN NN O
) NN NN O
or NN NN O
C-terminus NN NN O
( NN NN O
L618S NN NN O
) NN NN O
of NN NN O
the NN NN O
GALC NN NN O
enzyme NN NN O
, NN NN O
whereas NN NN O
the NN NN O
reported NN NN O
mutations NN NN O
in NN NN O
the NN NN O
infantile NN NN O
form NN NN O
( NN NN O
IF-GLD NN NN B-SpecificDisease
) NN NN O
are NN NN O
in NN NN O
the NN NN O
central NN NN O
domain NN NN O
. NN NN O

This NN NN O
difference NN NN O
in NN NN O
mutation NN NN O
sites NN NN O
may NN NN O
affect NN NN O
the NN NN O
clinical NN NN O
features NN NN O
of NN NN O
GLD NN NN B-SpecificDisease
. NN NN O

